<full-text-retrieval-response xmlns="http://www.elsevier.com/xml/svapi/article/dtd" xmlns:bk="http://www.elsevier.com/xml/bk/dtd" xmlns:cals="http://www.elsevier.com/xml/common/cals/dtd" xmlns:ce="http://www.elsevier.com/xml/common/dtd" xmlns:ja="http://www.elsevier.com/xml/ja/dtd" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:sa="http://www.elsevier.com/xml/common/struct-aff/dtd" xmlns:sb="http://www.elsevier.com/xml/common/struct-bib/dtd" xmlns:tb="http://www.elsevier.com/xml/common/table/dtd" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xocs="http://www.elsevier.com/xml/xocs/dtd" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:prism="http://prismstandard.org/namespaces/basic/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><coredata><prism:url>https://api.elsevier.com/content/article/pii/S0223523419306361</prism:url><dc:identifier>doi:10.1016/j.ejmech.2019.07.015</dc:identifier><eid>1-s2.0-S0223523419306361</eid><prism:doi>10.1016/j.ejmech.2019.07.015</prism:doi><pii>S0223-5234(19)30636-1</pii><dc:title>Curcumin as tyrosine kinase inhibitor in cancer treatment </dc:title><prism:publicationName>European Journal of Medicinal Chemistry</prism:publicationname><prism:aggregationType>Journal</prism:aggregationtype><pubType>rev</pubtype><prism:issn>02235234</prism:issn><prism:volume>181</prism:volume><prism:startingPage>111512</prism:startingpage><prism:pageRange>111512</prism:pagerange><articleNumber>111512</articlenumber><dc:format>text/xml</dc:format><prism:coverDate>2019-11-01</prism:coverdate><prism:coverDisplayDate>1 November 2019</prism:coverdisplaydate><prism:copyright>© 2020 The Authors. Published by Elsevier Masson SAS.</prism:copyright><prism:publisher>The Authors. Published by Elsevier Masson SAS.</prism:publisher><dc:creator>Golonko, A.</dc:creator><dc:creator>Lewandowska, H.</dc:creator><dc:creator>Świsłocka, R.</dc:creator><dc:creator>Jasińska, U.T.</dc:creator><dc:creator>Priebe, W.</dc:creator><dc:creator>Lewandowski, W.</dc:creator><dc:description>
                  Curcumin is a natural substance known for ages, exhibiting a multidirectional effect in cancer prevention and adjuvant cancer therapies. The great advantage of using nutraceuticals of vegetable origin in comparison to popular cytostatic drugs is the minimized side effect and reduced toxicity. The targets in oncological therapy are, among others, tyrosine kinases, important mediators of signaling pathways whose impaired expression is observed in many types of cancer. Unfortunately, the hydrophobic nature of the curcumin molecule often limits its bioavailability, which is why many studies focus on the chemical modification of this compound. Current research is aimed at modifying structures that improve the pharmacokinetic parameters of curcumin, e.g. the formation of nanoparticles, complexes with metals or the synthesis of curcumin derivatives with functional substituents that allow tumor targeting. The article is a review and analysis of current literature on the properties of curcumin and its derivatives in the treatment of cancers directed to signaling pathways of tyrosine kinases and confronts the problem of low assimilation of curcumin with potential therapeutic effects.
               </dc:description><openaccess>1</openaccess><openaccessArticle>true</openaccessarticle><openaccessType>Full</openaccesstype><openArchiveArticle>false</openarchivearticle><openaccessSponsorName>Poland Institutes</openaccesssponsorname><openaccessSponsorType>FundingBody</openaccesssponsortype><openaccessUserLicense>http://creativecommons.org/licenses/by-nc-nd/4.0/</openaccessuserlicense><dcterms:subject>Tyrosine kinases</dcterms:subject><dcterms:subject>Curcumin</dcterms:subject><dcterms:subject>Nanoparticles</dcterms:subject><dcterms:subject>Complexes</dcterms:subject><dcterms:subject>Growth factors</dcterms:subject><dcterms:subject>Cancer therapy</dcterms:subject><link href="https://api.elsevier.com/content/article/pii/S0223523419306361" rel="self"/></link><link href="https://www.sciencedirect.com/science/article/pii/S0223523419306361" rel="scidir"/></link></coredata><objects><object ref="gr6" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="624" height="444" size="63666">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419306361-gr6.jpg?httpAccept=%2A%2F%2A</object><object ref="gr2" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="389" height="196" size="27411">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419306361-gr2.jpg?httpAccept=%2A%2F%2A</object><object ref="gr1" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="580" height="460" size="53296">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419306361-gr1.jpg?httpAccept=%2A%2F%2A</object><object ref="fx1" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="215" height="244" size="25320">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419306361-fx1.jpg?httpAccept=%2A%2F%2A</object><object ref="gr7" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="314" height="206" size="10337">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419306361-gr7.jpg?httpAccept=%2A%2F%2A</object><object ref="gr3" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="536" height="163" size="17528">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419306361-gr3.jpg?httpAccept=%2A%2F%2A</object><object ref="gr4" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="536" height="422" size="34210">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419306361-gr4.jpg?httpAccept=%2A%2F%2A</object><object ref="gr8" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="224" height="93" size="4469">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419306361-gr8.jpg?httpAccept=%2A%2F%2A</object><object ref="gr5" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="735" height="425" size="95393">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419306361-gr5.jpg?httpAccept=%2A%2F%2A</object><object ref="gr6" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="156" size="10059">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419306361-gr6.sml?httpAccept=%2A%2F%2A</object><object ref="gr2" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="110" size="8076">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419306361-gr2.sml?httpAccept=%2A%2F%2A</object><object ref="gr1" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="207" height="164" size="7281">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419306361-gr1.sml?httpAccept=%2A%2F%2A</object><object ref="fx1" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="144" height="164" size="9149">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419306361-fx1.sml?httpAccept=%2A%2F%2A</object><object ref="gr7" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="144" size="4284">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419306361-gr7.sml?httpAccept=%2A%2F%2A</object><object ref="gr3" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="67" size="3795">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419306361-gr3.sml?httpAccept=%2A%2F%2A</object><object ref="gr4" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="208" height="164" size="5301">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419306361-gr4.sml?httpAccept=%2A%2F%2A</object><object ref="gr8" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="91" size="3229">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419306361-gr8.sml?httpAccept=%2A%2F%2A</object><object ref="gr5" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="127" size="9952">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419306361-gr5.sml?httpAccept=%2A%2F%2A</object><object ref="gr6" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2764" height="1965" size="548437">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419306361-gr6_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr2" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="1723" height="869" size="221592">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419306361-gr2_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr1" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2567" height="2036" size="433111">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419306361-gr1_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx1" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="955" height="1085" size="240563">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419306361-fx1_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr7" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="1390" height="911" size="88381">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419306361-gr7_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr3" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2376" height="723" size="142910">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419306361-gr3_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr4" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2376" height="1869" size="290731">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419306361-gr4_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr8" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="994" height="411" size="35857">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419306361-gr8_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr5" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3256" height="1883" size="739368">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419306361-gr5_lrg.jpg?httpAccept=%2A%2F%2A</object></objects><scopus-id>85070195944</scopus-id><scopus-eid>2-s2.0-85070195944</scopus-eid><pubmed-id>31404861</pubmed-id><link href="https://api.elsevier.com/content/abstract/scopus_id/85070195944" rel="abstract"/></link><originalText><xocs:doc xsi:schemaLocation="http://www.elsevier.com/xml/xocs/dtd http://null/schema/dtds/document/fulltext/xcr/xocs-article.xsd"><xocs:meta xmlns:xoe="http://www.elsevier.com/xml/xoe/dtd">
      <xocs:content-family>serial</xocs:content-family>
      <xocs:content-type>JL</xocs:content-type>
      <xocs:cid>271932</xocs:cid>
      <xocs:ssids>
         <xocs:ssid type="alllist">291210</xocs:ssid>
         <xocs:ssid type="subj">291732</xocs:ssid>
         <xocs:ssid type="subj">291789</xocs:ssid>
         <xocs:ssid type="subj">291858</xocs:ssid>
         <xocs:ssid type="subj">291928</xocs:ssid>
         <xocs:ssid type="content">31</xocs:ssid>
         <xocs:ssid type="oa">90</xocs:ssid>
      </xocs:ssids>
      <xocs:srctitle>European Journal of Medicinal Chemistry</xocs:srctitle>
      <xocs:normalized-srctitle>EUROPEANJOURNALMEDICINALCHEMISTRY</xocs:normalized-srctitle>
      <xocs:orig-load-date yyyymmdd="20190715">2019-07-15</xocs:orig-load-date>
      <xocs:available-online-date yyyymmdd="20190715">2019-07-15</xocs:available-online-date>
      <xocs:vor-load-date yyyymmdd="20190809">2019-08-09</xocs:vor-load-date>
      <xocs:vor-available-online-date yyyymmdd="20190809">2019-08-09</xocs:vor-available-online-date>
      <xocs:ew-transaction-id>2020-02-01T16:43:50</xocs:ew-transaction-id>
      <xocs:eid>1-s2.0-S0223523419306361</xocs:eid>
      <xocs:pii-formatted>S0223-5234(19)30636-1</xocs:pii-formatted>
      <xocs:pii-unformatted>S0223523419306361</xocs:pii-unformatted>
      <xocs:doi>10.1016/j.ejmech.2019.07.015</xocs:doi>
      <xocs:item-stage>S300</xocs:item-stage>
      <xocs:item-version-number>S300.2</xocs:item-version-number>
      <xocs:item-weight>FULL-TEXT</xocs:item-weight>
      <xocs:hub-eid>1-s2.0-S0223523419X00185</xocs:hub-eid>
      <xocs:timestamp yyyymmdd="20200201">2020-02-01T17:06:02.794331Z</xocs:timestamp>
      <xocs:dco>0</xocs:dco>
      <xocs:tomb>0</xocs:tomb>
      <xocs:date-search-begin>20191101</xocs:date-search-begin>
      <xocs:year-nav>2019</xocs:year-nav>
      <xocs:indexeddate epoch="1563235024">2019-07-15T23:57:04.662267Z</xocs:indexeddate>
      <xocs:articleinfo>absattachment articleinfo articlenumber articletitlenorm authfirstinitialnorm authfirstsurnamenorm cid cids contenttype copyright crossmark dateloaded dateloadedtxt datesearch datesort dateupdated dco docsubtype doctype doi eid ewtransactionid fundingbodyid hubeid indexeddate issn issnnorm itemstage itemtransactionid itemweight oauserlicense openaccess openarchive pg pgfirst pii piinorm pubdatestart pubdatetxt pubyr sectiontitle sortorder sponsoredaccesstype srctitle srctitlenorm srctype ssids alllist content oa subj subheadings suppl tomb volfirst volissue volumelist webpdf webpdfpagecount yearnav figure table body acknowledge affil articletitle auth authfirstini authfull authkeywords authlast grantnumber grantsponsor grantsponsorid highlightsabst orcid primabst pubtype ref specialabst</xocs:articleinfo>
      <xocs:issns>
         <xocs:issn-primary-formatted>0223-5234</xocs:issn-primary-formatted>
         <xocs:issn-primary-unformatted>02235234</xocs:issn-primary-unformatted>
      </xocs:issns>
      <xocs:sponsored-access-type>UNLIMITED</xocs:sponsored-access-type>
      <xocs:funding-body-id>ICM</xocs:funding-body-id>
      <xocs:crossmark is-crossmark="1">true</xocs:crossmark>
      <xocs:vol-first>181</xocs:vol-first>
      <xocs:volume-list>
         <xocs:volume>181</xocs:volume>
      </xocs:volume-list>
      <xocs:suppl>C</xocs:suppl>
      <xocs:vol-iss-suppl-text>Volume 181</xocs:vol-iss-suppl-text>
      <xocs:sort-order>7</xocs:sort-order>
      <xocs:first-fp>111512</xocs:first-fp>
      <xocs:article-number>111512</xocs:article-number>
      <xocs:pages>
         <xocs:first-page>111512</xocs:first-page>
      </xocs:pages>
      <xocs:cover-date-orig>
         <xocs:start-date>20191101</xocs:start-date>
      </xocs:cover-date-orig>
      <xocs:cover-date-text>1 November 2019</xocs:cover-date-text>
      <xocs:cover-date-start>2019-11-01</xocs:cover-date-start>
      <xocs:cover-date-year>2019</xocs:cover-date-year>
      <xocs:hub-sec>
         <xocs:hub-sec-title>Review articles</xocs:hub-sec-title>
      </xocs:hub-sec>
      <xocs:document-type>article</xocs:document-type>
      <xocs:document-subtype>rev</xocs:document-subtype>
      <xocs:copyright-line>© 2020 The Authors. Published by Elsevier Masson SAS.</xocs:copyright-line>
      <xocs:normalized-article-title>CURCUMINTYROSINEKINASEINHIBITORINCANCERTREATMENT</xocs:normalized-article-title>
      <xocs:normalized-first-auth-surname>GOLONKO</xocs:normalized-first-auth-surname>
      <xocs:normalized-first-auth-initial>A</xocs:normalized-first-auth-initial>
      <xocs:item-toc>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>1</xocs:item-toc-label>
            <xocs:item-toc-section-title>The role of tyrosine kinases in cellular metabolism, apoptosis and cancer</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>2</xocs:item-toc-label>
            <xocs:item-toc-section-title>Chemical structure of curcumin responsible for its anticancer properties</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>3</xocs:item-toc-label>
            <xocs:item-toc-section-title>Curcumin as an inhibitor of receptor tyrosine kinases</xocs:item-toc-section-title>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>3.1</xocs:item-toc-label>
               <xocs:item-toc-section-title>Epidermal growth factor receptor (EGFR)</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>3.2</xocs:item-toc-label>
               <xocs:item-toc-section-title>Insulin-like growth factor (IGF)</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>3.3</xocs:item-toc-label>
               <xocs:item-toc-section-title>Vascular epidermal growth factor receptor (VEGFR)</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>3.4</xocs:item-toc-label>
               <xocs:item-toc-section-title>Fibroblast growth factor receptor (FGFR)</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>3.5</xocs:item-toc-label>
               <xocs:item-toc-section-title>Platelet-derived growth factor receptor (PDGFR)</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>3.6</xocs:item-toc-label>
               <xocs:item-toc-section-title>Hepatocyte growth factor receptor (HGFR)</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>3.7</xocs:item-toc-label>
               <xocs:item-toc-section-title>Tyrosine-protein kinase receptor UFO (AXL)</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>4</xocs:item-toc-label>
               <xocs:item-toc-section-title>Curcumin as an inhibitor of non-receptor tyrosine kinases</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>4.1</xocs:item-toc-label>
               <xocs:item-toc-section-title>Abelson murine leukemia viral oncogene homologue (ABL)</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>4.2</xocs:item-toc-label>
               <xocs:item-toc-section-title>Focal adhesion kinase (FAK)</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>4.3</xocs:item-toc-label>
               <xocs:item-toc-section-title>Janus kinases (JAK)</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>4.4</xocs:item-toc-label>
               <xocs:item-toc-section-title>Proto-oncogene tyrosine-protein kinase Src</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>5</xocs:item-toc-label>
            <xocs:item-toc-section-title>Curcumin modifications of potential oncological use</xocs:item-toc-section-title>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>5.1</xocs:item-toc-label>
               <xocs:item-toc-section-title>Synthetic analogs of curcumin</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>5.2</xocs:item-toc-label>
               <xocs:item-toc-section-title>Modifications of diketo group</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>5.3</xocs:item-toc-label>
               <xocs:item-toc-section-title>Aromatic side-chain modifications</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>5.4</xocs:item-toc-label>
               <xocs:item-toc-section-title>Double bond reduction</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>5.5</xocs:item-toc-label>
               <xocs:item-toc-section-title>Metal complexes of curcuminoids</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>5.6</xocs:item-toc-label>
               <xocs:item-toc-section-title>Conjugates of curcumin</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>5.7</xocs:item-toc-label>
               <xocs:item-toc-section-title>Nanoformulations of curcumin</xocs:item-toc-section-title>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>5.8</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Anti-cancer properties of curcumin nanoformulations</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
            </xocs:item-toc-entry>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>6</xocs:item-toc-label>
            <xocs:item-toc-section-title>Conclusion</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-section-title>Declarations</xocs:item-toc-section-title>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-section-title>Ethics approval and consent to participate</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-section-title>Consent for publication</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-section-title>Availability of data and material</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-section-title>Competing interests</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-section-title>Funding</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-section-title>Authors' contributions</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:acknowledgment">
            <xocs:item-toc-section-title>Acknowledgements</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:bibliography">
            <xocs:item-toc-section-title>References</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
      </xocs:item-toc>
      <xocs:references>
         <xocs:ref-info refid="sref1">
            <xocs:ref-normalized-surname>DERVISIS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>N</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref2">
            <xocs:ref-normalized-surname>MITCHISON</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref3">
            <xocs:ref-normalized-surname>ZHANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref4">
            <xocs:ref-normalized-surname>JANNE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref5">
            <xocs:ref-normalized-surname>PAUL</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2004</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref6">
            <xocs:ref-normalized-surname>VALIATHAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref7">
            <xocs:ref-normalized-surname>LENGYEL</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2007</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>E</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref8">
            <xocs:ref-normalized-surname>HUGHES</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2006</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref9">
            <xocs:ref-normalized-surname>SHAW</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref10">
            <xocs:ref-normalized-surname>MITELMAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2004</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>F</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref11">
            <xocs:ref-normalized-surname>MCFARLAND</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref12">
            <xocs:ref-normalized-surname>STRATTON</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref13">
            <xocs:ref-normalized-surname>PON</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref14">
            <xocs:ref-normalized-surname>TAKEUCHI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref15">
            <xocs:ref-normalized-surname>TORKAMANI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref16">
            <xocs:ref-normalized-surname>DRAKE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref17">
            <xocs:ref-normalized-surname>LEMMON</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref18">
            <xocs:ref-normalized-surname>MCDONELL</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref19">
            <xocs:ref-normalized-surname>REICHERT</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2007</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref20">
            <xocs:ref-normalized-surname>SHAWVER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2002</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref21">
            <xocs:ref-normalized-surname>ELDARFINKELMAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref22">
            <xocs:ref-normalized-surname>WORKS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref23">
            <xocs:ref-normalized-surname>HUBBARD</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2002</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref24">
            <xocs:ref-normalized-surname>COHEN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2002</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref25">
            <xocs:ref-normalized-surname>COHEN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2003</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref26">
            <xocs:ref-normalized-surname>GOTINK</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref27">
            <xocs:ref-normalized-surname>ONGUSAHA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2003</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref28">
            <xocs:ref-normalized-surname>SHINTANI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref29">
            <xocs:ref-normalized-surname>MASFERRER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2000</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref30">
            <xocs:ref-normalized-surname>KIM</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref31">
            <xocs:ref-normalized-surname>RAMMAL</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref32">
            <xocs:ref-normalized-surname>RANIERI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>G</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref33">
            <xocs:ref-normalized-surname>NARDI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2004</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>V</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref34">
            <xocs:ref-normalized-surname>PARK</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>W</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref35">
            <xocs:ref-normalized-surname>TUORKEY</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref36">
            <xocs:ref-normalized-surname>HEMALSWARYA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2006</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref37">
            <xocs:ref-normalized-surname>RAMACHANDRAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2005</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref38">
            <xocs:ref-normalized-surname>TROSELJ</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref39">
            <xocs:ref-normalized-surname>PRIYADARSINI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref40">
            <xocs:ref-normalized-surname>GHALANDARLAKI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>N</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref41">
            <xocs:ref-normalized-surname>ANAND</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref42">
            <xocs:ref-normalized-surname>SEGALINY</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref43">
            <xocs:ref-normalized-surname>MALIK</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref44">
            <xocs:ref-normalized-surname>INDIRAPRIYADARSINI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref45">
            <xocs:ref-normalized-surname>TEITEN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref46">
            <xocs:ref-normalized-surname>SORDILLO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref47">
            <xocs:ref-normalized-surname>BIMONTE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref48">
            <xocs:ref-normalized-surname>MIRZAEI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref49">
            <xocs:ref-normalized-surname>CHAUHAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2002</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref50">
            <xocs:ref-normalized-surname>AGGARWAL</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2003</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>B</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref51">
            <xocs:ref-normalized-surname>SHANMUGAM</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref52">
            <xocs:ref-normalized-surname>SHISHODIA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2007</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref53">
            <xocs:ref-normalized-surname>SHEHZAD</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref54">
            <xocs:ref-normalized-surname>RAVINDRAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref55">
            <xocs:ref-normalized-surname>SAIF</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>I</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref56">
            <xocs:ref-normalized-surname>TABERLAY</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref57">
            <xocs:ref-normalized-surname>LINK</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref58">
            <xocs:ref-normalized-surname>JIANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref59">
            <xocs:ref-normalized-surname>REUTER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref60">
            <xocs:ref-normalized-surname>VANERK</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2004</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref61">
            <xocs:ref-normalized-surname>JANKUN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref62">
            <xocs:ref-normalized-surname>PRASAD</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref63">
            <xocs:ref-normalized-surname>SCALTRITI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2006</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref64">
            <xocs:ref-normalized-surname>BASELGA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2002</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref65">
            <xocs:ref-normalized-surname>SANADA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref66">
            <xocs:ref-normalized-surname>GRAUSPORTA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1997</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref67">
            <xocs:ref-normalized-surname>KRUCZAK</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>315</xocs:ref-first-fp>
            <xocs:ref-last-lp>323</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref68">
            <xocs:ref-normalized-surname>HONG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1999</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref69">
            <xocs:ref-normalized-surname>LAI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref70">
            <xocs:ref-normalized-surname>VENKITESWARAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>1</xocs:ref-first-fp>
            <xocs:ref-last-lp>8</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref71">
            <xocs:ref-normalized-surname>MATKAR</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref72">
            <xocs:ref-normalized-surname>HUANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref73">
            <xocs:ref-normalized-surname>CHEN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref74">
            <xocs:ref-normalized-surname>MUDDULURU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>G</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref75">
            <xocs:ref-normalized-surname>TAVERNA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref76">
            <xocs:ref-normalized-surname>LI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>107</xocs:ref-first-fp>
            <xocs:ref-last-lp>118</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>W</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref77">
            <xocs:ref-normalized-surname>YIMIM</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>W</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref78">
            <xocs:ref-normalized-surname>DORAI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2000</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref79">
            <xocs:ref-normalized-surname>KIM</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2006</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref80">
            <xocs:ref-normalized-surname>THANGAPAZHAM</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref81">
            <xocs:ref-normalized-surname>MCNALLY</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2007</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref82">
            <xocs:ref-normalized-surname>ZHANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2007</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref83">
            <xocs:ref-normalized-surname>YAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2005</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref84">
            <xocs:ref-normalized-surname>STAROK</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref85">
            <xocs:ref-normalized-surname>CHADALAPAKA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>G</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref86">
            <xocs:ref-normalized-surname>ZHEN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref87">
            <xocs:ref-normalized-surname>KORUTLA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1994</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref88">
            <xocs:ref-normalized-surname>REDDY</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2006</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref89">
            <xocs:ref-normalized-surname>LEE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref90">
            <xocs:ref-normalized-surname>YANO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref91">
            <xocs:ref-normalized-surname>ORGAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref92">
            <xocs:ref-normalized-surname>SEOL</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2000</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref93">
            <xocs:ref-normalized-surname>YE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref94">
            <xocs:ref-normalized-surname>HU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref95">
            <xocs:ref-normalized-surname>JIAO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref96">
            <xocs:ref-normalized-surname>CHEN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>Q</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref97">
            <xocs:ref-normalized-surname>CHEN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>Q</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref98">
            <xocs:ref-normalized-surname>TEITEN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref99">
            <xocs:ref-normalized-surname>ZHA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref100">
            <xocs:ref-normalized-surname>CHEN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref101">
            <xocs:ref-normalized-surname>HWA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1999</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>V</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref102">
            <xocs:ref-normalized-surname>DENDULURI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref103">
            <xocs:ref-normalized-surname>KIM</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref104">
            <xocs:ref-normalized-surname>XIA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2007</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref105">
            <xocs:ref-normalized-surname>UMAYAHARA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1994</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref106">
            <xocs:ref-normalized-surname>LEVARI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2006</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref107">
            <xocs:ref-normalized-surname>BICHELL</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1993</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref108">
            <xocs:ref-normalized-surname>WANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref109">
            <xocs:ref-normalized-surname>PERKS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref110">
            <xocs:ref-normalized-surname>PERKS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref111">
            <xocs:ref-normalized-surname>JOHNSON</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref112">
            <xocs:ref-normalized-surname>PATEL</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>B</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref113">
            <xocs:ref-normalized-surname>CHANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref114">
            <xocs:ref-normalized-surname>GOEL</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref115">
            <xocs:ref-normalized-surname>GAO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref116">
            <xocs:ref-normalized-surname>YOYSUNGNOEN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2006</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref117">
            <xocs:ref-normalized-surname>BINION</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref118">
            <xocs:ref-normalized-surname>FU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>Z</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref119">
            <xocs:ref-normalized-surname>MASOUD</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>G</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref120">
            <xocs:ref-normalized-surname>BAE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2006</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref121">
            <xocs:ref-normalized-surname>SHAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>B</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref122">
            <xocs:ref-normalized-surname>DA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>W</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref123">
            <xocs:ref-normalized-surname>KALINSKI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref124">
            <xocs:ref-normalized-surname>CARROLL</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref125">
            <xocs:ref-normalized-surname>CHAKRABORTY</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>G</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref126">
            <xocs:ref-normalized-surname>BHATTACHARYYA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2007</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref127">
            <xocs:ref-normalized-surname>TERLIKOWSKA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref128">
            <xocs:ref-normalized-surname>KATOH</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref129">
            <xocs:ref-normalized-surname>ORNITZ</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref130">
            <xocs:ref-normalized-surname>LI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>W</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref131">
            <xocs:ref-normalized-surname>ABUHARBEID</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2006</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref132">
            <xocs:ref-normalized-surname>AHMAD</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>I</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref133">
            <xocs:ref-normalized-surname>LAFITTE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref134">
            <xocs:ref-normalized-surname>MOHAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2000</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref135">
            <xocs:ref-normalized-surname>SHAO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2002</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>Z</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref136">
            <xocs:ref-normalized-surname>YU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref137">
            <xocs:ref-normalized-surname>WANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref138">
            <xocs:ref-normalized-surname>LATIMER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>B</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref139">
            <xocs:ref-normalized-surname>HOWELLS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2007</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref140">
            <xocs:ref-normalized-surname>HELDIN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref141">
            <xocs:ref-normalized-surname>RANZA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2007</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>E</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref142">
            <xocs:ref-normalized-surname>JECHLINGER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2006</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref143">
            <xocs:ref-normalized-surname>MATEI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2006</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref144">
            <xocs:ref-normalized-surname>ZHANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2007</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref145">
            <xocs:ref-normalized-surname>TSIOUMPEKOU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref146">
            <xocs:ref-normalized-surname>YANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref147">
            <xocs:ref-normalized-surname>PICCALUGA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref148">
            <xocs:ref-normalized-surname>FLEMING</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1992</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref149">
            <xocs:ref-normalized-surname>PUPUTTI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2006</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref150">
            <xocs:ref-normalized-surname>OCHOA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref151">
            <xocs:ref-normalized-surname>LOURESTANPOUR</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref152">
            <xocs:ref-normalized-surname>CHEN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2007</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref153">
            <xocs:ref-normalized-surname>SUNDARESAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1995</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref154">
            <xocs:ref-normalized-surname>CHEN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2004</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref155">
            <xocs:ref-normalized-surname>LANGE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref156">
            <xocs:ref-normalized-surname>WANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>Z</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref157">
            <xocs:ref-normalized-surname>LO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref158">
            <xocs:ref-normalized-surname>YANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2006</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>X</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref159">
            <xocs:ref-normalized-surname>ZHAO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>Z</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref160">
            <xocs:ref-normalized-surname>TOLBERT</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>W</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref161">
            <xocs:ref-normalized-surname>SIERRA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref162">
            <xocs:ref-normalized-surname>COMOGLIO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref163">
            <xocs:ref-normalized-surname>HUH</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2004</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref164">
            <xocs:ref-normalized-surname>BOROWIAK</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2004</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref165">
            <xocs:ref-normalized-surname>EDER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref166">
            <xocs:ref-normalized-surname>MATSUMOTO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref167">
            <xocs:ref-normalized-surname>PEINADO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref168">
            <xocs:ref-normalized-surname>ENGELMAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2007</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref169">
            <xocs:ref-normalized-surname>BARDELLI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref170">
            <xocs:ref-normalized-surname>ACCORNERO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref171">
            <xocs:ref-normalized-surname>WATSON</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2006</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>G</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref172">
            <xocs:ref-normalized-surname>HOYEN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref173">
            <xocs:ref-normalized-surname>LAM</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>B</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref174">
            <xocs:ref-normalized-surname>CHANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref175">
            <xocs:ref-normalized-surname>WU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>X</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref176">
            <xocs:ref-normalized-surname>KARIOLIS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref177">
            <xocs:ref-normalized-surname>KIM</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref178">
            <xocs:ref-normalized-surname>BRUZZESE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2006</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>F</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref179">
            <xocs:ref-normalized-surname>SATHE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>G</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref180">
            <xocs:ref-normalized-surname>WANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref181">
            <xocs:ref-normalized-surname>WANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref182">
            <xocs:ref-normalized-surname>HANTSCHEL</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>O</xocs:ref-normalized-initial>
            <xocs:ref-normalized-srctitle>STRUCTUREREGULATIONSIGNALINGTARGETINGABLKINASESINCANCERGENESCANCER</xocs:ref-normalized-srctitle>
         </xocs:ref-info>
         <xocs:ref-info refid="sref183">
            <xocs:ref-normalized-surname>LIN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref184">
            <xocs:ref-normalized-surname>GU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref185">
            <xocs:ref-normalized-surname>GREUBER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>E</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref186">
            <xocs:ref-normalized-surname>WILLIAM</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>B</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref187">
            <xocs:ref-normalized-surname>GUO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref188">
            <xocs:ref-normalized-surname>ZHANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2007</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref189">
            <xocs:ref-normalized-surname>GUO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref190">
            <xocs:ref-normalized-surname>WANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2000</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref191">
            <xocs:ref-normalized-surname>KAMATH</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2007</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref192">
            <xocs:ref-normalized-surname>ROBINSON</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2000</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref193">
            <xocs:ref-normalized-surname>GOLUBOVSKAYA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>V</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref194">
            <xocs:ref-normalized-surname>TAI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref195">
            <xocs:ref-normalized-surname>HALDER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2007</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref196">
            <xocs:ref-normalized-surname>BEIERLE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>E</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref197">
            <xocs:ref-normalized-surname>GOLUBOVSKAYA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>V</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref198">
            <xocs:ref-normalized-surname>GOLUBOVSKAYA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>V</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref199">
            <xocs:ref-normalized-surname>SULZMAIER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>F</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref200">
            <xocs:ref-normalized-surname>LIU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref201">
            <xocs:ref-normalized-surname>WILLIAMS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref202">
            <xocs:ref-normalized-surname>MITRA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2006</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref203">
            <xocs:ref-normalized-surname>MUKHERJEE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref204">
            <xocs:ref-normalized-surname>CHEN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref205">
            <xocs:ref-normalized-surname>LEE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref206">
            <xocs:ref-normalized-surname>BOSE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref207">
            <xocs:ref-normalized-surname>SORDILLO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref208">
            <xocs:ref-normalized-surname>LEU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2003</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref209">
            <xocs:ref-normalized-surname>CONSTANTINESCU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref210">
            <xocs:ref-normalized-surname>THOMAS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref211">
            <xocs:ref-normalized-surname>SRIURANPONG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2003</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>V</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref212">
            <xocs:ref-normalized-surname>BUCHERT</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref213">
            <xocs:ref-normalized-surname>CHUANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref214">
            <xocs:ref-normalized-surname>KIM</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2003</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref215">
            <xocs:ref-normalized-surname>YANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref216">
            <xocs:ref-normalized-surname>BLASIUS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2006</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref217">
            <xocs:ref-normalized-surname>ALEXANDROW</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref218">
            <xocs:ref-normalized-surname>ZHAO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>W</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref219">
            <xocs:ref-normalized-surname>GUEST</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref220">
            <xocs:ref-normalized-surname>MANEK</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref221">
            <xocs:ref-normalized-surname>PATEL</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref222">
            <xocs:ref-normalized-surname>CHEN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref223">
            <xocs:ref-normalized-surname>GUARINO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref224">
            <xocs:ref-normalized-surname>WILSON</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref225">
            <xocs:ref-normalized-surname>NAGATHIHALLI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>N</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref226">
            <xocs:ref-normalized-surname>KE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref227">
            <xocs:ref-normalized-surname>VLAEMINCKGUILLEM</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>V</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref228">
            <xocs:ref-normalized-surname>LIU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref229">
            <xocs:ref-normalized-surname>SAINI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref230">
            <xocs:ref-normalized-surname>SHAKIBAEI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref231">
            <xocs:ref-normalized-surname>ZHANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref232">
            <xocs:ref-normalized-surname>NELSON</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref233">
            <xocs:ref-normalized-surname>RODRIGUES</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>F</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref234">
            <xocs:ref-normalized-surname>SALEHI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>B</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref235">
            <xocs:ref-normalized-surname>VYAS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>2047</xocs:ref-first-fp>
            <xocs:ref-last-lp>2069</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref236">
            <xocs:ref-normalized-surname>YIMIM</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>W</xocs:ref-normalized-initial>
            <xocs:ref-normalized-srctitle>INSILICOSTUDYCURCUMINANALOGSHER2KINASEINHIBITORS</xocs:ref-normalized-srctitle>
         </xocs:ref-info>
         <xocs:ref-info refid="sref237">
            <xocs:ref-normalized-surname>AHSAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref238">
            <xocs:ref-normalized-surname>ISHIDA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2002</xocs:ref-pub-year>
            <xocs:ref-first-fp>3481</xocs:ref-first-fp>
            <xocs:ref-last-lp>3487</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref239">
            <xocs:ref-normalized-surname>DUTTA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2005</xocs:ref-pub-year>
            <xocs:ref-first-fp>2738</xocs:ref-first-fp>
            <xocs:ref-last-lp>2744</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref240">
            <xocs:ref-normalized-surname>AGRAWAL</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>818</xocs:ref-first-fp>
            <xocs:ref-last-lp>860</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref241">
            <xocs:ref-normalized-surname>DAS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>6196</xocs:ref-first-fp>
            <xocs:ref-last-lp>6202</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref242">
            <xocs:ref-normalized-surname>AMOLINS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>360</xocs:ref-first-fp>
            <xocs:ref-last-lp>367</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref243">
            <xocs:ref-normalized-surname>SIMONI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-first-fp>845</xocs:ref-first-fp>
            <xocs:ref-last-lp>849</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref244">
            <xocs:ref-normalized-surname>ADAMS</xocs:ref-normalized-surname>
            <xocs:ref-normalized-initial>B</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref245">
            <xocs:ref-normalized-surname>LIN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref246">
            <xocs:ref-normalized-surname>YAMAKOSHI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref247">
            <xocs:ref-normalized-surname>MASUDA</xocs:ref-normalized-surname>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref248">
            <xocs:ref-normalized-surname>SIMON</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1998</xocs:ref-pub-year>
            <xocs:ref-first-fp>111</xocs:ref-first-fp>
            <xocs:ref-last-lp>116</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref249">
            <xocs:ref-normalized-surname>ALHUJAILY</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>97</xocs:ref-first-fp>
            <xocs:ref-last-lp>107</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>E</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref250">
            <xocs:ref-normalized-surname>LIANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>2623</xocs:ref-first-fp>
            <xocs:ref-last-lp>2631</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>G</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref251">
            <xocs:ref-normalized-surname>DETERS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-first-fp>1822</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref252">
            <xocs:ref-normalized-surname>CHEN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2006</xocs:ref-pub-year>
            <xocs:ref-first-fp>526</xocs:ref-first-fp>
            <xocs:ref-last-lp>535</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>W</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref253">
            <xocs:ref-normalized-surname>FENG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>11041</xocs:ref-first-fp>
            <xocs:ref-last-lp>11046</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref254">
            <xocs:ref-normalized-surname>LU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>840</xocs:ref-first-fp>
            <xocs:ref-last-lp>860</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref255">
            <xocs:ref-normalized-surname>LEE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>870</xocs:ref-first-fp>
            <xocs:ref-last-lp>878</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref256">
            <xocs:ref-normalized-surname>HATCHER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-first-fp>1631</xocs:ref-first-fp>
            <xocs:ref-last-lp>1652</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref257">
            <xocs:ref-normalized-surname>KATSORI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>863</xocs:ref-first-fp>
            <xocs:ref-last-lp>878</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref258">
            <xocs:ref-normalized-surname>SOMERSEDGAR</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>87</xocs:ref-first-fp>
            <xocs:ref-last-lp>97</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref259">
            <xocs:ref-normalized-surname>LIMTRAKUL</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2007</xocs:ref-pub-year>
            <xocs:ref-first-fp>85</xocs:ref-first-fp>
            <xocs:ref-last-lp>95</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref260">
            <xocs:ref-normalized-surname>CHANGTAM</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>941</xocs:ref-first-fp>
            <xocs:ref-last-lp>956</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref261">
            <xocs:ref-normalized-surname>AGGARWAL</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>185</xocs:ref-first-fp>
            <xocs:ref-last-lp>205</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>B</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref262">
            <xocs:ref-normalized-surname>PAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1999</xocs:ref-pub-year>
            <xocs:ref-first-fp>486</xocs:ref-first-fp>
            <xocs:ref-last-lp>494</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref263">
            <xocs:ref-normalized-surname>HOEHLE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2006</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref264">
            <xocs:ref-normalized-surname>SANDUR</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2007</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref265">
            <xocs:ref-normalized-surname>WANNINGER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>4986</xocs:ref-first-fp>
            <xocs:ref-last-lp>5002</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref266">
            <xocs:ref-normalized-surname>DEPTULA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref267">
            <xocs:ref-normalized-surname>MOHAMMADI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2005</xocs:ref-pub-year>
            <xocs:ref-first-fp>2217</xocs:ref-first-fp>
            <xocs:ref-last-lp>2225</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref268">
            <xocs:ref-normalized-surname>KRISHNANKUTTY</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2003</xocs:ref-pub-year>
            <xocs:ref-first-fp>343</xocs:ref-first-fp>
            <xocs:ref-last-lp>358</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref269">
            <xocs:ref-normalized-surname>JOHN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2006</xocs:ref-pub-year>
            <xocs:ref-first-fp>477</xocs:ref-first-fp>
            <xocs:ref-last-lp>482</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>V</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref270">
            <xocs:ref-normalized-surname>VERMA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2003</xocs:ref-pub-year>
            <xocs:ref-first-fp>104</xocs:ref-first-fp>
            <xocs:ref-last-lp>108</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref271">
            <xocs:ref-normalized-surname>ANNARAJ</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2005</xocs:ref-pub-year>
            <xocs:ref-first-fp>669</xocs:ref-first-fp>
            <xocs:ref-last-lp>676</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref272">
            <xocs:ref-normalized-surname>BARIK</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2005</xocs:ref-pub-year>
            <xocs:ref-first-fp>811</xocs:ref-first-fp>
            <xocs:ref-last-lp>822</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref273">
            <xocs:ref-normalized-surname>BARIK</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2007</xocs:ref-pub-year>
            <xocs:ref-first-fp>431</xocs:ref-first-fp>
            <xocs:ref-last-lp>439</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref274">
            <xocs:ref-normalized-surname>VAJRAGUPTA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2004</xocs:ref-pub-year>
            <xocs:ref-first-fp>303</xocs:ref-first-fp>
            <xocs:ref-last-lp>314</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>O</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref275">
            <xocs:ref-normalized-surname>OHIGASHI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2000</xocs:ref-pub-year>
            <xocs:ref-first-fp>C66</xocs:ref-first-fp>
            <xocs:ref-last-lp>C72</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref276">
            <xocs:ref-normalized-surname>PARVATHY</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref277">
            <xocs:ref-normalized-surname>ARAFA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref278">
            <xocs:ref-normalized-surname>MANJU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref279">
            <xocs:ref-normalized-surname>TANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref280">
            <xocs:ref-normalized-surname>HARISA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>G</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref281">
            <xocs:ref-normalized-surname>BOBO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref282">
            <xocs:ref-normalized-surname>MUKERJEE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref283">
            <xocs:ref-normalized-surname>WAGHELA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>B</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref284">
            <xocs:ref-normalized-surname>YALLAPU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref285">
            <xocs:ref-normalized-surname>ESMAILI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref286">
            <xocs:ref-normalized-surname>RUTTALA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref287">
            <xocs:ref-normalized-surname>GAWDE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref288">
            <xocs:ref-normalized-surname>KIM</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>B</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref289">
            <xocs:ref-normalized-surname>NAKSURIYA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>O</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref290">
            <xocs:ref-normalized-surname>YALLAPU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref291">
            <xocs:ref-normalized-surname>ANITHA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref292">
            <xocs:ref-normalized-surname>GAO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref293">
            <xocs:ref-normalized-surname>ZHANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>W</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref294">
            <xocs:ref-normalized-surname>CHEN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>W</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref295">
            <xocs:ref-normalized-surname>YALLAPU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref296">
            <xocs:ref-normalized-surname>KUNWAR</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref297">
            <xocs:ref-normalized-surname>MONTAZERI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref298">
            <xocs:ref-normalized-surname>XIAO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>Z</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref299">
            <xocs:ref-normalized-surname>THULASIDASAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref300">
            <xocs:ref-normalized-surname>ZHAI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>G</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref301">
            <xocs:ref-normalized-surname>MANJU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref302">
            <xocs:ref-normalized-surname>MANJU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref303">
            <xocs:ref-normalized-surname>MATHEW</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref304">
            <xocs:ref-normalized-surname>GANDAPU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>U</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref305"/></xocs:ref-info>
         <xocs:ref-info refid="sref306">
            <xocs:ref-normalized-surname>DUAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref307">
            <xocs:ref-normalized-surname>WANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref308">
            <xocs:ref-normalized-surname>GANTA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref309">
            <xocs:ref-normalized-surname>YALLAPU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
      </xocs:references>
      <xocs:refkeys>
         <xocs:refkey3>GOLONKOX2019X111512</xocs:refkey3>
         <xocs:refkey4ai>GOLONKOX2019X111512XA</xocs:refkey4ai>
      </xocs:refkeys>
      <xocs:open-access>
         <xocs:oa-article-status is-open-access="1" is-open-archive="0">Full</xocs:oa-article-status>
         <xocs:oa-access-effective-date>2020-01-24T11:41:07Z</xocs:oa-access-effective-date>
         <xocs:oa-sponsor>
            <xocs:oa-sponsor-type>FundingBody</xocs:oa-sponsor-type>
            <xocs:oa-sponsor-name>Poland Institutes</xocs:oa-sponsor-name>
         </xocs:oa-sponsor>
         <xocs:oa-user-license>http://creativecommons.org/licenses/by-nc-nd/4.0/</xocs:oa-user-license>
      </xocs:open-access>
      <xocs:open-research>
         <xocs:or-embargo-opening-date>2021-08-09T00:00:00.000Z</xocs:or-embargo-opening-date>
      </xocs:open-research>
      <xocs:self-archiving>
         <xocs:sa-start-date>2021-08-09T00:00:00.000Z</xocs:sa-start-date>
         <xocs:sa-user-license>http://creativecommons.org/licenses/by-nc-nd/4.0/</xocs:sa-user-license>
      </xocs:self-archiving>
      <xocs:copyright-info>
         <xocs:cp-license-lines>
            <xocs:cp-license-line lang="en">This is an open access article under the CC BY-NC-ND license.</xocs:cp-license-line>
         </xocs:cp-license-lines>
         <xocs:cp-notices>
            <xocs:cp-notice lang="en">© 2020 The Authors. Published by Elsevier Masson SAS.</xocs:cp-notice>
         </xocs:cp-notices>
      </xocs:copyright-info>
      <xocs:funding-list has-funding-info="1">
         <xocs:funding-addon-generated-timestamp>2020-01-24T11:38:00.674Z</xocs:funding-addon-generated-timestamp>
         <xocs:funding-addon-type>http://vtw.elsevier.com/data/voc/AddOnTypes/50.7/eoas</xocs:funding-addon-type>
         <xocs:funding>
            <xocs:funding-agency-acronym>BUT</xocs:funding-agency-acronym>
            <xocs:funding-agency>Politechnika Bialostocka</xocs:funding-agency>
            <xocs:funding-agency-id>http://data.elsevier.com/vocabulary/SciValFunders/501100005033</xocs:funding-agency-id>
            <xocs:funding-agency-country>http://sws.geonames.org/798544</xocs:funding-agency-country>
         </xocs:funding>
      </xocs:funding-list>
      <xocs:attachment-metadata-doc>
         <xocs:attachment-set-type>item</xocs:attachment-set-type>
         <xocs:pii-formatted>S0223-5234(19)30636-1</xocs:pii-formatted>
         <xocs:pii-unformatted>S0223523419306361</xocs:pii-unformatted>
         <xocs:eid>1-s2.0-S0223523419306361</xocs:eid>
         <xocs:doi>10.1016/j.ejmech.2019.07.015</xocs:doi>
         <xocs:cid>271932</xocs:cid>
         <xocs:timestamp>2020-02-01T17:06:02.794331Z</xocs:timestamp>
         <xocs:cover-date-start>2019-11-01</xocs:cover-date-start>
         <xocs:sponsored-access-type>UNLIMITED</xocs:sponsored-access-type>
         <xocs:funding-body-id>ICM</xocs:funding-body-id>
         <xocs:attachments>
            <xocs:web-pdf>
               <xocs:attachment-eid>1-s2.0-S0223523419306361-main.pdf</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523419306361/MAIN/application/pdf/dc9f28a02e154328ef727e04c8815a86/main.pdf</xocs:ucs-locator>
               <xocs:filename>main.pdf</xocs:filename>
               <xocs:extension>pdf</xocs:extension>
               <xocs:pdf-optimized>true</xocs:pdf-optimized>
               <xocs:filesize>2009708</xocs:filesize>
               <xocs:web-pdf-purpose>MAIN</xocs:web-pdf-purpose>
               <xocs:web-pdf-page-count>25</xocs:web-pdf-page-count>
               <xocs:web-pdf-images>
                  <xocs:web-pdf-image>
                     <xocs:attachment-eid>1-s2.0-S0223523419306361-main_1.png</xocs:attachment-eid>
                     <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523419306361/PREVIEW/image/png/a3f4803d67b19897a5f48332d709e44c/main_1.png</xocs:ucs-locator>
                     <xocs:filename>main_1.png</xocs:filename>
                     <xocs:extension>png</xocs:extension>
                     <xocs:filesize>46208</xocs:filesize>
                     <xocs:pixel-height>849</xocs:pixel-height>
                     <xocs:pixel-width>656</xocs:pixel-width>
                     <xocs:attachment-type>IMAGE-WEB-PDF</xocs:attachment-type>
                     <xocs:pdf-page-num>1</xocs:pdf-page-num>
                  </xocs:web-pdf-image>
               </xocs:web-pdf-images>
            </xocs:web-pdf>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419306361-gr6.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523419306361/gr6/DOWNSAMPLED/image/jpeg/4465c3e43496a8c580ece78c72cf4f86/gr6.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr6</xocs:file-basename>
               <xocs:filename>gr6.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>63666</xocs:filesize>
               <xocs:pixel-height>444</xocs:pixel-height>
               <xocs:pixel-width>624</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419306361-gr2.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523419306361/gr2/DOWNSAMPLED/image/jpeg/2c5a97aae28da7324c869ca722a62513/gr2.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr2</xocs:file-basename>
               <xocs:filename>gr2.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>27411</xocs:filesize>
               <xocs:pixel-height>196</xocs:pixel-height>
               <xocs:pixel-width>389</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419306361-gr1.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523419306361/gr1/DOWNSAMPLED/image/jpeg/fcb0a7868d8892978c6cfea5d9f41768/gr1.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr1</xocs:file-basename>
               <xocs:filename>gr1.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>53296</xocs:filesize>
               <xocs:pixel-height>460</xocs:pixel-height>
               <xocs:pixel-width>580</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419306361-fx1.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523419306361/fx1/DOWNSAMPLED/image/jpeg/eab6ea4fdf71c9cecd75da97cb7ef819/fx1.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx1</xocs:file-basename>
               <xocs:abstract-attachment>true</xocs:abstract-attachment>
               <xocs:filename>fx1.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>25320</xocs:filesize>
               <xocs:pixel-height>244</xocs:pixel-height>
               <xocs:pixel-width>215</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419306361-gr7.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523419306361/gr7/DOWNSAMPLED/image/jpeg/80bd6f570b71c93eb2934128991c35f5/gr7.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr7</xocs:file-basename>
               <xocs:filename>gr7.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>10337</xocs:filesize>
               <xocs:pixel-height>206</xocs:pixel-height>
               <xocs:pixel-width>314</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419306361-gr3.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523419306361/gr3/DOWNSAMPLED/image/jpeg/c753018c0c2ad1676cf2762923ac290f/gr3.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr3</xocs:file-basename>
               <xocs:filename>gr3.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>17528</xocs:filesize>
               <xocs:pixel-height>163</xocs:pixel-height>
               <xocs:pixel-width>536</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419306361-gr4.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523419306361/gr4/DOWNSAMPLED/image/jpeg/b80b050b861550ab182d9cb454d06a63/gr4.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr4</xocs:file-basename>
               <xocs:filename>gr4.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>34210</xocs:filesize>
               <xocs:pixel-height>422</xocs:pixel-height>
               <xocs:pixel-width>536</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419306361-gr8.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523419306361/gr8/DOWNSAMPLED/image/jpeg/c6bc5b8865edd6b7d1ca5729a15fda90/gr8.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr8</xocs:file-basename>
               <xocs:filename>gr8.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>4469</xocs:filesize>
               <xocs:pixel-height>93</xocs:pixel-height>
               <xocs:pixel-width>224</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419306361-gr5.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523419306361/gr5/DOWNSAMPLED/image/jpeg/cc44a4142d498672271967cc7755c89d/gr5.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr5</xocs:file-basename>
               <xocs:filename>gr5.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>95393</xocs:filesize>
               <xocs:pixel-height>425</xocs:pixel-height>
               <xocs:pixel-width>735</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419306361-gr6.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523419306361/gr6/THUMBNAIL/image/gif/4828ff764a9e3e21e51d22cd4a48d02e/gr6.sml</xocs:ucs-locator>
               <xocs:file-basename>gr6</xocs:file-basename>
               <xocs:filename>gr6.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>10059</xocs:filesize>
               <xocs:pixel-height>156</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419306361-gr2.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523419306361/gr2/THUMBNAIL/image/gif/88b7d41f810d117c64164c39b767e19d/gr2.sml</xocs:ucs-locator>
               <xocs:file-basename>gr2</xocs:file-basename>
               <xocs:filename>gr2.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>8076</xocs:filesize>
               <xocs:pixel-height>110</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419306361-gr1.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523419306361/gr1/THUMBNAIL/image/gif/18cd1fce25d852222f9b17591aa7d572/gr1.sml</xocs:ucs-locator>
               <xocs:file-basename>gr1</xocs:file-basename>
               <xocs:filename>gr1.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>7281</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>207</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419306361-fx1.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523419306361/fx1/THUMBNAIL/image/gif/2e6111df2839ea95c6acf4b9609c022a/fx1.sml</xocs:ucs-locator>
               <xocs:file-basename>fx1</xocs:file-basename>
               <xocs:abstract-attachment>true</xocs:abstract-attachment>
               <xocs:filename>fx1.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>9149</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>144</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419306361-gr7.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523419306361/gr7/THUMBNAIL/image/gif/203a7f513742752bfb983969b1a37650/gr7.sml</xocs:ucs-locator>
               <xocs:file-basename>gr7</xocs:file-basename>
               <xocs:filename>gr7.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>4284</xocs:filesize>
               <xocs:pixel-height>144</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419306361-gr3.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523419306361/gr3/THUMBNAIL/image/gif/151969a90bd0248d8ad276be1fafdf24/gr3.sml</xocs:ucs-locator>
               <xocs:file-basename>gr3</xocs:file-basename>
               <xocs:filename>gr3.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>3795</xocs:filesize>
               <xocs:pixel-height>67</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419306361-gr4.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523419306361/gr4/THUMBNAIL/image/gif/801d5f2514c238737325be164007f062/gr4.sml</xocs:ucs-locator>
               <xocs:file-basename>gr4</xocs:file-basename>
               <xocs:filename>gr4.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>5301</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>208</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419306361-gr8.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523419306361/gr8/THUMBNAIL/image/gif/ad86467038dd9317c65b63e0161526f4/gr8.sml</xocs:ucs-locator>
               <xocs:file-basename>gr8</xocs:file-basename>
               <xocs:filename>gr8.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>3229</xocs:filesize>
               <xocs:pixel-height>91</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419306361-gr5.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523419306361/gr5/THUMBNAIL/image/gif/909711468df33d658ee36ae032a656c8/gr5.sml</xocs:ucs-locator>
               <xocs:file-basename>gr5</xocs:file-basename>
               <xocs:filename>gr5.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>9952</xocs:filesize>
               <xocs:pixel-height>127</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419306361-gr6_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523419306361/gr6/HIGHRES/image/jpeg/ae29ff197d4b59958cf3e8322a4dc3bd/gr6_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr6</xocs:file-basename>
               <xocs:filename>gr6_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>548437</xocs:filesize>
               <xocs:pixel-height>1965</xocs:pixel-height>
               <xocs:pixel-width>2764</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419306361-gr2_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523419306361/gr2/HIGHRES/image/jpeg/a9ee34c0a0ad24530e413118a147eca9/gr2_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr2</xocs:file-basename>
               <xocs:filename>gr2_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>221592</xocs:filesize>
               <xocs:pixel-height>869</xocs:pixel-height>
               <xocs:pixel-width>1723</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419306361-gr1_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523419306361/gr1/HIGHRES/image/jpeg/d4308c245273b1aa2021ce4b71394ba9/gr1_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr1</xocs:file-basename>
               <xocs:filename>gr1_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>433111</xocs:filesize>
               <xocs:pixel-height>2036</xocs:pixel-height>
               <xocs:pixel-width>2567</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419306361-fx1_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523419306361/fx1/HIGHRES/image/jpeg/707b9934df85da4a6969c4e227bb130f/fx1_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx1</xocs:file-basename>
               <xocs:abstract-attachment>true</xocs:abstract-attachment>
               <xocs:filename>fx1_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>240563</xocs:filesize>
               <xocs:pixel-height>1085</xocs:pixel-height>
               <xocs:pixel-width>955</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419306361-gr7_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523419306361/gr7/HIGHRES/image/jpeg/d9771d4f670fe2c52e5e4dbfce906a4c/gr7_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr7</xocs:file-basename>
               <xocs:filename>gr7_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>88381</xocs:filesize>
               <xocs:pixel-height>911</xocs:pixel-height>
               <xocs:pixel-width>1390</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419306361-gr3_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523419306361/gr3/HIGHRES/image/jpeg/31d04fcb189d24554213cbc15edc991b/gr3_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr3</xocs:file-basename>
               <xocs:filename>gr3_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>142910</xocs:filesize>
               <xocs:pixel-height>723</xocs:pixel-height>
               <xocs:pixel-width>2376</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419306361-gr4_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523419306361/gr4/HIGHRES/image/jpeg/8c0acbd90f377ba7bb5a5ab5aa28bd10/gr4_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr4</xocs:file-basename>
               <xocs:filename>gr4_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>290731</xocs:filesize>
               <xocs:pixel-height>1869</xocs:pixel-height>
               <xocs:pixel-width>2376</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419306361-gr8_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523419306361/gr8/HIGHRES/image/jpeg/93094ca5a7057df12fe9a7195ed16f27/gr8_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr8</xocs:file-basename>
               <xocs:filename>gr8_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>35857</xocs:filesize>
               <xocs:pixel-height>411</xocs:pixel-height>
               <xocs:pixel-width>994</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419306361-gr5_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523419306361/gr5/HIGHRES/image/jpeg/fde89a163a3d9b8c842fea067a6354e9/gr5_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr5</xocs:file-basename>
               <xocs:filename>gr5_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>739368</xocs:filesize>
               <xocs:pixel-height>1883</xocs:pixel-height>
               <xocs:pixel-width>3256</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
         </xocs:attachments>
      </xocs:attachment-metadata-doc>
   </xocs:meta><xocs:serial-item xmlns:xoe="http://www.elsevier.com/xml/xoe/dtd">
      <article xmlns="http://www.elsevier.com/xml/ja/dtd" docsubtype="rev" version="5.6" xml:lang="en">
         <item-info>
            <jid>EJMECH</jid>
            <aid>11512</aid>
            <ce:article-number>111512</ce:article-number>
            <ce:pii>S0223-5234(19)30636-1</ce:pii>
            <ce:doi>10.1016/j.ejmech.2019.07.015</ce:doi>
            <ce:copyright type="other" year="2020">The Authors</ce:copyright>
         </item-info>
         <ce:floats>
            <ce:figure id="fig1">
               <ce:label>Fig. 1</ce:label>
               <ce:caption id="cap0010">
                  <ce:simple-para id="fspara0010" view="all">Signal transduction pathways and biological processes mediated by receptor tyrosine kinases focused on angiogenesis Based on [<ce:cross-ref refid="bib26" id="crosref1715">26</ce:cross-ref>].</ce:simple-para>
                  <ce:simple-para id="fspara0050" view="all">a A selection of pathways activated by receptor tyrosine kinase involved in angiogenesis is shown. Pathway activation, for example by VEGFR or PDGFR, can result in a variety of angiogenic processes, such as cell proliferation, migration, survival, and vascular permeability. b The phosphatidylinositol 3′-kinase (PI3K) pathway is an important downstream pathway of diverse receptor tyrosine kinases and is involved in various cellular processes in angiogenesis. Akt/protein kinase B (PKB) is activated downstream of PI3K. BAD Bcl-2-associated death promoter; eNOS endothelial nitric oxide synthase; FAK focal adhesion kinase; Grb2 growth factor receptor-bound protein 2; GSK3 glycogen synthase kinase 3; MAPK mitogen-activated protein kinase; MEK MAPK and extracellular-signal-regulated kinase (ERK) kinase; mTOR mammalian target of rapamycin; NFκβ nuclear factor-κB; PIP3 phosphatidylinositol 3,4,5-triphosphate; PKC protein kinase C; PLCγ phospholipase C-γ; p70S6K p70S6 kinase; Shb SH2 and β-cells; TSAd T-cell specific adaptor.</ce:simple-para>
               </ce:caption>
               <ce:alt-text role="short" id="alttext0015">Fig. 1</ce:alt-text>
               <ce:link locator="gr1" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:href="pii:S0223523419306361/gr1"/></ce:link>
            </ce:figure>
            <ce:figure id="fig2">
               <ce:label>Fig. 2</ce:label>
               <ce:caption id="cap0015">
                  <ce:simple-para id="fspara0015" view="all">Fundamental pathways of tyrosine kinases involved in tumor progression.</ce:simple-para>
                  <ce:simple-para id="fspara0055" view="all">The processes of formation, progression, proliferation and metastasis of tumors reflect changes in signaling pathways that are altered as a result of mutation or their consequence. Many proteins, including tyrosine kinases, involved in these signaling pathways are potential targets for anti-cancer therapy. <ce:italic>Based on</ce:italic> [<ce:cross-ref refid="bib32" id="crosref0180">32</ce:cross-ref>]</ce:simple-para>
               </ce:caption>
               <ce:alt-text role="short" id="alttext0020">Fig. 2</ce:alt-text>
               <ce:link locator="gr2" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:href="pii:S0223523419306361/gr2"/></ce:link>
            </ce:figure>
            <ce:figure id="fig3">
               <ce:label>Fig. 3</ce:label>
               <ce:caption id="cap0020">
                  <ce:simple-para id="fspara0020" view="all">Analysis of the chemical structure of curcumin responsible for its biological properties. Based on [<ce:cross-ref refid="bib61" id="crosref1720">61</ce:cross-ref>].</ce:simple-para>
               </ce:caption>
               <ce:alt-text role="short" id="alttext0025">Fig. 3</ce:alt-text>
               <ce:link locator="gr3" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:href="pii:S0223523419306361/gr3"/></ce:link>
            </ce:figure>
            <ce:figure id="fig4">
               <ce:label>Fig. 4</ce:label>
               <ce:caption id="cap0025">
                  <ce:simple-para id="fspara0025" view="all">Chemical structure of curcuminoids. Based on [<ce:cross-ref refid="bib98" id="crosref1725">98</ce:cross-ref>].</ce:simple-para>
               </ce:caption>
               <ce:alt-text role="short" id="alttext0030">Fig. 4</ce:alt-text>
               <ce:link locator="gr4" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:href="pii:S0223523419306361/gr4"/></ce:link>
            </ce:figure>
            <ce:figure id="fig5">
               <ce:label>Fig. 5</ce:label>
               <ce:caption id="cap0030">
                  <ce:simple-para id="fspara0030" view="all">Oncogenic signaling targets many levels curcumin.</ce:simple-para>
                  <ce:simple-para id="fspara0060" view="all">Mechanism of curcumin action in cancer cells. Curcumin enhances apoptotic death, inhibits deregulated cellular proliferation, dedifferentiation and progression towards the neoplastic phenotype by altering key signaling molecules required for cell cycle progression.<ce:displayed-quote id="disp0010">
                        <ce:simple-para id="dspara0010" view="all">
                           <ce:italic>[EGFR: Epidermal growth factor receptor, JAK: Janus kinase, STAT: Signal transducer and activator of transcription protein family, Src: Proto-oncogene tyrosine-protein kinase, AKT: Serine/threonine-specific protein kinase, Ras: Ras family kinases, Rac:Subfamily of the Rho family of GTPases, p38 mitogen-activated protein kinases, PI3K: Phosphatidylinositol-4,5-bisphosphate 3-kinase, IκB: Inhibitor of κB, COX-2: Cyclooxygenase-2, GSK3β: Glycogen synthase kinase-3 beta, PPAR: Peroxisome proliferator-activated receptor, CDX-2: member of the caudal-related homeobox transcription factor family, NOTCH1: Neurogenic locus notch homolog protein 1, Bax: BCL2 associated X, apoptosis regulator, MEKK: MAP kinase kinase kinase, Ptch: Protein patched homolog, Shh: sonic hedgehog homolog ]</ce:italic> Based on [<ce:cross-ref refid="bib48" id="crosref0670">48</ce:cross-ref>,<ce:cross-ref refid="bib126" id="crosref0675">126</ce:cross-ref>,<ce:cross-ref refid="bib127" id="crosref0680">127</ce:cross-ref>].</ce:simple-para>
                     </ce:displayed-quote>
                  </ce:simple-para>
               </ce:caption>
               <ce:alt-text role="short" id="alttext0035">Fig. 5</ce:alt-text>
               <ce:link locator="gr5" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:href="pii:S0223523419306361/gr5"/></ce:link>
            </ce:figure>
            <ce:figure id="fig6">
               <ce:label>Fig. 6</ce:label>
               <ce:caption id="cap0035">
                  <ce:simple-para id="fspara0035" view="all">Kanonical Src signaling. Based on [<ce:cross-ref refid="bib231" id="crosref1730">231</ce:cross-ref>].</ce:simple-para>
                  <ce:simple-para id="fspara0065" view="all">Src is activated by many RTKs and other membrane receptors, e.g. integrins and EpoR (erythropoietin receptor). Activation of Src causes, among others, Act activation and enhancement of cell proliferation, activation of the Stat3 pathway responsible for the regulation of transcription factors involved in metastasis and angiogenesis (VEGF, MMPs, IL-8).</ce:simple-para>
               </ce:caption>
               <ce:alt-text role="short" id="alttext0040">Fig. 6</ce:alt-text>
               <ce:link locator="gr6" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:href="pii:S0223523419306361/gr6"/></ce:link>
            </ce:figure>
            <ce:figure id="fig7">
               <ce:label>Fig. 7</ce:label>
               <ce:caption id="cap0040">
                  <ce:simple-para id="fspara0040" view="all">Pyrazole ring curcuminoids are TRK inhibitors [<ce:cross-ref refid="bib77" id="crosref1735">77</ce:cross-ref>,<ce:cross-ref refid="bib237" id="crosref1740">237</ce:cross-ref>].</ce:simple-para>
               </ce:caption>
               <ce:alt-text role="short" id="alttext0045">Fig. 7</ce:alt-text>
               <ce:link locator="gr7" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:href="pii:S0223523419306361/gr7"/></ce:link>
            </ce:figure>
            <ce:figure id="fig8">
               <ce:label>Fig. 8</ce:label>
               <ce:caption id="cap0045">
                  <ce:simple-para id="fspara0045" view="all">Cyclocurcumin.</ce:simple-para>
               </ce:caption>
               <ce:alt-text role="short" id="alttext0050">Fig. 8</ce:alt-text>
               <ce:link locator="gr8" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:href="pii:S0223523419306361/gr8"/></ce:link>
            </ce:figure>
            <ce:table xmlns="http://www.elsevier.com/xml/common/cals/dtd" id="tbl1" frame="topbot" colsep="0" rowsep="0">
               <ce:label>Table 1</ce:label>
               <ce:caption id="cap0050">
                  <ce:simple-para id="tspara0010" view="all">Classification and characteristics of the human RTKs.</ce:simple-para>
               </ce:caption>
               <ce:alt-text role="short" id="alttext0055">Table 1</ce:alt-text>
               <tgroup cols="4">
                  <colspec colnum="1" colname="col1"/></colspec>
                  <colspec colnum="2" colname="col2"/></colspec>
                  <colspec colnum="3" colname="col3"/></colspec>
                  <colspec colnum="4" colname="col4"/></colspec>
                  <thead>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Class</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Family name</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Members</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Molecular characteristics of the extracellular domains</entry>
                     </row>
                  </thead>
                  <tbody>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">I</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">EGFR</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">EGFR, ERBB2, ERBB3, ERBB4</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2 cysteine-rich domains</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">II</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Insulin R</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">INSR IGFR</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2 chains α and β, with one cysteine-rich and 2 FNIII domains</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">III</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">PDGFR</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">PDGFRα, PDGFRβ, M-CSFR, KIT, FLT3L</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">5 Ig-like domains</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">IV</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">VEGFR</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">VEGFR1, VEGFR2, VEGFR3</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">7 Ig-like domains</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">V</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">FGFR</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">FGFR1, FGFR2, FGFR3, FGFR4</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">3 Ig-like domains, 1 acidic box</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">VI</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">CCK</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">CCK4</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">7 Ig-like domains</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">VII</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NGFR</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">TRKA, TRKB, TRKC</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2 Ig-like domains, rich leucin domains</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">VIII</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">HGFR</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">MET, RON</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1 transmenbrane α chain linked with one extracellular β chain</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">IX</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">EPHR</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">EPHA1 to 6, EPHB1 to 6</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1 Ig-like, 1 cysteine-rich and 2 FNIII-like domains</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">X</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">AXL</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">AXL, MER, TYRO3</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2 Ig-line, 2 FNIII-like domains</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">XI</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">TIE</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">TIE, TEK</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2 Ig-like, 1 EGF, and 3 FNIII-like domains</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">XII</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">RYK</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">RYK</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1 transmenbrane β chain linked with one extracellular α chain</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">XIII</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">DDR</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">DDR1, DDR2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1 discoidin-like domain</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">XIV</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">RET</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">RET</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1 cadherin-like domain</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">XV</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">ROS</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">ROS</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">6 FNIII-like domains</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">XVI</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">LTK</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">LTK, ALK</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1 cysteine-rich domain</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">XVII</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">ROR</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">ROR1, ROR2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1 Ig-domain, 1 cysteine-rich domain and one kringle-like domains</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">XVIII</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">MUSK</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">MUSK</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">4 Ig-like and 1 cysteine-rich domains</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">XIX</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">LMR</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">AATYK1, AATYK2, AATYK3</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">A short extracellular domain</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">XX</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Undetermined</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">RTK106</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">A short receptor chain with a short extracellular domain</entry>
                     </row>
                  </tbody>
               </tgroup>
               <ce:legend>
                  <ce:simple-para id="tspara0015" view="all">EGFR: epidermal growth factor receptor; InsR: insulin receptor; PDGFR: platelet-derived growth factor receptor; VEGFR: vascular endothelial growth factor receptor; FGFR: fibroblast growth factor receptor; CCK: colon carcinoma kinase; NGFR, nerve growth factor receptor; HGFR: hepatocyte growth factor receptor; EphR: ephrin receptor; Axl: from the Greek word anex-elekto, or uncontrolled, a Tyro3 protein tyrosine kinase; TIE: tyrosine kinase receptor in endothelial cells; RYK: receptor related to tyrosine kinases; DDR: discoidin domain receptor; Ret: rearranged during transfection; ROS: RPTK expressed in some epithelial cell types; LTK: leukocyte tyrosine kinase; ROR: receptor orphan; MuSK: muscle-specific kinase; LMR: Lemur; Ig: immunoglobulin; FN: fibronectin. Adopted from [<ce:cross-ref refid="bib42" id="crosref1745">42</ce:cross-ref>]: [This is an open access article under the CC BY-NC-ND license].</ce:simple-para>
               </ce:legend>
            </ce:table>
            <ce:table xmlns="http://www.elsevier.com/xml/common/cals/dtd" id="tbl2" frame="topbot" colsep="0" rowsep="0">
               <ce:label>Table 2</ce:label>
               <ce:caption id="cap0055">
                  <ce:simple-para id="tspara0020" view="all">Bioavailability of curcumin in humans following oral administration.</ce:simple-para>
               </ce:caption>
               <ce:alt-text role="short" id="alttext0060">Table 2</ce:alt-text>
               <tgroup cols="10">
                  <colspec colnum="1" colname="col1"/></colspec>
                  <colspec colnum="2" colname="col2"/></colspec>
                  <colspec colnum="3" colname="col3"/></colspec>
                  <colspec colnum="4" colname="col4"/></colspec>
                  <colspec colnum="5" colname="col5"/></colspec>
                  <colspec colnum="6" colname="col6"/></colspec>
                  <colspec colnum="7" colname="col7"/></colspec>
                  <colspec colnum="8" colname="col8"/></colspec>
                  <colspec colnum="9" colname="col9"/></colspec>
                  <colspec colnum="10" colname="col10"/></colspec>
                  <thead>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Source</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Maximum dose (mg/d)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="colgroup" namest="col3" nameend="col4">C<inf loc="post">max</inf> plasma/serum (T<inf loc="post">max</inf>)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="colgroup" namest="col5" nameend="col6">Urinary/fecal excertion</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="colgroup" namest="col7" nameend="col8">Tissue levels (nmol/g)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="colgroup" namest="col9" nameend="col10">Metabolites</entry>
                     </row>
                  </thead>
                  <tbody>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Curcumin</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">800 (3 months)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.77 μmol/L1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">60–120 min</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Urine</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">ND</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" namest="col7" nameend="col8"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="1" align="left">Curcumin extract (8,2% curcumin)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="1" align="left">2200 (up to 4 months)<br/></br>(=180 mg/d curcumin)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="1" namest="col3" nameend="col4" align="left">ND</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Urine</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">ND</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" namest="col7" nameend="col8"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Plasma/urine</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">ND</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Faeces (dried)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">64–1054 nmol/g</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" namest="col7" nameend="col8"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Faeces</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">CS detected in one case</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="1" align="left">Curcumin</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="1" align="left">3600 (7 days)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="1" namest="col3" nameend="col4" align="left">low nM (systemic/portal)<br/></br>(Sampled 60 min post-dose)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="1"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="1"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Liver</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">ND</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Blood</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">CS/CG (low nM)</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Bile</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">ND</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Liver</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Hexahydrocurcumin & hexahydrocurcuminol (trace)</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="2" align="left">Curcuminoid capsules (90% curcumin)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="2" align="left">3600 curcumin (up to 4 months)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="2" align="left">11.1 nM</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="2" align="left">(60 min)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="1" align="left">Urine</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="1" align="left">1.3 μM</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="2" namest="col7" nameend="col8"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Plasma</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">CS (8.9 nM); CG (15.8 nM)</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Urine</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">CS (45 nM); CG (510 nM)</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Faeces (dried)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">25–116 nmol/g</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Faeces</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">CS (trace)</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="1" align="left">Curcuminoid capsules (90% curcumin)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="1" align="left">3600 curcumin (up to 4 months)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="1" align="left"><3 nM (Sampled 60 min post-dose)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="1"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="1"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="1"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Colorectal mucosa</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">7.7</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Plasma</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">ND</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">CR cancer</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">12.7</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Colon</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">CS/CG detected</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Curcumin extract (75% curcumin)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">12,000 (one dose)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">150 nM<cross-ref refid="tbl2fna" id="crosref1750">
                              <sup loc="post">a</sup>
                           </cross-ref>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">(60 min)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" namest="col5" nameend="col6"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" namest="col7" nameend="col8"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" namest="col9" nameend="col10"/></entry>
                     </row>
                  </tbody>
               </tgroup>
               <ce:legend>
                  <ce:simple-para id="tspara0025" view="all">
                     <ce:sup loc="post">1</ce:sup>Serum level declined within 12 h; figures given are maximum levels achieved unless otherwise indicated.</ce:simple-para>
               </ce:legend>
               <ce:table-footnote id="tbl2fna">
                  <ce:label>a</ce:label>
                  <ce:note-para id="ntpara0010" view="all">Curcumin detectable in only one of three patients receiving this dose, no curcumin detectable at doses <8000 mg/day. ND, not detected; CS, curcumin sulphate; CG, curcumin glucuronide. Source [<ce:cross-ref refid="bib139" id="crosref1755">139</ce:cross-ref>].</ce:note-para>
               </ce:table-footnote>
            </ce:table>
            <ce:table xmlns="http://www.elsevier.com/xml/common/cals/dtd" id="tbl3" frame="topbot" colsep="0" rowsep="0">
               <ce:label>Table 3</ce:label>
               <ce:caption id="cap0060">
                  <ce:simple-para id="tspara0030" view="all">Summary of clinical trials with curcumin in various cancers. The table has been adapted from Ref. [<ce:cross-ref refid="bib51" id="crosref1760">51</ce:cross-ref>], (CC BY 4.0).</ce:simple-para>
               </ce:caption>
               <ce:alt-text role="short" id="alttext0065">Table 3</ce:alt-text>
               <tgroup cols="6">
                  <colspec colnum="1" colname="col1"/></colspec>
                  <colspec colnum="2" colname="col2"/></colspec>
                  <colspec colnum="3" colname="col3"/></colspec>
                  <colspec colnum="4" colname="col4"/></colspec>
                  <colspec colnum="5" colname="col5"/></colspec>
                  <colspec colnum="6" colname="col6"/></colspec>
                  <thead>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Serial</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Study</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Number of Patients</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Health Condition</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Dose</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Outcome</entry>
                     </row>
                  </thead>
                  <tbody>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Double blind crossover</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">62</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Cancer lesions</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Topical ointment</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Symptomatic relief to patients</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Pilot study</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">16</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Lung cancer</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1500 mg/day; 30 days (turmeric)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Urinary excretion of mutagens was decreased in smokers</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">3</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Pilot study</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">58</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Cancer lesions</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">3600 mg/day; 3 months (turmeric)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Micronuclei number in mucosal cells and circulating lymphocytes decreased</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">4</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Prospective Phase I trial</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">25</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Cancer lesions</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">8000 mg/day; 3 months</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Histologic improvement of precancerous lesions</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">5</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Prospective Phase I trial</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">15</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Colorectal cancer</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">36–180 mg; 4 months</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Decrease in glutathione S-transferase activity</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">6</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Phase I trial</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">12</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Hepatic metastases from colorectal cancer</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">450–3600 mg/day; 1 week</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Low bioavailability of oral dose such that the dose of curcumin required to exert its pharmacological activity at hepatic level is not feasible in humans</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">7</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Phase I trial</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">15</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Colorectal cancer</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">450–3600 mg/day; 4 months oral dose</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">PGE2 production reduced</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">8</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Phase I trial</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">12</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Colorectal cancer</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">450–3600 mg/day; 7 days</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">M1G levels decreased</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">9</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Pilot study</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">5</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Colorectal cancer (Familial adenomatous polyposis)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1440 mg/day; 6 months, combined with quercetin</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">The number and size of polyps reduced without any significant toxicity</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">10</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Prospective Phase I trial</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">24</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Healthy volunteers</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">500–1200 mg; single oral dose</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Overall well tolerated but 30% subjects had minor adverse events</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">11</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Randomized, placebo controlled, double blind</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">100</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Cancer lesions in oral lichen planus</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2000 mg/day; 7 weeks, combined with prednisone</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Not efficacious but well tolerated</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">12</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Phase I/II trial</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">29</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Multiple myeloma</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2000–12,000 mg/day; 12 weeks combined with Bioperine</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Well tolerated, improved bioavailability and decrease in NFκβ, COX2 and STAT3</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">13</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Phase II trial</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">25</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Advanced pancreatic cancer</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">8000 mg/day; 2 months</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Well tolerated but absorption was limited and was effective only in some patients</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">14</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Single blind, cross over</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">26</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Multiple myeloma</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">4000 g m/day; 6 months</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Urinary <italic>N</italic>-telopeptide of type I collagen and paraprotein levels reduced</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">15</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Phase I, open-label, dose escalation trial</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">14</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Advanced and metastatic breast cancer</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">6000 mg/day; 7 days, every 3 weeks, combined with docetaxel</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Well tolerated and efficacious</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">16</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Open-label, phase II trial</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">17</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Advanced pancreatic cancer</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">8000 mg/day; 4 weeks; combined with gemcitabine</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Modest efficacy, therapy not a feasible</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">17</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Randomized, double blind, controlled</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">85</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Prostate cancer</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">100 mg/day; 6 months, combined with soy isoflavones</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Serum PSA content decreased</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">18</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Pilot study</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">75</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Pre-cancerous lesions</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1000 mg/day; 7 days</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">MDA and 8-OHdG levels increased in saliva and serum while Vitamin C and E levels reduced</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">19</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Phase IIa trial</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">44</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Colorectal cancer</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2000–4000 mg/day; 1 month</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Aberrant Crypt Foci formation reduced only in smokers</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">20</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Pilot study</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">126</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Colorectal cancer</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1080 mg/day; 10–30 days</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Increased p53 expression, decrease in serum TNF-α and improved body weight</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">21</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Phase I/II</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">21</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Gemcitabine-resistant pancreatic cancer</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">8000 mg/day</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Well tolerated</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">22</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Pilot study</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">39</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Head and neck cancer</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2 curcumin tablets</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">IKKβ kinase activity decreased which correlated with IL-8 decrease in saliva</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">23</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Randomized, double blind, placebo controlled</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">20</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Cancer lesions in oral lichen planus</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">6000 mg/day; 14 days</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Clinical symptoms reduced with no adverse effects</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">24</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Randomized, double blind, placebo controlled, cross over followed by open label study</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">36</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Multiple myeloma</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">4000 mg/day; 3 months followed by 8000 mg/day; 3 months</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Slowed down disease progression</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">25</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Randomized, open label</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">50</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Chronic myeloid leukemia</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">15,000 mg/day; 6 weeks in combination with imatinib</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Enhanced decrease in nitric oxide levels</entry>
                     </row>
                  </tbody>
               </tgroup>
            </ce:table>
            <ce:table xmlns="http://www.elsevier.com/xml/common/cals/dtd" id="tbl4" frame="topbot" colsep="0" rowsep="0">
               <ce:label>Table 4</ce:label>
               <ce:caption id="cap0065">
                  <ce:simple-para id="tspara0035" view="all">Classification of the human non receptor tyrosine kinases. Source: [<ce:cross-ref refid="bib192" id="crosref1765">192</ce:cross-ref>].</ce:simple-para>
               </ce:caption>
               <ce:alt-text role="short" id="alttext0070">Table 4</ce:alt-text>
               <tgroup cols="3">
                  <colspec colnum="1" colname="col1"/></colspec>
                  <colspec colnum="2" colname="col2"/></colspec>
                  <colspec colnum="3" colname="col3"/></colspec>
                  <thead>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">No</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Family name</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Members</entry>
                     </row>
                  </thead>
                  <tbody>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">ABL</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">ABL1, ABL2 (ARG)</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">ACK</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">TNK1, TNK2 (ACK1)</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">3</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">CSK</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">CSK, MATK</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">4</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">FAK</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">PTK2 (FAK), PTK2B (PYK2)</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">5</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">FES</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">FER, FES</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">6</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">FRK</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">FRK, PTK6 (BRK), SRMS</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">7</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">JAK</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">JAK1, JAK2, JAK3, TYK2</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">8</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">SRC-A</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">FGR, FYN, SRC, YES1</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">9</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">SRC-B</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">BLK, HCK, LCK, LYN</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">10</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">TEC</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">BTK, ITK, TEC, TXK</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">11</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">SYK</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">SYK, ZAP70</entry>
                     </row>
                  </tbody>
               </tgroup>
            </ce:table>
         </ce:floats>
         <head>
            <ce:dochead id="dhead0010">
               <ce:textfn>Review article</ce:textfn>
            </ce:dochead>
            <ce:title id="title0010">Curcumin as tyrosine kinase inhibitor in cancer treatment</ce:title>
            <ce:author-group id="augrp0010">
               <ce:author id="au1" orcid="0000-0002-8387-7961" author-id="S0223523419306361-13d9ab901f435e6d14f21e0a554c211a">
                  <ce:given-name>A.</ce:given-name>
                  <ce:surname>Golonko</ce:surname>
                  <ce:cross-ref refid="aff1" id="crosref0010">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
                  
               </ce:author>
               <ce:author id="au2" author-id="S0223523419306361-778b1c8997bb2917e5feb6a706016571">
                  <ce:given-name>H.</ce:given-name>
                  <ce:surname>Lewandowska</ce:surname>
                  <ce:cross-ref refid="aff2" id="crosref0015">
                     <ce:sup loc="post">b</ce:sup>
                  </ce:cross-ref>
                  
               </ce:author>
               <ce:author id="au3" orcid="0000-0001-7034-9126" author-id="S0223523419306361-909ed817bcdbd5305a873504b87850ef">
                  <ce:given-name>R.</ce:given-name>
                  <ce:surname>Świsłocka</ce:surname>
                  <ce:cross-ref refid="aff3" id="crosref0020">
                     <ce:sup loc="post">c</ce:sup>
                  </ce:cross-ref>
                  
               </ce:author>
               <ce:author id="au4" author-id="S0223523419306361-59e79475cfb06e40289a0b3efccd1d1a">
                  <ce:given-name>U.T.</ce:given-name>
                  <ce:surname>Jasińska</ce:surname>
                  <ce:cross-ref refid="aff1" id="crosref0025">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
                  
               </ce:author>
               <ce:author id="au5" author-id="S0223523419306361-97ad74ea8916015ee1daa83ebbf1c46b">
                  <ce:given-name>W.</ce:given-name>
                  <ce:surname>Priebe</ce:surname>
                  <ce:cross-ref refid="aff4" id="crosref0030">
                     <ce:sup loc="post">d</ce:sup>
                  </ce:cross-ref>
                  
               </ce:author>
               <ce:author id="au6" orcid="0000-0002-5427-9815" author-id="S0223523419306361-6b6800a09ad8ddaa50efd9860d544bde">
                  <ce:given-name>W.</ce:given-name>
                  <ce:surname>Lewandowski</ce:surname>
                  <ce:cross-ref refid="aff1" id="crosref0035">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref refid="cor1" id="crosref0040">
                     <ce:sup loc="post">∗</ce:sup>
                  </ce:cross-ref>
                  
               </ce:author>
               <ce:affiliation id="aff1" affiliation-id="S0223523419306361-d7c9dd3bb1f2172cfd523aa891211a75">
                  <ce:label>a</ce:label>
                  <ce:textfn>Institute of Agricultural and Food Biotechnology, Rakowiecka 36, 02-532, Warsaw, Poland</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>Institute of Agricultural and Food Biotechnology</sa:organization>
                     <sa:address-line>Rakowiecka 36</sa:address-line>
                     <sa:city>Warsaw</sa:city>
                     <sa:postal-code>02-532</sa:postal-code>
                     <sa:country>Poland</sa:country>
                  </sa:affiliation>
                  <ce:source-text id="srct0010">Institute of Agricultural and Food Biotechnology, Rakowiecka 36, 02-532 Warsaw, Poland</ce:source-text>
               </ce:affiliation>
               <ce:affiliation id="aff2" affiliation-id="S0223523419306361-1562fda22fd6928f353ff464d31b87e8">
                  <ce:label>b</ce:label>
                  <ce:textfn>Institute of Nuclear Chemistry and Technology, Centre for Radiobiology and Biological Dosimetry, Dorodna 16, 03-195, Warsaw, Poland</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>Institute of Nuclear Chemistry and Technology</sa:organization>
                     <sa:organization>Centre for Radiobiology and Biological Dosimetry</sa:organization>
                     <sa:address-line>Dorodna 16</sa:address-line>
                     <sa:city>Warsaw</sa:city>
                     <sa:postal-code>03-195</sa:postal-code>
                     <sa:country>Poland</sa:country>
                  </sa:affiliation>
                  <ce:source-text id="srct0015">Institute of Nuclear Chemistry and Technology, Centre for Radiobiology and Biological Dosimetry, Dorodna 16, 03-195 Warsaw, Poland</ce:source-text>
               </ce:affiliation>
               <ce:affiliation id="aff3" affiliation-id="S0223523419306361-3816b7282b8ff9b81d3bf4c1716e47b0">
                  <ce:label>c</ce:label>
                  <ce:textfn>Bialystok University of Technology, Faculty of Civil Engineering and Environmental Engineering, Department of Chemistry, Biology and Biotechnology, Wiejska 45E, 15-351, Bialystok, Poland</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>Bialystok University of Technology</sa:organization>
                     <sa:organization>Faculty of Civil Engineering and Environmental Engineering</sa:organization>
                     <sa:organization>Department of Chemistry</sa:organization>
                     <sa:organization>Biology and Biotechnology</sa:organization>
                     <sa:address-line>Wiejska 45E</sa:address-line>
                     <sa:city>Bialystok</sa:city>
                     <sa:postal-code>15-351</sa:postal-code>
                     <sa:country>Poland</sa:country>
                  </sa:affiliation>
                  <ce:source-text id="srct0020">Bialystok University of Technology, Faculty of Civil Engineering and Environmental Engineering, Department of Chemistry, Biology and Biotechnology, Wiejska 45E, 15-351, Bialystok, Poland</ce:source-text>
               </ce:affiliation>
               <ce:affiliation id="aff4" affiliation-id="S0223523419306361-47f6872aef1daac8fd8aab290b0fa28d">
                  <ce:label>d</ce:label>
                  <ce:textfn>Department of Experimental Therapeutics, University of Texas MD, Anderson Cancer Center, Houston, TX, USA</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>Department of Experimental Therapeutics</sa:organization>
                     <sa:organization>University of Texas MD</sa:organization>
                     <sa:organization>Anderson Cancer Center</sa:organization>
                     <sa:city>Houston</sa:city>
                     <sa:state>TX</sa:state>
                     <sa:country>USA</sa:country>
                  </sa:affiliation>
                  <ce:source-text id="srct0025">Department of Experimental Therapeutics, University of Texas MD, Anderson Cancer Center, Houston, TX, USA</ce:source-text>
               </ce:affiliation>
               <ce:correspondence id="cor1">
                  <ce:label>∗</ce:label>
                  <ce:text>Corresponding author.</ce:text>
               </ce:correspondence>
            </ce:author-group>
            <ce:date-received day="6" month="5" year="2019"/></ce:date-received>
            <ce:date-revised day="3" month="7" year="2019"/></ce:date-revised>
            <ce:date-accepted day="4" month="7" year="2019"/></ce:date-accepted>
            <ce:abstract xml:lang="en" id="abs0010" view="all" class="author"><ce:abstract-sec id="abssec0010" view="all">
                  <ce:simple-para id="abspara0010" view="all">Curcumin is a natural substance known for ages, exhibiting a multidirectional effect in cancer prevention and adjuvant cancer therapies. The great advantage of using nutraceuticals of vegetable origin in comparison to popular cytostatic drugs is the minimized side effect and reduced toxicity. The targets in oncological therapy are, among others, tyrosine kinases, important mediators of signaling pathways whose impaired expression is observed in many types of cancer. Unfortunately, the hydrophobic nature of the curcumin molecule often limits its bioavailability, which is why many studies focus on the chemical modification of this compound. Current research is aimed at modifying structures that improve the pharmacokinetic parameters of curcumin, e.g. the formation of nanoparticles, complexes with metals or the synthesis of curcumin derivatives with functional substituents that allow tumor targeting. The article is a review and analysis of current literature on the properties of curcumin and its derivatives in the treatment of cancers directed to signaling pathways of tyrosine kinases and confronts the problem of low assimilation of curcumin with potential therapeutic effects.</ce:simple-para>
               </ce:abstract-sec></ce:abstract>
            <ce:abstract class="graphical" id="abs0015" view="all">
               <ce:section-title id="sectitle0015">Graphical abstract</ce:section-title>
               <ce:abstract-sec id="abssec0015" view="all">
                  <ce:simple-para id="abspara0015" view="all">
                     <ce:display>
                        <ce:figure id="undfig1">
                           <ce:alt-text role="short" id="alttext0010">Image 1</ce:alt-text>
                           <ce:link locator="fx1" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:href="pii:S0223523419306361/fx1"/></ce:link>
                        </ce:figure>
                     </ce:display>
                  </ce:simple-para>
               </ce:abstract-sec>
            </ce:abstract>
            
            <ce:keywords xml:lang="en" id="kwrds0010" view="all" class="keyword">
               <ce:section-title id="sectitle0025">Keywords</ce:section-title>
               <ce:keyword id="kwrd0010">
                  <ce:text>Tyrosine kinases</ce:text>
               </ce:keyword>
               <ce:keyword id="kwrd0015">
                  <ce:text>Curcumin</ce:text>
               </ce:keyword>
               <ce:keyword id="kwrd0020">
                  <ce:text>Nanoparticles</ce:text>
               </ce:keyword>
               <ce:keyword id="kwrd0025">
                  <ce:text>Complexes</ce:text>
               </ce:keyword>
               <ce:keyword id="kwrd0030">
                  <ce:text>Growth factors</ce:text>
               </ce:keyword>
               <ce:keyword id="kwrd0035">
                  <ce:text>Cancer therapy</ce:text>
               </ce:keyword>
            </ce:keywords>
         </head>
         <body view="all">
            <ce:sections>
               <ce:section id="sec1" view="all">
                  <ce:label>1</ce:label>
                  <ce:section-title id="sectitle0030">The role of tyrosine kinases in cellular metabolism, apoptosis and cancer</ce:section-title>
                  <ce:para id="p0025" view="all">The action of currently used chemotherapeutics is based on the induction of apoptosis and on the inhibition of mitosis by disturbing the cell cycle. The use of conventional cytotoxic chemotherapy methods, however, does not create larger prospects due to the lack of specificity of most drugs against cancer cells and high toxicity on healthy, rapidly dividing cells such as myelocytes, epithelial cells or gametocytes [<ce:cross-ref refid="bib1" id="crosref0045">1</ce:cross-ref>,<ce:cross-ref refid="bib2" id="crosref0050">2</ce:cross-ref>]. Higher hopes are associated with the use of small molecule kinase inhibitors, which, through selectivity and specificity, inhibit the activation of specific proteins, including receptors, responsible for oncogenesis [<ce:cross-ref refid="bib3" id="crosref0055">3</ce:cross-ref>,<ce:cross-ref refid="bib4" id="crosref0060">4</ce:cross-ref>].</ce:para>
                  <ce:para id="p0030" view="all">More and more studies show how the tyrosine kinases play an important role in the process of tumorigenesis. Due to their location in the cell, they are divided into: transmembrane receptor tyrosine kinases (RTK) (<ce:cross-ref refid="tbl1" id="crosref0065">Table 1</ce:cross-ref>
                     <ce:float-anchor refid="tbl1"/></ce:float-anchor>) and cytoplasmic non-receptor tyrosine kinases (NRTK). Ligands that cause tyrosine kinase receptor dimerisation are extracellular signal molecules e.g. growth factors such as EGF or PDGF [<ce:cross-ref refid="bib5" id="crosref0070">5</ce:cross-ref>]. Unlike RTK, non-receptor tyrosine kinases, e.g. SRC, Abl, Fak, Janus, are enzymes exhibiting significant structural variability and the mechanism of activation of these kinases is much more complex [<ce:cross-ref refid="bib5" id="crosref0075">5</ce:cross-ref>] (<ce:cross-ref refid="fig1" id="crosref0080">Fig. 1</ce:cross-ref>
                     <ce:float-anchor refid="fig1"/></ce:float-anchor>).</ce:para>
                  <ce:para id="p0035" view="all">The activity of tyrosine kinases is associated with several stages of cancer development and progression. The role of tyrosine kinases in cell signaling is, among others, the stimulation of growth, cell proliferation and inhibition of apoptosis. Hence, the genetic or epigenetic change in kinase expression is often responsible for the loss of cell growth control and gives it an oncogenic nature. It appears that nearly all cancers exhibit disturbances in the expression and thus the function of at least one receptor tyrosine kinase [<ce:cross-ref refid="bib6" id="crosref0085">6</ce:cross-ref>]. In humans, mutations in the genes of such tyrosine kinases as EGFR, c-Mer, c-Kit, PI3K, ABL, FGFR1, RET leading to tumorigenesis are described, although other mutations in the TK genes are often found as a result of genetic instability of neoplastic cells’ uncontrolled replication and proliferation [<ce:cross-refs refid="bib7 bib8 bib9 bib10 bib11 bib12 bib13 bib14 bib15 bib16" id="crosrefs0010">7–16</ce:cross-refs>]. In addition, for the identified 58 receptor tyrosine kinases (RTK) (<ce:cross-ref refid="tbl1" id="crosref0090">Table 1</ce:cross-ref>), a number of mutations causing many congenital malformations have been described [<ce:cross-ref refid="bib17" id="crosref0095">17</ce:cross-ref>]. Deregulation caused by a mutation in several RTK has been recognized as a source of simultaneous occurrence of tumors and developmental syndromes, as in the case of multiple endocrine neoplasia type IIB (Men2B). The disease is caused by repeated germline mutations in the RET proto-oncogene encoding tyrosine kinase receptor for GDNF glial growth factor, which manifests as a predisposition to the occurrence of medullary thyroid carcinoma, pheochromocytoma and hyperparathyroidism as well as other more rare tumors and congenital malformations [<ce:cross-ref refid="bib18" id="crosref0100">18</ce:cross-ref>].</ce:para>
                  <ce:para id="p0040" view="all">Considering the above, receptor tyrosine kinases are important targets of drug action. The majority of presently investigated potential therapeutics targeted against TKs can be divided into two groups: the first one comprises small molecule inhibitors that are targeted to the ATP binding site of the intracellular tyrosine kinase domain and the second group are monoclonal antibodies that act directly on RTK and by recruiting immune cells for RTK expressing cells [<ce:cross-ref refid="bib17" id="crosref0105">17</ce:cross-ref>,<ce:cross-ref refid="bib19" id="crosref0110">19</ce:cross-ref>,<ce:cross-ref refid="bib20" id="crosref0115">20</ce:cross-ref>]. The activity of tyrosine kinases can also be blocked indirectly by the modification of their chaperone proteins, mainly Hsp90 (Heat Shock Proteins), which are necessary to maintain the active conformation of the kinases. Another way of inhibiting the activity of kinases is the use of antisense oligonucleotides that bind [<ce:cross-ref refid="bib21" id="crosref0120">21</ce:cross-ref>,<ce:cross-ref refid="bib22" id="crosref0125">22</ce:cross-ref>].</ce:para>
                  <ce:para id="p0045" view="all">There are attempts to develop effective small molecule inhibitors with high specificity and many of them have promising results [<ce:cross-ref refid="bib23" id="crosref0130">23</ce:cross-ref>], to mention Gleevec (<ce:italic>Imatinib mesylate</ce:italic>) [<ce:cross-ref refid="bib24" id="crosref0135">24</ce:cross-ref>], Iressa <ce:italic>(Gefitinib)</ce:italic> [<ce:cross-ref refid="bib25" id="crosref0140">25</ce:cross-ref>] czy Terceva <ce:italic>(Erlotynib).</ce:italic>
                  </ce:para>
                  <ce:para id="p0055" view="all">The idea of therapy directed at RTK is very promising in cases when targeted RTK is the main regulator of the cancerous cell process and therefore genomic analysis of tumors and identification of “driver” genes is important for the use of therapy directed directly against altered genes or their expression products [<ce:cross-ref refid="bib15" id="crosref0145">15</ce:cross-ref>] (<ce:cross-ref refid="fig2" id="crosref0150">Fig. 2</ce:cross-ref>
                     <ce:float-anchor refid="fig2"/></ce:float-anchor>).</ce:para>
                  <ce:para id="p0060" view="all">Discoidin domain receptor tyrosine kinases, DDR1 and DDR2 are activated by the extracellular matrix protein. Activation of DDR1 and 2 triggers the pathways responsible for cell expansion and migration (p53-dependent activation of the experimental Ras/Raf/ERK and PI3K/Akt pathways [<ce:cross-ref refid="bib27" id="crosref0155">27</ce:cross-ref>]), cell adhesion, epithelial differentiation (with integrin β1, DDR1 triggers the p130CAS/JNK pathway, leading to increased regulation of N-cadherin [<ce:cross-ref refid="bib28" id="crosref0160">28</ce:cross-ref>]) and anti-apoptotic pathways (increases the NFκβ DNA binding activity and expression of cyclooxygenase-2 [<ce:cross-ref refid="bib29" id="crosref0165">29</ce:cross-ref>]; the Notch 1/Hes1 and Hey 2 routes are activated [<ce:cross-ref refid="bib30" id="crosref0170">30</ce:cross-ref>]), which results in oncogenic transformation of cells [<ce:cross-ref refid="bib31" id="crosref0175">31</ce:cross-ref>].</ce:para>
                  <ce:para id="p0070" view="all">Many years of research allowed a thorough analysis of the mechanism of tyrosine kinase activity and led to the emergence of new therapeutic methods using synthetic chemical compounds with the properties of kinase inhibitors. These drugs have extremely high efficacy in various types of cancer, but often the cells develop sequential resistance to a given drug [<ce:cross-ref refid="bib33" id="crosref0185">33</ce:cross-ref>].</ce:para>
                  <ce:para id="p0075" view="all">Due to the tendency of cancer cells to develop resistance and because of the adverse immune responses to chemotherapy, interest in natural compounds, including flavonoids, is increasing. They are considered as compounds preventing cancer caused by, among others, accumulation of ROS (reactive oxygen species) [<ce:cross-ref refid="bib34" id="crosref0190">34</ce:cross-ref>,<ce:cross-ref refid="bib35" id="crosref0195">35</ce:cross-ref>], and as well as substances that act synergistically with cytostatics, eg curcumin, acting as a factor strengthening the activity of doxorubicin, blocking the NFκβ pathway [<ce:cross-refs refid="bib36 bib37 bib38" id="crosrefs0015">36–38</ce:cross-refs>] Or else, directly as agents with therapeutic properties [<ce:cross-refs refid="bib36 bib37 bib38" id="crosrefs0020">36–38</ce:cross-refs>]. Modern tools to determine the detailed structure of compounds and relationships between molecular structure and biological activity allow to precisely modify molecules of natural origin in a targeted manner, e.g. by forming complexes with metals, formation of nanoparticle structures and development of a high-efficiency drug delivery system [<ce:cross-refs refid="bib39 bib40 bib41" id="crosrefs0025">39–41</ce:cross-refs>].</ce:para>
               </ce:section>
               <ce:section id="sec2" view="all">
                  <ce:label>2</ce:label>
                  <ce:section-title id="sectitle0035">Chemical structure of curcumin responsible for its anticancer properties</ce:section-title>
                  <ce:para id="p0080" view="all">The naturally occurring curcuminoids are a mixture of curcumin (77%), demethoxycurcumin DMC (17%) and bismethoxycurcumin BDMC (3%) (<ce:cross-ref refid="fig4" id="crosref0200">Fig. 4</ce:cross-ref>) [<ce:cross-ref refid="bib43" id="crosref0205">43</ce:cross-ref>]. The therapeutic effect of curcumin results from its chemical structure and unique physicochemical properties. Curcumin (IUPAC: 1E, 6E) −1,7-Bis (4-hydroxy-3-methoxyphenyl) hepta-1,6-diene-3,5-dione) contains two ferulic acid residues joined by a methylene bridge. The most important structural features related to the curcumin biological activity are: the o-methoxyphenol and methylene group responsible for the curcumin antioxidant activity (<ce:cross-ref refid="fig3" id="crosref0210">Fig. 3</ce:cross-ref>
                     <ce:float-anchor refid="fig3"/></ce:float-anchor>
                     <ce:float-anchor refid="fig4"/></ce:float-anchor>). The formation of hydrogen bonds and the hydrophobicity of curcumin resulting from the presence of aromatic and tautomeric structures together with the flexibility of linking groups are responsible for its non-covalent interactions. Covalent interactions with protein thiols are enabled by α-unsaturated bonds and β-diketone. In addition, the β-diketo- group forms complexes with transition metals, reducing the toxicity of these metals and their pro-oxidative activity [<ce:cross-ref refid="bib44" id="crosref0215">44</ce:cross-ref>]. The chelation of the transition metal can also proceed via curcumin's o-methoxy phenolic moiety, still in most cases chelation occurs only through diketo-groups. As noted by Anand et al. The curcuminoids described have similar diketo-groups, so their effect on toxicity caused by metals should be similar. However, the presence of the o-methoxy group in curcumin derivatives may indirectly affect the electron density on the diketo-group, which affects the ability to chelate metals [<ce:cross-ref refid="bib41" id="crosref0220">41</ce:cross-ref>]</ce:para>
                  <ce:para id="p0085" view="all">Many current studies focus on improving the solubility and bioavailability of curcumin. (The oral bioavailability of curcumin in patients is shown in <ce:cross-ref refid="tbl2" id="crosref0230">Table 2</ce:cross-ref>
                     <ce:float-anchor refid="tbl2"/></ce:float-anchor>). The improvement of pharmacological parameters of curcumin is carried out, among others, by chemical modification of the molecule, including curcumin with auxiliary substances, placing in liposomes, nanoparticles and hybrid molecules consisting of curcumin and antibodies or other natural compounds [<ce:cross-ref refid="bib45" id="crosref0235">45</ce:cross-ref>].</ce:para>
                  <ce:para id="p0090" view="all">Curcumin has demonstrated its anti-cancer properties as an individually used agent and in synergy with other antineoplastic agents, e.g. in the treatment of glioblastoma [<ce:cross-ref refid="bib46" id="crosref0240">46</ce:cross-ref>], pancreatic cancer [<ce:cross-ref refid="bib47" id="crosref0245">47</ce:cross-ref>], melanoma [<ce:cross-ref refid="bib48" id="crosref0250">48</ce:cross-ref>], colon cancer [<ce:cross-ref refid="bib49" id="crosref0255">49</ce:cross-ref>] and many others [<ce:cross-ref refid="bib50" id="crosref0260">50</ce:cross-ref>] (<ce:cross-ref refid="tbl3" id="crosref0265">Table 3</ce:cross-ref>
                     <ce:float-anchor refid="tbl3"/></ce:float-anchor>). Current studies describe that curcumin can inhibit initiation, course and metastasis of various tumor lines. These effects are related to the negative regulation of various transcription factors (NFκβ, AP-1, Egr-1, STATs, PPAR-gamma, nrf2, EpRE, p53, CBP, CREB-BP, β-catenin, HIF-1, Nrf −2, PPAR-γ, ERE) [<ce:cross-refs refid="bib51 bib52 bib53" id="crosrefs0030">51–53</ce:cross-refs>], growth factors (FGF, HGF, EGF, PDGF, TGF-β1, VEGF) [<ce:cross-ref refid="bib51" id="crosref0270">51</ce:cross-ref>], cell proliferation factors (cyclin D1, c-myc), cytokines, protein kinases (JNK, Akt, AMPK) [<ce:cross-ref refid="bib54" id="crosref0275">54</ce:cross-ref>] and many other cell signaling proteins [<ce:cross-ref refid="bib51" id="crosref0280">51</ce:cross-ref>] including COX2, 5-LOX and tubulin. Due to the fact that the curcumin molecule exerts an effect on many different signaling pathways, the probability of resistance to this compound is lower [<ce:cross-ref refid="bib54" id="crosref0285">54</ce:cross-ref>], on the other hand, there are great difficulties in controlling and directing the action of natural pleiotropic particles.</ce:para>
                  <ce:para id="p0095" view="all">Curcumin is also considered as a compound operating at the epigenetic level [<ce:cross-ref refid="bib55" id="crosref0290">55</ce:cross-ref>]. In many types of tumors, changes in cell epigenicity have been observed, e.g. hypermethylation of promoter regions of suppressor genes, which causes their inactivation [<ce:cross-ref refid="bib55" id="crosref0295">55</ce:cross-ref>]. On the other hand, global hypomethylation causes instability of the genome and contributes to the transformation of cells [<ce:cross-ref refid="bib56" id="crosref0300">56</ce:cross-ref>]. Unlike mutations, the DNA methylation process is reversible, so many natural substances (including curcumin) can affect the state of chromatin e.g. by affecting the regulation of transcription of the DMT3b methyltransferase gene or inhibiting HDAC activity [<ce:cross-refs refid="bib57 bib58 bib59" id="crosrefs0035">57–59</ce:cross-refs>].</ce:para>
                  <ce:para id="p0100" view="all">It is known that already at low concentrations of curcumin reflecting the <ce:italic>in vivo</ce:italic> status, significant changes in the expression of genes involved in DNA repair, signal transduction, transcription regulation, cell adhesion and xenobiotics metabolism are observed [<ce:cross-ref refid="bib60" id="crosref0305">60</ce:cross-ref>].</ce:para>
                  <ce:para id="p0105" view="all">Curcumin is one of the best-studied compounds with potential anti-cancer properties, but it is vital to recognize the detailed mechanism of action of this molecule at all levels of gene expression [<ce:cross-ref refid="bib62" id="crosref0310">62</ce:cross-ref>].</ce:para>
               </ce:section>
               <ce:section id="sec3" view="all">
                  <ce:label>3</ce:label>
                  <ce:section-title id="sectitle0040">Curcumin as an inhibitor of receptor tyrosine kinases</ce:section-title>
                  <ce:section id="sec3.1" view="all">
                     <ce:label>3.1</ce:label>
                     <ce:section-title id="sectitle0045">Epidermal growth factor receptor (EGFR)</ce:section-title>
                     <ce:para id="p0110" view="all">Existing epidermal growth factor (EGFR) on the surface of cells is activated by binding specific ligands, including epidermal growth factor and transforming growth factor alpha (TGFα). EGFR belongs to RTK families including erbB2/HER-2, erbB3/HER-3 and erbB4/HER-4 [<ce:cross-ref refid="bib63" id="crosref0315">63</ce:cross-ref>]. Autophosphorylation of the tyrosine residue and the terminal end of EGFR results in the activation of signaling proteins that initiate further signal transduction, including the KRAS/BRAF/MEK/ERK pathways, PI3K, gamma phospholipase C protein, anti-apoptotic AKT kinase pathway, STAT signaling pathway, leading to proliferation, migration, angiogenesis, survival and adhesion [<ce:cross-ref refid="bib68" id="crosref0320">68</ce:cross-ref>]. Deregulation of these processes is observed in tumors as a result of mutations of various genes involved in these pathways [<ce:cross-ref refid="bib69" id="crosref0325">69</ce:cross-ref>]. Six mammalian ligands binding to EGFR: EGF, TGFα, amphiregulin, heparin-binding EGF-like growth factor, betacellulin and epiregulin have been characterized [<ce:cross-ref refid="bib64" id="crosref0330">64</ce:cross-ref>]. It has also been determined that activation of EGFR can occur independently of the ligand, without affecting the activation of ERK and Akt, activating the IRF3 transcription factor. The presence of a ligand disables IRF2-dependent transcription and activates the ERK and Akt pathway. Then EGFR overexpressing cells become more sensitive to chemotherapy [<ce:cross-ref refid="bib65" id="crosref0335">65</ce:cross-ref>].</ce:para>
                     <ce:para id="p0115" view="all">The p185neu oncoprotein, encoded by the ERBB-2 (HER-2) gene, is located on the chromosome 17q71 [<ce:cross-ref refid="bib66" id="crosref0340">66</ce:cross-ref>]. HER-2 belongs to the family of transmembrane receptors, internal domain of which has tyrosine kinase activity. In 15–25% of cases of diagnosed breast cancer, the amplification of the HER-2 gene is observed, resulting in the multiplicity of receptors on the surface of the cell to reach over 2 million [<ce:cross-ref refid="bib67" id="crosref0345">67</ce:cross-ref>]. The team of Hong et al. noted that curcumin in a dose-dependent manner inhibits autophosphorylation and p185neu transphosphorylation <ce:italic>in vitro</ce:italic> and drastically reduces p185neu protein levels <ce:italic>in vivo</ce:italic> [<ce:cross-ref refid="bib68" id="crosref0350">68</ce:cross-ref>]. Curcumin can also be used as an adjuvant in the treatment with cytostatic drugs. In the breast cancer cell line BT-474, curcumin in combination with taxol caused a decrease in tumor volume to a degree comparable to taxol and herceptin. In addition to acting in conjunction with known cytostatics, curcumin itself can also modulate signaling pathways, including, for example, the extensive MAPK pathway and the effect on one of the key transcription factors - NFκβ. Treatment with curcumin alone for two breast cancer lines (BT-474 and SK-BR-3) led to a decrease in Akt and MAPK phosphorylation, and decreased expression of NFκβ factor [<ce:cross-ref refid="bib69" id="crosref0355">69</ce:cross-ref>]. Other studies have shown that curcumin treatment of the SK-BR-3 cells inhibits the expression of HER-2 mRNA (by 70%) and A, B1, D1, E cyclins (by 30–70%), while increasing the expression of p21 protein [<ce:cross-ref refid="bib70" id="crosref0360">70</ce:cross-ref>]. However, cancer cells overexpressing HER-2 often develop adaptive responses to HER-2 kinase inhibitors [<ce:cross-ref refid="bib71" id="crosref0365">71</ce:cross-ref>]. Studies have revealed that deregulation of the expression of micro-RNA (miRNA) molecules can promote the invasion and metastasis of cancer cells. Expression of miR-21 (presumably oncogenic miRNA, which is functionally involved in cell invasion) increases after stimulating HER2/neu signaling, so miR-21 can be inferred as a potential therapeutic target in preventing invasion and metastasis of breast cancer [<ce:cross-ref refid="bib72" id="crosref0370">72</ce:cross-ref>]. It turned out that curcumin reduces the level of miR-21, inter alia by inhibiting the binding of the AP-1 transcription factor to the promoter and inducing expression of the tumor suppressor Pdcd4 (programmed cel death protein 4), which is the target of miR-21 [<ce:cross-ref refid="bib73" id="crosref0375">73</ce:cross-ref>,<ce:cross-ref refid="bib74" id="crosref0380">74</ce:cross-ref>]. More and more evidence points to the important role of miR-21 in cancer processes including metastasis, proliferation, apoptosis and drug resistance. Identified miR-21 pathways include PTEN (phosphatase and tensin homologue), PI3K/Akt, PDCD2 and NFκβ pathways, so curcumin inhibiting miR-21 affects multiple signaling pathways simultaneously [<ce:cross-ref refid="bib73" id="crosref0385">73</ce:cross-ref>]. The reduction of miR-21 levels in cells and the inhibition of tumor growth after curcumin treatment may also be the result of increased secretion of exosomes to miR-plasma-derived cell microvesicles as observed in chronic myeloid leukemia cells [<ce:cross-ref refid="bib75" id="crosref0390">75</ce:cross-ref>]. Li and co-authors developed a multifunctional system of nanoparticles encapsulated in a calcium (V) phosphate shell on an amphiphilic gelatin core consisting of hydrophobic curcumin and hydrophilic doxorubicin. Such a nanoparticle in combination with herceptin may be a potential successor of combination therapy [<ce:cross-ref refid="bib76" id="crosref0395">76</ce:cross-ref>].</ce:para>
                     <ce:para id="p0120" view="all">Very interesting information was provided by computational and experimental studies of the Yim-im team, in which the effect of modifying the curcumin molecule on its interaction with the HER-2 kinase domain was assessed. It has been found that the presence of a benzene ring with a hydroxyl group leads to an increase in the affinity between the protein and the ligand (see section <ce:cross-ref refid="sec5" id="crosref0400">5</ce:cross-ref>). This modification may increase affinity by forming hydrophobic interactions and hydrogen bonds with a hydrophobic pocket. Similarly, hydroxyl, carbonyl and methoxy forming hydrogen bonds with residues in the adenine and sugar receptors of HER-2 receptors [<ce:cross-ref refid="bib74" id="crosref0405">74</ce:cross-ref>,<ce:cross-ref refid="bib77" id="crosref0410">77</ce:cross-ref>].</ce:para>
                     <ce:para id="p0125" view="all">The ability of curcumin to inhibit EGFR activity has been observed on androgen-dependent and androgen-independent prostate cancer cells [<ce:cross-ref refid="bib78" id="crosref0415">78</ce:cross-ref>]. Treatment with curcumin and beta-phenylethyl isothiocyanate (PEITC) induced apoptosis in the prostate cancer line PC-3 where disruption of caspase-3 as well as inhibition of EGFR and EGF-induced Akt and PI3K phosphorylation was observed [<ce:cross-ref refid="bib79" id="crosref0420">79</ce:cross-ref>]. Thangapazham et al. determined the effect of curcumin on transcriptome of two prostate cancer cell lines: LNCaP (androgen dependent) and C4–2 B (androgen independent) [<ce:cross-ref refid="bib80" id="crosref0425">80</ce:cross-ref>]. Observed inhibition of proliferation and cell growth, changes in the expression of genes involved in oxidative stress response pathways and other biochemical paths involving genes such as HO-1, ATF3, NKX3, confirmed previous reports [<ce:cross-refs refid="bib81 bib82 bib83" id="crosrefs0040">81–83</ce:cross-refs>]. A 25 fold expression increase of HO-1 protein was observed in response to curcumin treatment. There was also an increase in the level of DDIT-3 (DNA-demage-inducible transcript 3), activation of GADD45A (Growth arrest and DNA-damage-inducible protein) and TRIB3-negative regulator AKT [<ce:cross-ref refid="bib80" id="crosref0430">80</ce:cross-ref>]. Starok and colleagues have proven that curcumin can inhibit EGFR activity on two levels. This polyphenol is capable of inhibiting the enzymatic activity of the EGFR intracellular domain, but may also affect the EGFR binding environment to the cell membrane. Placement of the curcumin particle in the cell membrane increases membrane viscosity what in turn causes receptor lateral mobility decrease, and thus receptor dimerisation rate and modulation of autophosphorylation [<ce:cross-ref refid="bib84" id="crosref0435">84</ce:cross-ref>]. Curcumin reduces EGFR expression and EGFR mRNA levels in bladder cancer [<ce:cross-ref refid="bib85" id="crosref0440">85</ce:cross-ref>], reduces EGFR phosphorylation of oral squamous cell carcinoma [<ce:cross-ref refid="bib86" id="crosref0445">86</ce:cross-ref>], inhibits EGFR kinase activity in the epidermoid carcinoma cells [<ce:cross-ref refid="bib87" id="crosref0450">87</ce:cross-ref>] and in colon cancer cells [<ce:cross-ref refid="bib88" id="crosref0455">88</ce:cross-ref>].</ce:para>
                     <ce:para id="p0130" view="all">Experimental studies have also confirmed the positive effect of curcumin on the non-small cell lung cancer (NSCLC). In the case of patients with the exon 19 L858R mutation or deletion in EGFR Gefitinib, a synthetic inhibitor of tyrosine kinases is highly effective. However, in patients with wild type EGFR and acquired T790 M mutation, cancer cells are resistant to treatment with Gefitinib. In the study of Lee et al. it has been shown that curcumin improves the effectiveness of Gefitinib therapy, which was supported by <ce:italic>in vivo</ce:italic> and <ce:italic>in vitro</ce:italic> studies. Curcumin enhances the antitumor effect of cytostatics by inhibiting cell proliferation, inhibiting EGFR phosphorylation, and inducing ubiquitination of EGFR and apoptosis. These studies show that curcumin can be part of an adjuvant therapy, particularly in patients with Gefitinib-resistant NSCLC [<ce:cross-ref refid="bib89" id="crosref0460">89</ce:cross-ref>]. Another mechanism associated with acquired EGFR-TKI immunity involves MET amplification and, as observed, the administration of gefitinib and erlotinib in patients with MET-amplified lung carcinoma did not stop tumor progression, regardless of EGFR status. As it turned out, MET restores activation of the PI3K/Akt pathway in a manner independent of EGFR [<ce:cross-ref refid="bib90" id="crosref0465">90</ce:cross-ref>]. The ligand for c-Met is the HGF factor (hepatocyte growth factor) [<ce:cross-ref refid="bib91" id="crosref0470">91</ce:cross-ref>] and as has been demonstrated, activation of the c-Met gene by HGF is effectively inhibited by curcumin [<ce:cross-ref refid="bib92" id="crosref0475">92</ce:cross-ref>,<ce:cross-ref refid="bib93" id="crosref0480">93</ce:cross-ref>]. In the DU145 prostate cancer line, curcumin inhibits the spread and invasion of HGF-mediated cells and also reduces the expression of phosphorylated c-Met, ERK and Snail kinases [<ce:cross-ref refid="bib94" id="crosref0485">94</ce:cross-ref>]. Inhibition of c-Met phosphorylation by HGF and of further activation of Akt, mTOR and S6 by curcumin has also been observed in the A549 and PC-9 cell lines, indicating that this polyphenol may be an inhibitor of the Met/Akt/mTOR pathway and thus it can inhibit cell angiogenesis and migration processes [<ce:cross-ref refid="bib95" id="crosref0490">95</ce:cross-ref>]. Earlier, it had been shown that curcumin inhibits cell proliferation and induces apoptosis in lung cancer cells by modulating the lysosomal pathway and the mitochondrial pathway dependent on reactive oxygen species (ROS) [<ce:cross-ref refid="bib96" id="crosref0495">96</ce:cross-ref>,<ce:cross-ref refid="bib97" id="crosref0500">97</ce:cross-ref>]. (The effect of curcumin on the c-Met/HGF pathway is described in more detail in section <ce:cross-ref refid="sec3.6" id="crosref0505">3.6</ce:cross-ref>).</ce:para>
                  </ce:section>
                  <ce:section id="sec3.2" view="all">
                     <ce:label>3.2</ce:label>
                     <ce:section-title id="sectitle0050">Insulin-like growth factor (IGF)</ce:section-title>
                     <ce:para id="p0135" view="all">Insulin-like Growth Factor-1 (IGF-1)-related pathways are strongly associated with the risk of various cancers. <ce:italic>In vitro</ce:italic> and <ce:italic>in vivo</ce:italic> studies have shown that IGF-1R, IGF-1 and IF-2 signaling is associated with the progression of cancer. IGF-1R is an essential factor in non-adherent cell growth observed in malignant tumors. It is involved in cell proliferation by induction of the Ras/MAPK pathway by promoting the activity of transcription factors such as ELK1 [<ce:cross-ref refid="bib99" id="crosref0510">99</ce:cross-ref>]. IGF-1 and IGF-2 are potent mitogens in various types of cancer such as breast cancer, colon cancer or myeloma [<ce:cross-ref refid="bib100" id="crosref0515">100</ce:cross-ref>]. Increased levels of IGF-1 in blood serum have been observed in lung, colon, prostate and breast cancer [<ce:cross-ref refid="bib106" id="crosref0520">106</ce:cross-ref>]. The activity of ligands and IGF receptors is modulated by six IGF binding proteins (IFBPs), designated as IGBP-1, IGFBP-2, … IGFBP-6 [<ce:cross-ref refid="bib101" id="crosref0525">101</ce:cross-ref>]. Studies indicate that signaling pathways dependent on tyrosine kinases are interrelated (<ce:cross-ref refid="fig2" id="crosref0530">Fig. 2</ce:cross-ref>). For example, in EGFR-dependent glioma, activation of the Ins/IGF1R pathway has been shown responsible for the resistance to EGFR inhibitors by regulating the AKT factor [<ce:cross-ref refid="bib102" id="crosref0535">102</ce:cross-ref>].</ce:para>
                     <ce:para id="p0140" view="all">Curcumin appears to be a potent inhibitor of the IGF-1 signaling pathway, e.g. in the skin cancer of transgenic mice overexpressing IGF-1. It has been found that curcumin inhibits phosphorylation of the IGF-1 receptor, Akt, S6K and 4EBP1 [<ce:cross-ref refid="bib103" id="crosref0540">103</ce:cross-ref>]. It has also been shown that curcumin effectively suppresses the growth of MCF-7 carcinoma cells by inhibiting the activation of IGF-1R and its downstream signaling components in a dose-dependent manner (at a concentration of 40μM/48 h curcumin, complete inhibition of IGF-1 induced growth was observed). The results indicate that curcumin inhibits IGF-1R gene expression at the transcriptional level [<ce:cross-ref refid="bib104" id="crosref0545">104</ce:cross-ref>]. It is likely that reduction of IGF-1 secretion may occur by down regulation of the AP-1 transcription factor [<ce:cross-ref refid="bib105" id="crosref0550">105</ce:cross-ref>], as well as by inhibition of cyclooxygenase-2 (COX-2). This is due to the fact that COX-2 is responsible for the synthesis of prostaglandin E (2) [<ce:cross-ref refid="bib106" id="crosref0555">106</ce:cross-ref>], which stimulates the transcription of IGF-1 factor [<ce:cross-ref refid="bib107" id="crosref0560">107</ce:cross-ref>].</ce:para>
                     <ce:para id="p0145" view="all">The biological activity of IGF-1 depends on IGFBPs, which, by binding to IGF-1, inhibit its activity. The Insulin-like growth factor-binding protein (IGFBP) genes are identified among the most common that can be abnormally altered in tumors. It has been shown that in human melanoma cells, IGFBP-5 is a tumor suppressor, it also reduces the expression of E-cadherin, key stem cell markers: Nanog, Sox 2, Oct 4, Klf4 and CD133 and also exerts an inhibitory effect on IGF1R, ERK1/2, p38 kinase -MAPK and reduces the expression of HIF1α and its target genes - VEGF and MMP9 [<ce:cross-ref refid="bib108" id="crosref0565">108</ce:cross-ref>]. In the case of the IGFBP-3 binding protein, both positive and negative effects on cell function have been demonstrated. A lot of cancer research has been carried out on IGFBP-3 as a pro-apoptotic molecule <ce:italic>in vitro</ce:italic>. These pro-apoptotic properties, however, do not correlate with several studies combining high levels of IGFBP-3 in breast cancer tissue with rapid growth and poor prognosis [<ce:cross-ref refid="bib109" id="crosref0570">109</ce:cross-ref>,<ce:cross-ref refid="bib110" id="crosref0575">110</ce:cross-ref>]. There is evidence that IGFBP-3 also has pro-survival and growth promoting properties <ce:italic>in vitro</ce:italic> [<ce:cross-ref refid="bib111" id="crosref0580">111</ce:cross-ref>]. The overall effect of IGFBP-3 leading to cell death or survival seems to be dependent on the complex relationship between cell microenvironment and the presence of IGFBP-3 cell binding partners and growth factor receptors. Also an effect of curcumin on the particular IGFBPs is determined in a complex way. Curcumin induces an increase in IGFBP-3 production in human colon carcinoma HCT116 and HT-29 as well as in the MCF-7 line [<ce:cross-ref refid="bib104" id="crosref0585">104</ce:cross-ref>,<ce:cross-ref refid="bib112" id="crosref0590">112</ce:cross-ref>], whereas in oral cancer, curcumin causes an increase in IGFBP-5 expression by activation of p38, and p38 activates C/EBPalpha transactivator through interaction with IGFBP-5 promoter binding elements [<ce:cross-ref refid="bib113" id="crosref0595">113</ce:cross-ref>].</ce:para>
                     <ce:para id="p0150" view="all">As a bottom line, interactions of genes and proteins in signaling pathways indicate that curcumin activity on RTK should be considered in a global way, because curcumin activity on the same receptor, but in different types of cancer cells or under different conditions can include other signal transduction pathways [<ce:cross-ref refid="bib17" id="crosref0600">17</ce:cross-ref>,<ce:cross-ref refid="bib54" id="crosref0605">54</ce:cross-ref>] (<ce:cross-ref refid="fig5" id="crosref0225">Fig. 5</ce:cross-ref>
                        <ce:float-anchor refid="fig5"/></ce:float-anchor>).</ce:para>
                  </ce:section>
                  <ce:section id="sec3.3" view="all">
                     <ce:label>3.3</ce:label>
                     <ce:section-title id="sectitle0055">Vascular epidermal growth factor receptor (VEGFR)</ce:section-title>
                     <ce:para id="p0155" view="all">The function of vascular endothelial growth factor (VEGF) in tumors is not limited only to angiogenesis and vascular permeability, but is involved in key elements of oncogenesis, inter alia, directing the functions of cancer stem cells and the process of tumor initiation [<ce:cross-ref refid="bib114" id="crosref0610">114</ce:cross-ref>]. The studies concluded that curcumin is capable of lowering the expression of VEGF, VEGFR and K-Ras, which results in repression of tumor growth and acts through the same signaling pathways as bevacizumab, a humanized anti-VEGF monoclonal antibody. In addition, the combination of curcumin and bevacizumab has a synergistic, but not competitive effect, which confirms the potential benefits of the combined use of the drug and nutraceutical [<ce:cross-ref refid="bib115" id="crosref0615">115</ce:cross-ref>]. The antiangiogenic effect of curcumin has been demonstrated on the HepG2 liver cancer cell line, which may be associated with the reduction of angiogenic biomarkers, COX-2 and VEGF [<ce:cross-ref refid="bib116" id="crosref0620">116</ce:cross-ref>]. On the line of primary intestinal mucosal endothelial cells (HIMEC), stimulated with VEGF, curcumin inhibited proliferation migration and angiogenesis by inhibiting the expression of COX-2 induced by VEGF via the MAPK pathway. These studies also indicate that curcumin may have a direct effect on local microvascular populations [<ce:cross-ref refid="bib117" id="crosref0625">117</ce:cross-ref>]. In HUVEC cells, curcumin inhibited proliferation, cell migration stimulated with VEGF, induced apoptosis and blocked the activation of VEGFR2 and its downstream signaling pathways. In contrast, in the VEGF overexpressing model, curcumin significantly inhibited the growth of VEGF-dependent cancer in a dose-dependent manner. In addition, curcumin normalized liver vascular structures and decreased the density of tumor microvessels [<ce:cross-ref refid="bib118" id="crosref0630">118</ce:cross-ref>].</ce:para>
                     <ce:para id="p0160" view="all">Many recent studies have provided evidence of a strong correlation between elevated levels of HIF-1 (hypoxia-inducible factor 1) and metastatic tumor, angiogenesis, poor prognosis as well as resistance to cancer treatment. Recent reports have identified HIF-1α as one of the important targets of anticancer drugs [<ce:cross-ref refid="bib119" id="crosref0635">119</ce:cross-ref>]. Curcumin significantly reduces the level of HIF-1α protein in the HEPG2 line and, moreover, suppresses its transcriptional activity, which leads to a decrease in VEGF expression [<ce:cross-ref refid="bib120" id="crosref0640">120</ce:cross-ref>]. Similarly in the pituitary adenoma line, curcumin inhibits mRNA synthesis and HIF-1α production as well as VEGF-A synthesis and secretion, which indicates the inhibitory effect of curcumin on neovascularization processes [<ce:cross-ref refid="bib121" id="crosref0645">121</ce:cross-ref>]. In a mouse model of stomach cancer curcumin lowers the expression of VEGFR-3, Prox-1 and podoplanin [<ce:cross-ref refid="bib122" id="crosref0650">122</ce:cross-ref>], and in the chondrosarcoma line, it inhibits IL-1 signaling responsible for the activation of the NFκβ factor regulating the expression of various genes (including VEGF) responsible for proliferation, metastasis, angiogenesis and cell invasion. Curcumin prevents recruiting IRAK (IL-1 receptor associated kinase) to the IL-1 receptor, blocks the expression of Il-1, VEGF-A, and IL-1β-induced angiogenesis [<ce:cross-ref refid="bib123" id="crosref0655">123</ce:cross-ref>]. Curcumin also has the ability to block the secretion of VEGF expression of which is stimulated by progestins (synthetic progesterone) in the T47-D breast cancer cell line. Because progestogens are often used in hormone therapy, curcumin can be a useful substance that inhibits the production of VEGF in a preventive context [<ce:cross-ref refid="bib124" id="crosref0660">124</ce:cross-ref>]. Similarly to progesterone, the chemokine-like ECM-associated protein osteopontin (OPN) has been shown to trigger angiogenesis by upregulating expression of VEGF in a human breast cancer model. As shown, curcumin inhibited the expression of OPN-induced VEGF by the NFκβ/ATF-4 pathway [<ce:cross-ref refid="bib125" id="crosref0665">125</ce:cross-ref>].</ce:para>
                  </ce:section>
                  <ce:section id="sec3.4" view="all">
                     <ce:label>3.4</ce:label>
                     <ce:section-title id="sectitle0060">Fibroblast growth factor receptor (FGFR)</ce:section-title>
                     <ce:para id="p0170" view="all">Fibroblast growth factor (FGF) is involved in many embryonic development cell processes and in oncogenesis by regulating mechanisms such as proliferation, drug resistance and angiogenesis [<ce:cross-ref refid="bib128" id="crosref0685">128</ce:cross-ref>]. In adult cells, these proteins mediate metabolic functions, repair and regeneration of tissues. Internal FGF regulated signaling pathways include RAS-MAPK, PI3K-AKT, PLCγ, STAT and WNT pathways [<ce:cross-ref refid="bib128" id="crosref0690">128</ce:cross-ref>,<ce:cross-ref refid="bib129" id="crosref0695">129</ce:cross-ref>]. The RAS-MAPK pathway, regulated by FGF and the canonical WNT pathway, regulates transcription programming. The PI3K-AKT, Hedgehog, Noth, TGFβ and non-canon cascade WNT pathways, which are subject to FGF signaling, are responsible for epithelial-to-mesenchymal transition (EMT) and invasion [<ce:cross-ref refid="bib128" id="crosref0700">128</ce:cross-ref>]. Mutations in the FGF receptor (FGFR) genes are responsible for the occurrence of numerous types of tumors. Amplification of the FGFR1 gene is observed in lung cancer and estrogen-dependent breast cancer, FGFR2 in gastric cancer and triple negative breast cancer, chromosomal translocation in the FGFR3 gene is observed in multiple myeloma, but there are also missense mutations eg FGFR2 in uterine cancer [<ce:cross-ref refid="bib128" id="crosref0705">128</ce:cross-ref>]. Among the factors regulating the FGF activity, binding proteins FGF binding proteins (FGFBP) should be distinguished. It has been observed that the amount of FGFBP is increased in many types of tumors, primarily in the early stages of their formation, in which angiogenesis plays an important role [<ce:cross-ref refid="bib130" id="crosref0710">130</ce:cross-ref>,<ce:cross-ref refid="bib131" id="crosref0715">131</ce:cross-ref>]. Due to the fact that the decreased expression of FGFR2 has been observed in many subtypes of cancer, it has been suggested that this gene has the properties of a suppressor gene [<ce:cross-ref refid="bib132" id="crosref0720">132</ce:cross-ref>]. It has been shown that the FGFR3 receptor has a dualistic nature: it can be a tumor growth suppressor in pancreatic epithelial cells with simultaneous oncogenic properties in pancreatic mesenchymal cells, indicating that FGFR3 inhibitors can have an adverse effect if used in the wrong cell type [<ce:cross-ref refid="bib133" id="crosref0725">133</ce:cross-ref>].</ce:para>
                     <ce:para id="p0175" view="all">To date, there are no studies confirming unambiguously the effect of curcumin and curcuminoids on the expression and activity of FGFR. Often, curcumin may not affect the receptor itself, but the pathway that depends on it. For example, FGF stimulates the binding activity of the transcription factor - AP-1, and this stimulation is inhibited by curcuminoids. It has been also shown that curcuminoids inhibit the expression of gelatinase B, dependent on the factor AP-1, which confirms their anti-angiogenic potential [<ce:cross-ref refid="bib134" id="crosref0730">134</ce:cross-ref>]. Curcumin can also inhibit the transcript of two major angiogenesis factors: VEGF and basic fibroblast growth factor (b-FGF) in breast cancer cells [<ce:cross-ref refid="bib135" id="crosref0735">135</ce:cross-ref>]. Interestingly, the 3-h exposure of HT29 cells to high concentrations of curcumin (100 μmol/L) caused an increase in FGFR1 expression 1.78-fold, similar to VEGF and AREG and other redox-sensitive genes [<ce:cross-ref refid="bib60" id="crosref0740">60</ce:cross-ref>]. The reverse effect was obtained on squamous cell carcinoma cells in which the mTOR/FGFR pathway plays a key role. Mice treated with the curcumin C3 complex (standardized with a mixture of three curcuminoids) showed significantly lower activity of mTORC1, mTORC2 and FGFR2 stimulated by UVB [<ce:cross-ref refid="bib136" id="crosref0745">136</ce:cross-ref>]. Liang et al. described curcumin analogs A114 and A117 as effective therapeutic and preventive agents in FGFR1-dependent tumors [<ce:cross-ref refid="bib137" id="crosref0750">137</ce:cross-ref>]. In patients with HNSCC (head and neck cancer), it was observed that curcumin administered in the form of a microgranules, and absorbed through the mucosa, reduces the expression of FGF-2 as well as GM-CSF and IL-17 interleukin [<ce:cross-ref refid="bib138" id="crosref0755">138</ce:cross-ref>].</ce:para>
                  </ce:section>
                  <ce:section id="sec3.5" view="all">
                     <ce:label>3.5</ce:label>
                     <ce:section-title id="sectitle0065">Platelet-derived growth factor receptor (PDGFR)</ce:section-title>
                     <ce:para id="p0180" view="all">Various isoforms of PDGF and PDGF receptors (PDGFR) play important roles in regulating the growth and survival of various cell types during embryonic development as well as in tissue repair in adult organisms [<ce:cross-ref refid="bib140" id="crosref0760">140</ce:cross-ref>]. These receptor-ligand pairs regulate proliferation, differentiation and migration processes [<ce:cross-ref refid="bib141" id="crosref0765">141</ce:cross-ref>], and are often overexpressed in various malignant tumors [<ce:cross-ref refid="bib141" id="crosref0770">141</ce:cross-ref>], for example in breast cancer. Metastatic potential of breast epithelial cells requires an autocrine PDGF/PDGFR loop that is formed by the TGF-β-induced EMT [<ce:cross-ref refid="bib142" id="crosref0775">142</ce:cross-ref>], whereas autocrine PDGFR activation promotes the development of ovarian cancer [<ce:cross-ref refid="bib143" id="crosref0780">143</ce:cross-ref>]. It has been found that PDGFRs are crucial for PI3K/AKT activation and are negatively regulated by mTOR. In addition, PI3K/Akt/mTOR activation reduces PDGFR expression and mTOR inhibition restores PDGFR expression and Akt activation [<ce:cross-ref refid="bib144" id="crosref0785">144</ce:cross-ref>]. Activation of PDGFR initiates many further signaling pathways including PI3K kinase, Cγ phololipase and MAP kinase pathways [<ce:cross-ref refid="bib145" id="crosref0790">145</ce:cross-ref>]. In cancer diseases, mutations in the genes of <ce:italic>PDGFR</ce:italic> family are very often observed, e.g., point mutations in the <ce:italic>PDGFRA</ce:italic> gene in about 5% of cases in gastrointestinal stromal tumors [<ce:cross-ref refid="bib140" id="crosref0795">140</ce:cross-ref>]. <ce:italic>PDGFR</ce:italic> gene rearrangements have been observed in certain types of leukemias [<ce:cross-ref refid="bib146" id="crosref0800">146</ce:cross-ref>,<ce:cross-ref refid="bib147" id="crosref0805">147</ce:cross-ref>], and in 5–10% of glioblastoma multiforme cases, PDGF receptors were overexpressed and amplified [<ce:cross-ref refid="bib140" id="crosref0810">140</ce:cross-ref>,<ce:cross-refs refid="bib148 bib149 bib150" id="crosrefs0045">148–150</ce:cross-refs>]. One of the reasons for the formation of PDGF-dependent tumors is a mutation in the <ce:italic>p53</ce:italic> gene, which is a phenomenon observed in 50% of tumors [<ce:cross-ref refid="bib140" id="crosref0815">140</ce:cross-ref>].</ce:para>
                     <ce:para id="p0185" view="all">Curcumin as a PDGF inhibitor can be considered in the antioxidant context. <ce:italic>PDGF</ce:italic> is a gene which expression increases due to oxidative stress. An increase in PDGF expression in the presence of hydrogen peroxide was observed, whereas in the presence of curcumin and H<ce:inf loc="post">2</ce:inf>O<ce:inf loc="post">2</ce:inf> a significant decrease in the expression level of the PDGF gene was demonstrated compared to the control group [<ce:cross-ref refid="bib151" id="crosref0820">151</ce:cross-ref>]. There is a lot of evidence for the participation of ROS (reactive oxygen species) in the regulation of PDGF signaling pathways, wherein the same PDGF factor, like EGF, angiotensin II and many cytokines, generate endogenous hydrogen peroxide [<ce:cross-refs refid="bib152 bib153 bib154 bib155 bib156" id="crosrefs0050">152–156</ce:cross-refs>]. This indicates that the antioxidative properties of curcumin may be a key property in modulating certain PDGF-dependent signaling pathways [<ce:cross-ref refid="bib152" id="crosref0825">152</ce:cross-ref>,<ce:cross-ref refid="bib157" id="crosref0830">157</ce:cross-ref>]. Curcumin has demonstrated strong inhibitory properties on PDGF in vascular smooth muscle cells (VSMCs) [<ce:cross-ref refid="bib158" id="crosref0835">158</ce:cross-ref>], whereas in HSC-T6 cells expressing <ce:italic>PDGFB, PDGFRβ</ce:italic> and <ce:italic>ERK1</ce:italic>, a decrease in mRNA expression of these genes was observed in a way depending on the concentration of curcumin [<ce:cross-ref refid="bib159" id="crosref0840">159</ce:cross-ref>].</ce:para>
                  </ce:section>
                  <ce:section id="sec3.6" view="all">
                     <ce:label>3.6</ce:label>
                     <ce:section-title id="sectitle0070">Hepatocyte growth factor receptor (HGFR)</ce:section-title>
                     <ce:para id="p0190" view="all">c-Met, also called the Met receptor tyrosine kinase or hepatocyte growth factor receptor (HGFR), is encoded by the <ce:italic>MET</ce:italic> gene in humans. The hepatocyte growth factor (HGF) and its splicing forms NK1 and NK2 are the only known ligands of the MET receptor [<ce:cross-ref refid="bib160" id="crosref0845">160</ce:cross-ref>].</ce:para>
                     <ce:para id="p0195" view="all">C-Met after binding to the ligand, activates a number of different cellular pathways, including proliferation, migration and invasion [<ce:cross-ref refid="bib91" id="crosref0850">91</ce:cross-ref>]. In addition, this factor protects against apoptosis and promotes angiogenesis [<ce:cross-ref refid="bib161" id="crosref0855">161</ce:cross-ref>]. The kinase receptor is found on the surface of epithelial cells in many organs including the liver, pancreas, prostate, kidneys, muscles and bone marrow during embryogenesis and in adult organisms, where it participates in tissue repair [<ce:cross-refs refid="bib162 bib163 bib164" id="crosrefs0055">162–164</ce:cross-refs>]. Deregulation and pathological c-met signaling occurs as a result of various mechanisms including gene amplification, overexpression resulting from mutation, autocrine or paracrine ligand-dependent stimulation and interaction with other receptors on the cell surface [<ce:cross-ref refid="bib161" id="crosref0860">161</ce:cross-ref>]. C-Met overexpression was observed in lung, breast, ovarian, kidney, colon, thyroid, liver and stomach cancer [<ce:cross-ref refid="bib161" id="crosref0865">161</ce:cross-ref>]. Numerous evidence shows that incorrect regulation of c-Met signaling is associated with an aggressive cancer phenotype [<ce:cross-ref refid="bib165" id="crosref0870">165</ce:cross-ref>]. Recent studies have shown that the oncoprotein MET present in exosomes derived from melanoma cancer cells facilitates the formation of primary tumors and metastases [<ce:cross-ref refid="bib166" id="crosref0875">166</ce:cross-ref>,<ce:cross-ref refid="bib167" id="crosref0880">167</ce:cross-ref>] in addition, it plays a significant role in the regulation of drug resistance to chemotherapeutics. For example, in lung cancer, resistance to Gefitinib may be due to MET amplification that activates the ER3-dependent PI3K pathway [<ce:cross-ref refid="bib168" id="crosref0885">168</ce:cross-ref>]. Similarly for colorectal cancer, the acquired resistance to anti-EGFR treatment is due to the activation of MET [<ce:cross-ref refid="bib169" id="crosref0890">169</ce:cross-ref>]. Due to the pleiotropic role of the c-Met factor in neoplastic processes and cancer progression, it is considered an important target of cancer therapy [<ce:cross-refs refid="bib170 bib171 bib172 bib173" id="crosrefs0060">170–173</ce:cross-refs>].</ce:para>
                     <ce:para id="p0200" view="all">One of the first studies on the effect of curcumin on HGF, have shown that activation of HGF depends on the AP-1 factor and that this process can be inhibited by curcumin [<ce:cross-ref refid="bib92" id="crosref0895">92</ce:cross-ref>,<ce:cross-ref refid="bib93" id="crosref0900">93</ce:cross-ref>]. Studies of Hu and co-workers have shown that curcumin inhibits migration, scattering and invasion of DU145 cells induced by HGF, as well as inhibits the increase in the level of vimentin by lowering the expression of phosphorylated c-Met kinase and Snai1 protein [<ce:cross-ref refid="bib94" id="crosref0905">94</ce:cross-ref>]. The HGF/c-met signaling is crucial for the EMT - a process characteristic of embryonic development and pathological conditions, such as cancers [<ce:cross-ref refid="bib95" id="crosref0910">95</ce:cross-ref>,<ce:cross-ref refid="bib174" id="crosref0915">174</ce:cross-ref>]. It has been observed that curcumin inhibits EMT induced by HGF, moreover polyphenol has an inhibitory effect on the HGF/c-Met pathway and the expression of Snail and c-Met. Probably the inhibitory effect of curcumin on c-Met is caused by inhibition of AP-1 and FAS expression, however, this theory needs confirmation in further studies [<ce:cross-ref refid="bib94" id="crosref0920">94</ce:cross-ref>]. Curcumin also inhibits growth, migration and HGF-induced invasion in the A549 and PC-9 lung cancer cell lines and the EMT process by modulating the c-Met-dependent signal pathway PI3K/Akt/mTOR. In a mouse model study, curcumin inhibited tumor growth stimulated with HGF, induced increased expression of e-cadherin and decreased expression of vimetin, CD-34 and VEGF [<ce:cross-ref refid="bib95" id="crosref0925">95</ce:cross-ref>].</ce:para>
                  </ce:section>
                  <ce:section id="sec3.7" view="all">
                     <ce:label>3.7</ce:label>
                     <ce:section-title id="sectitle0075">Tyrosine-protein kinase receptor UFO (AXL)</ce:section-title>
                     <ce:para id="p0205" view="all">AXL kinase and its major GAS6 ligand are over-expressed in many types of cancers, including lung, breast and pancreatic cancer. Often, the increased level of these proteins is correlated with poor prognosis, greater invasiveness, metastasis, EMT phenotype and drug resistance [<ce:cross-ref refid="bib175" id="crosref0930">175</ce:cross-ref>]. It has been observed that inhibition of the GAS6/AXL pathway increases the effectiveness of chemotherapy. In addition, there is a relationship between AXL and cellular response to DNA damage - loss of AXL signaling causes accumulation of γH2AX, 53BP1 and RAD51 DNA-damage markers [<ce:cross-ref refid="bib176" id="crosref0935">176</ce:cross-ref>].</ce:para>
                     <ce:para id="p0210" view="all">In studies on NSCLC (non-small cell lung cancer) A549 and H460 cells, it was observed that curcumin causes a significant decrease in the amount of the Axl protein and a decrease in transcript concentration in a dose-dependent and time-dependent manner. In addition, after curcumin activity, the activity of the Axl promoter decreased, which indicates that this polyphenol is already active at the transcription level. In addition, curcumin exhibits an inhibitory effect on Ax6-induced Axl activation [<ce:cross-ref refid="bib177" id="crosref0940">177</ce:cross-ref>]. Interestingly, in the case of NSCLC, it has been shown that curcumin can act synergistically in combination with Gefitinib. In addition to the effective inhibition of cell growth, curcumin reduces the level of AXL kinase at both mRNA and protein level [<ce:cross-ref refid="bib178" id="crosref0945">178</ce:cross-ref>]. Proteomic analysis showed that curcumin induces changes in the phosphorylation of kinases Axl, TNK2, FRK, MAPK12 [<ce:cross-ref refid="bib179" id="crosref0950">179</ce:cross-ref>].</ce:para>
                  </ce:section>
                  <ce:section id="sec3.8" view="all">
                     <ce:label>4</ce:label>
                     <ce:section-title id="sectitle0080">Curcumin as an inhibitor of non-receptor tyrosine kinases</ce:section-title>
                     <ce:para id="p0215" view="all">Non-receptor tyrosine kinases (NRTKs) are cytoplasmic proteins exhibiting high structural variability. In conditions of homeostasis, the level of phosphorylation of the cellular tyrosine kinase is tightly controlled thanks to the antagonistic effects of tyrosine kinases and tyrosine phosphatases [<ce:cross-ref refid="bib5" id="crosref0955">5</ce:cross-ref>]. Classification of non-receptor tyrosine kinases is shown in <ce:cross-ref refid="tbl4" id="crosref0960">Table 4</ce:cross-ref>
                        <ce:float-anchor refid="tbl4"/></ce:float-anchor>.</ce:para>
                  </ce:section>
                  <ce:section id="sec3.9" view="all">
                     <ce:label>4.1</ce:label>
                     <ce:section-title id="sectitle0085">Abelson murine leukemia viral oncogene homologue (ABL)</ce:section-title>
                     <ce:para id="p0220" view="all">ABL cytoplasmic kinase is involved in the processes of cell differentiation and division, adhesion and stress response. The fusion gene formed as a result of <ce:italic>BCR/ABL</ce:italic> chromosomal translocation is the cause of chronic myeloid leukemia [<ce:cross-ref refid="bib180" id="crosref0965">180</ce:cross-ref>]. ABL overexpression, mutations and amplifications are observed in many solid tumors, which is why many studies focus on the use of small molecule inhibitors of Abl kinases in the treatment of this type of cancer [<ce:cross-refs refid="bib181 bib182 bib183" id="crosrefs0065">181–183</ce:cross-refs>]. For example, the ABL1 and ABL2 kinases promote metastasis of lung cancer cells exhibiting an EGFR or KRAS mutation [<ce:cross-ref refid="bib184" id="crosref0970">184</ce:cross-ref>] yet, overexpression or amplification of these genes is also seen in breast, ovarian and squamous cell carcinoma of the lungs [<ce:cross-ref refid="bib185" id="crosref0975">185</ce:cross-ref>]. ABL also plays a role in cell polarization, and it is suspected that it may contribute to the loss of epithelial polarity in the early stages of cancer development [<ce:cross-ref refid="bib185" id="crosref0980">185</ce:cross-ref>].</ce:para>
                     <ce:para id="p0225" view="all">It has been observed that curcumin at low concentrations inhibits proliferation and induces apoptosis of wild-type leukemia cells or the T315I BCL-ABL mutation. This polyphenol lowers the level of NFκβ factor and raises p53. In wild-type cells, an increase in c-Abl expression was observed, unfortunately this effect was not observed in the case of the BCR-ABL oncogene [<ce:cross-ref refid="bib186" id="crosref0985">186</ce:cross-ref>]. In the work of Guo et al. It has been reported that curcumin can induce apoptosis by inhibiting the Akt/mTOR pathway, ABL/STAT5 signaling, decreasing BCR/ABL expression. Interestingly, curcumin exhibits a synergistic effect with Imatinib by inhibiting the AKT/mTOR pathway and decreasing the BCR/ABL expression. In addition, curcumin inhibits the proliferation of leukemic cells, also in patients resistant to Imatinib [<ce:cross-ref refid="bib187" id="crosref0990">187</ce:cross-ref>]. This polyphenol has also shown a synergistic effect with PS-ASODN on the K562 line where there was a reduction in the level of P210bcr/abl and NFκβ [<ce:cross-ref refid="bib188" id="crosref0995">188</ce:cross-ref>]. Recent studies have confirmed the therapeutic role of curcumin in Ph + ALL lymphoblastic leukemia, where induction of autophagy by RAF/MEK/ERK and inhibition of the Akt-mTOR and ABL/STAT5 pathway have been observed [<ce:cross-ref refid="bib189" id="crosref1000">189</ce:cross-ref>].</ce:para>
                     <ce:para id="p0230" view="all">On the other hand, the kinase function of c-Abl kinase is an important link in the cell death induction pathway [<ce:cross-ref refid="bib190" id="crosref1005">190</ce:cross-ref>]. The results of the work of Kamath et al. show that curcumin by stimulating reactive oxygen forms stimulates catalytic functions of c-Abl kinase. Activation of this kinase simultaneously activates two independent Abl/p53 and Abl/JNK pathways, with the Abl/JNK pathway being an important element in the induction of cell death initiated by curcumin [<ce:cross-ref refid="bib191" id="crosref1010">191</ce:cross-ref>].</ce:para>
                  </ce:section>
                  <ce:section id="sec3.10" view="all">
                     <ce:label>4.2</ce:label>
                     <ce:section-title id="sectitle0090">Focal adhesion kinase (FAK)</ce:section-title>
                     <ce:para id="p0235" view="all">The pathways mediated by FAK kinase are important in regulating the survival of cancer cells. The main function of these kinases is the transmission of signal from integrin receptors involved in cell adhesion [<ce:cross-ref refid="bib193" id="crosref1015">193</ce:cross-ref>]. Overexpression of FAK correlates with the ability of cancer cells to migrate, invade and create metastases. In addition, overexpression of FAK is associated with activation of the PI3K-AKT pathway and expression of protein inhibitors of apoptosis. This kinase also has the ability to bind to the functional domain of the TNF receptor superfamily [<ce:cross-ref refid="bib194" id="crosref1020">194</ce:cross-ref>]. Elevated FAK levels have been observed, inter alia, in invasive and metastatic breast cancer, indicating that this kinase may be a marker of tumor invasiveness [<ce:cross-ref refid="bib195" id="crosref1025">195</ce:cross-ref>], as in the case of neuroblastoma, where in the vast majority of tumor samples, the presence of FAK kinase was observed [<ce:cross-ref refid="bib196" id="crosref1030">196</ce:cross-ref>]. Inhibition of FAK kinase can also be important in cancer such as pancreatic cancer, ovarian cancer, cervical cancer and osteosarcoma [<ce:cross-ref refid="bib197" id="crosref1035">197</ce:cross-ref>]. Many studies have shown that FAK kinase also plays an important role in the regulation of cancer stem cells [<ce:cross-refs refid="bib198 bib199 bib200 bib201" id="crosrefs0070">198–201</ce:cross-refs>].</ce:para>
                     <ce:para id="p0240" view="all">It has been found that curcumin reduces tumor cell invasion and metastasis of laryngeal squamous cell carcinoma. Mitra et al. suggest that curcumin inhibits the expression of MMP-2 of one of the major metastases associated with metastasis by modulation of FAK and MT1-MMP signaling pathways [<ce:cross-ref refid="bib202" id="crosref1040">202</ce:cross-ref>]. It turns out that curcumin inhibits the activity of Sp-1 transcription factor and Sp-1-regulated genes: ADEM10, calmodulin, EPHB2, HDAC4 and SEPP1. In addition, it inhibits CD24 expression, phosphorylation of FAK kinase and enhances the expression of many components of the cell matrix. Probably the anti-metastatic effect of curcumin results from its ability to inhibit the activity of SP-1, FAK, CD24 and promote the expression of E-cadherin [<ce:cross-ref refid="bib203" id="crosref1045">203</ce:cross-ref>,<ce:cross-ref refid="bib204" id="crosref1050">204</ce:cross-ref>]. Other reports indicate that curcumin inhibits the activity of SLUG, SNAI1, FAK, TWIST and other transcription factors essential for the process of metastasis [<ce:cross-ref refid="bib205" id="crosref1055">205</ce:cross-ref>], as well as many adhesion proteins and extracellular matrix molecules such as CCRX4, COX2, ELAM1, ECAM1 [<ce:cross-ref refid="bib53" id="crosref1060">53</ce:cross-ref>,<ce:cross-ref refid="bib206" id="crosref1065">206</ce:cross-ref>]. In addition, curcumin exhibits a cytotoxic effect against cancer stem cells, while being characterized by low toxicity to healthy stem cells. As suggested by Sordillo et al. this may be due to the inhibition of cytokine release, especially Il-6, Il-8, IL-1 and effects on the Wnt, Notch, Hedgehog and FAK pathways [<ce:cross-ref refid="bib207" id="crosref1070">207</ce:cross-ref>]. Curcumin can also inhibit cell growth and migration by suppressing FAK and Src kinase activity [<ce:cross-ref refid="bib208" id="crosref1075">208</ce:cross-ref>].</ce:para>
                  </ce:section>
                  <ce:section id="sec3.11" view="all">
                     <ce:label>4.3</ce:label>
                     <ce:section-title id="sectitle0095">Janus kinases (JAK)</ce:section-title>
                     <ce:para id="p0245" view="all">The JAK/STAT pathway regulates embryonic development processes, controls the maintenance of stem cells, hematopoiesis and inflammatory responses. The JAK/STAT pathway mediates cytokine signal transduction, controlling survival, proliferation and differentiation of various cell types [<ce:cross-ref refid="bib209" id="crosref1080">209</ce:cross-ref>]. Components of the JAK/STAT pathway also have an effect on gene expression outside the “canonical” phosphorylation cascade, contributing to the epigenetic modification of chromatin [<ce:cross-ref refid="bib210" id="crosref1085">210</ce:cross-ref>]. Activation of the JAK/STAT pathway is observed in hematopoietic tumors and also is the subject of research in the treatment of solid tumors [<ce:cross-ref refid="bib210" id="crosref1090">210</ce:cross-ref>]. The mechanism that causes inappropriate activation of this pathway in tumors is not fully known. In head and neck squamous cell carcinoma, STAT3 phosphorylation is the result of increased IL-6 production by tumor cells [<ce:cross-ref refid="bib211" id="crosref1095">211</ce:cross-ref>]. Excessive Jak/STAT activity is often observed in the tumor microenvironment [<ce:cross-ref refid="bib212" id="crosref1100">212</ce:cross-ref>], and in tumor cells, STAT3 activates survival genes such as Bcl-XL, BCl-2, Mcl-1 and Survivin, and proliferation genes, e.g. c-Myc, CyclinD1 and Cdc2 [<ce:cross-ref refid="bib212" id="crosref1105">212</ce:cross-ref>]. Recent research indicates that the metastasis of lung cancer depends on pro-metastatic genes including Cd109, which are guided by the newly discovered CD109-JAK-STAT3 signaling axis. The authors propose that inhibition of JAK kinase can provide many therapeutic benefits, including inhibition of metastasis of some cancers [<ce:cross-ref refid="bib213" id="crosref1110">213</ce:cross-ref>].</ce:para>
                     <ce:para id="p0250" view="all">It turns out that curcumin inhibits the Jak/STAT pathway by activating SHP-2 (Src homology 2 domain-containing protein tyrosine phosphatases) - a negative regulator of JAK activity [<ce:cross-ref refid="bib214" id="crosref1115">214</ce:cross-ref>]. In small cell lung cancer cells, curcumin inhibits invasion and angiogenesis through the JAK/STAT3 signaling pathway, thereby reducing the expression of proteins associated with proliferation and invasion: Survivin, Bcl-X (L), Cyclin B1, VEGF, MMP-2, MMP-7, ICAM-1 [<ce:cross-ref refid="bib215" id="crosref1120">215</ce:cross-ref>]. In the cells of chronic K562 leukemia, curcumin reduces the expression of Janus 2 kinase mRNA as well as cyclin D1 and the <ce:italic>v-Src</ce:italic> gene [<ce:cross-ref refid="bib216" id="crosref1125">216</ce:cross-ref>]. Studies indicate that the activity of the STAT3 pathway can be inhibited by curcumin with simultaneous inhibition of proliferation in lung cancer cells [<ce:cross-ref refid="bib217" id="crosref1130">217</ce:cross-ref>]. Zhao et al. noted that curcumin induces apoptosis in the SK-MES-1 squamous cell lung cancer line in a dose-dependent manner. Curcumin induces an increase in the expression of PCNA, POLL, MUTYH, STAT5A, AKT1 genes and reduces the expression of MAPK1, ARRB2, PTK2, MAPK14, VEGFA and NFKB1. These genes are involved in various signaling pathways such as BER, JAK/STAT and MAPK, which may explain the potential mechanism of the anti-tumor activity of curcumin in the examined cells [<ce:cross-ref refid="bib218" id="crosref1135">218</ce:cross-ref>].</ce:para>
                  </ce:section>
                  <ce:section id="sec3.12" view="all">
                     <ce:label>4.4</ce:label>
                     <ce:section-title id="sectitle0100">Proto-oncogene tyrosine-protein kinase Src</ce:section-title>
                     <ce:para id="p0255" view="all">Src kinase is currently the subject of many studies as a target for anti-cancer therapy [<ce:cross-refs refid="bib219 bib220 bib221" id="crosrefs0075">219–221</ce:cross-refs>]. Src is activated after stimulation of membrane receptors including receptor tyrosine kinases and integrins. Src activation is the starting point for many biochemical signaling pathways including PI3K, Akt, MAPK, STAT3, Il-8 and VEGFR [<ce:cross-ref refid="bib222" id="crosref1140">222</ce:cross-ref>]. It transmits cell survival signals, mitogenesis, affects cytoskeleton reorganization and adhesion, thereby regulating cell migration and invasion [<ce:cross-ref refid="bib223" id="crosref1145">223</ce:cross-ref>] (<ce:cross-ref refid="fig6" id="crosref1150">Fig. 6</ce:cross-ref>
                        <ce:float-anchor refid="fig6"/></ce:float-anchor>). Src kinase also participates in the EMT transition [<ce:cross-ref refid="bib224" id="crosref1155">224</ce:cross-ref>,<ce:cross-ref refid="bib225" id="crosref1160">225</ce:cross-ref>]. Increased Src activity has a common occurrence in human tumors [<ce:cross-ref refid="bib223" id="crosref1165">223</ce:cross-ref>] e.g. in colon cancer, where Src overexpression is shown in 80% of cases. This is associated with accelerated metastasis and resistance to chemotherapeutics [<ce:cross-ref refid="bib222" id="crosref1170">222</ce:cross-ref>]. In nasopharyngeal cancer [<ce:cross-ref refid="bib226" id="crosref1175">226</ce:cross-ref>] and in prostate cancer cells [<ce:cross-ref refid="bib227" id="crosref1180">227</ce:cross-ref>], c-Src activation promotes metastasis and EMT in the PI3K/Akt pathway. In addition, Src kinase mediates the communication of pathways between immune and cancer cells to facilitate the development and progression of cancer [<ce:cross-ref refid="bib228" id="crosref1185">228</ce:cross-ref>].</ce:para>
                     <ce:para id="p0260" view="all">
                        <ce:italic>In vitro</ce:italic> experiments show that curcumin can directly inhibit Src and FAK kinase. Curcumin not only inhibits phosphorylation of FAKs on the Src pathway but also inhibits the Src kinase enzymatic activity [<ce:cross-ref refid="bib208" id="crosref1190">208</ce:cross-ref>]. It is known that curcumin can mediate epigenetic modulation of microRNA expression. It turns out that it induces hypomethylation of the miRNA suppressor region, miR-203, which targets Akt 2 and Src, the level of which is then lowered [<ce:cross-ref refid="bib229" id="crosref1195">229</ce:cross-ref>]. Interestingly, curcumin increases the effect of a chemotherapeutic agent in the treatment of colorectal cancer by inhibiting the activation of NFκβ and the Src signaling pathway [<ce:cross-ref refid="bib230" id="crosref1200">230</ce:cross-ref>].</ce:para>
                  </ce:section>
               </ce:section>
               <ce:section id="sec4" view="all">
                  <ce:label>5</ce:label>
                  <ce:section-title id="sectitle0105">Curcumin modifications of potential oncological use</ce:section-title>
                  <ce:para id="p0270" view="all">Despite its unusual activity in relation to the enormous number of enzymes, the use of curcumin as a medicine is hampered by its low solubility, physicochemical instability, poor bioavailability, rapid metabolism and poor pharmacokinetics [<ce:cross-ref refid="bib232" id="crosref1205">232</ce:cross-ref>]. However, these problems can be overcome by using an effective delivery system. In recent years research has focused on conjugations and modifications of curcumin that allow to improve its pharmacokinetics, systemic bioavailability and biological activity. Among the many strategies are the microencapsulation of curcumin or its loading into nanoparticles, hybridization with specific adjuvants and modifications of curcumin's chemical structure [<ce:cross-ref refid="bib233" id="crosref1210">233</ce:cross-ref>]. In the last decade a significant number of such formulations have emerged, giving hope for successful treatment after completion of clinical trials [<ce:cross-ref refid="bib234" id="crosref1215">234</ce:cross-ref>].</ce:para>
                  <ce:section id="sec4.1" view="all">
                     <ce:label>5.1</ce:label>
                     <ce:section-title id="sectitle0110">Synthetic analogs of curcumin</ce:section-title>
                     <ce:para id="p0275" view="all">In general modifications are attempted at improving curcumin solubility and bioavailability, its improved stability and prolonged turnover. As well the emphasis is put on antioxidative potential and cytostatic effect of the new derivatives. The strategy for development of therapeutic curcumin derivatives includes the modification of the diketo functionality, double bonds in the aliphatic chains, aromatic ring sidechain, including the introduction of aromatic ring substituents, and the formation of curcumin and its derivatives with metal ions. The detailed review on the many obtained modifications of curcumin and its synthetic analogs has been given by Vyas et al. [<ce:cross-ref refid="bib235" id="crosref1220">235</ce:cross-ref>]. Here let us summarize the most apparent effects of curcumin structure modifications.</ce:para>
                  </ce:section>
                  <ce:section id="sec4.2" view="all">
                     <ce:label>5.2</ce:label>
                     <ce:section-title id="sectitle0115">Modifications of diketo group</ce:section-title>
                     <ce:para id="p0280" view="all">Wannarat Yim-im et al. [<ce:cross-ref refid="bib236" id="crosref1225">236</ce:cross-ref>], knowing that curcumin has been used as a natural medicine to inhibit cancer activity, evaluated the efficacy of natural curcumins and curcumin analogs as HER2 inhibitors using <ce:italic>in silico</ce:italic> studies. This computational analysis showed that two benzene rings of curcumin could form interactions with the hydrophobic pocket and adenine region. The carbonyl group at the linkage chain could form a hydrogen bond with the key residue Thr862. With these crucial interactions, curcumin could be a potential candidate for HER2 inhibitor. Indeed, further <ce:italic>in vitro</ce:italic> and <ce:italic>in silico</ce:italic> studies gave some promising results. The curcumin analogs classified in 4 groups accordingly to their core structure, i.e. containing β-diketone, monoketone, pyrazole, or isoxazole were further studied <ce:italic>in sillico</ce:italic> [<ce:cross-ref refid="bib77" id="crosref1230">77</ce:cross-ref>] (<ce:cross-ref refid="fig7" id="crosref1235">Fig. 7</ce:cross-ref>
                        <ce:float-anchor refid="fig7"/></ce:float-anchor>). The specificity of curcumin analogs selected from the in sillico docking was examined against human breast cancer cell lines. The screened curcumin compounds were then subjected to molecular dynamics simulation study. The most potent inhibitory activity was found for two curcumin analogs: bisdemethylcurcumin compound (AS-KTC006, CAS no. 60,831-46-1) and 3,5-bis((E)-3,4-dimethoxystyryl)isoxazole (AS-KTC021, CAS no. 1,118,765-46-0). They interacted with the HER2-TK stronger than the other known inhibitors. MM-PBSA binding calculation suggested that non-polar contributions from curcumin benzene rings are not only significant with all ligand(s)-HER2TK systems but also a major factor of the ligand-protein interactions.</ce:para>
                     <ce:para id="p0285" view="all">As reported by Ishida et al. [<ce:cross-ref refid="bib238" id="crosref1240">238</ce:cross-ref>] and Dutta et al. [<ce:cross-ref refid="bib239" id="crosref1245">239</ce:cross-ref>] the degree of cell division inhibition depends on the type of derivative, e.g. pyrazole derivative exhibits significantly higher antitumor activity compared to a derivative containing free ketone group. Pyrazole derivatives were also shown to have potential antiangiogenic activity, inhibit tumor cell proliferation and inhibit lipoxygenase activity, and thus inflammatory response [<ce:cross-ref refid="bib240" id="crosref1250">240</ce:cross-ref>]. Das and coworkers [<ce:cross-ref refid="bib241" id="crosref1255">241</ce:cross-ref>] investigated the role of carbonyl and hydroxyl groups in PKC binding by synthetic pyrazole and isoxazole derivatives of curcumin. Compared with curcumin, these derivatives exhibited increased cell growth inhibitory and pro-apoptotic effects in liver cancer HA22T/VGH cells as well as in other tumor cell types.</ce:para>
                     <ce:para id="p0290" view="all">Curcumin derivatives with blocked ketone moiety, e.g. by association with amines, have in turn weaker cytotoxic properties [<ce:cross-ref refid="bib240" id="crosref1260">240</ce:cross-ref>,<ce:cross-ref refid="bib242" id="crosref1265">242</ce:cross-ref>]. In terms of antioxidant activity, it was found that curcumin substituted within one of the ketone groups with semicarbazone reacted with free radicals at a slower rate than the base compound. However, this did not significantly affect the activity of the modified molecule [<ce:cross-ref refid="bib239" id="crosref1270">239</ce:cross-ref>]. Paradoxically, the antioxidant potential of the phenolic group for the semicarbazone derivative was found higher. This phenomenon can be explained by a change in the electron charge distribution. Upon binding to free radicals, the double bond between two nitrogen atoms in semicarbazone is displaced. This allows formation of a conjugated double bond system along the whole molecule and increases the stability of the resulting radical. Another modification of the diketone system is the introduction of a substituted benzyl oxime. This modification increases the anti-proliferative activity of HA22T/AGH (hepatic tumors), MCF-7 (breast cancer) and MCF-7R (multidrug-resistant breast cancer) [<ce:cross-ref refid="bib243" id="crosref1275">243</ce:cross-ref>].</ce:para>
                     <ce:para id="p0295" view="all">There have been promising reports on the synthetic curcumin analogs, where the central motif was a five-carbon chain with two symmetric double bonds and a central carbonyl group [<ce:cross-refs refid="bib244 bib245 bib246" id="crosrefs0080">244–246</ce:cross-refs>]. It must be here mentioned that 1,5-bis(4-hydroxy-3-methoxyphenyl)-penta-(1E,4E)-1,4-dien-3-one, the so-called C5-curcumin is a natural analogue of curcumin isolated from the rhizomes of Curcuma domestica Val. (Zingiberacea) [<ce:cross-ref refid="bib247" id="crosref1280">247</ce:cross-ref>]. Efficacy of such monocarbonyl derivatives (methoxy –substituted at various positions in aryl moieties) was investigated in eight different breast and prostate cancer cell lines [<ce:cross-ref refid="bib245" id="crosref1285">245</ce:cross-ref>]. The compounds were substantially more effective than curcumin in inhibiting AKT phosphorylation and down-regulating the expression of HER2/neu. In addition, they also inhibited phosphorylation of STAT3, an oncogene protein being a substrate of janus kinases in JAK/STAT signaling pathway.</ce:para>
                     <ce:para id="p0300" view="all">Similarly, Yamakoshi and co-workers [<ce:cross-ref refid="bib246" id="crosref1290">246</ce:cross-ref>] evaluated cytotoxicities of C5-curcumin analogs against human colon cancer HCT-116 cell line. The compounds belonging to the symmetric 3, 5-methoxymethoxy- substituted series, (GO-YO30 and GO-YO31) were found to be the most potent analogs.</ce:para>
                     <ce:para id="p0305" view="all">An interesting group of curcumin derivatives in terms of anticancer activity are compounds, where the keto-moiety has been replaced by a cyclic ketone [<ce:cross-ref refid="bib240" id="crosref1295">240</ce:cross-ref>,<ce:cross-ref refid="bib248" id="crosref1300">248</ce:cross-ref>]. The simplest derivative of curcumin containing the cyclic element in the alkyl link between the rings is cyclocurcumin (<ce:cross-ref refid="fig8" id="crosref1305">Fig. 8</ce:cross-ref>
                        <ce:float-anchor refid="fig8"/></ce:float-anchor>).</ce:para>
                     <ce:para id="p0310" view="all">Simon et al. [<ce:cross-ref refid="bib248" id="crosref1310">248</ce:cross-ref>] have shown that cyclocurcumin is an inefficient inhibitor of cell proliferation. Nevertheless, an idea to design a cyclic ketone derivatives proved promising in the mentioned C5-curcumin derivatives. Among them, the highest antiproliferative activity in relation to the various tumor cell lines show analogs in which the formed cyclic moiety contains a heteroatom [<ce:cross-ref refid="bib244" id="crosref1315">244</ce:cross-ref>]. Al-Hujaily et al. [<ce:cross-ref refid="bib249" id="crosref1320">249</ce:cross-ref>] have investigated the anticancer activity of 5-Bis (4-hydroxy-3-methoxybenzylidene)-<ce:italic>N</ce:italic>-methyl-4-piperidone (PAC) against normal and breast cancer cells found it to be five times more efficient than curcumin in inducing apoptosis at 40 μM dose. This effect was 10-fold higher against estrogen receptor negative breast cancer cells. In addition, <ce:bold>PAC</ce:bold> delayed the cell cycle at G2/M phase with a stronger effect on estrogen receptor negative cells. In mice the compound exhibited higher stability in blood and greater bio-distribution and bioavailability than curcumin. Similar monoketo-curcumin analogs having cyclopentanone, and cyclohexanone as well as acetone central motifs have also been synthesized [<ce:cross-ref refid="bib250" id="crosref1325">250</ce:cross-ref>]. Their cytotoxicity was evaluated against seven human tumor cell lines (BGC823, CNE, HL-60, KB, LS174T, PC3, and HeLa) and the mentioned derivatives exhibited a considerable activity against some of these cell lines. Structure-activity relationship studies indicated that the presence of strong electron withdrawing substituents at 2′ position may be important for the enhancement of cytotoxicity.</ce:para>
                  </ce:section>
                  <ce:section id="sec4.3" view="all">
                     <ce:label>5.3</ce:label>
                     <ce:section-title id="sectitle0120">Aromatic side-chain modifications</ce:section-title>
                     <ce:para id="p0315" view="all">Another target of curcumin modification are its aromatic side-chains. These modifications may be aimed at e.g. improving solubility, or steric adjustment of the molecule to the desired receptors. Hence many modifications of the aromatic chains of curcumin rely on coupling with larger structures of specific functions. Such conjugations will be discussed in more detail in section 5.6. As well, minor modifications are made and studied. Some of them were shown to improve antioxidant properties. Other alter the structure of the molecule in a way that changes their metabolic profile. Fine modifications of substituents can lead to significant changes in the electron charge distribution and thus substantially affect the chemical properties of a whole molecule.</ce:para>
                     <ce:para id="p0320" view="all">The simplest imaginable modification is by replacing the hydroxyl and methoxy groups as it is in the isocurcumin molecule. Both curcumin and isocurcumin have the same antitumor effect, while for scavenging free radicals, isocurcumin exhibits weaker antioxidant activity [<ce:cross-ref refid="bib251" id="crosref1335">251</ce:cross-ref>].</ce:para>
                     <ce:para id="p0325" view="all">The antioxidant properties of curcumin derivatives positively depend on the number of hydroxyl groups in the molecule [<ce:cross-refs refid="bib251 bib252 bib253" id="crosrefs0085">251–253</ce:cross-refs>]. This observation confirms the well-known affinity of hydroxyl groups for reactive oxygen species (ROS) [<ce:cross-ref refid="bib254" id="crosref1340">254</ce:cross-ref>]. The studies on human melanoma (RPMI 7951) and breast cancer cells (MDA-MB-231) showed that in terms of cytotoxic activity the best location for the hydroxyl group in curcumin analogs, in the absence of the methoxy group, was the <ce:italic>ortho-</ce:italic>position. Compounds with substitutions in the <ce:italic>meta-</ce:italic> or <ce:italic>para-</ce:italic>positions were not as active [<ce:cross-ref refid="bib244" id="crosref1345">244</ce:cross-ref>].</ce:para>
                     <ce:para id="p0330" view="all">The hydroxyl groups of the aromatic ring are reactive, which provides a great potential for modification. In the naturally occurring curcumin the hydroxyl groups on each ring at C7 are blocked by methyl ether. The etheric bond is one of the most <ce:italic>in vivo-</ce:italic>stable modifications of the hydroxyl group, thus it is worth to look into such possible modifications of the other –OH groups of curcumin. It turns out that conversion of hydroxyl-group to methoxy-increases the cytotoxic activity of the compound, as demonstrated in breast cancer (MCF-7, SKBr3), lung (A-549), kidney (CAKI-1), leukemia (HCT-8) melanoma (SKMEL-2), brain (U-87-MG), bone (aHOS), liver (HepG2) and prostate (PC-3, LNCaP) <ce:italic>in vitro</ce:italic> studies [<ce:cross-ref refid="bib238" id="crosref1350">238</ce:cross-ref>,<ce:cross-ref refid="bib242" id="crosref1355">242</ce:cross-ref>,<ce:cross-ref refid="bib255" id="crosref1360">255</ce:cross-ref>]. Curcumin derivatives after such modifications exhibit greater stability [<ce:cross-ref refid="bib255" id="crosref1365">255</ce:cross-ref>,<ce:cross-ref refid="bib256" id="crosref1370">256</ce:cross-ref>].</ce:para>
                     <ce:para id="p0335" view="all">It appears advantageous for anti-tumor activity of curcumin when the oxygen atom is linked to the aromatic ring. Replacing it with a halogen or an alkyl chain causes the loss of antineoplastic properties [<ce:cross-ref refid="bib240" id="crosref1375">240</ce:cross-ref>].</ce:para>
                     <ce:para id="p0340" view="all">Another modification that proved beneficial in evolving anti-cancer agents is the replacement of the phenyl group with heterocyclic rings [<ce:cross-ref refid="bib257" id="crosref1380">257</ce:cross-ref>,<ce:cross-ref refid="bib258" id="crosref1385">258</ce:cross-ref>]. Somers-Edgar and co-workers [<ce:cross-ref refid="bib258" id="crosref1390">258</ce:cross-ref>] have synthesized pirymidinylmethylene curcumin analogs, 2,6-bis(pyridin-3-ylmethylene)-cyclohexanone and 2,6-bis(pyridin-4-ylmethylene)-cyclohexanone. These analogs exhibited remarkable anti-cancer activity towards MDA-MB-231 and SKBr3 human breast cancer cells, as compared to curcumin. Mechanistically these compounds induced G2/M-phase cell cycle arrest and caused apoptosis. They also modulated the expression of key cell signaling proteins including tyrosine kinases Her-2, and downstream, Akt and NFκβ in a time-dependent manner. In case of MDA-MB-231 cells, EGFR protein levels were decreased, while β-catenin protein level and the activity of P38 MAPK, Akt and JNK1/2 were increased.</ce:para>
                     <ce:para id="p0345" view="all">Many other modifications of aryl chains in curcumin, with the reference to their antineoplastic activity are given e.g. in a comprehensive review by Vyas et al. [<ce:cross-ref refid="bib235" id="crosref1395">235</ce:cross-ref>] and Rodrigues [<ce:cross-ref refid="bib233" id="crosref1400">233</ce:cross-ref>].</ce:para>
                  </ce:section>
                  <ce:section id="sec4.4" view="all">
                     <ce:label>5.4</ce:label>
                     <ce:section-title id="sectitle0125">Double bond reduction</ce:section-title>
                     <ce:para id="p0350" view="all">Curcumin derivatives with reduced double bonds in the aliphatic chain, i.e. tetrahydrocurcumin, hexahydrocurcumin and octahydrocurcumin have been shown in a cell-free environment to have better antioxidant properties than curcumin [<ce:cross-ref refid="bib251" id="crosref1405">251</ce:cross-ref>]. Tetrahydrocurcumin (THC) additionally exhibits inhibitory activity against ABC transporters [<ce:cross-ref refid="bib259" id="crosref1410">259</ce:cross-ref>]. THC is superior to curcumin for induction of GSH peroxidase, glutathione-S-transferase, NADPH: quinone reductase. These enzymes participate in the removal of ROS thus indirectly counteract in tumorigenesis. Nevertheless, reducing double bonds in the alkyl portion of curcumin weakens or even abolishes the antitumor activity of curcumin derivatives with respect to tumor cells (and as well to trypanosomes and leishmania), which does not exclude that double bonds in the alkyl chain are necessary for the action of curcumin with certain proteins regulating the cell cycle [<ce:cross-ref refid="bib238" id="crosref1415">238</ce:cross-ref>,<ce:cross-ref refid="bib251" id="crosref1420">251</ce:cross-ref>,<ce:cross-ref refid="bib260" id="crosref1425">260</ce:cross-ref>]. Curcumin, but not THC, can bind and inhibit numerous targets including DNA (cytosine-5)-methyltransferase-1, heme oxygenase-1, Nrf2, β-catenin, cyclooxygenase-2, NFκβ, inducible nitric oxide synthase, nitric oxide, amyloid plaques, ROS, VEGFR, cyclin D1, glutathione, P300/CBP, 5-lipoxygenase, cytosolic phospholipase A2, prostaglandin E2, inhibitor of NFκβ kinase-1, -2, P38MAPK, p-Tau, tumor necrosis factor-α, forkhead box O3a, CRAC. Curcumin can inhibit tumor cell growth and suppress cellular entry of viruses such as influenza A virus and hepatitis C virus much more effectively than THC. Curcumin also affects membrane mobility and is more effective than THC in suppressing phorbol-ester-induced tumor promotion [<ce:cross-ref refid="bib261" id="crosref1430">261</ce:cross-ref>], and references therein). It must be borne in mind that dihydrocurcumin and tetrahydrocurcumin are natural curcumin metabolites. Studies have shown that curcumin given intraperitoneally is first biotransformed to dihydrocurcumin and then to more easily absorbed THC [<ce:cross-ref refid="bib262" id="crosref1435">262</ce:cross-ref>]. Therefore these derivatives are largely responsible for dietary effects of curcumin.</ce:para>
                     <ce:para id="p0355" view="all">There appears a question, to what extent curcumin metabolites can be responsible for curcuminoids cellular activity and if the effects measured for curcumin apply to curcumin's metabolites. Commercially available curcumin used for research and for clinical trials (curcumin mix) contains ∼77% pure curcumin (Cur), 17% demethoxycurcumin (DMC) and 3% bisdemethoxycurcumin (BDMC). Additionally when cells are treated with curcumin, one of the major metabolites is tetrahydrocurcumin (THC) [<ce:cross-ref refid="bib263" id="crosref1440">263</ce:cross-ref>]. Sandur et al. took this into account and measured effects of TNF-induced VEGF, cyclin-D1 and COX-2 expression. They found that the expression of these proteins was inhibited by curcumin, but not by its metabolites DMC, BDMC and THC [<ce:cross-ref refid="bib264" id="crosref1445">264</ce:cross-ref>].</ce:para>
                  </ce:section>
                  <ce:section id="sec4.5" view="all">
                     <ce:label>5.5</ce:label>
                     <ce:section-title id="sectitle0130">Metal complexes of curcuminoids</ce:section-title>
                     <ce:para id="p0360" view="all">Coordination compounds comprising curcumin and its derivatives as ligands have been reported for most metals in the periodic table [<ce:cross-ref refid="bib265" id="crosref1450">265</ce:cross-ref>]. An important group among the derivatives of curcumin are complexes with these metals which can relatively easily change their degree of oxidation. Such complexes may exhibit both oxidative and antioxidant effects. Among these metals are manganese, copper and iron [<ce:cross-ref refid="bib266" id="crosref1455">266</ce:cross-ref>].</ce:para>
                     <ce:para id="p0365" view="all">Curcumin complexes with vanadium, indium and gallium were been found to be more effective than curcumin as inhibitors of tumor cell proliferation (by MTT test), as demonstrated in mouse lymphoma [<ce:cross-ref refid="bib267" id="crosref1460">267</ce:cross-ref>]. Similarly, Four new curcuminoid (1,7-diaryl-1,6-heptadiene-3,5-diones) analogs and their vanadyl (IV), cobalt (II), nickel (II) and copper (II) chelates of ML<ce:inf loc="post">2</ce:inf> stoichiometry were tested <ce:italic>in vitro</ce:italic> and <ce:italic>in vivo</ce:italic> on Ehrlich ascites carcinoma. Antitumor activity of these 1,7-diarylheptanoids and their copper (II) chelates showed that chelation remarkably enhanced cytotoxic activity and other antitumor properties [<ce:cross-ref refid="bib268" id="crosref1465">268</ce:cross-ref>]. However, the most effective appear to be curcuminoid complexes with copper. In the case of culture studies, concentrations needed for 50% cell death were around 5 μg/ml for copper complexes and 10 μg/ml for curcuminoid analogs.</ce:para>
                     <ce:para id="p0370" view="all">Copper chelates of some curcuminoid analogs showed also a significant reduction (<ce:italic>p</ce:italic> < 0.001) of solid tumor volume in mice, as compared to ligands themselves [<ce:cross-ref refid="bib269" id="crosref1470">269</ce:cross-ref>]. In contrast, the effect of curcumin that inhibits the growth of both estrogen receptor-positive and -negative breast tumor cells appreciably decreased in the presence of Cu<ce:sup loc="post">2+</ce:sup>. This effect was attributed to the copper well-known tendency to overwhelmingly bind with proteins [<ce:cross-ref refid="bib270" id="crosref1475">270</ce:cross-ref>]. Such possible effects shall be borne in mind when designing curcumin preparations with metal ions.</ce:para>
                     <ce:para id="p0375" view="all">Metal complexation of curcumin can also introduce functional co-ligands, such as, e.g. the DNA intercalators. Annaraj et al. [<ce:cross-ref refid="bib271" id="crosref1480">271</ce:cross-ref>] obtained ternary copper (II) complexes of curcumin Schiff base-type condensates involving phenanthroline/bipyridyl as ancillary ligands and examined their binding mode with DNA by spectral and electrochemical techniques. The complexes were shown to strongly interact with DNA intercalatively through the insertion of phen/bpy moieties. Additionally, curcumin itself could weakly interact with the DNA, likely through the formation of hydrogen bond between the phenolic hydroxyl groups of the curcumin and the nucleotides.</ce:para>
                     <ce:para id="p0380" view="all">Curcumin is a bidentate, spatial ligand, and therefore antioxidative potentials of curcumin complexes highly depend on their configuration. Cu and Mn complexes of curcumin catalyze the dismutation of superoxide anion, similarly to superoxide dismutase (SOD) [<ce:cross-refs refid="bib272 bib273 bib274" id="crosrefs0090">272–274</ce:cross-refs>]. Barik et al. [<ce:cross-ref refid="bib272" id="crosref1485">272</ce:cross-ref>,<ce:cross-ref refid="bib273" id="crosref1490">273</ce:cross-ref>] studied the mononuclear copper complexes of curcumin 1:1 and 1:2 complex:ligand molar ratio, for its SOD activity. The two complexes showed similar electron and hydrogen atom transfer reactions with free radicals and produced the phenoxyl radicals similar to those produced from curcumin. Yet interestingly, it was found that 1:1 Cu(II)–curcumin complex was nearly ten times more potent as SOD mimic than the 1:2 Cu(II)–curcumin complex. Similarly the rate constant for the scavenging of superoxide radical of the 1:1 complex was found to be seven times higher than that of the 1:2 Cu(II)–curcumin complex. Also, 1:1 Cu(II)–curcumin complex inhibited radiation-induced lipid peroxidation to a greater extent than the 1:2 Cu(II)–curcumin complex. Based on these experimental and on theoretical results It was concluded, that steric hindrance, O–H bond dissociation energies and ionization potential highly influence the catalytic power of curcumin complexes. Increasing flexibility of the complex to accommodate the reduced cuprous species in tetrahedral or linear environments during superoxide radical reaction plays a crucial role in the overall antioxidant and SOD activity.</ce:para>
                     <ce:para id="p0385" view="all">Tyrosine kinases are considered members of signal transduction between androgen receptor activation and bcl-2 expression [<ce:cross-ref refid="bib275" id="crosref1495">275</ce:cross-ref>]. Up-regulation of Bax and down-regulation of Bcl-2 proteins was induced by a water soluble ternary Pd (II) complex containing curcumin and bipyridyl ligands in human prostate LNCaP, PC-3, and DU-145 cancer cells [<ce:cross-ref refid="bib274" id="crosref1500">274</ce:cross-ref>]. This was accompanied by mitochondrial membrane depolarization and ROS-mediated apoptosis.</ce:para>
                  </ce:section>
                  <ce:section id="sec4.6" view="all">
                     <ce:label>5.6</ce:label>
                     <ce:section-title id="sectitle0135">Conjugates of curcumin</ce:section-title>
                     <ce:para id="p0390" view="all">The strategy to increase the availability of curcumin in tissues based on conjugation with small hydrophilic molecules as well as natural or synthetic polymers has recently gained attention.</ce:para>
                     <ce:para id="p0395" view="all">A synthesis of alkyl-substituted amino acid derivatives of curcumin was proposed by Parvathy et al. [<ce:cross-ref refid="bib276" id="crosref1505">276</ce:cross-ref>]. The amino acid moiety was linked to the diketo group linking carbon. The synthesis was carried out in dry dioxane using e.g. N,N0-dicyclohexylcarbodiimide (DCC) as coupling agent, and (4-dimethylaminopyridine (DMAP) and triethylamine (TEA)) as catalysts. These amino acid conjugations increased curcumin's aqueous solubility to 1–10 mg/ml. Derivatives of curcumin with alanine, valine, serine and cysteine, exhibited smaller IC<ce:inf loc="post">50</ce:inf> values (∼50%) than did curcumin in antioxidant assays. With respect to antimutagenicity against <ce:italic>Salmonella typhimurium</ce:italic> TA 98 and TA 1531, the derivatives showed an effect stronger than or, in a few cases, similar to curcumin. Beside the effect of obtained amino acid derivatives themselves the new compounds seem promissing as building blocks for modified peptides of a desired cellular targeting.</ce:para>
                     <ce:para id="p0400" view="all">Glycoconjugates represent the latest trend in cancer chemotherapy, which adopts the concept of selective targeting of tumor cells by selective binding to specific transmembrane glucose transporters. Glycoside derivatives are preferentially taken to tumor cells, where they undergo enzymatic cleavage by specific beta-glycosidases to release free active aglycones that act selectively on tumor cells and spare non-cancer cells. In this sense, the cytotoxicity of a number of newly synthesized, including curcumin beta-glucoside glycoconjugates (glycoside bond by the OH group of aromatic ring), perilylalcohol beta-glucoside, perilylalcohol beta-galactoside, diethylstilbestrogen beta-glucoside, and diethylstropole-beta-galactoside was studied for 24–96 h in a panel of human colon carcinoma cells [<ce:cross-ref refid="bib281" id="crosref1516">281</ce:cross-ref>]. Initiation and activation of apoptosis was increased in all colon cancer cells after exposure to most glycoconjugates. Curcumin beta-glucoside was the strongest of all glycoconjugates tested. The sensitivity of the cell lines to the product correlated well with the beta-glucosidase activity assessed in these cell lines [<ce:cross-ref refid="bib277" id="crosref1510">277</ce:cross-ref>].</ce:para>
                     <ce:para id="p0405" view="all">One of the advantages of the obtained curcumin conjugates with small hydrophilic molecules is the increased stability of curcumin in aqueous solutions. This is due to the spontaneous formation of micelles by the resulting amphiphilic structures.</ce:para>
                     <ce:para id="p0410" view="all">Manju et al. reported the coupling of hyaluronic acid and curcumin dissolved in a water/DMSO mixture using DCC and DMAP as a coupling agent and catalyst [<ce:cross-ref refid="bib278" id="crosref1515">278</ce:cross-ref>], respectively. The conjugates were amphiphilic due to the hydrophobic groups of curcumin and as a result self assembled into micelles with a size between 300 and 600 nm and a negative zeta potential (−25 to −75 mV). It was found that curcumin conjugated with hyaluronic acid remained intact at 90% after incubation in an aqueous solution with pH 7.4 for 8 h, while free curcumin showed 60% degradation within 25 min. Similarly, a conjugate of curcumin with two short oligo (ethylene glycol) linkages through the b-thioester linkages with OH groups of aryl curcumin [<ce:cross-ref refid="bib279" id="crosref1520">279</ce:cross-ref>] formed 37 nm micelles that released less than 12% of the coupled amount of curcumin by hydrolysis within 24 h pH 7.4 and 5.0, indicating good stability of this system in PBS.</ce:para>
                  </ce:section>
                  <ce:section id="sec4.7" view="all">
                     <ce:label>5.7</ce:label>
                     <ce:section-title id="sectitle0140">Nanoformulations of curcumin</ce:section-title>
                     <ce:para id="p0415" view="all">For several decades, nanoparticle (NP) technology has been widely used in medicine, including cancer therapy [<ce:cross-ref refid="bib280" id="crosref1525">280</ce:cross-ref>]. As nanocarriers of the drug, nanoparticles have several attractive features: (i) NPs consist a medium in which the substance can be easily dissolved. NPs volume allows to contain a payload of the drug or diagnostic in a milieu formulated according to the particular properties of a given compound. (ii) NPs improve stability of a drug. The surface of the NP is a target for functionalization. By modifying the NPs surface with hydrophilic moieties one can improve NPs stability in the biological fluids. Charged functional groups provide adequate zeta potential and prevent their aggregation and precipitation. Nanocarriers can also protect anti-cancer compounds from biodegradation or excretion and thus influence the pharmacokinetic profile of a compound. (iii) NPs can provide selectivity improvement. Due to particular features of NPs, including their size and possibility to functionalize them with targeting molecules it is possible to increase the drug concentration at desired sites of action and reduce systemic levels of the drug and its toxic derivatives in healthy tissues. (iv) controlled, responsive to stimuli, remote activation and drug release properties can be designed on demand. Therefore a large number of nanostructures of anticancer drugs are currently in the clinical or preclinical trial phase. Some of the nanoformulations have been approved by the FDA and are currently available on the market [<ce:cross-ref refid="bib281" id="crosref1517">281</ce:cross-ref>]. Preparations of nutrients such as carotenoids, coenzyme Q10, vitamins (A, D, E, K), phytosterols, minerals and natural extracts are available in the form of nanoparticles for 60 years [<ce:cross-ref refid="bib279" id="crosref1530">279</ce:cross-ref>].</ce:para>
                     <ce:para id="p0420" view="all">Free curcumin is poorly soluble in aqueous media (<0.1 mg/ml = 0.01% in water), but soluble in less polar solvents (ethanol 10 mg/ml = ca 1%, DMSO 25 mg/ml = ca 2.5%), In sunflower oil, soybean oil and flax oil solubilities are 0.015%, 0.02% and 0.035%, respectively [<ce:cross-ref refid="bib84" id="crosref1535">84</ce:cross-ref>]. Curcumin also tends to accumulate in lipophillic parts of the cells such as lipid membranes [<ce:cross-ref refid="bib84" id="crosref1540">84</ce:cross-ref>]. Therefore the most promising medium that allows increasing curcumin tissue saturation are liposomes. The liposome formulations characterize with a suitable release kinetics ranging 10 to above 200 h for 90% release. Among the solubilizers of the highest capacity are phospholipid and cholesterol-based.</ce:para>
                     <ce:para id="p0425" view="all">Biodegradable polymers are widely applied in drug delivery, therefore many polymer-based nanoformulations of curcumin are also being developed. Among these the PLGA-based formulations released curcumin in a sustainable manner with the half-lifetime of 9 days <ce:italic>in vitro</ce:italic> [<ce:cross-ref refid="bib282" id="crosref1545">282</ce:cross-ref>]. Curcumin-PLGA conjugate efficiently inhibits cell proliferation and cell survival in human colon carcinoma cells [<ce:cross-ref refid="bib283" id="crosref1550">283</ce:cross-ref>]. Oligo- and polysaccharides such as cellulose and cyclodextrins are also studied as curcumin conveyors [<ce:cross-ref refid="bib284" id="crosref1555">284</ce:cross-ref>]. Among the biocompatible polymers that can be carriers of curcumin, proteins as completely natural are an attractive option. Therefore, proteins such as casein [<ce:cross-ref refid="bib285" id="crosref1560">285</ce:cross-ref>] and albumin [<ce:cross-refs refid="bib286 bib287 bib288" id="crosrefs0095">286–288</ce:cross-refs>]. are tested as curcumin carriers. Some recent curcumin nanoformulations are reviewed in Refs. [<ce:cross-ref refid="bib289" id="crosref1565">289</ce:cross-ref>,<ce:cross-ref refid="bib290" id="crosref1570">290</ce:cross-ref>].</ce:para>
                     <ce:para id="p0430" view="all">Release of curcumin from nanoformulations can be pH [<ce:cross-ref refid="bib291" id="crosref1575">291</ce:cross-ref>] and temperature [<ce:cross-ref refid="bib292" id="crosref1580">292</ce:cross-ref>,<ce:cross-ref refid="bib293" id="crosref1585">293</ce:cross-ref>] –dependent. Thus, careful modification of nanoformulation composition can result in a precise control of curcumin release in disease-related circumstances such as inflammation. Presently applied modifications of nano-carriers often allow for a precise release of curcumin in desired cell compartments [<ce:cross-ref refid="bib294" id="crosref1590">294</ce:cross-ref>].</ce:para>
                     <ce:section id="sec4.7.1" view="all">
                        <ce:label>5.8</ce:label>
                        <ce:section-title id="sectitle0145">Anti-cancer properties of curcumin nanoformulations</ce:section-title>
                        <ce:para id="p0435" view="all">The antitumor properties of each curcumin nanoformulation depend on the mechanism of specific accumulation or affinity of released curcumin in tumor cells [<ce:cross-ref refid="bib295" id="crosref1595">295</ce:cross-ref>,<ce:cross-ref refid="bib296" id="crosref1600">296</ce:cross-ref>]. The activity of the same preparation may vary in different cancer cell lines. For example, the mPEG2000-curcumin conjugate formulation is active against Caco-2 (colon), KB (oral cavity), MCF-7 (breast) and NCI–H187 (lung) with IC 50 values in the 1–6 μM range, similar to that observed for curcumin alone [<ce:cross-ref refid="bib298" id="crosref1605">298</ce:cross-ref>]. Treated cells were much smaller in size compared to untreated cells and lost intercellular adhesion. NanoCurc ™ not only increases the bioavailability of curcumin in plasma and tissues, but also inhibits tumor growth in xenograft and athymic mouse models of human pancreatic cancer. Inhibition of tumor growth after administration of NanoCurc ™ together with gemcitabine was attributed, inter alia, to downregulation of the insulin-like growth factor pathway (IGF).</ce:para>
                        <ce:para id="p0440" view="all">In many studies, it was noted that curcumin nanoformulations are effective in down-regulating pro-survival proteins, proapoptotic regulation [<ce:cross-ref refid="bib290" id="crosref1610">290</ce:cross-ref>,<ce:cross-ref refid="bib297" id="crosref1615">297</ce:cross-ref>]. This activity is rarely seen with free curcumin. The main reason for the greater apoptosis is that the nanoformulation of curcumin is internalized in cancer cells by endocytosis, which can result in the release of curcumin in an active form inside the cell, bypassing metabolism. The presence of high concentrations of native form of curcumin makes it available in such cell compartments as the cell nucleus, where it can induce propapoptotic activity [<ce:cross-ref refid="bib290" id="crosref1620">290</ce:cross-ref>]. The apoptotic action of curcumin in the cell nucleus is in turn associated with its tendency to induce telomerases [<ce:cross-ref refid="bib298" id="crosref1625">298</ce:cross-ref>].</ce:para>
                        <ce:para id="p0445" view="all">Passive targeting is a key property of nanoparticles and this property promotes tumor accumulation (the enhanced permeability and retention effect) [<ce:cross-ref refid="bib290" id="crosref1630">290</ce:cross-ref>]. However, there are more and more attempts to obtain curcumin nanopreparations that are actively targeted. One of the targeting vectors is folic acid (FA). This small molecule binds to folic acid receptors to facilitate receptor-mediated endocytosis in a variety of tumor cells [<ce:cross-ref refid="bib299" id="crosref1635">299</ce:cross-ref>,<ce:cross-ref refid="bib300" id="crosref1640">300</ce:cross-ref>]. The magnetic formulation of these curcumin nanoparticles with transferrin ligand shows active targeting of K562 cancer cells (myeloid leukemia) [<ce:cross-ref refid="bib300" id="crosref1645">300</ce:cross-ref>]. The composite of curcumin PVP and hyaluronic acid (HA) drugs increased endocytosis via the hyaluronic acid receptor to target tumor cells (glioma cells and Caco-2 cells) [<ce:cross-ref refid="bib301" id="crosref1650">301</ce:cross-ref>]. Increased efficacy of conjugated HA curcumin with conjugated gold nanoparticle folates was shown in HeLa cells, glioblastoma and Caco 2 cells [<ce:cross-ref refid="bib302" id="crosref1655">302</ce:cross-ref>]. Similarly, curcumin nanoparticles conjugated to Tet-1 peptide [<ce:cross-ref refid="bib303" id="crosref1660">303</ce:cross-ref>], apotransferin and peptide apolipoprotein E (ApoE) [<ce:cross-ref refid="bib304" id="crosref1665">304</ce:cross-ref>] improved the therapeutic value of curcumin.</ce:para>
                        <ce:para id="p0450" view="all">Drug resistance or multidrug resistance is a phenomenon that causes cancer cells to become resistant to primary anticancer drugs. It is known that curcumin sensitizes cancer cells to chemotherapy therapies [<ce:cross-ref refid="bib305" id="crosref1670">305</ce:cross-ref>]. Hence, a number of studies have been devoted to nanoparticles containing simultaneously curcumin and cytostatics. The most known instances of such co-treatment include the simultaneous use of curcumin and doxorubicin (DOX). Formulation of this type in poly (butyl-cyanoacrylate) nanoparticles caused the highest inversion of drug resistance and lower expression of P-glycoprotein in MCF-7/ADR breast cancer cell lines [<ce:cross-ref refid="bib304" id="crosref1675">304</ce:cross-ref>]. Similarly, curcumin and doxorubicin encapsulated in the liposomal formulation supported greater antitumor activity <ce:italic>in vitro</ce:italic> against A549 adenocarcinoma cells compared to free DOX [<ce:cross-ref refid="bib306" id="crosref1680">306</ce:cross-ref>], [<ce:cross-ref refid="bib307" id="crosref1681">307</ce:cross-ref>]. Curcumin and paclitaxel loaded nanoparticles are another widely studied therapeutics in increased drug resistance cancer models [<ce:cross-ref refid="bib286" id="crosref1685">286</ce:cross-ref>,<ce:cross-ref refid="bib299" id="crosref1690">299</ce:cross-ref>,<ce:cross-ref refid="bib308" id="crosref1695">308</ce:cross-ref>]. Treatment with curcumin effectively sensitized cisplatin-resistant ovarian cancer cells (A2780CP) to cisplatin and radiation [<ce:cross-ref refid="bib309" id="crosref1700">309</ce:cross-ref>].</ce:para>
                     </ce:section>
                  </ce:section>
               </ce:section>
               <ce:section id="sec5" role="conclusion" view="all">
                  <ce:label>6</ce:label>
                  <ce:section-title id="sectitle0150">Conclusion</ce:section-title>
                  <ce:para id="p0455" view="all">Research on curcumin confirms its chemotherapeutic ability in various types of cancer. A characteristic feature of most natural polyphenols, including curcumin, is its simultaneous activity at many levels of cell signaling. This pleiotropic nature of curcumin is in line with current trends in oncology pharmacology, where it is to replace certain drugs, in favor of global and multidirectional therapies. A wide group of proteins responsible for cell growth, proliferation, cell cycle control, migration and inhibition of apoptosis are tyrosine kinases. Complex mechanisms of activation of tyrosine kinases and their important role in the functioning of cells prompted the development of drugs directed against TK. Curcumin, in addition to its ability to directly inhibit certain tyrosine kinases and/or their phosphorylation, modulates many TK-dependent signaling pathways. This is associated with a lower risk of resistance resulting from the activation of alternative signal transduction pathways, which is often observed when using standard TKI inhibitors. The use of the unusual properties of curcumin is, unfortunately, hampered by its poor solubility, bioavailability and instability in the cellular environment, which is why methods for delivering it to the body of patients in an active but non-toxic form are sought. The formation of synthetic analogs of curcumin, modifications of functional groups in the molecule and the formation of complexes with metals significantly affect the change in biological properties of curcumin. Changes in physicochemical properties give hope for obtaining substances with high bioavailability. The modifications carried out may cause changes in the electron charge distribution, which determine the improvement of the pharmacodynamic and pharmacokinetic properties of the potential drug.</ce:para>
                  <ce:para id="p0460" view="all">However, it should be remembered that there are still no randomized trials that would clearly confirm the benefits of curcumin in oncological therapy. This topic is still widely studied and the problem of bioavailability is a big limitation in the use of many substances of natural origin. We want to draw attention to the fact that despite promising results obtained in many research models, pleiotropic particles are still insufficiently researched. Despite the limited bioavailability of curcumin and the many health benefits of eating Curcuma longa, it is suspected that additional supplementation of this compound may stimulate cancerogenesis. We underline the need for more toxicological studies of curcumin, its metabolites and derivatives at the systemic, tissue and cellular level. Currently, the prevailing trend of supplementation of high doses of antioxidants in the form of plant extracts requires confrontation with the results of scientific research and determination of safe doses among healthy and oncological patients.</ce:para>
               </ce:section>
               <ce:section id="sec6" view="all">
                  <ce:section-title id="sectitle0155">Declarations</ce:section-title>
                  <ce:section id="sec6.1" view="all">
                     <ce:section-title id="sectitle0160">Ethics approval and consent to participate</ce:section-title>
                     <ce:para id="p0465" view="all">Not applicable.</ce:para>
                  </ce:section>
                  <ce:section id="sec6.2" view="all">
                     <ce:section-title id="sectitle0165">Consent for publication</ce:section-title>
                     <ce:para id="p0470" view="all">Not applicable.</ce:para>
                  </ce:section>
                  <ce:section id="sec6.3" view="all">
                     <ce:section-title id="sectitle0170">Availability of data and material</ce:section-title>
                     <ce:para id="p0475" view="all">The datasets generated and/or analysed during the current study are available in the cited papers, as indicated in the References.</ce:para>
                  </ce:section>
                  <ce:section id="sec6.4" view="all">
                     <ce:section-title id="sectitle0175">Competing interests</ce:section-title>
                     <ce:para id="p0480" view="all">The authors declare that they have no competing interests.</ce:para>
                  </ce:section>
               </ce:section>
               <ce:section id="sec7" view="all">
                  <ce:section-title id="sectitle0180">Funding</ce:section-title>
                  <ce:para id="p0485" view="all">This work was financially supported by <ce:grant-sponsor id="gs1" sponsor-id="https://doi.org/10.13039/501100004442" xlink:type="simple" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor">National Science Centre, Poland</ce:grant-sponsor>, under the research project number <ce:grant-number refid="gs1">2015/17/B/NZ9/03581</ce:grant-number>.</ce:para>
               </ce:section>
               <ce:section id="sec8" view="all">
                  <ce:section-title id="sectitle0185">Authors' contributions</ce:section-title>
                  <ce:para id="p0490" view="all">AG authored sections <ce:cross-refs refid="sec1 sec3 sec4" id="crosrefs0100">1, 3 and 4</ce:cross-refs>; HL authored sections <ce:cross-refs refid="sec2 sec5" id="crosrefs0105">2 and 5</ce:cross-refs>; RŚ elaborated and prepared figures and tables; UTJ co-participated in the review of literature; WP held discussion and substantive consultations, WL authored conclusions, the concept of the article, held discussions and substantive consultations, and supervised the project funding the publication. All authors reviewed and approved the manuscript.</ce:para>
               </ce:section>
            </ce:sections>
            <ce:acknowledgment id="ack0010" view="all">
               <ce:section-title id="sectitle0195">Acknowledgements</ce:section-title>
               <ce:para id="p0500" view="all">This work was financially supported by <ce:grant-sponsor id="gs2" sponsor-id="https://doi.org/10.13039/501100004442" xlink:type="simple" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor">National Science Centre, Poland</ce:grant-sponsor>, under the research project number <ce:grant-number refid="gs2">2015/17/B/NZ9/03581</ce:grant-number>.</ce:para>
            </ce:acknowledgment>
         </body>
         <tail view="all">
            <ce:bibliography id="cebib0010" view="all">
               <ce:section-title id="sectitle0200">References</ce:section-title>
               <ce:bibliography-sec id="cebibsec0010" view="all">
                  <ce:bib-reference id="bib1">
                     <ce:label>[1]</ce:label>
                     <sb:reference id="sref1">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Dervisis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Klahn</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Therapeutic innovations: tyrosine kinase inhibitors in cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]. Multidisciplinary Digital Publishing Institute</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Vet. Sci.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2016 Nov 12];3:4. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.mdpi.com/2306-7381/3/1/4" id="intref0010" xlink:type="simple">http://www.mdpi.com/2306-7381/3/1/4</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0030">Dervisis N, Klahn S. Therapeutic innovations: tyrosine kinase inhibitors in cancer. Vet. Sci. [Internet]. Multidisciplinary Digital Publishing Institute; 2016 [cited 2016 Nov 12];3:4. Available from:: http://www.mdpi.com/2306-7381/3/1/4</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib2">
                     <ce:label>[2]</ce:label>
                     <sb:reference id="sref2">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.J.</ce:given-name>
                                 <ce:surname>Mitchison</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The proliferation rate paradox in antimitotic chemotherapy</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]. American Society for Cell Biology</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Mol. Biol. Cell</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>cited 2017 Feb 14];23:1–6. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.molbiolcell.org/cgi/doi/10.1091/mbc.E10-04-0335" id="intref0015" xlink:type="simple">http://www.molbiolcell.org/cgi/doi/10.1091/mbc.E10-04-0335</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0035">Mitchison TJ. The proliferation rate paradox in antimitotic chemotherapy. Mol. Biol. Cell [Internet]. American Society for Cell Biology; 2012 [cited 2017 Feb 14];23:1-6. Available from:: http://www.molbiolcell.org/cgi/doi/10.1091/mbc.E10-04-0335</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib3">
                     <ce:label>[3]</ce:label>
                     <sb:reference id="sref3">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.L.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.S.</ce:given-name>
                                 <ce:surname>Gray</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Targeting cancer with small molecule kinase inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]. Nature Publishing Group</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Cancer</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2016 Nov 12];9:28–39. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.nature.com/doifinder/10.1038/nrc2559" id="intref0020" xlink:type="simple">http://www.nature.com/doifinder/10.1038/nrc2559</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0040">Zhang J, Yang PL, Gray NS. Targeting cancer with small molecule kinase inhibitors. Nat. Rev. Cancer [Internet]. Nature Publishing Group; 2009 [cited 2016 Nov 12];9:28-39. Available from: http://www.nature.com/doifinder/10.1038/nrc2559</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib4">
                     <ce:label>[4]</ce:label>
                     <sb:reference id="sref4">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.A.</ce:given-name>
                                 <ce:surname>Jänne</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Gray</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Settleman</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Factors underlying sensitivity of cancers to small-molecule kinase inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Drug Discov.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Feb 15];8:709–23. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/19629074" id="intref0025" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/19629074</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0045">Janne PA, Gray N, Settleman J. Factors underlying sensitivity of cancers to small-molecule kinase inhibitors. Nat. Rev. Drug Discov. [Internet]. 2009 [cited 2017 Feb 15];8:709-23. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19629074</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib5">
                     <ce:label>[5]</ce:label>
                     <sb:reference id="sref5">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.K.</ce:given-name>
                                 <ce:surname>Paul</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.K.</ce:given-name>
                                 <ce:surname>Mukhopadhyay</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Tyrosine kinase - role and significance in cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]. Ivyspring International Publisher</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Int. J. Med. Sci.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2004</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2016 Nov 12];1:101–15. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/15912202" id="intref0030" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/15912202</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0050">Paul MK, Mukhopadhyay AK. Tyrosine kinase - role and significance in cancer. Int. J. Med. Sci. [Internet]. Ivyspring International Publisher; 2004 [cited 2016 Nov 12];1:101-15. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15912202</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib6">
                     <ce:label>[6]</ce:label>
                     <sb:reference id="sref6">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.R.</ce:given-name>
                                 <ce:surname>Valiathan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Marco</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Leitinger</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.G.</ce:given-name>
                                 <ce:surname>Kleer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Fridman</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discoidin domain receptor tyrosine kinases: new players in cancer progression</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]. NIH Public Access</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancer Metastasis Rev.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Feb 14];31:295–321. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/22366781" id="intref0035" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/22366781</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0055">Valiathan RR, Marco M, Leitinger B, Kleer CG, Fridman R. Discoidin domain receptor tyrosine kinases: new players in cancer progression. Cancer Metastasis Rev. [Internet]. NIH Public Access; 2012 [cited 2017 Feb 14];31:295-321. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22366781</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib7">
                     <ce:label>[7]</ce:label>
                     <sb:reference id="sref7">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Lengyel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Sawada</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Salgia</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Tyrosine kinase mutations in human cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Curr. Mol. Med.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2007</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2016 Nov 12];7:77–84. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.eurekaselect.com/openurl/content.php?genre=article&amp;issn=1566-5240&amp;volume=7&amp;issue=1&amp;spage=77" id="intref0040" xlink:type="simple">http://www.eurekaselect.com/openurl/content.php?genre=article&issn=1566-5240&volume=7&issue=1&spage=77</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0060">Lengyel E, Sawada K, Salgia R. Tyrosine kinase mutations in human cancer. Curr. Mol. Med. [Internet]. 2007 [cited 2016 Nov 12];7:77-84. Available from: http://www.eurekaselect.com/openurl/content.php?genre=article&issn=1566-5240&volume=7&issue=1&spage=77</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib8">
                     <ce:label>[8]</ce:label>
                     <sb:reference id="sref8">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Hughes</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Deininger</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Hochhaus</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Branford</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Radich</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Kaeda</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Baccarani</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Cortes</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.C.P.</ce:given-name>
                                 <ce:surname>Cross</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.J.</ce:given-name>
                                 <ce:surname>Druker</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Blood</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2006</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Feb 15];108:28–37. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/16522812" id="intref0045" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/16522812</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0065">Hughes T, Deininger M, Hochhaus A, Branford S, Radich J, Kaeda J, Baccarani M, Cortes J, Cross NCP, Druker BJ, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood [Internet]. 2006 [cited 2017 Feb 15];108:28-37. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16522812</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib9">
                     <ce:label>[9]</ce:label>
                     <sb:reference id="sref9">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.T.</ce:given-name>
                                 <ce:surname>Shaw</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.P.</ce:given-name>
                                 <ce:surname>Hsu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.M.</ce:given-name>
                                 <ce:surname>Awad</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.A.</ce:given-name>
                                 <ce:surname>Engelman</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Tyrosine kinase gene rearrangements in epithelial malignancies</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Cancer</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Feb 15];13:772–87. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/24132104" id="intref0050" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/24132104</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0070">Shaw AT, Hsu PP, Awad MM, Engelman JA. Tyrosine kinase gene rearrangements in epithelial malignancies. Nat. Rev. Cancer [Internet]. 2013 [cited 2017 Feb 15];13:772-87. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24132104</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib10">
                     <ce:label>[10]</ce:label>
                     <sb:reference id="sref10">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Mitelman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Johansson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Mertens</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Fusion genes and rearranged genes as a linear function of chromosome aberrations in cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Genet.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2004</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Feb 15];36:331–4. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/15054488" id="intref0055" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/15054488</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0075">Mitelman F, Johansson B, Mertens F. Fusion genes and rearranged genes as a linear function of chromosome aberrations in cancer. Nat. Genet. [Internet]. 2004 [cited 2017 Feb 15];36:331-4. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15054488</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib11">
                     <ce:label>[11]</ce:label>
                     <sb:reference id="sref11">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.D.</ce:given-name>
                                 <ce:surname>McFarland</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.S.</ce:given-name>
                                 <ce:surname>Korolev</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.V.</ce:given-name>
                                 <ce:surname>Kryukov</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.R.</ce:given-name>
                                 <ce:surname>Sunyaev</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.A.</ce:given-name>
                                 <ce:surname>Mirny</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Impact of deleterious passenger mutations on cancer progression</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]. National Academy of Sciences</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Proc. Natl. Acad. Sci.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Jan 7];110:2910–5. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.pnas.org/cgi/doi/10.1073/pnas.1213968110" id="intref0060" xlink:type="simple">http://www.pnas.org/cgi/doi/10.1073/pnas.1213968110</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0080">McFarland CD, Korolev KS, Kryukov G V., Sunyaev SR, Mirny LA. Impact of deleterious passenger mutations on cancer progression. Proc. Natl. Acad. Sci. [Internet]. National Academy of Sciences; 2013 [cited 2017 Jan 7];110:2910-5. Available from: http://www.pnas.org/cgi/doi/10.1073/pnas.1213968110</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib12">
                     <ce:label>[12]</ce:label>
                     <sb:reference id="sref12">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.R.</ce:given-name>
                                 <ce:surname>Stratton</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.J.</ce:given-name>
                                 <ce:surname>Campbell</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.A.</ce:given-name>
                                 <ce:surname>Futreal</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The cancer genome</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]. Nature Publishing Group</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nature</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>cited 2017 Jan 7];458:719–24. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.nature.com/doifinder/10.1038/nature07943" id="intref0065" xlink:type="simple">http://www.nature.com/doifinder/10.1038/nature07943</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0085">Stratton MR, Campbell PJ, Futreal PA. The cancer genome. Nature [Internet]. Nature Publishing Group; 2009 [cited 2017 Jan 7];458:719-24. Available from: http://www.nature.com/doifinder/10.1038/nature07943</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib13">
                     <ce:label>[13]</ce:label>
                     <sb:reference id="sref13">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.R.</ce:given-name>
                                 <ce:surname>Pon</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.A.</ce:given-name>
                                 <ce:surname>Marra</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Driver and passenger mutations in cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Annu. Rev. Pathol.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Jan 7];10:25–50. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.annualreviews.org/doi/10.1146/annurev-pathol-012414-040312" id="intref0070" xlink:type="simple">http://www.annualreviews.org/doi/10.1146/annurev-pathol-012414-040312</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0090">Pon JR, Marra MA. Driver and passenger mutations in cancer. Annu. Rev. Pathol. [Internet]. 2015 [cited 2017 Jan 7];10:25-50. Available from: http://www.annualreviews.org/doi/10.1146/annurev-pathol-012414-040312</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib14">
                     <ce:label>[14]</ce:label>
                     <sb:reference id="sref14">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Takeuchi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Ito</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Receptor tyrosine kinases and targeted cancer therapeutics</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Biol. Pharm. Bull.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Jan 6];34:1774–80. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/22130229" id="intref0075" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/22130229</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0095">Takeuchi K, Ito F. Receptor tyrosine kinases and targeted cancer therapeutics. Biol. Pharm. Bull. [Internet]. 2011 [cited 2017 Jan 6];34:1774-80. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22130229</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib15">
                     <ce:label>[15]</ce:label>
                     <sb:reference id="sref15">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Torkamani</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Verkhivker</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.J.</ce:given-name>
                                 <ce:surname>Schork</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Cancer driver mutations in protein kinase genes</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancer Lett.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Feb 14];281:117–27. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/19081671" id="intref0080" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/19081671</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0100">Torkamani A, Verkhivker G, Schork NJ. Cancer driver mutations in protein kinase genes. Cancer Lett. [Internet]. 2009 [cited 2017 Feb 14];281:117-27. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19081671</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib16">
                     <ce:label>[16]</ce:label>
                     <sb:reference id="sref16">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.M.</ce:given-name>
                                 <ce:surname>Drake</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.K.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>O.N.</ce:given-name>
                                 <ce:surname>Witte</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Clinical targeting of mutated and wild-type protein tyrosine kinases in cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]. American Society for Microbiology</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Mol. Cell. Biol.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Feb 15];34:1722–32. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://mcb.asm.org/cgi/doi/10.1128/MCB.01592-13" id="intref0085" xlink:type="simple">http://mcb.asm.org/cgi/doi/10.1128/MCB.01592-13</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0105">Drake JM, Lee JK, Witte ON. Clinical targeting of mutated and wild-type protein tyrosine kinases in cancer. Mol. Cell. Biol. [Internet]. American Society for Microbiology; 2014 [cited 2017 Feb 15];34:1722-32. Available from: http://mcb.asm.org/cgi/doi/10.1128/MCB.01592-13</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib17">
                     <ce:label>[17]</ce:label>
                     <sb:reference id="sref17">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.A.</ce:given-name>
                                 <ce:surname>Lemmon</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Schlessinger</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Cell signaling by receptor tyrosine kinases</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]. NIH Public Access</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cell</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Feb 15];141:1117–34. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/20602996" id="intref0090" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/20602996</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0110">Lemmon MA, Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell [Internet]. NIH Public Access; 2010 [cited 2017 Feb 15];141:1117-34. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20602996</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib18">
                     <ce:label>[18]</ce:label>
                     <sb:reference id="sref18">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.M.</ce:given-name>
                                 <ce:surname>McDonell</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.D.</ce:given-name>
                                 <ce:surname>Kernohan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.M.</ce:given-name>
                                 <ce:surname>Boycott</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.L.</ce:given-name>
                                 <ce:surname>Sawyer</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Receptor tyrosine kinase mutations in developmental syndromes and cancer: two sides of the same coin</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]. Oxford University Press</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Hum. Mol. Genet.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Jan 6];24:R60–6. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/26152202" id="intref0095" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/26152202</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0115">McDonell LM, Kernohan KD, Boycott KM, Sawyer SL. Receptor tyrosine kinase mutations in developmental syndromes and cancer: two sides of the same coin. Hum. Mol. Genet. [Internet]. Oxford University Press; 2015 [cited 2017 Jan 6];24:R60-6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26152202</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib19">
                     <ce:label>[19]</ce:label>
                     <sb:reference id="sref19">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.M.</ce:given-name>
                                 <ce:surname>Reichert</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.E.</ce:given-name>
                                 <ce:surname>Valge-Archer</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Development trends for monoclonal antibody cancer therapeutics</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Drug Discov.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2007</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Feb 16];6:349–56. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/17431406" id="intref0100" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/17431406</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0120">Reichert JM, Valge-Archer VE. Development trends for monoclonal antibody cancer therapeutics. Nat. Rev. Drug Discov. [Internet]. 2007 [cited 2017 Feb 16];6:349-56. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17431406</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib20">
                     <ce:label>[20]</ce:label>
                     <sb:reference id="sref20">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.K.</ce:given-name>
                                 <ce:surname>Shawver</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Slamon</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Ullrich</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Smart drugs: tyrosine kinase inhibitors in cancer therapy</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancer Cell</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2002</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Feb 16];1:117–23. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/12086869" id="intref0105" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/12086869</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0125">Shawver LK, Slamon D, Ullrich A. Smart drugs: tyrosine kinase inhibitors in cancer therapy. Cancer Cell [Internet]. 2002 [cited 2017 Feb 16];1:117-23. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12086869</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib21">
                     <ce:label>[21]</ce:label>
                     <sb:reference id="sref21">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Eldar-Finkelman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Eisenstein</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Peptide inhibitors targeting protein kinases</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Curr. Pharmaceut. Des.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2018 Apr 3];15:2463–70. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/19601843" id="intref0110" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/19601843</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0130">Eldar-Finkelman H, Eisenstein M. Peptide inhibitors targeting protein kinases. Curr. Pharmaceut. Des. [Internet]. 2009 [cited 2018 Apr 3];15:2463-70. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19601843</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib22">
                     <ce:label>[22]</ce:label>
                     <sb:reference id="sref22">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.G.</ce:given-name>
                                 <ce:surname>Works</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Song</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Kibler</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.J.</ce:given-name>
                                 <ce:surname>Tanga</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.K.</ce:given-name>
                                 <ce:surname>Galande</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>D'Andrea</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Design of a peptide inhibitor of tyrosine kinase 2</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Protein Pept. Lett.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2018 Apr 3];21:419–25. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/24304386" id="intref0115" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/24304386</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0135">Works MG, Song B, Kibler P, Tanga MJ, Galande AK, D'Andrea A. Design of a peptide inhibitor of tyrosine kinase 2. Protein Pept. Lett. [Internet]. 2014 [cited 2018 Apr 3];21:419-25. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24304386</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib23">
                     <ce:label>[23]</ce:label>
                     <sb:reference id="sref23">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.R.</ce:given-name>
                                 <ce:surname>Hubbard</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Protein tyrosine kinases: autoregulation and small-molecule inhibition</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]. Elsevier Current Trends</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Curr. Opin. Struct. Biol.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2002</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2018 Apr 3];12:735–41. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://www.sciencedirect.com/science/article/pii/S0959440X02003834?via%3Dihub" id="intref0120" xlink:type="simple">https://www.sciencedirect.com/science/article/pii/S0959440X02003834?via%3Dihub</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0140">Hubbard SR. Protein tyrosine kinases: autoregulation and small-molecule inhibition. Curr. Opin. Struct. Biol. [Internet]. Elsevier Current Trends; 2002 [cited 2018 Apr 3];12:735-41. Available from: https://www.sciencedirect.com/science/article/pii/S0959440X02003834?via%3Dihub</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib24">
                     <ce:label>[24]</ce:label>
                     <sb:reference id="sref24">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.H.</ce:given-name>
                                 <ce:surname>Cohen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.L.</ce:given-name>
                                 <ce:surname>Moses</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Pazdur</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Gleevec for the treatment of chronic myelogenous leukemia: US. Food and Drug Administration regulatory mechanisms, accelerated approval, and orphan drug status</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]. AlphaMed Press</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncologist</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2002</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2018 Apr 3];7:390–2. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/12401900" id="intref0125" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/12401900</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0145">Cohen MH, Moses ML, Pazdur R. Gleevec for the treatment of chronic myelogenous leukemia: US. Food and Drug Administration regulatory mechanisms, accelerated approval, and orphan drug status. The Oncologist [Internet]. AlphaMed Press; 2002 [cited 2018 Apr 3];7:390-2. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12401900</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib25">
                     <ce:label>[25]</ce:label>
                     <sb:reference id="sref25">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.H.</ce:given-name>
                                 <ce:surname>Cohen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.A.</ce:given-name>
                                 <ce:surname>Williams</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Sridhara</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Pazdur</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]. AlphaMed Press</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>The Oncologist</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2003</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2018 Apr 3];8:303–6. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/12897327" id="intref0130" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/12897327</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0150">Cohen MH, Williams GA, Sridhara R, Chen G, Pazdur R. FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets. The Oncologist [Internet]. AlphaMed Press; 2003 [cited 2018 Apr 3];8:303-6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12897327</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib26">
                     <ce:label>[26]</ce:label>
                     <sb:reference id="sref26">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.J.</ce:given-name>
                                 <ce:surname>Gotink</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.M.W.</ce:given-name>
                                 <ce:surname>Verheul</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Angiogenesis</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2018 Sep 28];13:1–14. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/20012482" id="intref0135" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/20012482</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0155">Gotink KJ, Verheul HMW. Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action? Angiogenesis [Internet]. 2010 [cited 2018 Sep 28];13:1-14. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20012482</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib27">
                     <ce:label>[27]</ce:label>
                     <sb:reference id="sref27">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.P.</ce:given-name>
                                 <ce:surname>Ongusaha</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Kim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Fang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.W.</ce:given-name>
                                 <ce:surname>Wong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.D.</ce:given-name>
                                 <ce:surname>Yancopoulos</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.A.</ce:given-name>
                                 <ce:surname>Aaronson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.W.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>p53 induction and activation of DDR1 kinase counteract p53-mediated apoptosis and influence p53 regulation through a positive feedback loop</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]. Wiley-Blackwell</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>EMBO J.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2003</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2018 Apr 3];22:1289–301. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://emboj.embopress.org/cgi/doi/10.1093/emboj/cdg129" id="intref0140" xlink:type="simple">http://emboj.embopress.org/cgi/doi/10.1093/emboj/cdg129</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0160">Ongusaha PP, Kim J, Fang L, Wong TW, Yancopoulos GD, Aaronson SA, Lee SW. p53 induction and activation of DDR1 kinase counteract p53-mediated apoptosis and influence p53 regulation through a positive feedback loop. EMBO J. [Internet]. Wiley-Blackwell; 2003 [cited 2018 Apr 3];22:1289-301. Available from: http://emboj.embopress.org/cgi/doi/10.1093/emboj/cdg129</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib28">
                     <ce:label>[28]</ce:label>
                     <sb:reference id="sref28">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Shintani</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Fukumoto</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Chaika</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Svoboda</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.J.</ce:given-name>
                                 <ce:surname>Wheelock</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.R.</ce:given-name>
                                 <ce:surname>Johnson</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Collagen I–mediated up-regulation of N-cadherin requires cooperative signals from integrins and discoidin domain receptor 1</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Cell Biol.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2018 Apr 3];180:1277–89. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/18362184" id="intref0145" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/18362184</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0165">Shintani Y, Fukumoto Y, Chaika N, Svoboda R, Wheelock MJ, Johnson KR. Collagen I-mediated up-regulation of N-cadherin requires cooperative signals from integrins and discoidin domain receptor 1. J. Cell Biol. [Internet]. 2008 [cited 2018 Apr 3];180:1277-89. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18362184</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib29">
                     <ce:label>[29]</ce:label>
                     <sb:reference id="sref29">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.L.</ce:given-name>
                                 <ce:surname>Masferrer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.M.</ce:given-name>
                                 <ce:surname>Leahy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.T.</ce:given-name>
                                 <ce:surname>Koki</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.S.</ce:given-name>
                                 <ce:surname>Zweifel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.L.</ce:given-name>
                                 <ce:surname>Settle</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.M.</ce:given-name>
                                 <ce:surname>Woerner</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.A.</ce:given-name>
                                 <ce:surname>Edwards</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.G.</ce:given-name>
                                 <ce:surname>Flickinger</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.J.</ce:given-name>
                                 <ce:surname>Moore</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Seibert</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]. American Association for Cancer Research</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancer Res.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2000</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2018 Apr 3];60:1306–11. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/10728691" id="intref0150" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/10728691</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0170">Masferrer JL, Leahy KM, Koki AT, Zweifel BS, Settle SL, Woerner BM, Edwards DA, Flickinger AG, Moore RJ, Seibert K. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res. [Internet]. American Association for Cancer Research; 2000 [cited 2018 Apr 3];60:1306-11. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10728691</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib30">
                     <ce:label>[30]</ce:label>
                     <sb:reference id="sref30">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.-G.</ce:given-name>
                                 <ce:surname>Kim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.-Y.</ce:given-name>
                                 <ce:surname>Hwang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.A.</ce:given-name>
                                 <ce:surname>Aaronson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Mandinova</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.W.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>DDR1 receptor tyrosine kinase promotes prosurvival pathway through Notch1 activation</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]. American Society for Biochemistry and Molecular Biology</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Biol. Chem.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2018 Apr 3];286:17672–81. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/21398698" id="intref0155" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/21398698</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0175">Kim H-G, Hwang S-Y, Aaronson SA, Mandinova A, Lee SW. DDR1 receptor tyrosine kinase promotes prosurvival pathway through Notch1 activation. J. Biol. Chem. [Internet]. American Society for Biochemistry and Molecular Biology; 2011 [cited 2018 Apr 3];286:17672-81. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21398698</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib31">
                     <ce:label>[31]</ce:label>
                     <sb:reference id="sref31">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Rammal</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Saby</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Magnien</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Van-Gulick</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Garnotel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Buache</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>El Btaouri</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Jeannesson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Morjani</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discoidin domain receptors: potential actors and targets in cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]. Frontiers Media SA</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Front. Pharmacol.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Feb 15];7:55. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/27014069" id="intref0160" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/27014069</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0180">Rammal H, Saby C, Magnien K, Van-Gulick L, Garnotel R, Buache E, El Btaouri H, Jeannesson P, Morjani H. Discoidin domain receptors: potential actors and targets in cancer. Front. Pharmacol. [Internet]. Frontiers Media SA; 2016 [cited 2017 Feb 15];7:55. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27014069</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib32">
                     <ce:label>[32]</ce:label>
                     <sb:reference id="sref32">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Ranieri</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Pantaleo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Piccinno</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Roncetti</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Mutinati</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Marech</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Patruno</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Rizzo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.L.</ce:given-name>
                                 <ce:surname>Sciorsci</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Tyrosine kinase inhibitors (TKIs) in human and pet tumours with special reference to breast cancer: a comparative review</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]. Elsevier</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Crit. Rev. Oncol. Hematol.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2018 Aug 11];88:293–308. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://bazy.pb.edu.pl:2112/science/article/pii/S1040842813001030#fig0005" id="intref0165" xlink:type="simple">https://bazypbedupl:2112/science/article/pii/S1040842813001030#fig0005</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0185">Ranieri G, Pantaleo M, Piccinno M, Roncetti M, Mutinati M, Marech I, Patruno R, Rizzo A, Sciorsci RL. Tyrosine kinase inhibitors (TKIs) in human and pet tumours with special reference to breast cancer: a comparative review. Crit. Rev. Oncol. Hematol. [Internet]. Elsevier; 2013 [cited 2018 Aug 11];88:293-308. Available from: https://bazypbedupl:2112/science/article/pii/S1040842813001030#fig0005</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib33">
                     <ce:label>[33]</ce:label>
                     <sb:reference id="sref33">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Nardi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Azam</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.Q.</ce:given-name>
                                 <ce:surname>Daley</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Mechanisms and implications of imatinib resistance mutations in BCR-ABL</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Curr. Opin. Hematol.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2004</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Feb 14];11:35–43. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/14676625" id="intref0170" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/14676625</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0190">Nardi V, Azam M, Daley GQ. Mechanisms and implications of imatinib resistance mutations in BCR-ABL. Curr. Opin. Hematol. [Internet]. 2004 [cited 2017 Feb 14];11:35-43. Available from: http://www.ncbi.nlm.nih.gov/pubmed/14676625</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib34">
                     <ce:label>[34]</ce:label>
                     <sb:reference id="sref34">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Park</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.R.M.</ce:given-name>
                                 <ce:surname>Ruhul Amin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.G.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.M.</ce:given-name>
                                 <ce:surname>Shin</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>New perspectives of curcumin in cancer prevention</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]. NIH Public Access</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancer Prev. Res.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Feb 15];6:387–400. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/23466484" id="intref0175" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/23466484</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0195">Park W, Ruhul Amin ARM, Chen ZG, Shin DM. New perspectives of curcumin in cancer prevention. Cancer Prev. Res. [Internet]. NIH Public Access; 2013 [cited 2017 Feb 15];6:387-400. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23466484</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib35">
                     <ce:label>[35]</ce:label>
                     <sb:reference id="sref35">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Tuorkey</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Curcumin a potent cancer preventive agent: mechanisms of cancer cell killing</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]. Akadémiai Kiadó</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Interv. Med. Appl. Sci.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Feb 15];6:139–46. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.akademiai.com/doi/abs/10.1556/IMAS.6.2014.4.1" id="intref0180" xlink:type="simple">http://www.akademiai.com/doi/abs/10.1556/IMAS.6.2014.4.1</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0200">Tuorkey M. Curcumin a potent cancer preventive agent: mechanisms of cancer cell killing. Interv. Med. Appl. Sci. [Internet]. Akademiai Kiado; 2014 [cited 2017 Feb 15];6:139-46. Available from: http://www.akademiai.com/doi/abs/10.1556/IMAS.6.2014.4.1</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib36">
                     <ce:label>[36]</ce:label>
                     <sb:reference id="sref36">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Hemalswarya</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Doble</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Potential synergism of natural products in the treatment of cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Phyther. Res.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2006</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Feb 15];20:239–49. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/16557604" id="intref0185" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/16557604</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0205">Hemalswarya S, Doble M. Potential synergism of natural products in the treatment of cancer. Phyther. Res. [Internet]. 2006 [cited 2017 Feb 15];20:239-49. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16557604</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib37">
                     <ce:label>[37]</ce:label>
                     <sb:reference id="sref37">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Ramachandran</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Rodriguez</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Ramachandran</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.K.R.</ce:given-name>
                                 <ce:surname>Nair</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Fonseca</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Khatib</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Escalon</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.J.</ce:given-name>
                                 <ce:surname>Melnick</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Expression profiles of apoptotic genes induced by curcumin in human breast cancer and mammary epithelial cell lines</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Anticancer Res.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2005</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Feb 15];25:3293–302. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/16101141" id="intref0190" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/16101141</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0210">Ramachandran C, Rodriguez S, Ramachandran R, Nair PKR, Fonseca H, Khatib Z, Escalon E, Melnick SJ. Expression profiles of apoptotic genes induced by curcumin in human breast cancer and mammary epithelial cell lines. Anticancer Res. [Internet]. 2005 [cited 2017 Feb 15];25:3293-302. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16101141</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib38">
                     <ce:label>[38]</ce:label>
                     <sb:reference id="sref38">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.G.</ce:given-name>
                                 <ce:surname>Troselj</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.N.</ce:given-name>
                                 <ce:surname>Kujundzic</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Curcumin in combined cancer therapy</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Curr. Pharmaceut. Des.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Feb 15];20:6682–96. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/25341940" id="intref0195" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/25341940</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0215">Troselj KG, Kujundzic RN. Curcumin in combined cancer therapy. Curr. Pharmaceut. Des. [Internet]. 2014 [cited 2017 Feb 15];20:6682-96. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25341940</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib39">
                     <ce:label>[39]</ce:label>
                     <sb:reference id="sref39">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.I.</ce:given-name>
                                 <ce:surname>Priyadarsini</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The chemistry of curcumin: from extraction to therapeutic agent</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Molecules</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Feb 16];19:20091–112. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.mdpi.com/1420-3049/19/12/20091/" id="intref0200" xlink:type="simple">http://www.mdpi.com/1420-3049/19/12/20091/</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0220">Priyadarsini KI. The chemistry of curcumin: from extraction to therapeutic agent. Molecules [Internet]. 2014 [cited 2017 Feb 16];19:20091-112. Available from: http://www.mdpi.com/1420-3049/19/12/20091/</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib40">
                     <ce:label>[40]</ce:label>
                     <sb:reference id="sref40">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Ghalandarlaki</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.M.</ce:given-name>
                                 <ce:surname>Alizadeh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Ashkani-Esfahani</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Nanotechnology-applied curcumin for different diseases therapy</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>BioMed Res. Int.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>2014</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>Hindawi Publishing Corporation</sb:comment>
                     </sb:reference>
                     <ce:source-text id="srct0225">Ghalandarlaki N, Alizadeh AM, Ashkani-Esfahani S. Nanotechnology-applied curcumin for different diseases therapy. Biomed Res Int. Hindawi Publishing Corporation; 2014;2014.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib41">
                     <ce:label>[41]</ce:label>
                     <sb:reference id="sref41">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Anand</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.G.</ce:given-name>
                                 <ce:surname>Thomas</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.B.</ce:given-name>
                                 <ce:surname>Kunnumakkara</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Sundaram</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.B.</ce:given-name>
                                 <ce:surname>Harikumar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Sung</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.T.</ce:given-name>
                                 <ce:surname>Tharakan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Misra</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.K.</ce:given-name>
                                 <ce:surname>Priyadarsini</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.N.</ce:given-name>
                                 <ce:surname>Rajasekharan</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Biological activities of curcumin and its analogues (Congeners) made by man and Mother Nature</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Biochem. Pharmacol.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Feb 16];76:1590–611. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://linkinghub.elsevier.com/retrieve/pii/S0006295208005546" id="intref0205" xlink:type="simple">http://linkinghub.elsevier.com/retrieve/pii/S0006295208005546</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0230">Anand P, Thomas SG, Kunnumakkara AB, Sundaram C, Harikumar KB, Sung B, Tharakan ST, Misra K, Priyadarsini IK, Rajasekharan KN, et al. Biological activities of curcumin and its analogues (Congeners) made by man and Mother Nature. Biochem. Pharmacol. [Internet]. 2008 [cited 2017 Feb 16];76:1590-611. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0006295208005546</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib42">
                     <ce:label>[42]</ce:label>
                     <sb:reference id="sref42">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.I.</ce:given-name>
                                 <ce:surname>Ségaliny</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Tellez-Gabriel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.F.</ce:given-name>
                                 <ce:surname>Heymann</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Heymann</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Receptor tyrosine kinases: characterisation, mechanism of action and therapeutic interests for bone cancers</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]. Elsevier</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Bone. Oncol.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Mar 5];4:1–12. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/26579483" id="intref0210" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/26579483</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0235">Segaliny AI, Tellez-Gabriel M, Heymann MF, Heymann D. Receptor tyrosine kinases: characterisation, mechanism of action and therapeutic interests for bone cancers. J. Bone. Oncol. [Internet]. Elsevier; 2015 [cited 2017 Mar 5];4:1-12. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26579483</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib43">
                     <ce:label>[43]</ce:label>
                     <sb:reference id="sref43">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Malik</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.K.</ce:given-name>
                                 <ce:surname>Mukherjee</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Structure-function elucidation of antioxidative and prooxidative activities of the polyphenolic compound curcumin</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]. Hindawi Publishing Corporation</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Chin. J. Biol.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>cited 2017 Feb 16];2014:1–8. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.hindawi.com/archive/2014/396708/" id="intref0215" xlink:type="simple">http://www.hindawi.com/archive/2014/396708/</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0240">Malik P, Mukherjee TK. Structure-function elucidation of antioxidative and prooxidative activities of the polyphenolic compound curcumin. Chin. J. Biol. [Internet]. Hindawi Publishing Corporation; 2014 [cited 2017 Feb 16];2014:1-8. Available from: http://www.hindawi.com/archive/2014/396708/</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib44">
                     <ce:label>[44]</ce:label>
                     <sb:reference id="sref44">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Indira Priyadarsini</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Chemical and structural features influencing the biological activity of curcumin</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Curr. Pharmaceut. Des.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2016 Nov 13];19:2093–100. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://openurl.ingenta.com/content/xref?genre=article&amp;issn=1381-6128&amp;volume=19&amp;issue=11&amp;spage=2093" id="intref0220" xlink:type="simple">http://openurl.ingenta.com/content/xref?genre=article&issn=1381-6128&volume=19&issue=11&spage=2093</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0245">Indira Priyadarsini K. Chemical and structural features influencing the biological activity of curcumin. Curr. Pharmaceut. Des. [Internet]. 2013 [cited 2016 Nov 13];19:2093-100. Available from: http://openurl.ingenta.com/content/xref?genre=article&issn=1381-6128&volume=19&issue=11&spage=2093</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib45">
                     <ce:label>[45]</ce:label>
                     <sb:reference id="sref45">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.H.</ce:given-name>
                                 <ce:surname>Teiten</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Dicato</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Diederich</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Hybrid curcumin compounds: a new strategy for cancer treatment</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Molecules</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Feb 15];19:20839–63. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/25514225" id="intref0225" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/25514225</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0250">Teiten MH, Dicato M, Diederich M. Hybrid curcumin compounds: a new strategy for cancer treatment. Molecules [Internet]. 2014 [cited 2017 Feb 15];19:20839-63. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25514225</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib46">
                     <ce:label>[46]</ce:label>
                     <sb:reference id="sref46">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.A.</ce:given-name>
                                 <ce:surname>Sordillo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.P.</ce:given-name>
                                 <ce:surname>Sordillo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Helson</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Curcumin for the treatment of glioblastoma</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Anticancer Res.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2016 Nov 13];35:6373–8. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/26637846" id="intref0230" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/26637846</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0255">Sordillo LA, Sordillo PP, Helson L. Curcumin for the treatment of glioblastoma. Anticancer Res. [Internet]. 2015 [cited 2016 Nov 13];35:6373-8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26637846</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib47">
                     <ce:label>[47]</ce:label>
                     <sb:reference id="sref47">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Bimonte</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Barbieri</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Leongito</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Piccirillo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Giudice</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Pivonello</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>De Angelis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Granata</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Palaia</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Izzo</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Curcumin anticancer studies in pancreatic cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nutrients</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2016 Nov 13];8:433. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.mdpi.com/2072-6643/8/7/433" id="intref0235" xlink:type="simple">http://www.mdpi.com/2072-6643/8/7/433</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0260">Bimonte S, Barbieri A, Leongito M, Piccirillo M, Giudice A, Pivonello C, De Angelis C, Granata V, Palaia R, Izzo F. Curcumin anticancer studies in pancreatic cancer. Nutrients [Internet]. 2016 [cited 2016 Nov 13];8:433. Available from: http://www.mdpi.com/2072-6643/8/7/433</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib48">
                     <ce:label>[48]</ce:label>
                     <sb:reference id="sref48">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Mirzaei</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Naseri</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Rezaee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Mohammadi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Banikazemi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.R.</ce:given-name>
                                 <ce:surname>Mirzaei</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Salehi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Peyvandi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.M.</ce:given-name>
                                 <ce:surname>Pawelek</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Sahebkar</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Curcumin: a new candidate for melanoma therapy?</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Int. J. Cancer</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2016 Nov 13];139:1683–95. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://doi.wiley.com/10.1002/ijc.30224" id="intref0240" xlink:type="simple">http://doi.wiley.com/10.1002/ijc.30224</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0265">Mirzaei H, Naseri G, Rezaee R, Mohammadi M, Banikazemi Z, Mirzaei HR, Salehi H, Peyvandi M, Pawelek JM, Sahebkar A. Curcumin: a new candidate for melanoma therapy? Int. J. Cancer [Internet]. 2016 [cited 2016 Nov 13];139:1683-95. Available from: http://doi.wiley.com/10.1002/ijc.30224</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib49">
                     <ce:label>[49]</ce:label>
                     <sb:reference id="sref49">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.P.</ce:given-name>
                                 <ce:surname>Chauhan</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Chemotherapeutic potential of curcumin for colorectal cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Curr. Pharmaceut. Des.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2002</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2016 Nov 13];8:1695–706. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/12171541" id="intref0245" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/12171541</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0270">Chauhan DP. Chemotherapeutic potential of curcumin for colorectal cancer. Curr. Pharmaceut. Des. [Internet]. 2002 [cited 2016 Nov 13];8:1695-706. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12171541</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib50">
                     <ce:label>[50]</ce:label>
                     <sb:reference id="sref50">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>B.B.</ce:given-name>
                                 <ce:surname>Aggarwal</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Kumar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.C.</ce:given-name>
                                 <ce:surname>Bharti</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Anticancer potential of curcumin: preclinical and clinical studies</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Anticancer Res.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2003</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2016 Nov 13];23:363–98. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/12680238" id="intref0250" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/12680238</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0275">Aggarwal BB, Kumar A, Bharti AC. Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res. [Internet]. 2003 [cited 2016 Nov 13];23:363-98. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12680238</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib51">
                     <ce:label>[51]</ce:label>
                     <sb:reference id="sref51">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.K.</ce:given-name>
                                 <ce:surname>Shanmugam</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Rane</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.M.</ce:given-name>
                                 <ce:surname>Kanchi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Arfuso</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Chinnathambi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.E.</ce:given-name>
                                 <ce:surname>Zayed</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.A.</ce:given-name>
                                 <ce:surname>Alharbi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.K.H.</ce:given-name>
                                 <ce:surname>Tan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.P.</ce:given-name>
                                 <ce:surname>Kumar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Sethi</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The multifaceted role of curcumin in cancer prevention and treatment</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Molecules</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2016 Nov 13];20:2728–69. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.mdpi.com/1420-3049/20/2/2728/" id="intref0255" xlink:type="simple">http://www.mdpi.com/1420-3049/20/2/2728/</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0280">Shanmugam MK, Rane G, Kanchi MM, Arfuso F, Chinnathambi A, Zayed ME, Alharbi SA, Tan BKH, Kumar AP, Sethi G. The multifaceted role of curcumin in cancer prevention and treatment. Molecules [Internet]. 2015 [cited 2016 Nov 13];20:2728-69. Available from: http://www.mdpi.com/1420-3049/20/2/2728/</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib52">
                     <ce:label>[52]</ce:label>
                     <sb:reference id="sref52">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Shishodia</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Singh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.M.</ce:given-name>
                                 <ce:surname>Chaturvedi</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Modulation of transcription factors by curcumin</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Adv. Exp. Med. Biol.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2007</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2016 Nov 13];595:127–48. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/17569208" id="intref0260" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/17569208</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0285">Shishodia S, Singh T, Chaturvedi MM. Modulation of transcription factors by curcumin. Adv. Exp. Med. Biol. [Internet]. 2007 [cited 2016 Nov 13];595:127-48. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17569208</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib53">
                     <ce:label>[53]</ce:label>
                     <sb:reference id="sref53">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Shehzad</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.S.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Molecular mechanisms of curcumin action: signal transduction</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Biofactors</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Feb 15];39:27–36. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/23303697" id="intref0265" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/23303697</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0290">Shehzad A, Lee YS. Molecular mechanisms of curcumin action: signal transduction. Biofactors [Internet]. 2013 [cited 2017 Feb 15];39:27-36. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23303697</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib54">
                     <ce:label>[54]</ce:label>
                     <sb:reference id="sref54">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Ravindran</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Prasad</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.B.</ce:given-name>
                                 <ce:surname>Aggarwal</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Curcumin and cancer cells: how many ways can curry kill tumor cells selectively?</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]. Springer</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>AAPS J.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2016 Nov 13];11:495–510. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.springerlink.com/index/10.1208/s12248-009-9128-x" id="intref0270" xlink:type="simple">http://www.springerlink.com/index/10.1208/s12248-009-9128-x</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0295">Ravindran J, Prasad S, Aggarwal BB. Curcumin and cancer cells: how many ways can curry kill tumor cells selectively? AAPS J. [Internet]. Springer; 2009 [cited 2016 Nov 13];11:495-510. Available from: http://www.springerlink.com/index/10.1208/s12248-009-9128-x</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib55">
                     <ce:label>[55]</ce:label>
                     <sb:reference id="sref55">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Saif</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Kasmi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Allali</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.M.</ce:given-name>
                                 <ce:surname>Ennaji</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Prediction of DNA methylation in the promoter of gene suppressor tumor</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Gene</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2018 Apr 3];651:166–73. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/29408272" id="intref0275" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/29408272</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0300">Saif I, Kasmi Y, Allali K, Ennaji MM. Prediction of DNA methylation in the promoter of gene suppressor tumor. Gene [Internet]. 2018 [cited 2018 Apr 3];651:166-73. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29408272</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib56">
                     <ce:label>[56]</ce:label>
                     <sb:reference id="sref56">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.C.</ce:given-name>
                                 <ce:surname>Taberlay</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.A.</ce:given-name>
                                 <ce:surname>Jones</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>DNA methylation and cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Prog. Drug Res.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2016 Nov 13];67:1–23. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/20920744" id="intref0280" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/20920744</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0305">Taberlay PC, Jones PA. DNA methylation and cancer. Prog. Drug Res. [Internet]. 2011 [cited 2016 Nov 13];67:1-23. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20920744</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib57">
                     <ce:label>[57]</ce:label>
                     <sb:reference id="sref57">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Link</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Balaguer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Shen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.J.</ce:given-name>
                                 <ce:surname>Lozano</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.C.E.</ce:given-name>
                                 <ce:surname>Leung</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.R.</ce:given-name>
                                 <ce:surname>Boland</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Goel</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Curcumin modulates DNA methylation in colorectal cancer cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]. Public Library of Science</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:editors>
                                 <sb:editor>
                                    <ce:given-name>W.-G.</ce:given-name>
                                    <ce:surname>Zhu</ce:surname>
                                 </sb:editor>
                              </sb:editors>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>PLoS One</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2016 Nov 13];8:e57709. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://dx.plos.org/10.1371/journal.pone.0057709" id="intref0285" xlink:type="simple">http://dx.plos.org/10.1371/journal.pone.0057709</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0310">Link A, Balaguer F, Shen Y, Lozano JJ, Leung HCE, Boland CR, Goel A. Curcumin modulates DNA methylation in colorectal cancer cells. Zhu W-G, editor. PLoS One [Internet]. Public Library of Science; 2013 [cited 2016 Nov 13];8:e57709. Available from: http://dx.plos.org/10.1371/journal.pone.0057709</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib58">
                     <ce:label>[58]</ce:label>
                     <sb:reference id="sref58">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Jiang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Shan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Jiang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Feng</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Curcumin reactivates silenced tumor suppressor gene RARβ by reducing DNA methylation</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Phyther. Res.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2016 Nov 13];29:1237–45. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://doi.wiley.com/10.1002/ptr.5373" id="intref0290" xlink:type="simple">http://doi.wiley.com/10.1002/ptr.5373</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0315">Jiang A, Wang X, Shan X, Li Y, Wang P, Jiang P, Feng Q. Curcumin reactivates silenced tumor suppressor gene RARβ by reducing DNA methylation. Phyther. Res. [Internet]. 2015 [cited 2016 Nov 13];29:1237-45. Available from: http://doi.wiley.com/10.1002/ptr.5373</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib59">
                     <ce:label>[59]</ce:label>
                     <sb:reference id="sref59">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Reuter</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.C.</ce:given-name>
                                 <ce:surname>Gupta</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Park</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Goel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.B.</ce:given-name>
                                 <ce:surname>Aggarwal</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Epigenetic changes induced by curcumin and other natural compounds</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]. BioMed Central</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Genes. Nutr.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2016 Nov 13];6:93–108. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/21516481" id="intref0295" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/21516481</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0320">Reuter S, Gupta SC, Park B, Goel A, Aggarwal BB. Epigenetic changes induced by curcumin and other natural compounds. Genes. Nutr. [Internet]. BioMed Central; 2011 [cited 2016 Nov 13];6:93-108. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21516481</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib60">
                     <ce:label>[60]</ce:label>
                     <sb:reference id="sref60">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.J.</ce:given-name>
                                 <ce:surname>Van Erk</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Teuling</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.C.</ce:given-name>
                                 <ce:surname>Staal</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Huybers</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.J.</ce:given-name>
                                 <ce:surname>Van Bladeren</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.M.</ce:given-name>
                                 <ce:surname>Aarts</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Van Ommen</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Time- and dose-dependent effects of curcumin on gene expression in human colon cancer cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]. Medknow Publications</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Carcinog.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2004</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Mar 21];3:8. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/15140256" id="intref0300" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/15140256</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0325">Van Erk MJ, Teuling E, Staal YCMC, Huybers S, Van Bladeren PJ, Aarts JMMMJG, Van Ommen B. Time- and dose-dependent effects of curcumin on gene expression in human colon cancer cells. J. Carcinog. [Internet]. Medknow Publications; 2004 [cited 2017 Mar 21];3:8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15140256</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib61">
                     <ce:label>[61]</ce:label>
                     <sb:reference id="sref61">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Jankun</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Wyganowska-Swiatkowska</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Dettlaff</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>JelinSka</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Surdacka</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Watróbska-Swietlikowska</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Skrzypczak-Jankun</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Determining whether curcumin degradation/condensation is actually bioactivation (Review)</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Int. J. Mol. Med.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Jan 9];37:1151–8. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.spandidos-publications.com/10.3892/ijmm.2016.2524" id="intref0305" xlink:type="simple">http://www.spandidos-publications.com/10.3892/ijmm.2016.2524</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0330">Jankun J, Wyganowska-Swiatkowska M, Dettlaff K, JelinSka A, Surdacka A, Watrobska-Swietlikowska D, Skrzypczak-Jankun E. Determining whether curcumin degradation/condensation is actually bioactivation (Review). Int. J. Mol. Med. [Internet]. 2016 [cited 2017 Jan 9];37:1151-8. Available from: http://www.spandidos-publications.com/10.3892/ijmm.2016.2524</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib62">
                     <ce:label>[62]</ce:label>
                     <sb:reference id="sref62">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Prasad</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.K.</ce:given-name>
                                 <ce:surname>Tyagi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.B.</ce:given-name>
                                 <ce:surname>Aggarwal</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Recent developments in delivery, bioavailability, absorption and metabolism of curcumin: the golden pigment from golden spice</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]. Korean Cancer Association</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancer Res. Treat.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2016 Nov 13];46:2–18. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/24520218" id="intref0310" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/24520218</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0335">Prasad S, Tyagi AK, Aggarwal BB. Recent developments in delivery, bioavailability, absorption and metabolism of curcumin: the golden pigment from golden spice. Cancer Res. Treat. [Internet]. Korean Cancer Association; 2014 [cited 2016 Nov 13];46:2-18. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24520218</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib63">
                     <ce:label>[63]</ce:label>
                     <sb:reference id="sref63">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Scaltriti</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Baselga</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The epidermal growth factor receptor pathway: a model for targeted therapy</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]. American Association for Cancer Research</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Clin. Cancer Res.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2006</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Feb 19];12:5268–72. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/17000658" id="intref0315" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/17000658</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0340">Scaltriti M, Baselga J. The epidermal growth factor receptor pathway: a model for targeted therapy. Clin. Cancer Res. [Internet]. American Association for Cancer Research; 2006 [cited 2017 Feb 19];12:5268-72. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17000658</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib64">
                     <ce:label>[64]</ce:label>
                     <sb:reference id="sref64">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Baselga</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Albanell</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Epithelial growth factor receptor interacting agents</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Hematol. Oncol. Clin. N. Am.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2002</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Feb 19];16:1041–63. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/12512382" id="intref0320" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/12512382</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0345">Baselga J, Albanell J. Epithelial growth factor receptor interacting agents. Hematol. Oncol. Clin. N. Am. [Internet]. 2002 [cited 2017 Feb 19];16:1041-63. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12512382</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib65">
                     <ce:label>[65]</ce:label>
                     <sb:reference id="sref65">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Sanada</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Osada</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Tokuyama</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Tanaka</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Takahashi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Yamaguchi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Yoshida</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Critical role of c-Met and Ki67 in progress of biliary carcinoma</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]. Hindawi Publishing Corporation</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Am. Surg.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Feb 19];76:372–9. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/23986907" id="intref0325" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/23986907</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0350">Sanada Y, Osada S, Tokuyama Y, Tanaka Y, Takahashi T, Yamaguchi K, Yoshida K. Critical role of c-Met and Ki67 in progress of biliary carcinoma. Am. Surg. [Internet]. Hindawi Publishing Corporation; 2010 [cited 2017 Feb 19];76:372-9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23986907</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib66">
                     <ce:label>[66]</ce:label>
                     <sb:reference id="sref66">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Graus-Porta</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.R.</ce:given-name>
                                 <ce:surname>Beerli</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.M.</ce:given-name>
                                 <ce:surname>Daly</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.E.</ce:given-name>
                                 <ce:surname>Hynes</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]. European Molecular Biology Organization</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>EMBO J.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>1997</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>cited 2016 Aug 28];16:1647–55. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/9130710" id="intref0330" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/9130710</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0355">Graus-Porta D, Beerli RR, Daly JM, Hynes NE. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J. [Internet]. European Molecular Biology Organization; 1997 [cited 2016 Aug 28];16:1647-55. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9130710</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib67">
                     <ce:label>[67]</ce:label>
                     <sb:reference id="sref67">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Kruczak</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Rozmus-Piętoń</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Ocena statusu HER2 w raku piersi. diagnostyka Lab</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Lab. Diagn.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>45</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>315</sb:first-page>
                              <sb:last-page>323</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0360">Kruczak A, Rozmus-Pieton M. Ocena statusu HER2 w raku piersi. diagnostyka Lab J Lab Diagnostics. 2009;45:315-323.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib68">
                     <ce:label>[68]</ce:label>
                     <sb:reference id="sref68">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.L.</ce:given-name>
                                 <ce:surname>Hong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.H.</ce:given-name>
                                 <ce:surname>Spohn</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.C.</ce:given-name>
                                 <ce:surname>Hung</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Curcumin inhibits tyrosine kinase activity of p185neu and also depletes p185neu</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Clin. Cancer Res.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>1999</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2016 Aug 28];5:1884–91. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/10430096" id="intref0335" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/10430096</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0365">Hong RL, Spohn WH, Hung MC. Curcumin inhibits tyrosine kinase activity of p185neu and also depletes p185neu. Clin. Cancer Res. [Internet]. 1999 [cited 2016 Aug 28];5:1884-91. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10430096</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib69">
                     <ce:label>[69]</ce:label>
                     <sb:reference id="sref69">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.-W.</ce:given-name>
                                 <ce:surname>Lai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.-Y.</ce:given-name>
                                 <ce:surname>Chien</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.-J.</ce:given-name>
                                 <ce:surname>Kuo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.-M.</ce:given-name>
                                 <ce:surname>Tseng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.-Y.</ce:given-name>
                                 <ce:surname>Lin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.-W.</ce:given-name>
                                 <ce:surname>Chi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.-R.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The potential utility of curcumin in the treatment of HER-2-overexpressed breast cancer: an in vitro and in vivo comparison study with herceptin</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]. Hindawi Publishing Corporation</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Evid. Based Complement Altern. Med.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2016 Aug 30];2012:1–12. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.hindawi.com/journals/ecam/2012/486568/" id="intref0340" xlink:type="simple">http://www.hindawi.com/journals/ecam/2012/486568/</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0370">Lai H-W, Chien S-Y, Kuo S-J, Tseng L-M, Lin H-Y, Chi C-W, Chen D-R. The potential utility of curcumin in the treatment of HER-2-overexpressed breast cancer: an in vitro and in vivo comparison study with herceptin. Evid. Based Complement Altern. Med. [Internet]. Hindawi Publishing Corporation; 2012 [cited 2016 Aug 30];2012:1-12. Available from: http://www.hindawi.com/journals/ecam/2012/486568/</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib70">
                     <ce:label>[70]</ce:label>
                     <sb:reference id="sref70">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Venkiteswaran</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Hsu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Curcumin interferes with HER-2 signaling in a redox-dependent manner in SK-BR-3 human breast cancer cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Human Nutr. Food Sci.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>2</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1</sb:first-page>
                              <sb:last-page>8</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0375">Venkiteswaran S, Hsu H, Yang P. Curcumin Interferes with HER-2 Signaling in a Redox-Dependent Manner in SK-BR-3 Human Breast Cancer Cells. J Hum Nutr Food Sci. 2014;2:1-8.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib71">
                     <ce:label>[71]</ce:label>
                     <sb:reference id="sref71">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Matkar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Sharma</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Gao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Gurung</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.W.</ce:given-name>
                                 <ce:surname>Katona</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Liao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.B.</ce:given-name>
                                 <ce:surname>Muhammad</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.C.</ce:given-name>
                                 <ce:surname>Kong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Jin</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>An epigenetic pathway regulates sensitivity of breast cancer cells to HER2 inhibition via FOXO/c-Myc Axis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancer Cell</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2016 Sep 12];28:472–85. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/26461093" id="intref0345" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/26461093</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0380">Matkar S, Sharma P, Gao S, Gurung B, Katona BW, Liao J, Muhammad AB, Kong XC, Wang L, Jin G, et al. An epigenetic pathway regulates sensitivity of breast cancer cells to HER2 inhibition via FOXO/c-Myc Axis. Cancer Cell [Internet]. 2015 [cited 2016 Sep 12];28:472-85. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26461093</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib72">
                     <ce:label>[72]</ce:label>
                     <sb:reference id="sref72">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.H.</ce:given-name>
                                 <ce:surname>Huang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Wu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.B.</ce:given-name>
                                 <ce:surname>Loeb</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Hsu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Heidersbach</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Brincat</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Horiuchi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.J.</ce:given-name>
                                 <ce:surname>Lebbink</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.Y.</ce:given-name>
                                 <ce:surname>Mo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Goga</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Up-regulation of miR-21 by HER2/neu signaling promotes cell invasion</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Biol. Chem.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2016 Nov 13];284:18515–24. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.jbc.org/cgi/doi/10.1074/jbc.M109.006676" id="intref0350" xlink:type="simple">http://www.jbc.org/cgi/doi/10.1074/jbc.M109.006676</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0385">Huang TH, Wu F, Loeb GB, Hsu R, Heidersbach A, Brincat A, Horiuchi D, Lebbink RJ, Mo YY, Goga A, et al. Up-regulation of miR-21 by HER2/neu signaling promotes cell invasion. J. Biol. Chem. [Internet]. 2009 [cited 2016 Nov 13];284:18515-24. Available from: http://www.jbc.org/cgi/doi/10.1074/jbc.M109.006676</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib73">
                     <ce:label>[73]</ce:label>
                     <sb:reference id="sref73">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Xu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The critical roles of miR-21 in anti-cancer effects of curcumin</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Ann. Transl. Med.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2016 Nov 13];3:330. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4691004&amp;tool=pmcentrez&amp;rendertype=abstract" id="intref0355" xlink:type="simple">http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4691004&tool=pmcentrez&rendertype=abstract</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0390">Chen J, Xu T, Chen C. The critical roles of miR-21 in anti-cancer effects of curcumin. Ann. Transl. Med. [Internet]. 2015 [cited 2016 Nov 13];3:330. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4691004&tool=pmcentrez&rendertype=abstract</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib74">
                     <ce:label>[74]</ce:label>
                     <sb:reference id="sref74">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Mudduluru</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.N.</ce:given-name>
                                 <ce:surname>George-William</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Muppala</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.A.</ce:given-name>
                                 <ce:surname>Asangani</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Kumarswamy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.D.</ce:given-name>
                                 <ce:surname>Nelson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Allgayer</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Curcumin regulates miR-21 expression and inhibits invasion and metastasis in colorectal cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Biosci. Rep.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Feb 16];31:185–97. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/20815812" id="intref0360" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/20815812</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0395">Mudduluru G, George-William JN, Muppala S, Asangani IA, Kumarswamy R, Nelson LD, Allgayer H. Curcumin regulates miR-21 expression and inhibits invasion and metastasis in colorectal cancer. Biosci. Rep. [Internet]. 2011 [cited 2017 Feb 16];31:185-97. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20815812</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib75">
                     <ce:label>[75]</ce:label>
                     <sb:reference id="sref75">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Taverna</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Giallombardo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Pucci</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Flugy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Manno</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Raccosta</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Rolfo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>De Leo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Alessandro</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Curcumin inhibits in vitro and in vivo chronic myelogenous leukemia cells growth: a possible role for exosomal disposal of miR-21</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncotarget</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Feb 16];6:21918–33. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.oncotarget.com/fulltext/4204" id="intref0365" xlink:type="simple">http://www.oncotarget.com/fulltext/4204</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0400">Taverna S, Giallombardo M, Pucci M, Flugy A, Manno M, Raccosta S, Rolfo C, De Leo G, Alessandro R. Curcumin inhibits in vitro and in vivo chronic myelogenous leukemia cells growth: a possible role for exosomal disposal of miR-21. Oncotarget [Internet]. 2015 [cited 2017 Feb 16];6:21918-33. Available from:: http://www.oncotarget.com/fulltext/4204</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib76">
                     <ce:label>[76]</ce:label>
                     <sb:reference id="sref76">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>W.M.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.S.</ce:given-name>
                                 <ce:surname>Chiang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.C.</ce:given-name>
                                 <ce:surname>Huang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.W.</ce:given-name>
                                 <ce:surname>Su</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.Y.</ce:given-name>
                                 <ce:surname>Chiang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.Y.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.Y.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Amifostine-conjugated pH-sensitive calcium phosphate-covered magnetic-amphiphilic gelatin nanoparticles for controlled intracellular dual drug release for dual-targeting in HER-2-overexpressing breast cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Control. Release</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>220</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>107</sb:first-page>
                              <sb:last-page>118</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0405">Li WM, Chiang CS, Huang WC, Su CW, Chiang MY, Chen JY, Chen SY. Amifostine-conjugated pH-sensitive calcium phosphate-covered magnetic-amphiphilic gelatin nanoparticles for controlled intracellular dual drug release for dual-targeting in HER-2-overexpressing breast cancer. J Control Release. 2015;220:107-118.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib77">
                     <ce:label>[77]</ce:label>
                     <sb:reference id="sref77">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Yim-im</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>O.</ce:given-name>
                                 <ce:surname>Sawatdichaikul</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Semsri</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Horata</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Mokmak</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Tongsima</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Suksamrarn</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Choowongkomon</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Computational analyses of curcuminoid analogs against kinase domain of HER2</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]. BioMed Central</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>BMC Bioinf.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>cited 2016 Oct 19];15:261. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://bmcbioinformatics.biomedcentral.com/articles/10.1186/1471-2105-15-261" id="intref0370" xlink:type="simple">http://bmcbioinformatics.biomedcentral.com/articles/10.1186/1471-2105-15-261</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0410">Yim-im W, Sawatdichaikul O, Semsri S, Horata N, Mokmak W, Tongsima S, Suksamrarn A, Choowongkomon K. Computational analyses of curcuminoid analogs against kinase domain of HER2. BMC Bioinf. [Internet]. BioMed Central; 2014 [cited 2016 Oct 19];15:261. Available from: http://bmcbioinformatics.biomedcentral.com/articles/10.1186/1471-2105-15-261</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib78">
                     <ce:label>[78]</ce:label>
                     <sb:reference id="sref78">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Dorai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Gehani</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Katz</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Therapeutic potential of curcumin in human prostate cancer. II. Curcumin inhibits tyrosine kinase activity of epidermal growth factor receptor and depletes the protein</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Mol. Urol.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2000</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2016 Aug 28];4:1–6. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/10851300" id="intref0375" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/10851300</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0415">Dorai T, Gehani N, Katz A. Therapeutic potential of curcumin in human prostate cancer. II. Curcumin inhibits tyrosine kinase activity of epidermal growth factor receptor and depletes the protein. Mol. Urol. [Internet]. 2000 [cited 2016 Aug 28];4:1-6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10851300</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib79">
                     <ce:label>[79]</ce:label>
                     <sb:reference id="sref79">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.H.</ce:given-name>
                                 <ce:surname>Kim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Xu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.S.</ce:given-name>
                                 <ce:surname>Keum</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Reddy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Conney</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.N.T.</ce:given-name>
                                 <ce:surname>Kong</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Inhibition of EGFR signaling in human prostate cancer PC-3 cells by combination treatment with β-phenylethyl isothiocyanate and curcumin</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Carcinogenesis</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2006</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Feb 20];27:475–82. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/16299382" id="intref0380" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/16299382</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0420">Kim JH, Xu C, Keum YS, Reddy B, Conney A, Kong ANT. Inhibition of EGFR signaling in human prostate cancer PC-3 cells by combination treatment with β-phenylethyl isothiocyanate and curcumin. Carcinogenesis [Internet]. 2006 [cited 2017 Feb 20];27:475-82. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16299382</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib80">
                     <ce:label>[80]</ce:label>
                     <sb:reference id="sref80">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.L.</ce:given-name>
                                 <ce:surname>Thangapazham</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Shaheduzzaman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.H.</ce:given-name>
                                 <ce:surname>Kim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Passi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Tadese</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Vahey</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Dobi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Srivastava</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.K.</ce:given-name>
                                 <ce:surname>Maheshwari</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Androgen responsive and refractory prostate cancer cells exhibit distinct curcumin regulated transcriptome</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancer Biol. Ther.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Feb 20];7:1427–35. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/18719366" id="intref0385" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/18719366</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0425">Thangapazham RL, Shaheduzzaman S, Kim KH, Passi N, Tadese A, Vahey M, Dobi A, Srivastava S, Maheshwari RK. Androgen responsive and refractory prostate cancer cells exhibit distinct curcumin regulated transcriptome. Cancer Biol. Ther. Internet]. 2008 [cited 2017 Feb 20];7:1427-35. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18719366</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib81">
                     <ce:label>[81]</ce:label>
                     <sb:reference id="sref81">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.J.</ce:given-name>
                                 <ce:surname>McNally</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.M.</ce:given-name>
                                 <ce:surname>Harrison</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.A.</ce:given-name>
                                 <ce:surname>Ross</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>O.J.</ce:given-name>
                                 <ce:surname>Garden</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.J.</ce:given-name>
                                 <ce:surname>Wigmore</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Curcumin induces heme oxygenase 1 through generation of reactive oxygen species, p38 activation and phosphatase inhibition</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Int. J. Mol. Med.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2007</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Feb 20];19:165–72. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/17143561" id="intref0390" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/17143561</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0430">McNally SJ, Harrison EM, Ross JA, Garden OJ, Wigmore SJ. Curcumin induces heme oxygenase 1 through generation of reactive oxygen species, p38 activation and phosphatase inhibition. Int. J. Mol. Med. [Internet]. 2007 [cited 2017 Feb 20];19:165-72. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17143561</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib82">
                     <ce:label>[82]</ce:label>
                     <sb:reference id="sref82">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.N.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.X.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.J.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.W.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.L.</ce:given-name>
                                 <ce:surname>Jiang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Kong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.T.</ce:given-name>
                                 <ce:surname>Deng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.Y.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.Y.F.</ce:given-name>
                                 <ce:surname>Young</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Curcumin downregulates homeobox gene NKX3.1 in prostate cancer cell LNCaP</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Acta Pharmacol. Sin.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2007</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Feb 20];28:423–30. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/17303007" id="intref0395" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/17303007</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0435">Zhang HN, Yu CX, Zhang PJ, Chen WW, Jiang AL, Kong F, Deng JT, Zhang JY, Young CYF. Curcumin downregulates homeobox gene NKX3.1 in prostate cancer cell LNCaP. Acta Pharmacol. Sin. [Internet]. 2007 [cited 2017 Feb 20];28:423-30. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17303007</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib83">
                     <ce:label>[83]</ce:label>
                     <sb:reference id="sref83">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Yan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.S.</ce:given-name>
                                 <ce:surname>Jamaluddin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Aggarwal</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Myers</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.D.</ce:given-name>
                                 <ce:surname>Boyd</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Gene expression profiling identifies activating transcription factor 3 as a novel contributor to the proapoptotic effect of curcumin</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Mol. Cancer Ther.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2005</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Feb 20];4:233–41. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;id=15713895&amp;retmode=ref&amp;cmd=prlinks%5Cnpapers2://publication/uuid/BAF0FDED-4D94-48C9-A031-236E804AD875" id="intref0400" xlink:type="simple">http://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=15713895&retmode=ref&cmd=prlinks%5Cnpapers2://publication/uuid/BAF0FDED-4D94-48C9-A031-236E804AD875</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0440">Yan C, Jamaluddin MS, Aggarwal B, Myers J, Boyd DD. Gene expression profiling identifies activating transcription factor 3 as a novel contributor to the proapoptotic effect of curcumin. Mol. Cancer Ther. [Internet]. 2005 [cited 2017 Feb 20];4:233-41. Available from: http://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=15713895&retmode=ref&cmd=prlinks%5Cnpapers2://publication/uuid/BAF0FDED-4D94-48C9-A031-236E804AD875</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib84">
                     <ce:label>[84]</ce:label>
                     <sb:reference id="sref84">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Starok</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Preira</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Vayssade</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Haupt</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Salomé</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Rossi</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>EGFR inhibition by curcumin in cancer cells: a dual mode of action</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Biomacromolecules</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2016 Aug 30];16:1634–42. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/25893361" id="intref0405" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/25893361</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0445">Starok M, Preira P, Vayssade M, Haupt K, Salome L, Rossi C. EGFR inhibition by curcumin in cancer cells: a dual mode of action. Biomacromolecules [Internet]. 2015 [cited 2016 Aug 30];16:1634-42. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25893361</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib85">
                     <ce:label>[85]</ce:label>
                     <sb:reference id="sref85">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Chadalapaka</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Jutooru</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Burghardt</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Safe</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Drugs that target specificity proteins downregulate epidermal growth factor receptor in bladder cancer cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Mol. Cancer Res.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Mar 30];8:739–50. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/20407012%0Ahttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC2872686" id="intref0410" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/20407012%0Ahttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC2872686</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0450">Chadalapaka G, Jutooru I, Burghardt R, Safe S. Drugs that target specificity proteins downregulate epidermal growth factor receptor in bladder cancer cells. Mol. Cancer Res. [Internet]. 2010 [cited 2017 Mar 30];8:739-50. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20407012%0Ahttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC2872686</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib86">
                     <ce:label>[86]</ce:label>
                     <sb:reference id="sref86">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Zhen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Fan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Yi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Cao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Curcumin inhibits oral squamous cell carcinoma proliferation and invasion via EGFR signaling pathways</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]. e-Century Publishing Corporation</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Int. J. Clin. Exp. Pathol.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>cited 2017 Mar 30];7:6438–46. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/25400722" id="intref0415" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/25400722</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0455">Zhen L, Fan D, Yi X, Cao X, Chen D, Wang L. Curcumin inhibits oral squamous cell carcinoma proliferation and invasion via EGFR signaling pathways. Int. J. Clin. Exp. Pathol. [Internet]. e-Century Publishing Corporation; 2014 [cited 2017 Mar 30];7:6438-46. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25400722</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib87">
                     <ce:label>[87]</ce:label>
                     <sb:reference id="sref87">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Korutla</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Kumar</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Inhibitory effect of curcumin on epidermal growth factor receptor kinase activity in A431 cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Biochim. Biophys. Acta Mol. Cell Res.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>1994</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Mar 30];1224:597–600. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/7803521" id="intref0420" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/7803521</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0460">Korutla L, Kumar R. Inhibitory effect of curcumin on epidermal growth factor receptor kinase activity in A431 cells. Biochim. Biophys. Acta Mol. Cell Res. [Internet]. 1994 [cited 2017 Mar 30];1224:597-600. Available from: http://www.ncbi.nlm.nih.gov/pubmed/7803521</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib88">
                     <ce:label>[88]</ce:label>
                     <sb:reference id="sref88">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Reddy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.K.</ce:given-name>
                                 <ce:surname>Rishi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Xu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Levi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.H.</ce:given-name>
                                 <ce:surname>Sarkar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.P.N.</ce:given-name>
                                 <ce:surname>Majumdar</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Mechanisms of curcumin- and EGF-receptor related protein (ERRP)-dependent growth inhibition of colon cancer cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nutr. Cancer</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2006</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Mar 30];55:185–94. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/17044774" id="intref0425" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/17044774</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0465">Reddy S, Rishi AK, Xu H, Levi E, Sarkar FH, Majumdar APN. Mechanisms of curcumin- and EGF-receptor related protein (ERRP)-dependent growth inhibition of colon cancer cells. Nutr. Cancer [Internet]. 2006 [cited 2017 Mar 30];55:185-94. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17044774</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib89">
                     <ce:label>[89]</ce:label>
                     <sb:reference id="sref89">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.Y.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.M.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.C.</ce:given-name>
                                 <ce:surname>Chang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.L.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.Y.</ce:given-name>
                                 <ce:surname>Hsieh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.J.W.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.W.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.C.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Curcumin induces EGFR degradation in lung adenocarcinoma and modulates p38 activation in intestine: the versatile adjuvant for gefitinib therapy. Blagosklonny M</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]. Public Library of Science</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>PLoS One</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2016 Aug 30];6:e23756. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://dx.plos.org/10.1371/journal.pone.0023756" id="intref0430" xlink:type="simple">http://dx.plos.org/10.1371/journal.pone.0023756</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0470">Lee JY, Lee YM, Chang GC, Yu SL, Hsieh WY, Chen JJW, Chen HW, Yang PC. Curcumin induces EGFR degradation in lung adenocarcinoma and modulates p38 activation in intestine: the versatile adjuvant for gefitinib therapy. Blagosklonny M, editor. PLoS One [Internet]. Public Library of Science; 2011 [cited 2016 Aug 30];6:e23756. Available from: http://dx.plos.org/10.1371/journal.pone.0023756</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib90">
                     <ce:label>[90]</ce:label>
                     <sb:reference id="sref90">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Yano</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Matsumoto</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Sakurama</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Nakamura</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Ogino</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Kakiuchi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Hanibuchi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Nishioka</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancer Res.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Feb 19];68:9479–87. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/19010923" id="intref0435" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/19010923</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0475">Yano S, Wang W, Li Q, Matsumoto K, Sakurama H, Nakamura T, Ogino H, Kakiuchi S, Hanibuchi M, Nishioka Y, et al. Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. Cancer Res. [Internet]. 2008 [cited 2017 Feb 19];68:9479-87. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19010923</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib91">
                     <ce:label>[91]</ce:label>
                     <sb:reference id="sref91">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.L.</ce:given-name>
                                 <ce:surname>Organ</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.-S.S.</ce:given-name>
                                 <ce:surname>Tsao</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>An overview of the c-MET signaling pathway</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]. SAGE Publications</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Ther. Adv. Med. Oncol.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Feb 19];3:S7–19. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/22128289" id="intref0440" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/22128289</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0480">Organ SL, Tsao M-SS. An overview of the c-MET signaling pathway. Ther. Adv. Med. Oncol. [Internet]. SAGE Publications; 2011 [cited 2017 Feb 19];3:S7-19. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22128289</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib92">
                     <ce:label>[92]</ce:label>
                     <sb:reference id="sref92">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.-W.W.</ce:given-name>
                                 <ce:surname>Seol</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Zarnegar</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Transcriptional activation of the hepatocyte growth factor receptor (c-met) gene by its ligand (hepatocyte growth factor) is mediated through AP-1</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]. Nature Publishing Group</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncogene</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2000</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Feb 19];19:1132–7. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.nature.com/doifinder/10.1038/sj.onc.1203404" id="intref0445" xlink:type="simple">http://www.nature.com/doifinder/10.1038/sj.onc.1203404</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0485">Seol D-WW, Chen Q, Zarnegar R. Transcriptional activation of the hepatocyte growth factor receptor (c-met) gene by its ligand (hepatocyte growth factor) is mediated through AP-1. Oncogene [Internet]. Nature Publishing Group; 2000 [cited 2017 Feb 19];19:1132-7. Available from: http://www.nature.com/doifinder/10.1038/sj.onc.1203404</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib93">
                     <ce:label>[93]</ce:label>
                     <sb:reference id="sref93">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.X.</ce:given-name>
                                 <ce:surname>Ye</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Yin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Curcumin: updated molecular mechanisms and intervention targets in human lung cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]. Multidisciplinary Digital Publishing Institute (MDPI)</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Int. J. Mol. Sci.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Feb 19];13:3959–78. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/22489192" id="intref0450" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/22489192</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0490">Ye MX, Li Y, Yin H, Zhang J. Curcumin: updated molecular mechanisms and intervention targets in human lung cancer. Int. J. Mol. Sci. [Internet]. Multidisciplinary Digital Publishing Institute (MDPI); 2012 [cited 2017 Feb 19];13:3959-78. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22489192</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib94">
                     <ce:label>[94]</ce:label>
                     <sb:reference id="sref94">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.J.</ce:given-name>
                                 <ce:surname>Hu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.L.</ce:given-name>
                                 <ce:surname>Lin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.H.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.J.</ce:given-name>
                                 <ce:surname>Fan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.W.</ce:given-name>
                                 <ce:surname>Zou</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Curcumin mediates reversion of HGF-induced epithelial-mesenchymal transition via inhibition of c-Met expression in DU145 cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]. Spandidos Publications</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncol. Lett.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Feb 19];11:1499–505. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/26893768" id="intref0455" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/26893768</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0495">Hu HJ, Lin XL, Liu MH, Fan XJ, Zou WW. Curcumin mediates reversion of HGF-induced epithelial-mesenchymal transition via inhibition of c-Met expression in DU145 cells. Oncol. Lett. [Internet]. Spandidos Publications; 2016 [cited 2017 Feb 19];11:1499-505. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26893768</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib95">
                     <ce:label>[95]</ce:label>
                     <sb:reference id="sref95">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Jiao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Lu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Tang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Mou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.Y.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Curcumin inhibited HGF-induced EMT and angiogenesis through regulating c-Met dependent PI3K/Akt/mTOR signaling pathways in lung cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]. American Society of Gene & Cell Therapy</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Mol. Ther. Oncolytics</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Feb 19];3:16018. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/27525306" id="intref0460" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/27525306</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0500">Jiao D, Wang J, Lu W, Tang X, Chen J, Mou H, Chen QY. Curcumin inhibited HGF-induced EMT and angiogenesis through regulating c-Met dependent PI3K/Akt/mTOR signaling pathways in lung cancer. Mol. Ther. Oncolytics [Internet]. American Society of Gene & Cell Therapy; 2016 [cited 2017 Feb 19];3:16018. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27525306</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib96">
                     <ce:label>[96]</ce:label>
                     <sb:reference id="sref96">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Xu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Lu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Ying</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Wu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Zhan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Fang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Wu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Zhou</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Curcumin induces apoptosis in human lung adenocarcinoma A549 cells through a reactive oxygen species-dependent mitochondrial signaling pathway</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncol. Rep.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Feb 19];23:397–403. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/20043100" id="intref0465" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/20043100</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0505">Chen Q, Wang Y, Xu K, Lu G, Ying Z, Wu L, Zhan J, Fang R, Wu Y, Zhou J. Curcumin induces apoptosis in human lung adenocarcinoma A549 cells through a reactive oxygen species-dependent mitochondrial signaling pathway. Oncol. Rep. [Internet]. 2010 [cited 2017 Feb 19];23:397-403. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20043100</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib97">
                     <ce:label>[97]</ce:label>
                     <sb:reference id="sref97">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Q.-Y.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.-G.</ce:given-name>
                                 <ce:surname>Shi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.-H.</ce:given-name>
                                 <ce:surname>Yao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.-M.</ce:given-name>
                                 <ce:surname>Jiao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.-Y.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.-Z.</ce:given-name>
                                 <ce:surname>Hu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.-Q.</ce:given-name>
                                 <ce:surname>Wu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Song</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Yan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.-J.</ce:given-name>
                                 <ce:surname>Wu</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Lysosomal membrane permeabilization is involved in curcumin-induced apoptosis of A549 lung carcinoma cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Mol. Cell. Biochem.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Feb 19];359:389–98. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://link.springer.com/10.1007/s11010-011-1033-9" id="intref0470" xlink:type="simple">http://link.springer.com/10.1007/s11010-011-1033-9</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0510">Chen Q-Y, Shi J-G, Yao Q-H, Jiao D-M, Wang Y-Y, Hu H-Z, Wu Y-Q, Song J, Yan J, Wu L-J. Lysosomal membrane permeabilization is involved in curcumin-induced apoptosis of A549 lung carcinoma cells. Mol. Cell. Biochem. [Internet]. 2012 [cited 2017 Feb 19];359:389-98. Available from: http://link.springer.com/10.1007/s11010-011-1033-9</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib98">
                     <ce:label>[98]</ce:label>
                     <sb:reference id="sref98">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.H.</ce:given-name>
                                 <ce:surname>Teiten</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Gaascht</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Eifes</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Dicato</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Diederich</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Chemopreventive potential of curcumin in prostate cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]. BioMed Central</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Genes. Nutr.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Feb 20];5:61–74. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/19806380" id="intref0475" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/19806380</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0515">Teiten MH, Gaascht F, Eifes S, Dicato M, Diederich M. Chemopreventive potential of curcumin in prostate cancer. Genes. Nutr. [Internet]. BioMed Central; 2010 [cited 2017 Feb 20];5:61-74. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19806380</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib99">
                     <ce:label>[99]</ce:label>
                     <sb:reference id="sref99">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Zha</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.R.</ce:given-name>
                                 <ce:surname>Lackner</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Targeting the insulin-like growth factor receptor-1R pathway for cancer therapy</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Clin. Cancer Res.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Mar 3];16:2512–7. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/20388853" id="intref0480" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/20388853</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0520">Zha J, Lackner MR. Targeting the insulin-like growth factor receptor-1R pathway for cancer therapy. Clin. Cancer Res. [Internet]. 2010 [cited 2017 Mar 3];16:2512-7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20388853</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib100">
                     <ce:label>[100]</ce:label>
                     <sb:reference id="sref100">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.X.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Sharon</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>IGF-1R as an anti-cancer target-trials and tribulation</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]. BioMed Central</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Chin. J. Canc.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Mar 3];32:242–52. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/23601239" id="intref0485" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/23601239</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0525">Chen HX, Sharon E. IGF-1R as an anti-cancer target-trials and tribulation. Chin. J. Canc. [Internet]. BioMed Central; 2013 [cited 2017 Mar 3];32:242-52. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23601239</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib101">
                     <ce:label>[101]</ce:label>
                     <sb:reference id="sref101">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Hwa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Oh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.G.</ce:given-name>
                                 <ce:surname>Rosenfeld</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The insulin-like growth factor-binding protein (IGFBP) superfamily <ce:sup loc="post">1</ce:sup>
                              </sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Endocr. Rev.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>1999</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Mar 3];20:761–87. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://academic.oup.com/edrv/article-lookup/doi/10.1210/edrv.20.6.0382" id="intref0490" xlink:type="simple">https://academic.oup.com/edrv/article-lookup/doi/10.1210/edrv.20.6.0382</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0530">Hwa V, Oh Y, Rosenfeld RG. The insulin-like growth factor-binding protein (IGFBP) superfamily 1. Endocr. Rev. [Internet]. 1999 [cited 2017 Mar 3];20:761-87. Available from: https://academic.oup.com/edrv/article-lookup/doi/10.1210/edrv.20.6.0382</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib102">
                     <ce:label>[102]</ce:label>
                     <sb:reference id="sref102">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.K.</ce:given-name>
                                 <ce:surname>Denduluri</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>O.</ce:given-name>
                                 <ce:surname>Idowu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Liao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Yan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.K.</ce:given-name>
                                 <ce:surname>Mohammed</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Ye</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Wei</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Zhao</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Insulin-like growth factor (IGF) signaling intumorigenesis and the development ofcancer drug resistance</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Gene. Dis.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Mar 3];2:13–25. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/25984556" id="intref0495" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/25984556</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0535">Denduluri SK, Idowu O, Wang Z, Liao Z, Yan Z, Mohammed MK, Ye J, Wei Q, Wang J, Zhao L, et al. Insulin-like growth factor (IGF) signaling intumorigenesis and the development ofcancer drug resistance. Gene. Dis. [Internet]. 2015 [cited 2017 Mar 3];2:13-25. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25984556</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib103">
                     <ce:label>[103]</ce:label>
                     <sb:reference id="sref103">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Kim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Park</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.-H.</ce:given-name>
                                 <ce:surname>Tak</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.Y.</ce:given-name>
                                 <ce:surname>Bu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Kim</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Chemopreventive effects of curcumin on chemically induced mouse skin carcinogenesis in BK5.insulin-like growth factor-1 transgenic mice</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>In Vitro Cell. Dev. Biol. Anim.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2016 Nov 13];50:883–92. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://link.springer.com/10.1007/s11626-014-9791-9" id="intref0500" xlink:type="simple">http://link.springer.com/10.1007/s11626-014-9791-9</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0540">Kim H, Park J, Tak K-H, Bu SY, Kim E. Chemopreventive effects of curcumin on chemically induced mouse skin carcinogenesis in BK5.insulin-like growth factor-1 transgenic mice. In Vitro Cell. Dev. Biol. Anim. [Internet]. 2014 [cited 2016 Nov 13];50:883-92. Available from: http://link.springer.com/10.1007/s11626-014-9791-9</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib104">
                     <ce:label>[104]</ce:label>
                     <sb:reference id="sref104">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Xia</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Jin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Xue</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Xu</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The potentiation of curcumin on insulin-like growth factor-1 action in MCF-7 human breast carcinoma cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Life Sci.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2007</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Mar 5];80:2161–9. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/17499312" id="intref0505" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/17499312</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0545">Xia Y, Jin L, Zhang B, Xue H, Li Q, Xu Y. The potentiation of curcumin on insulin-like growth factor-1 action in MCF-7 human breast carcinoma cells. Life Sci. [Internet]. 2007 [cited 2017 Mar 5];80:2161-9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17499312</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib105">
                     <ce:label>[105]</ce:label>
                     <sb:reference id="sref105">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Umayahara</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Kawamori</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Watada</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Imano</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Iwama</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Morishima</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Yamasaki</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Kajimoto</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Kamada</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Estrogen regulation of the insulin-like growth factor I gene transcription involves an AP-1 enhancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Biol. Chem.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>1994</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Mar 7];269:16433–42. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/8206951" id="intref0510" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/8206951</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0550">Umayahara Y, Kawamori R, Watada H, Imano E, Iwama N, Morishima T, Yamasaki Y, Kajimoto Y, Kamada T. Estrogen regulation of the insulin-like growth factor I gene transcription involves an AP-1 enhancer. J. Biol. Chem. [Internet]. 1994 [cited 2017 Mar 7];269:16433-42. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8206951</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib106">
                     <ce:label>[106]</ce:label>
                     <sb:reference id="sref106">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Lev-Ari</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Maimon</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Strier</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Kazanov</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Arber</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Down-regulation of prostaglandin E2 by curcumin is correlated with inhibition of cell growth and induction of apoptosis in human colon carcinoma cell lines</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Soc. Integr. Oncol.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2006</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Mar 7];4:21–6. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/16737669" id="intref0515" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/16737669</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0555">Lev-Ari S, Maimon Y, Strier L, Kazanov D, Arber N. Down-regulation of prostaglandin E2 by curcumin is correlated with inhibition of cell growth and induction of apoptosis in human colon carcinoma cell lines. J. Soc. Integr. Oncol. [Internet]. 2006 [cited 2017 Mar 7];4:21-6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16737669</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib107">
                     <ce:label>[107]</ce:label>
                     <sb:reference id="sref107">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.P.</ce:given-name>
                                 <ce:surname>Bichell</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Rotwein</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.L.</ce:given-name>
                                 <ce:surname>McCarthy</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Prostaglandin E2 rapidly stimulates insulin-like growth factor-I gene expression in primary rat osteoblast cultures: evidence for transcriptional control</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Endocrinology</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>1993</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Mar 7];133:1020–8. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/8396006" id="intref0520" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/8396006</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0560">Bichell DP, Rotwein P, McCarthy TL. Prostaglandin E2 rapidly stimulates insulin-like growth factor-I gene expression in primary rat osteoblast cultures: evidence for transcriptional control. Endocrinology [Internet]. 1993 [cited 2017 Mar 7];133:1020-8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8396006</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib108">
                     <ce:label>[108]</ce:label>
                     <sb:reference id="sref108">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Ding</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Cheng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Deng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Ruan</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Insulin-like growth factor binding protein 5 (IGFBP5) functions as a tumor suppressor in human melanoma cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncotarget</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>6</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>24</sb:issue-nr>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Mar 7];6:20636–49. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.impactjournals.com/oncotarget/index.php?journal=oncotarget&amp;amp%5Cnpage=article&amp;amp%5Cnop=view&amp;amp%5Cnpath%5B%5D=4114" id="intref0525" xlink:type="simple">http://www.impactjournals.com/oncotarget/index.php?journal=oncotarget&amp%5Cnpage=article&amp%5Cnop=view&amp%5Cnpath%5B%5D=4114</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0565">Wang J, Ding N, Li Y, Cheng H, Wang D, Yang Q, Deng Y, Yang Y, Li Y, Ruan X, et al. Insulin-like growth factor binding protein 5 (IGFBP5) functions as a tumor suppressor in human melanoma cells. Oncotarget; Vol 6, No 24 [Internet]. 2015 [cited 2017 Mar 7];6:20636-49. Available from: http://www.impactjournals.com/oncotarget/index.php?journal=oncotarget&amp%5Cnpage=article&amp%5Cnop=view&amp%5Cnpath%5B%5D=4114</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib109">
                     <ce:label>[109]</ce:label>
                     <sb:reference id="sref109">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.M.</ce:given-name>
                                 <ce:surname>Perks</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.M.P.</ce:given-name>
                                 <ce:surname>Holly</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>IGF binding proteins (IGFBPs) and regulation of breast cancer biology</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Mammary Gland Biol. Neoplasia</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Mar 5];13:455–69. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://link.springer.com/10.1007/s10911-008-9106-4" id="intref0530" xlink:type="simple">http://link.springer.com/10.1007/s10911-008-9106-4</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0570">Perks CM, Holly JMP. IGF binding proteins (IGFBPs) and regulation of breast cancer biology. J. Mammary Gland Biol. Neoplasia [Internet]. 2008 [cited 2017 Mar 5];13:455-69. Available from: http://link.springer.com/10.1007/s10911-008-9106-4</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib110">
                     <ce:label>[110]</ce:label>
                     <sb:reference id="sref110">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.M.</ce:given-name>
                                 <ce:surname>Perks</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.M.P.</ce:given-name>
                                 <ce:surname>Holly</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Epigenetic regulation of insulin-like growth factor binding protein-3 (IGFBP-3) in cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]. Springer</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Cell Commun. Signal</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Mar 5];9:159–66. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/25920743" id="intref0535" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/25920743</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0575">Perks CM, Holly JMP. Epigenetic regulation of insulin-like growth factor binding protein-3 (IGFBP-3) in cancer. J. Cell Commun. Signal [Internet]. Springer; 2015 [cited 2017 Mar 5];9:159-66. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25920743</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib111">
                     <ce:label>[111]</ce:label>
                     <sb:reference id="sref111">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.A.</ce:given-name>
                                 <ce:surname>Johnson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.M.</ce:given-name>
                                 <ce:surname>Firth</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>IGFBP-3: a cell fate pivot in cancer and disease</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Growth Hormone IGF Res.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2018 Aug 11];24:164–73. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/24953254" id="intref0540" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/24953254</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0580">Johnson MA, Firth SM. IGFBP-3: a cell fate pivot in cancer and disease. Growth Hormone IGF Res. [Internet]. 2014 [cited 2018 Aug 11];24:164-73. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24953254</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib112">
                     <ce:label>[112]</ce:label>
                     <sb:reference id="sref112">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>B.B.</ce:given-name>
                                 <ce:surname>Patel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Sengupta</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Qazi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Vachhani</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.K.</ce:given-name>
                                 <ce:surname>Rishi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.P.N.</ce:given-name>
                                 <ce:surname>Majumdar</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Curcumin enhances the effects of 5-fluorouracil and oxaliplatin in mediating growth inhibition of colon cancer cells by modulating EGFR and IGF-1R</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Int. J. Cancer</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Mar 5];122:267–73. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/17918158" id="intref0545" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/17918158</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0585">Patel BB, Sengupta R, Qazi S, Vachhani H, Yu Y, Rishi AK, Majumdar APN. Curcumin enhances the effects of 5-fluorouracil and oxaliplatin in mediating growth inhibition of colon cancer cells by modulating EGFR and IGF-1R. Int. J. Cancer [Internet]. 2008 [cited 2017 Mar 5];122:267-73. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17918158</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib113">
                     <ce:label>[113]</ce:label>
                     <sb:reference id="sref113">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.W.</ce:given-name>
                                 <ce:surname>Chang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.S.</ce:given-name>
                                 <ce:surname>Hung</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.Y.</ce:given-name>
                                 <ce:surname>Lin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.P.</ce:given-name>
                                 <ce:surname>Hou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.K.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.M.</ce:given-name>
                                 <ce:surname>Tsai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.C.</ce:given-name>
                                 <ce:surname>Lin</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Curcumin upregulates insulin-like growth factor binding protein-5 (IGFBP-5) and C/EBP? during oral cancer suppression</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Int. J. Cancer</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Mar 7];127:9–20. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/20127863" id="intref0550" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/20127863</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0590">Chang KW, Hung PS, Lin IY, Hou CP, Chen LK, Tsai YM, Lin SC. Curcumin upregulates insulin-like growth factor binding protein-5 (IGFBP-5) and C/EBP? during oral cancer suppression. Int. J. Cancer [Internet]. 2010 [cited 2017 Mar 7];127:9-20. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20127863</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib114">
                     <ce:label>[114]</ce:label>
                     <sb:reference id="sref114">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.L.</ce:given-name>
                                 <ce:surname>Goel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.M.</ce:given-name>
                                 <ce:surname>Mercurio</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>VEGF targets the tumour cell</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]. Nature Research</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Cancer</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Mar 11];13:871–82. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.nature.com/doifinder/10.1038/nrc3627" id="intref0555" xlink:type="simple">http://www.nature.com/doifinder/10.1038/nrc3627</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0595">Goel HL, Mercurio AM. VEGF targets the tumour cell. Nat. Rev. Cancer [Internet]. Nature Research; 2013 [cited 2017 Mar 11];13:871-82. Available from: http://www.nature.com/doifinder/10.1038/nrc3627</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib115">
                     <ce:label>[115]</ce:label>
                     <sb:reference id="sref115">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.-Z.</ce:given-name>
                                 <ce:surname>Gao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.-L.</ce:given-name>
                                 <ce:surname>DU</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.-L.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.-X.</ce:given-name>
                                 <ce:surname>Wei</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.-Z.</ce:given-name>
                                 <ce:surname>Guo</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Synergistic effects of curcumin and bevacizumab on cell signaling pathways in hepatocellular carcinoma</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>Spandidos Publications</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncol. Lett.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2016 Nov 13];9:295–9. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4246621&amp;tool=pmcentrez&amp;rendertype=abstract" id="intref0560" xlink:type="simple">http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4246621&tool=pmcentrez&rendertype=abstract</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0600">Gao J-Z, DU J-L, Wang Y-L, Li J, Wei L-X, Guo M-Z. Synergistic effects of curcumin and bevacizumab on cell signaling pathways in hepatocellular carcinoma. Oncol. Lett. [Internet]. Spandidos Publications; 2015 [cited 2016 Nov 13];9:295-9. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4246621&tool=pmcentrez&rendertype=abstract</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib116">
                     <ce:label>[116]</ce:label>
                     <sb:reference id="sref116">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Yoysungnoen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Wirachwong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Bhattarakosol</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Niimi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Patumraj</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Effects of curcumin on tumor angiogenesis and biomarkers, COX-2 and VEGF, in hepatocellular carcinoma cell-implanted nude mice</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Clin. Hemorheol. Microcirc.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2006</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Mar 11];34:109–15. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/16543625" id="intref0565" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/16543625</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0605">Yoysungnoen P, Wirachwong P, Bhattarakosol P, Niimi H, Patumraj S. Effects of curcumin on tumor angiogenesis and biomarkers, COX-2 and VEGF, in hepatocellular carcinoma cell-implanted nude mice. Clin. Hemorheol. Microcirc. [Internet]. 2006 [cited 2017 Mar 11];34:109-15. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16543625</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib117">
                     <ce:label>[117]</ce:label>
                     <sb:reference id="sref117">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.G.</ce:given-name>
                                 <ce:surname>Binion</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.F.</ce:given-name>
                                 <ce:surname>Otterson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Rafiee</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Curcumin inhibits VEGF-mediated angiogenesis in human intestinal microvascular endothelial cells through COX-2 and MAPK inhibition</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]. BMJ Group</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Gut</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Mar 13];57:1509–17. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/18596194" id="intref0570" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/18596194</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0610">Binion DG, Otterson MF, Rafiee P. Curcumin inhibits VEGF-mediated angiogenesis in human intestinal microvascular endothelial cells through COX-2 and MAPK inhibition. Gut [Internet]. BMJ Group; 2008 [cited 2017 Mar 13];57:1509-17. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18596194</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib118">
                     <ce:label>[118]</ce:label>
                     <sb:reference id="sref118">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Fu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Guan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Yan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Lin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.-C.</ce:given-name>
                                 <ce:surname>Hua</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Curcumin inhibits angiogenesis and improves defective hematopoiesis induced by tumor-derived VEGF in tumor model through modulating VEGF-VEGFR2 signaling pathway</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]. Impact Journals</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncotarget</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>cited 2017 Mar 11];6:19469–82. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://oncotarget.com/abstract/3625" id="intref0575" xlink:type="simple">http://oncotarget.com/abstract/3625</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0615">Fu Z, Chen X, Guan S, Yan Y, Lin H, Hua Z-C. Curcumin inhibits angiogenesis and improves defective hematopoiesis induced by tumor-derived VEGF in tumor model through modulating VEGF-VEGFR2 signaling pathway. Oncotarget [Internet]. Impact Journals; 2015 [cited 2017 Mar 11];6:19469-82. Available from: http://oncotarget.com/abstract/3625</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib119">
                     <ce:label>[119]</ce:label>
                     <sb:reference id="sref119">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>G.N.</ce:given-name>
                                 <ce:surname>Masoud</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>HIF-1α pathway: role, regulation and intervention for cancer therapy</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Acta Pharm. Sin. B</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Mar 13];5:378–89. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://linkinghub.elsevier.com/retrieve/pii/S2211383515000817" id="intref0580" xlink:type="simple">http://linkinghub.elsevier.com/retrieve/pii/S2211383515000817</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0620">Masoud GN, Li W. HIF-1α pathway: role, regulation and intervention for cancer therapy. Acta Pharm. Sin. B [Internet]. 2015 [cited 2017 Mar 13];5:378-89. Available from: http://linkinghub.elsevier.com/retrieve/pii/S2211383515000817</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib120">
                     <ce:label>[120]</ce:label>
                     <sb:reference id="sref120">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.K.</ce:given-name>
                                 <ce:surname>Bae</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.H.</ce:given-name>
                                 <ce:surname>Kim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.W.</ce:given-name>
                                 <ce:surname>Jeong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.M.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.S.</ce:given-name>
                                 <ce:surname>Kim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.R.</ce:given-name>
                                 <ce:surname>Kim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Yun</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.K.</ce:given-name>
                                 <ce:surname>Bae</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.W.</ce:given-name>
                                 <ce:surname>Kim</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Curcumin inhibits hypoxia-induced angiogenesis via down-regulation of HIF-1</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncol. Rep.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2006</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Mar 13];15:1557–62. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/16685395" id="intref0585" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/16685395</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0625">Bae MK, Kim SH, Jeong JW, Lee YM, Kim HS, Kim SR, Yun I, Bae SK, Kim KW. Curcumin inhibits hypoxia-induced angiogenesis via down-regulation of HIF-1. Oncol. Rep. [Internet]. 2006 [cited 2017 Mar 13];15:1557-62. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16685395</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib121">
                     <ce:label>[121]</ce:label>
                     <sb:reference id="sref121">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Shan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Schaaf</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Schmidt</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Lucia</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Buchfelder</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Losa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Kuhlen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Kreutzer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.J.</ce:given-name>
                                 <ce:surname>Perone</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Arzt</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Curcumin suppresses HIF1A synthesis and VEGFA release in pituitary adenomas</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Endocrinol.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Mar 13];214:389–98. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/22739211" id="intref0590" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/22739211</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0630">Shan B, Schaaf C, Schmidt A, Lucia K, Buchfelder M, Losa M, Kuhlen D, Kreutzer J, Perone MJ, Arzt E, et al. Curcumin suppresses HIF1A synthesis and VEGFA release in pituitary adenomas. J. Endocrinol. [Internet]. 2012 [cited 2017 Mar 13];214:389-98. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22739211</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib122">
                     <ce:label>[122]</ce:label>
                     <sb:reference id="sref122">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Da</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Zhu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Sun</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Curcumin suppresses lymphatic vessel density in an <ce:italic>in vivo</ce:italic> human gastric cancer model</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Tumor Biol.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Mar 13];36:5215–23. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/25874494" id="intref0595" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/25874494</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0635">Da W, Zhu J, Wang L, Sun Q. Curcumin suppresses lymphatic vessel density in an in vivo human gastric cancer model. Tumor Biol. [Internet]. 2015 [cited 2017 Mar 13];36:5215-23. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25874494</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib123">
                     <ce:label>[123]</ce:label>
                     <sb:reference id="sref123">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Kalinski</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Sel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Hütten</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Röpke</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Roessner</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Nass</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Curcumin blocks interleukin-1 signaling in chondrosarcoma cells. Filleur S</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>PLoS One</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Mar 13];9:e99296. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/24901233" id="intref0600" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/24901233</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0640">Kalinski T, Sel S, Hutten H, Ropke M, Roessner A, Nass N. Curcumin blocks interleukin-1 signaling in chondrosarcoma cells. Filleur S, editor. PLoS One [Internet]. 2014 [cited 2017 Mar 13];9:e99296. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24901233</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib124">
                     <ce:label>[124]</ce:label>
                     <sb:reference id="sref124">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.E.</ce:given-name>
                                 <ce:surname>Carroll</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.R.</ce:given-name>
                                 <ce:surname>Ellersieck</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.M.</ce:given-name>
                                 <ce:surname>Hyder</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Curcumin inhibits MPA-induced secretion of VEGF from T47-D human breast cancer cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Menopause</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Mar 13];15:570–4. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/18467956" id="intref0605" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/18467956</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0645">Carroll CE, Ellersieck MR, Hyder SM. Curcumin inhibits MPA-induced secretion of VEGF from T47-D human breast cancer cells. Menopause [Internet]. 2008 [cited 2017 Mar 13];15:570-4. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18467956</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib125">
                     <ce:label>[125]</ce:label>
                     <sb:reference id="sref125">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Chakraborty</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Jain</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Kale</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Raja</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Kumar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Mishra</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.C.</ce:given-name>
                                 <ce:surname>Kundu</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Curcumin suppresses breast tumor angiogenesis by abrogating osteopontin-induced VEGF expression</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Mol. Med. Rep.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Mar 13];1:641–6. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://www.spandidos-publications.com/mmr/1/5/641/download" id="intref0610" xlink:type="simple">https://www.spandidos-publications.com/mmr/1/5/641/download</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0650">Chakraborty G, Jain S, Kale S, Raja R, Kumar S, Mishra R, Kundu GC. Curcumin suppresses breast tumor angiogenesis by abrogating osteopontin-induced VEGF expression. Mol. Med. Rep. [Internet]. 2008 [cited 2017 Mar 13];1:641-6. Available from: https://www.spandidos-publications.com/mmr/1/5/641/download</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib126">
                     <ce:label>[126]</ce:label>
                     <sb:reference id="sref126">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Bhattacharyya</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Mandal</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Saha</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.S.</ce:given-name>
                                 <ce:surname>Sen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Das</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Sa</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Curcumin prevents tumor-induced T cell apoptosis through Stat-5a-mediated Bcl-2 induction</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]. BioMed Central</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Biol. Chem.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2007</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Mar 5];282:15954–64. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.jbc.org/cgi/doi/10.1074/jbc.M608189200" id="intref0615" xlink:type="simple">http://www.jbc.org/cgi/doi/10.1074/jbc.M608189200</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0655">Bhattacharyya S, Mandal D, Saha B, Sen GS, Das T, Sa G. Curcumin prevents tumor-induced T cell apoptosis through Stat-5a-mediated Bcl-2 induction. J. Biol. Chem. [Internet]. BioMed Central; 2007 [cited 2017 Mar 5];282:15954-64. Available from: http://www.jbc.org/cgi/doi/10.1074/jbc.M608189200</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib127">
                     <ce:label>[127]</ce:label>
                     <sb:reference id="sref127">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Terlikowska</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Witkowska</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Zujko</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Dobrzycka</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Terlikowski</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Potential application of curcumin and its analogues in the treatment strategy of patients with primary epithelial ovarian cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Int. J. Mol. Sci.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2018 Oct 3];15:21703–22. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/25429431" id="intref0620" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/25429431</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0660">Terlikowska K, Witkowska A, Zujko M, Dobrzycka B, Terlikowski S. Potential application of curcumin and its analogues in the treatment strategy of patients with primary epithelial ovarian cancer. Int. J. Mol. Sci. [Internet]. 2014 [cited 2018 Oct 3];15:21703-22. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25429431</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib128">
                     <ce:label>[128]</ce:label>
                     <sb:reference id="sref128">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Katoh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Nakagama</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>FGF receptors: cancer biology and therapeutics</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Med. Res. Rev.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Mar 17];34:280–300. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/23696246" id="intref0625" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/23696246</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0665">Katoh M, Nakagama H. FGF receptors: cancer biology and therapeutics. Med. Res. Rev. [Internet]. 2014 [cited 2017 Mar 17];34:280-300. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23696246</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib129">
                     <ce:label>[129]</ce:label>
                     <sb:reference id="sref129">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.M.</ce:given-name>
                                 <ce:surname>Ornitz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Itoh</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The fibroblast growth factor signaling pathway</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]. Wiley-Blackwell</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Wiley Interdiscipl. Rev. Dev. Biol.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Mar 17];4:215–66. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/25772309" id="intref0630" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/25772309</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0670">Ornitz DM, Itoh N. The fibroblast growth factor signaling pathway. Wiley Interdiscipl. Rev. Dev. Biol. [Internet]. Wiley-Blackwell; 2015 [cited 2017 Mar 17];4:215-66. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25772309</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib130">
                     <ce:label>[130]</ce:label>
                     <sb:reference id="sref130">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.K.</ce:given-name>
                                 <ce:surname>Juhn</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.G.</ce:given-name>
                                 <ce:surname>Ondrey</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Lin</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Expression of fibroblast growth factor binding protein in head and neck cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Arch. Otolaryngol. Neck Surg.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Mar 18];135:896. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/19770422" id="intref0635" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/19770422</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0675">Li W, Wang C, Juhn SK, Ondrey FG, Lin J. Expression of fibroblast growth factor binding protein in head and neck cancer. Arch. Otolaryngol. Neck Surg. [Internet]. 2009 [cited 2017 Mar 18];135:896. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19770422</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib131">
                     <ce:label>[131]</ce:label>
                     <sb:reference id="sref131">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Abuharbeid</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Czubayko</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Aigner</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The fibroblast growth factor-binding protein FGF-BP</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Int. J. Biochem. Cell Biol.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2006</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Mar 18];38:1463–8. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/16324873" id="intref0640" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/16324873</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0680">Abuharbeid S, Czubayko F, Aigner A. The fibroblast growth factor-binding protein FGF-BP. Int. J. Biochem. Cell Biol. [Internet]. 2006 [cited 2017 Mar 18];38:1463-8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16324873</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib132">
                     <ce:label>[132]</ce:label>
                     <sb:reference id="sref132">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Ahmad</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Iwata</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.Y.</ce:given-name>
                                 <ce:surname>Leung</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Mechanisms of FGFR-mediated carcinogenesis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Biochim. Biophys. Acta Mol. Cell Res.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Mar 18];1823:850–60. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://linkinghub.elsevier.com/retrieve/pii/S0167488912000067" id="intref0645" xlink:type="simple">http://linkinghub.elsevier.com/retrieve/pii/S0167488912000067</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0685">Ahmad I, Iwata T, Leung HY. Mechanisms of FGFR-mediated carcinogenesis. Biochim. Biophys. Acta Mol. Cell Res. [Internet]. 2012 [cited 2017 Mar 18];1823:850-60. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0167488912000067</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib133">
                     <ce:label>[133]</ce:label>
                     <sb:reference id="sref133">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Lafitte</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Rousseau</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Moranvillier</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Taillepierre</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Peuchant</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Guyonnet-Dupérat</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Bedel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Dubus</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>de Verneuil</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Moreau-Gaudry</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>In vivo gene transfer targeting in pancreatic adenocarcinoma with cell surface antigens</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]. BioMed Central</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Mol. Cancer</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Mar 21];11:81. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://molecular-cancer.biomedcentral.com/articles/10.1186/1476-4598-11-81" id="intref0650" xlink:type="simple">http://molecular-cancer.biomedcentral.com/articles/10.1186/1476-4598-11-81</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0690">Lafitte M, Rousseau B, Moranvillier I, Taillepierre M, Peuchant E, Guyonnet-Duperat V, Bedel A, Dubus P, de Verneuil H, Moreau-Gaudry F, et al. In vivo gene transfer targeting in pancreatic adenocarcinoma with cell surface antigens. Mol. Cancer [Internet]. BioMed Central; 2012 [cited 2017 Mar 21];11:81. Available from: http://molecular-cancer.biomedcentral.com/articles/10.1186/1476-4598-11-81</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib134">
                     <ce:label>[134]</ce:label>
                     <sb:reference id="sref134">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Mohan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Sivak</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Ashton</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.A.</ce:given-name>
                                 <ce:surname>Russo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.Q.</ce:given-name>
                                 <ce:surname>Pham</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Kasahara</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.B.</ce:given-name>
                                 <ce:surname>Raizman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.E.</ce:given-name>
                                 <ce:surname>Fini</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Curcuminoids inhibit the angiogenic response stimulated by fibroblast growth factor-2, including expression of matrix metalloproteinase gelatinase B</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Biol. Chem.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2000</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Mar 19];275:10405–12. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/10744729" id="intref0655" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/10744729</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0695">Mohan R, Sivak J, Ashton P, Russo LA, Pham BQ, Kasahara N, Raizman MB, Fini ME. Curcuminoids inhibit the angiogenic response stimulated by fibroblast growth factor-2, including expression of matrix metalloproteinase gelatinase B. J. Biol. Chem. [Internet]. 2000 [cited 2017 Mar 19];275:10405-12. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10744729</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib135">
                     <ce:label>[135]</ce:label>
                     <sb:reference id="sref135">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Z.-M.</ce:given-name>
                                 <ce:surname>Shao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.-Z.</ce:given-name>
                                 <ce:surname>Shen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.-H.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.R.</ce:given-name>
                                 <ce:surname>Sartippour</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.L.</ce:given-name>
                                 <ce:surname>Go</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Heber</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Nguyen</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Curcumin exerts multiple suppressive effects on human breast carcinoma cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Int. J. Cancer</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2002</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Mar 22];98:234–40. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://doi.wiley.com/10.1002/ijc.10183" id="intref0660" xlink:type="simple">http://doi.wiley.com/10.1002/ijc.10183</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0700">Shao Z-M, Shen Z-Z, Liu C-H, Sartippour MR, Go VL, Heber D, Nguyen M. Curcumin exerts multiple suppressive effects on human breast carcinoma cells. Int. J. Cancer [Internet]. 2002 [cited 2017 Mar 22];98:234-40. Available from: http://doi.wiley.com/10.1002/ijc.10183</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib136">
                     <ce:label>[136]</ce:label>
                     <sb:reference id="sref136">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Shen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.O.</ce:given-name>
                                 <ce:surname>Khor</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.-H.</ce:given-name>
                                 <ce:surname>Kim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.-N.T.</ce:given-name>
                                 <ce:surname>Kong</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Curcumin inhibits Akt/mammalian target of rapamycin signaling through protein phosphatase-dependent mechanism</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]. American Association for Cancer Research</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Mol. Cancer Ther.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>cited 2017 Mar 21];7:2609–20. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://mct.aacrjournals.org/cgi/doi/10.1158/1535-7163.MCT-07-2400" id="intref0665" xlink:type="simple">http://mct.aacrjournals.org/cgi/doi/10.1158/1535-7163.MCT-07-2400</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0705">Yu S, Shen G, Khor TO, Kim J-H, Kong A-NT. Curcumin inhibits Akt/mammalian target of rapamycin signaling through protein phosphatase-dependent mechanism. Mol. Cancer Ther. [Internet]. American Association for Cancer Research; 2008 [cited 2017 Mar 21];7:2609-20. Available from: http://mct.aacrjournals.org/cgi/doi/10.1158/1535-7163.MCT-07-2400</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib137">
                     <ce:label>[137]</ce:label>
                     <sb:reference id="sref137">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Cai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Ji</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Zhao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Zhao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Wei</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Shen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery and identification of new non-ATP competitive FGFR1 inhibitors with therapeutic potential on non-small-cell lung cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancer Lett.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Mar 21];344:82–9. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://linkinghub.elsevier.com/retrieve/pii/S0304383513007453" id="intref0670" xlink:type="simple">http://linkinghub.elsevier.com/retrieve/pii/S0304383513007453</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0710">Wang Y, Cai Y, Ji J, Liu Z, Zhao C, Zhao Y, Wei T, Shen X, Zhang X, Li X, et al. Discovery and identification of new non-ATP competitive FGFR1 inhibitors with therapeutic potential on non-small-cell lung cancer. Cancer Lett. [Internet]. 2014 [cited 2017 Mar 21];344:82-9. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0304383513007453</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib138">
                     <ce:label>[138]</ce:label>
                     <sb:reference id="sref138">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Latimer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>O.</ce:given-name>
                                 <ce:surname>Ekshyyan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Nathan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Moore-Medlin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Rong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Ma</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Khandelwal</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.T.</ce:given-name>
                                 <ce:surname>Christy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Abreo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>McClure</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Enhanced systemic bioavailability of curcumin through transmucosal administration of a novel microgranular formulation</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]. International Institute of Anticancer Research</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Anticancer Res.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Mar 21];35:6411–8. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/26637850" id="intref0675" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/26637850</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0715">Latimer B, Ekshyyan O, Nathan N, Moore-Medlin T, Rong X, Ma X, Khandelwal A, Christy HT, Abreo F, McClure G, et al. Enhanced systemic bioavailability of curcumin through transmucosal administration of a novel microgranular formulation. Anticancer Res. [Internet]. International Institute of Anticancer Research; 2015 [cited 2017 Mar 21];35:6411-8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26637850</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib139">
                     <ce:label>[139]</ce:label>
                     <sb:reference id="sref139">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.M.</ce:given-name>
                                 <ce:surname>Howells</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.P.</ce:given-name>
                                 <ce:surname>Moiseeva</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.P.</ce:given-name>
                                 <ce:surname>Neal</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.E.</ce:given-name>
                                 <ce:surname>Foreman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.K.</ce:given-name>
                                 <ce:surname>Andreadi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.Y.</ce:given-name>
                                 <ce:surname>Sun</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.A.</ce:given-name>
                                 <ce:surname>Hudson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.M.</ce:given-name>
                                 <ce:surname>Manson</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Predicting the physiological relevance of <ce:italic>in vitro</ce:italic> cancer preventive activities of phytochemicals</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Acta Pharmacol. Sin.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2007</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Mar 21];28:1274–304. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/17723163" id="intref0680" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/17723163</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0720">Howells LM, Moiseeva EP, Neal CP, Foreman BE, Andreadi CK, Sun YY, Hudson EA, Manson MM. Predicting the physiological relevance of in vitro cancer preventive activities of phytochemicals. Acta Pharmacol. Sin. [Internet]. 2007 [cited 2017 Mar 21];28:1274-304. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17723163</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib140">
                     <ce:label>[140]</ce:label>
                     <sb:reference id="sref140">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.-H.H.</ce:given-name>
                                 <ce:surname>Heldin</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Targeting the PDGF signaling pathway in tumor treatment</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]. BioMed Central</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cell Commun. Signal.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Mar 23];11:97. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/24359404" id="intref0685" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/24359404</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0725">Heldin C-HH. Targeting the PDGF signaling pathway in tumor treatment. Cell Commun. Signal. [Internet]. BioMed Central; 2013 [cited 2017 Mar 23];11:97. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24359404</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib141">
                     <ce:label>[141]</ce:label>
                     <sb:reference id="sref141">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Ranza</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Facoetti</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Morbini</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Benericetti</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Nano</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Exogenous Platelet-Derived Growth Factor (PDGF) induces human astrocytoma cell line proliferation</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Anticancer Res.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2007</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Mar 23];27:2161–6. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/17695499" id="intref0690" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/17695499</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0730">Ranza E, Facoetti A, Morbini P, Benericetti E, Nano R. Exogenous Platelet-Derived Growth Factor (PDGF) induces human astrocytoma cell line proliferation. Anticancer Res. [Internet]. 2007 [cited 2017 Mar 23];27:2161-6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17695499</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib142">
                     <ce:label>[142]</ce:label>
                     <sb:reference id="sref142">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Jechlinger</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Sommer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Moriggl</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Seither</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Kraut</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Capodiecci</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Donovan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Cordon-Cardo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Beug</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Grünert</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Autocrine PDGFR signaling promotes mammary cancer metastasis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]. American Society for Clinical Investigation</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Clin. Investig.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2006</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>cited 2017 Mar 23];116:1561–70. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/16741576" id="intref0695" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/16741576</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0735">Jechlinger M, Sommer A, Moriggl R, Seither P, Kraut N, Capodiecci P, Donovan M, Cordon-Cardo C, Beug H, Grunert S. Autocrine PDGFR signaling promotes mammary cancer metastasis. J. Clin. Investig. [Internet]. American Society for Clinical Investigation; 2006 [cited 2017 Mar 23];116:1561-70. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16741576</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib143">
                     <ce:label>[143]</ce:label>
                     <sb:reference id="sref143">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Matei</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.E.</ce:given-name>
                                 <ce:surname>Emerson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.C.</ce:given-name>
                                 <ce:surname>Lai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.A.</ce:given-name>
                                 <ce:surname>Baldridge</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Rao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Yiannoutsos</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.B.</ce:given-name>
                                 <ce:surname>Donner</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Autocrine activation of PDGFRα promotes the progression of ovarian cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]. Nature Publishing Group</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncogene</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2006</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>cited 2017 Mar 23];25:2060–9. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.nature.com/doifinder/10.1038/sj.onc.1209232" id="intref0700" xlink:type="simple">http://www.nature.com/doifinder/10.1038/sj.onc.1209232</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0740">Matei D, Emerson RE, Lai YC, Baldridge LA, Rao J, Yiannoutsos C, Donner DB. Autocrine activation of PDGFRα promotes the progression of ovarian cancer. Oncogene [Internet]. Nature Publishing Group; 2006 [cited 2017 Mar 23];25:2060-9. Available from: http://www.nature.com/doifinder/10.1038/sj.onc.1209232</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib144">
                     <ce:label>[144]</ce:label>
                     <sb:reference id="sref144">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Bajraszewski</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Wu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.P.</ce:given-name>
                                 <ce:surname>Moseman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.L.</ce:given-name>
                                 <ce:surname>Dabora</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.D.</ce:given-name>
                                 <ce:surname>Griffin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.J.</ce:given-name>
                                 <ce:surname>Kwiatkowski</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]. American Society for Clinical Investigation</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Clin. Investig.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2007</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>cited 2017 Mar 23];117:730–8. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/17290308" id="intref0705" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/17290308</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0745">Zhang H, Bajraszewski N, Wu E, Wang H, Moseman AP, Dabora SL, Griffin JD, Kwiatkowski DJ. PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR. J. Clin. Investig. [Internet]. American Society for Clinical Investigation; 2007 [cited 2017 Mar 23];117:730-8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17290308</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib145">
                     <ce:label>[145]</ce:label>
                     <sb:reference id="sref145">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Tsioumpekou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Papadopoulos</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Burovic</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.H.</ce:given-name>
                                 <ce:surname>Heldin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Lennartsson</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Platelet-derived growth factor (PDGF)-induced activation of Erk 5 MAP-kinase is dependent on Mekk2, Mek1/2, PKC and PI3-kinase, and affects BMP signaling</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cell. Signal.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Mar 23];28:1422–31. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/27339033" id="intref0710" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/27339033</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0750">Tsioumpekou M, Papadopoulos N, Burovic F, Heldin CH, Lennartsson J. Platelet-derived growth factor (PDGF)-induced activation of Erk 5 MAP-kinase is dependent on Mekk2, Mek1/2, PKC and PI3-kinase, and affects BMP signaling. Cell. Signal. [Internet]. 2016 [cited 2017 Mar 23];28:1422-31. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27339033</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib146">
                     <ce:label>[146]</ce:label>
                     <sb:reference id="sref146">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.B.</ce:given-name>
                                 <ce:surname>Nyland</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.K.</ce:given-name>
                                 <ce:surname>Ryland</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Broeg</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.T.</ce:given-name>
                                 <ce:surname>Baab</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.R.</ce:given-name>
                                 <ce:surname>Jarbadan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Irby</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.P.</ce:given-name>
                                 <ce:surname>Loughran</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Platelet-derived growth factor mediates survival of leukemic large granular lymphocytes via an autocrine regulatory pathway</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]. American Society of Hematology</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Blood</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Mar 23];115:51–60. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/19880494" id="intref0715" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/19880494</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0755">Yang J, Liu X, Nyland SB, Zhang R, Ryland LK, Broeg K, Baab KT, Jarbadan NR, Irby R, Loughran TP. Platelet-derived growth factor mediates survival of leukemic large granular lymphocytes via an autocrine regulatory pathway. Blood [Internet]. American Society of Hematology; 2010 [cited 2017 Mar 23];115:51-60. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19880494</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib147">
                     <ce:label>[147]</ce:label>
                     <sb:reference id="sref147">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.P.</ce:given-name>
                                 <ce:surname>Piccaluga</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Rossi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Agostinelli</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Ricci</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Gazzola</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Righi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Fuligni</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.A.</ce:given-name>
                                 <ce:surname>Laginestra</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Mancini</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.R.</ce:given-name>
                                 <ce:surname>Sapienza</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Platelet-derived growth factor alpha mediates the proliferation of peripheral T-cell lymphoma cells via an autocrine regulatory pathway</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]. Nature Publishing Group</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Leukemia</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>cited 2017 Mar 23];28:1687–97. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.nature.com/doifinder/10.1038/leu.2014.50" id="intref0720" xlink:type="simple">http://www.nature.com/doifinder/10.1038/leu.2014.50</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0760">Piccaluga PP, Rossi M, Agostinelli C, Ricci F, Gazzola A, Righi S, Fuligni F, Laginestra MA, Mancini M, Sapienza MR, et al. Platelet-derived growth factor alpha mediates the proliferation of peripheral T-cell lymphoma cells via an autocrine regulatory pathway. Leukemia [Internet]. Nature Publishing Group; 2014 [cited 2017 Mar 23];28:1687-97. Available from: http://www.nature.com/doifinder/10.1038/leu.2014.50</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib148">
                     <ce:label>[148]</ce:label>
                     <sb:reference id="sref148">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.P.</ce:given-name>
                                 <ce:surname>Fleming</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Saxena</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.C.</ce:given-name>
                                 <ce:surname>Clark</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.T.</ce:given-name>
                                 <ce:surname>Robertson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.H.</ce:given-name>
                                 <ce:surname>Oldfield</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.A.</ce:given-name>
                                 <ce:surname>Aaronson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.U.</ce:given-name>
                                 <ce:surname>Ali</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.H.</ce:given-name>
                                 <ce:surname>Old</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.A.</ce:given-name>
                                 <ce:surname>Aaronson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.U.</ce:given-name>
                                 <ce:surname>Ali</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Amplification and/or overexpression of platelet-derived growth factor receptors and epidermal growth factor receptor in human glial tumors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancer Res.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>1992</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Mar 23];52:4550–3. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/1322795" id="intref0725" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/1322795</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0765">Fleming TP, Saxena A, Clark WC, Robertson JT, Oldfield EH, Aaronson SA, Ali IU, Old EH, Aaronson SA, Ali IU. Amplification and/or overexpression of platelet-derived growth factor receptors and epidermal growth factor receptor in human glial tumors. Cancer Res. [Internet]. 1992 [cited 2017 Mar 23];52:4550-3. Available from: http://www.ncbi.nlm.nih.gov/pubmed/1322795</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib149">
                     <ce:label>[149]</ce:label>
                     <sb:reference id="sref149">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Puputti</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>O.</ce:given-name>
                                 <ce:surname>Tynninen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Sihto</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Blom</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Maenpaa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Isola</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Paetau</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Joensuu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.N.</ce:given-name>
                                 <ce:surname>Nupponen</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Amplification of KIT, PDGFRA, VEGFR2, and EGFR in gliomas</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Mol. Cancer Res.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2006</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Mar 23];4:927–34. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://mcr.aacrjournals.org/cgi/doi/10.1158/1541-7786.MCR-06-0085" id="intref0730" xlink:type="simple">http://mcr.aacrjournals.org/cgi/doi/10.1158/1541-7786.MCR-06-0085</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0770">Puputti M, Tynninen O, Sihto H, Blom T, Maenpaa H, Isola J, Paetau A, Joensuu H, Nupponen NN. Amplification of KIT, PDGFRA, VEGFR2, and EGFR in gliomas. Mol. Cancer Res. [Internet]. 2006 [cited 2017 Mar 23];4:927-34. Available from: http://mcr.aacrjournals.org/cgi/doi/10.1158/1541-7786.MCR-06-0085</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib150">
                     <ce:label>[150]</ce:label>
                     <sb:reference id="sref150">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Ochoa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Jonikas</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.T.</ce:given-name>
                                 <ce:surname>Lawrence</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B El</ce:given-name>
                                 <ce:surname>Debs</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Selkrig</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Typas</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Villén</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.D.</ce:given-name>
                                 <ce:surname>Santos</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Beltrao</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>An atlas of human kinase regulation</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]. European Molecular Biology Organization</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Mol. Syst. Biol.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>cited 2017 Mar 23];12:1–14. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/27888226" id="intref0735" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/27888226</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0775">Ochoa D, Jonikas M, Lawrence RT, Debs B El, Selkrig J, Typas A, Villen J, Santos SD, Beltrao P. An atlas of human kinase regulation. Mol. Syst. Biol. [Internet]. European Molecular Biology Organization; 2016 [cited 2017 Mar 23];12:1-14. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27888226</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib151">
                     <ce:label>[151]</ce:label>
                     <sb:reference id="sref151">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Lourestanpour</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Babaahmadi-Rezaei</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Shahanipour</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Curcumin as an environmental potent antioxidant decreases risk of arthrosclerosis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]. Archives of Hygiene Sciences</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Arch. Hyg. Sci.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Mar 23];6:105–10. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://jhygiene.muq.ac.ir/browse.php?a_id=208&amp;sid=1&amp;slc_lang=en" id="intref0740" xlink:type="simple">http://jhygiene.muq.ac.ir/browse.php?a_id=208&sid=1&slc_lang=en</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0780">Lourestanpour P, Babaahmadi-Rezaei H, Shahanipour K. Curcumin as an environmental potent antioxidant decreases risk of arthrosclerosis. Arch. Hyg. Sci. [Internet]. Archives of Hygiene Sciences; 2017 [cited 2017 Mar 23];6:105-10. Available from: http://jhygiene.muq.ac.ir/browse.php?a_id=208&sid=1&slc_lang=en</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib152">
                     <ce:label>[152]</ce:label>
                     <sb:reference id="sref152">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.C.-W.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Zhou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.F.</ce:given-name>
                                 <ce:surname>Lou</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Control of PDGF-induced reactive oxygen species (ROS) generation and signal transduction in human lens epithelial cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]. Emory University</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Mol. Vis.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2007</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Mar 23];13:374–87. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/17392688" id="intref0745" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/17392688</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0785">Chen KC-W, Zhou Y, Zhang W, Lou MF. Control of PDGF-induced reactive oxygen species (ROS) generation and signal transduction in human lens epithelial cells. Mol. Vis. [Internet]. Emory University; 2007 [cited 2017 Mar 23];13:374-87. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17392688</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib153">
                     <ce:label>[153]</ce:label>
                     <sb:reference id="sref153">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Sundaresan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.-X.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.J.</ce:given-name>
                                 <ce:surname>Ferrans</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Irani</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Finkel</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Requirement for generation of H(2)O(2) for platelet-derived growth factor signal tran sduction</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Science</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>80</sb:volume-nr>
                              </sb:series>
                              <sb:date>1995</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Mar 25];270:296–9. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.sciencemag.org/cgi/doi/10.1126/science.270.5234.296" id="intref0750" xlink:type="simple">http://www.sciencemag.org/cgi/doi/10.1126/science.270.5234.296</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0790">Sundaresan M, Yu Z-X, Ferrans VJ, Irani K, Finkel T. Requirement for generation of H(2)O(2) for platelet-derived growth factor signal tran sduction. Science (80- ) [Internet]. 1995 [cited 2017 Mar 25];270:296-9. Available from: http://www.sciencemag.org/cgi/doi/10.1126/science.270.5234.296</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib154">
                     <ce:label>[154]</ce:label>
                     <sb:reference id="sref154">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.C.W.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Zhou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Xing</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Krysan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.F.</ce:given-name>
                                 <ce:surname>Lou</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Platelet derived growth factor (PDGF)-induced reactive oxygen species in the lens epithelial cells: the redox signaling</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Exp. Eye Res.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2004</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Mar 25];78:1057–67. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/15109912" id="intref0755" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/15109912</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0795">Chen KCW, Zhou Y, Xing K, Krysan K, Lou MF. Platelet derived growth factor (PDGF)-induced reactive oxygen species in the lens epithelial cells: the redox signaling. Exp. Eye Res. [Internet]. 2004 [cited 2017 Mar 25];78:1057-67. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15109912</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib155">
                     <ce:label>[155]</ce:label>
                     <sb:reference id="sref155">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Lange</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Heger</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Euler</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Wartenberg</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.M.</ce:given-name>
                                 <ce:surname>Piper</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Sauer</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Platelet-derived growth factor BB stimulates vasculogenesis of embryonic stem cell-derived endothelial cells by calcium-mediated generation of reactive oxygen species</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cardiovasc. Res.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Mar 25];81:159–68. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/cardiovascres/81/1/10.1093/cvr/cvn258/2/cvn258.pdf?Expires=1490745535&amp;Signature=N2pz4PeGq%7Em6PDGBlNg8u9D8Fk0txnAS-0l1sl6SUmlciGOlOh7k7oXKCMDvJ8BOMQoonzN00kwd5xUqNwzdRuE7hPkXDam3saSkBsbV4zH" id="intref0760" xlink:type="simple">https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/cardiovascres/81/1/10.1093/cvr/cvn258/2/cvn258.pdf?Expires=1490745535&Signature=N2pz4PeGq∼m6PDGBlNg8u9D8Fk0txnAS-0l1sl6SUmlciGOlOh7k7oXKCMDvJ8BOMQoonzN00kwd5xUqNwzdRuE7hPkXDam3saSkBsbV4zH</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0800">Lange S, Heger J, Euler G, Wartenberg M, Piper HM, Sauer H. Platelet-derived growth factor BB stimulates vasculogenesis of embryonic stem cell-derived endothelial cells by calcium-mediated generation of reactive oxygen species. Cardiovasc. Res. [Internet]. 2009 [cited 2017 Mar 25];81:159-68. Available from: https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/cardiovascres/81/1/10.1093/cvr/cvn258/2/cvn258.pdf?Expires=1490745535&Signature=N2pz4PeGq∼m6PDGBlNg8u9D8Fk0txnAS-0l1sl6SUmlciGOlOh7k7oXKCMDvJ8BOMQoonzN00kwd5xUqNwzdRuE7hPkXDam3saSkBsbV4zH</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib156">
                     <ce:label>[156]</ce:label>
                     <sb:reference id="sref156">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Ahmad</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Kong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.S.</ce:given-name>
                                 <ce:surname>Azmi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Banerjee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.H.</ce:given-name>
                                 <ce:surname>Sarkar</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Emerging roles of PDGF-D signaling pathway in tumor development and progression</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]. NIH Public Access</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Biochim. Biophys. Acta Rev. Canc.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Mar 27];1806:122–30. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/20434526" id="intref0765" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/20434526</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0805">Wang Z, Ahmad A, Li Y, Kong D, Azmi AS, Banerjee S, Sarkar FH. Emerging roles of PDGF-D signaling pathway in tumor development and progression. Biochim. Biophys. Acta Rev. Canc. [Internet]. NIH Public Access; 2010 [cited 2017 Mar 27];1806:122-30. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20434526</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib157">
                     <ce:label>[157]</ce:label>
                     <sb:reference id="sref157">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.-M.</ce:given-name>
                                 <ce:surname>Lo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.-J.</ce:given-name>
                                 <ce:surname>Tsai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.-Y.</ce:given-name>
                                 <ce:surname>Du</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.-J.</ce:given-name>
                                 <ce:surname>Tsou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.-B.</ce:given-name>
                                 <ce:surname>Wu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Ranelletti</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Bartoli</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Yoo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Yun</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Ramponi</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>A naturally occurring carotenoid, lutein, reduces PDGF and H 2 O 2 signaling and compromises migration in cultured vascular smooth muscle cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Biomed. Sci.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>191</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[Internet]. BioMed Central; 2012 [cited 2017 Mar 23];75:503–6. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://jbiomedsci.biomedcentral.com/articles/10.1186/1423-0127-19-18" id="intref0770" xlink:type="simple">https://jbiomedsci.biomedcentral.com/articles/10.1186/1423-0127-19-18</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0810">Lo H-M, Tsai Y-J, Du W-Y, Tsou C-J, Wu W-B, Ranelletti F, Bartoli G, Yoo H, Yun Y, Ramponi G. A naturally occurring carotenoid, lutein, reduces PDGF and H 2 O 2 signaling and compromises migration in cultured vascular smooth muscle cells. J. Biomed. Sci. 2012 191 [Internet]. BioMed Central; 2012 [cited 2017 Mar 23];75:503-6. Available from: https://jbiomedsci.biomedcentral.com/articles/10.1186/1423-0127-19-18</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib158">
                     <ce:label>[158]</ce:label>
                     <sb:reference id="sref158">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.P.</ce:given-name>
                                 <ce:surname>Thomas</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.W.</ce:given-name>
                                 <ce:surname>Culver</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.M.</ce:given-name>
                                 <ce:surname>Alexander</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.J.</ce:given-name>
                                 <ce:surname>Murdoch</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.N.A.</ce:given-name>
                                 <ce:surname>Rao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.A.</ce:given-name>
                                 <ce:surname>Tulis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Ren</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Sreejayan</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Curcumin inhibits platelet-derived growth factor-stimulated vascular smooth muscle cell function and injury-induced neointima formation</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet].</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Arterioscler. Thromb. Vasc. Biol.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2006</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Mar 25];26:85–90. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/16239599" id="intref0775" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/16239599</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0815">Yang X, Thomas DP, Zhang X, Culver BW, Alexander BM, Murdoch WJ, Rao MNA, Tulis DA, Ren J, Sreejayan N. Curcumin inhibits platelet-derived growth factor-stimulated vascular smooth muscle cell function and injury-induced neointima formation. Arterioscler. Thromb. Vasc. Biol. [Internet]. 2006 [cited 2017 Mar 25];26:85-90. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16239599</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib159">
                     <ce:label>[159]</ce:label>
                     <sb:reference id="sref159">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Z.D.</ce:given-name>
                                 <ce:surname>Zhao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.S.</ce:given-name>
                                 <ce:surname>Huang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>[Study on effects of curcumin on expressions of PDGF-BB, PDGFRbeta and ERK1 of HSC]</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Zhong Yao Cai</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Mar 25];32:732–5. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/19771848" id="intref0780" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/19771848</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0820">Zhao ZD, Huang ZS. [Study on effects of curcumin on expressions of PDGF-BB, PDGFRbeta and ERK1 of HSC]. Zhong Yao Cai [Internet]. 2009 [cited 2017 Mar 25];32:732-5. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19771848</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib160">
                     <ce:label>[160]</ce:label>
                     <sb:reference id="sref160">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>W.D.</ce:given-name>
                                 <ce:surname>Tolbert</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Daugherty-Holtrop</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Gherardi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Vande Woude</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.E.</ce:given-name>
                                 <ce:surname>Xu</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Structural basis for agonism and antagonism of hepatocyte growth factor</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]. National Academy of Sciences</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Proc. Natl. Acad. Sci.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Mar 26];107:13264–9. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.pnas.org/cgi/doi/10.1073/pnas.1005183107" id="intref0785" xlink:type="simple">http://www.pnas.org/cgi/doi/10.1073/pnas.1005183107</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0825">Tolbert WD, Daugherty-Holtrop J, Gherardi E, Vande Woude G, Xu HE. Structural basis for agonism and antagonism of hepatocyte growth factor. Proc. Natl. Acad. Sci. [Internet]. National Academy of Sciences; 2010 [cited 2017 Mar 26];107:13264-9. Available from: http://www.pnas.org/cgi/doi/10.1073/pnas.1005183107</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib161">
                     <ce:label>[161]</ce:label>
                     <sb:reference id="sref161">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.R.</ce:given-name>
                                 <ce:surname>Sierra</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.-S.S.</ce:given-name>
                                 <ce:surname>Tsao</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>c-MET as a potential therapeutic target and biomarker in cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]. SAGE Publications</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Ther. Adv. Med. Oncol.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Mar 26];3:S21–35. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/22128285" id="intref0790" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/22128285</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0830">Sierra JR, Tsao M-SS. c-MET as a potential therapeutic target and biomarker in cancer. Ther. Adv. Med. Oncol. [Internet]. SAGE Publications; 2011 [cited 2017 Mar 26];3:S21-35. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22128285</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib162">
                     <ce:label>[162]</ce:label>
                     <sb:reference id="sref162">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.M.</ce:given-name>
                                 <ce:surname>Comoglio</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Giordano</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Trusolino</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Drug development of MET inhibitors: targeting oncogene addiction and expedience</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Drug Discov.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Mar 26];7:504–16. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/18511928" id="intref0795" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/18511928</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0835">Comoglio PM, Giordano S, Trusolino L. Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat. Rev. Drug Discov. [Internet]. 2008 [cited 2017 Mar 26];7:504-16. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18511928</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib163">
                     <ce:label>[163]</ce:label>
                     <sb:reference id="sref163">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.-G.</ce:given-name>
                                 <ce:surname>Huh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.M.</ce:given-name>
                                 <ce:surname>Factor</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Sánchez</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Uchida</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E a</ce:given-name>
                                 <ce:surname>Conner</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.S.</ce:given-name>
                                 <ce:surname>Thorgeirsson</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Hepatocyte growth factor/c-met signaling pathway is required for efficient liver regeneration and repair</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Proc. Natl. Acad. Sci. U. S. A.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2004</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Mar 26];101:4477–82. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=384772%26tool=pmcentrez%26rendertype=abstract%5Cnhttp://www.ncbi.nlm.nih.gov/pubmed/15070743%5Cnhttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC384772" id="intref0800" xlink:type="simple">http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=384772&tool=pmcentrez&rendertype=abstract%5Cnhttp://www.ncbi.nlm.nih.gov/pubmed/15070743%5Cnhttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC384772</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0840">Huh C-G, Factor VM, Sanchez A, Uchida K, Conner E a, Thorgeirsson SS. Hepatocyte growth factor/c-met signaling pathway is required for efficient liver regeneration and repair. Proc. Natl. Acad. Sci. U. S. A. [Internet]. 2004 [cited 2017 Mar 26];101:4477-82. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=384772&tool=pmcentrez&rendertype=abstract%5Cnhttp://www.ncbi.nlm.nih.gov/pubmed/15070743%5Cnhttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC384772</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib164">
                     <ce:label>[164]</ce:label>
                     <sb:reference id="sref164">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Borowiak</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.N.</ce:given-name>
                                 <ce:surname>Garratt</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Wüstefeld</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Strehle</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Trautwein</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Birchmeier</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Met provides essential signals for liver regeneration</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Proc. Natl. Acad. Sci. U. S. A.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2004</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Mar 26];101:10608–13. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.pnas.org/content/101/29/10608.long" id="intref0805" xlink:type="simple">http://www.pnas.org/content/101/29/10608.long</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0845">Borowiak M, Garratt AN, Wustefeld T, Strehle M, Trautwein C, Birchmeier C. Met provides essential signals for liver regeneration. Proc. Natl. Acad. Sci. U. S. A. [Internet]. 2004 [cited 2017 Mar 26];101:10608-13. Available from: http://www.pnas.org/content/101/29/10608.long</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib165">
                     <ce:label>[165]</ce:label>
                     <sb:reference id="sref165">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.P.</ce:given-name>
                                 <ce:surname>Eder</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.F.</ce:given-name>
                                 <ce:surname>Vande Woude</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.A.</ce:given-name>
                                 <ce:surname>Boerner</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.M.</ce:given-name>
                                 <ce:surname>LoRusso</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Novel therapeutic inhibitors of the c-met signaling pathway in cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Clin. Cancer Res.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Mar 26];15:2207–14. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/19318488" id="intref0810" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/19318488</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0850">Eder JP, Vande Woude GF, Boerner SA, LoRusso PM. Novel therapeutic inhibitors of the c-met signaling pathway in cancer. Clin. Cancer Res. [Internet]. 2009 [cited 2017 Mar 26];15:2207-14. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19318488</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib166">
                     <ce:label>[166]</ce:label>
                     <sb:reference id="sref166">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Matsumoto</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Umitsu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.M.</ce:given-name>
                                 <ce:surname>De Silva</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Roy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.P.</ce:given-name>
                                 <ce:surname>Bottaro</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Hepatocyte growth factor/MET in cancer progression and biomarker discovery</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancer Sci.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Mar 26];108:296–307. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://doi.wiley.com/10.1111/cas.13156" id="intref0815" xlink:type="simple">http://doi.wiley.com/10.1111/cas.13156</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0855">Matsumoto K, Umitsu M, De Silva DM, Roy A, Bottaro DP. Hepatocyte growth factor/MET in cancer progression and biomarker discovery. Cancer Sci. [Internet]. 2017 [cited 2017 Mar 26];108:296-307. Available from: http://doi.wiley.com/10.1111/cas.13156</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib167">
                     <ce:label>[167]</ce:label>
                     <sb:reference id="sref167">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Peinado</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Alečković</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Lavotshkin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Matei</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Costa-Silva</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Moreno-Bueno</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Hergueta-Redondo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Williams</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>García-Santos</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.M.</ce:given-name>
                                 <ce:surname>Ghajar</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Med.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Mar 26];18:883–91. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/22635005" id="intref0820" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/22635005</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0860">Peinado H, Aleckovic M, Lavotshkin S, Matei I, Costa-Silva B, Moreno-Bueno G, Hergueta-Redondo M, Williams C, Garcia-Santos G, Ghajar CM, et al. Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat. Med. [Internet]. 2012 [cited 2017 Mar 26];18:883-91. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22635005</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib168">
                     <ce:label>[168]</ce:label>
                     <sb:reference id="sref168">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.A.</ce:given-name>
                                 <ce:surname>Engelman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Zejnullahu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Mitsudomi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Song</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Hyland</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>O.P.</ce:given-name>
                                 <ce:surname>Joon</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Lindeman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.M.</ce:given-name>
                                 <ce:surname>Gale</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Zhao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Christensen</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Science</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2007</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Mar 26];316:1039–43. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/17463250" id="intref0825" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/17463250</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0865">Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Joon OP, Lindeman N, Gale CM, Zhao X, Christensen J, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science (80- ) [Internet]. 2007 [cited 2017 Mar 26];316:1039-43. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17463250</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib169">
                     <ce:label>[169]</ce:label>
                     <sb:reference id="sref169">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Bardelli</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Corso</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Bertotti</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Hobor</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Valtorta</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Siravegna</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Sartore-Bianchi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Scala</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Cassingena</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Zecchin</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancer Discov.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Mar 26];3:658–73. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/23729478" id="intref0830" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/23729478</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0870">Bardelli A, Corso S, Bertotti A, Hobor S, Valtorta E, Siravegna G, Sartore-Bianchi A, Scala E, Cassingena A, Zecchin D, et al. Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. Cancer Discov. [Internet]. 2013 [cited 2017 Mar 26];3:658-73. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23729478</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib170">
                     <ce:label>[170]</ce:label>
                     <sb:reference id="sref170">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Accornero</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Lattanzio</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Mangano</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Chiarle</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Taulli</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Bersani</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.E.</ce:given-name>
                                 <ce:surname>Forni</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Miretti</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Scuoppo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Dastrù</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>An in vivo model of met-driven lymphoma as a tool to explore the therapeutic potential of met inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]. BioMed Central</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Clin. Cancer Res.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Mar 26];14:2220–6. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0432.CCR-07-2064" id="intref0835" xlink:type="simple">http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0432.CCR-07-2064</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0875">Accornero P, Lattanzio G, Mangano T, Chiarle R, Taulli R, Bersani F, Forni PE, Miretti S, Scuoppo C, Dastru W, et al. An in vivo model of met-driven lymphoma as a tool to explore the therapeutic potential of met inhibitors. Clin. Cancer Res. [Internet]. BioMed Central; 2008 [cited 2017 Mar 26];14:2220-6. Available from: http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0432.CCR-07-2064</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib171">
                     <ce:label>[171]</ce:label>
                     <sb:reference id="sref171">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>G.A.</ce:given-name>
                                 <ce:surname>Watson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.T.</ce:given-name>
                                 <ce:surname>Stang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.M.</ce:given-name>
                                 <ce:surname>Levy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.E.</ce:given-name>
                                 <ce:surname>Queiroz de Oliveira</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.E.</ce:given-name>
                                 <ce:surname>Gooding</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.G.</ce:given-name>
                                 <ce:surname>Christensen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.J.</ce:given-name>
                                 <ce:surname>Hughes</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Inhibition of c-met as a therapeutic strategy for esophageal adenocarcinoma</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]. Neoplasia Press</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Neoplasia</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2006</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Mar 26];8:949–55. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.sciencedirect.com/science/article/pii/S1476558606800795" id="intref0840" xlink:type="simple">http://www.sciencedirect.com/science/article/pii/S1476558606800795</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0880">Watson GA, Zhang X, Stang MT, Levy RM, Queiroz de Oliveira PE, Gooding WE, Christensen JG, Hughes SJ. Inhibition of c-met as a therapeutic strategy for esophageal adenocarcinoma. Neoplasia [Internet]. Neoplasia Press; 2006 [cited 2017 Mar 26];8:949-55. Available from: http://www.sciencedirect.com/science/article/pii/S1476558606800795</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib172">
                     <ce:label>[172]</ce:label>
                     <sb:reference id="sref172">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.M.</ce:given-name>
                                 <ce:surname>Ho-Yen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.L.</ce:given-name>
                                 <ce:surname>Jones</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Kermorgant</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The clinical and functional significance of c-Met in breast cancer: a review</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]. BioMed Central</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Breast Cancer Res.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Mar 26];17:52. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/25887320" id="intref0845" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/25887320</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0885">Ho-Yen CM, Jones JL, Kermorgant S. The clinical and functional significance of c-Met in breast cancer: a review. Breast Cancer Res. [Internet]. BioMed Central; 2015 [cited 2017 Mar 26];17:52. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25887320</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib173">
                     <ce:label>[173]</ce:label>
                     <sb:reference id="sref173">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>B.Q.</ce:given-name>
                                 <ce:surname>Lam</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Dai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Qin</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The role of HGF/c-MET signaling pathway in lymphoma</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]. BioMed Central</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Hematol. Oncol.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Mar 26];9:1–8. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/27923392" id="intref0850" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/27923392</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0890">Lam BQ, Dai L, Qin Z. The role of HGF/c-MET signaling pathway in lymphoma. J. Hematol. Oncol. [Internet]. BioMed Central; 2016 [cited 2017 Mar 26];9:1-8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27923392</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib174">
                     <ce:label>[174]</ce:label>
                     <sb:reference id="sref174">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.C.</ce:given-name>
                                 <ce:surname>Chang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Cancer stem cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Medicine (Baltim.)</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Mar 26];95:S20–5. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&amp;an=00005792-201609081-00005" id="intref0855" xlink:type="simple">http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00005792-201609081-00005</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0895">Chang JC. Cancer stem cells. Medicine (Baltim.) [Internet]. 2016 [cited 2017 Mar 26];95:S20-5. Available from: http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00005792-201609081-00005</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib175">
                     <ce:label>[175]</ce:label>
                     <sb:reference id="sref175">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Wu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Koul</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.Y.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Halmos</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>AXL kinase as a novel target for cancer therapy</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]. Impact Journals, LLC</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncotarget</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Mar 26];5:9546–63. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4259419&amp;tool=pmcentrez&amp;rendertype=abstract" id="intref0860" xlink:type="simple">http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4259419&tool=pmcentrez&rendertype=abstract</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0900">Wu X, Liu X, Koul S, Lee CY, Zhang Z, Halmos B. AXL kinase as a novel target for cancer therapy. Oncotarget [Internet]. Impact Journals, LLC; 2014 [cited 2017 Mar 26];5:9546-63. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4259419&tool=pmcentrez&rendertype=abstract</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib176">
                     <ce:label>[176]</ce:label>
                     <sb:reference id="sref176">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.S.</ce:given-name>
                                 <ce:surname>Kariolis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.R.</ce:given-name>
                                 <ce:surname>Miao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Diep</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.E.</ce:given-name>
                                 <ce:surname>Nash</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.M.</ce:given-name>
                                 <ce:surname>Olcina</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Jiang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.S.J.</ce:given-name>
                                 <ce:surname>Ii</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Kapur</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:surname>Mathews</ce:surname>
                                 <ce:suffix>II</ce:suffix>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.C.</ce:given-name>
                                 <ce:surname>Koong</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Inhibition of the GAS6/AXL pathway augments the efficacy of chemotherapies</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Clin. Investig.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Mar 26];127:183–98. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/27893463" id="intref0865" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/27893463</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0905">Kariolis MS, Miao YR, Diep A, Nash SE, Olcina MM, Jiang D, Ii DSJ, Kapur S, Mathews II, Koong AC, et al. Inhibition of the GAS6/AXL pathway augments the efficacy of chemotherapies. J. Clin. Investig. [Internet]. 2017 [cited 2017 Mar 26];127:183-98. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27893463</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib177">
                     <ce:label>[177]</ce:label>
                     <sb:reference id="sref177">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.C.</ce:given-name>
                                 <ce:surname>Kim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.H.</ce:given-name>
                                 <ce:surname>Baek</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Curcumin-induced downregulation of Axl receptor tyrosine kinase inhibits cell proliferation and circumvents chemoresistance in non-small Lung cancer cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Int. J. Oncol.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Mar 26];47:2296–303. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/26498137" id="intref0870" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/26498137</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0910">Kim KC, Baek SH, Lee C. Curcumin-induced downregulation of Axl receptor tyrosine kinase inhibits cell proliferation and circumvents chemoresistance in non-small Lung cancer cells. Int. J. Oncol. [Internet]. 2015 [cited 2017 Mar 26];47:2296-303. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26498137</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib178">
                     <ce:label>[178]</ce:label>
                     <sb:reference id="sref178">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Bruzzese</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Synergistic antitumor activity of epidermal growth factor receptor tyrosine kinase inhibitor gefitinib and IFN- in head and neck cancer cells <ce:italic>In vitro</ce:italic> and <ce:italic>In vivo</ce:italic>
                              </sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]. Waverly Press</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Clin. Cancer Res.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2006</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Mar 26];12:617–25. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0432.CCR-05-1671" id="intref0875" xlink:type="simple">http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0432.CCR-05-1671</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0915">Bruzzese F. Synergistic antitumor activity of epidermal growth factor receptor tyrosine kinase inhibitor gefitinib and IFN- in head and neck cancer cells In vitro and In vivo. Clin. Cancer Res. [Internet]. Waverly Press; 2006 [cited 2017 Mar 26];12:617-25. Available from: http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0432.CCR-05-1671</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib179">
                     <ce:label>[179]</ce:label>
                     <sb:reference id="sref179">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Sathe</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.M.</ce:given-name>
                                 <ce:surname>Pinto</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Syed</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Nanjappa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.S.</ce:given-name>
                                 <ce:surname>Solanki</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Renuse</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Chavan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.A.</ce:given-name>
                                 <ce:surname>Khan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.H.</ce:given-name>
                                 <ce:surname>Patil</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.S.</ce:given-name>
                                 <ce:surname>Nirujogi</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Phosphotyrosine profiling of curcumin-induced signaling</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Clin. Proteonomics</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Mar 26];13:13. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/27307780" id="intref0880" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/27307780</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0920">Sathe G, Pinto SM, Syed N, Nanjappa V, Solanki HS, Renuse S, Chavan S, Khan AA, Patil AH, Nirujogi RS, et al. Phosphotyrosine profiling of curcumin-induced signaling. Clin. Proteonomics [Internet]. 2016 [cited 2017 Mar 26];13:13. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27307780</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib180">
                     <ce:label>[180]</ce:label>
                     <sb:reference id="sref180">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.Y.J.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The capable ABL: what is its biological function?</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]. American Society for Microbiology (ASM)</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Mol. Cell. Biol.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Mar 28];34:1188–97. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://mcb.asm.org/cgi/doi/10.1128/MCB.01454-13" id="intref0885" xlink:type="simple">http://mcb.asm.org/cgi/doi/10.1128/MCB.01454-13</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0925">Wang JYJ. The capable ABL: what is its biological function? Mol. Cell. Biol. [Internet]. American Society for Microbiology (ASM); 2014 [cited 2017 Mar 28];34:1188-97. Available from: http://mcb.asm.org/cgi/doi/10.1128/MCB.01454-13</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib181">
                     <ce:label>[181]</ce:label>
                     <sb:reference id="sref181">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.M.</ce:given-name>
                                 <ce:surname>Pendergast</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The emerging role of ABL kinases in solid tumors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Trends Cancer</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Mar 28];1:110–23. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://linkinghub.elsevier.com/retrieve/pii/S2405803315000059" id="intref0890" xlink:type="simple">http://linkinghub.elsevier.com/retrieve/pii/S2405803315000059</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0930">Wang J, Pendergast AM. The emerging role of ABL kinases in solid tumors. Trends Cancer [Internet]. 2015 [cited 2017 Mar 28];1:110-23. Available from: http://linkinghub.elsevier.com/retrieve/pii/S2405803315000059</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib182">
                     <ce:label>[182]</ce:label>
                     <sb:reference id="sref182">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>O.</ce:given-name>
                                 <ce:surname>Hantschel</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Structure, Regulation, Signaling, and Targeting of Abl Kinases in Cancer. Genes and Cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:book>
                              <sb:date>2012</sb:date>
                              <sb:publisher>
                                 <sb:name>SAGE PublicationsSage CA</sb:name>
                                 <sb:location>Los Angeles, CA</sb:location>
                              </sb:publisher>
                           </sb:book>
                        </sb:host>
                        <sb:comment>[cited 2017 Mar 28];3:436–46. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://gan.sagepub.com/lookup/doi/10.1177/1947601912458584" id="intref0895" xlink:type="simple">http://gan.sagepub.com/lookup/doi/10.1177/1947601912458584</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0935">Hantschel O. Structure, Regulation, Signaling, and Targeting of Abl Kinases in Cancer. Genes and Cancer [Internet]. SAGE PublicationsSage CA: Los Angeles, CA; 2012 [cited 2017 Mar 28];3:436-46. Available from: http://gan.sagepub.com/lookup/doi/10.1177/1947601912458584</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib183">
                     <ce:label>[183]</ce:label>
                     <sb:reference id="sref183">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Lin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Arlinghaus</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Activated c-Abl tyrosine kinase in malignant solid tumors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]. Nature Publishing Group</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncogene</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>cited 2017 Mar 28];27:4385–91. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.nature.com/doifinder/10.1038/onc.2008.86" id="intref0900" xlink:type="simple">http://www.nature.com/doifinder/10.1038/onc.2008.86</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0940">Lin J, Arlinghaus R. Activated c-Abl tyrosine kinase in malignant solid tumors. Oncogene [Internet]. Nature Publishing Group; 2008 [cited 2017 Mar 28];27:4385-91. Available from: http://www.nature.com/doifinder/10.1038/onc.2008.86</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib184">
                     <ce:label>[184]</ce:label>
                     <sb:reference id="sref184">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.J.</ce:given-name>
                                 <ce:surname>Gu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Rouse</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Xu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.W.</ce:given-name>
                                 <ce:surname>Onaitis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.M.</ce:given-name>
                                 <ce:surname>Pendergast</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Inactivation of ABL kinases suppresses non–small cell lung cancer metastasis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]. American Society for Clinical Investigation</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>JCI Insight</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Mar 28];1:1–16. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://insight.jci.org/articles/view/89647" id="intref0905" xlink:type="simple">https://insight.jci.org/articles/view/89647</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0945">Gu JJ, Rouse C, Xu X, Wang J, Onaitis MW, Pendergast AM. Inactivation of ABL kinases suppresses non-small cell lung cancer metastasis. JCI Insight [Internet]. American Society for Clinical Investigation; 2016 [cited 2017 Mar 28];1:1-16. Available from: https://insight.jci.org/articles/view/89647</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib185">
                     <ce:label>[185]</ce:label>
                     <sb:reference id="sref185">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>E.K.</ce:given-name>
                                 <ce:surname>Greuber</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Smith-Pearson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.M.</ce:given-name>
                                 <ce:surname>Pendergast</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Role of ABL family kinases in cancer: from leukaemia to solid tumours</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]. NIH Public Access</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Cancer</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Mar 28];13:559–71. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/23842646" id="intref0910" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/23842646</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0950">Greuber EK, Smith-Pearson P, Wang J, Pendergast AM. Role of ABL family kinases in cancer: from leukaemia to solid tumours. Nat. Rev. Cancer [Internet]. NIH Public Access; 2013 [cited 2017 Mar 28];13:559-71. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23842646</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib186">
                     <ce:label>[186]</ce:label>
                     <sb:reference id="sref186">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>B.M.</ce:given-name>
                                 <ce:surname>William</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Goodrich</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Peng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Curcumin inhibits proliferation and induces apoptosis of leukemic cells expressing wild-type or T315I-BCR-ABL and prolongs survival of mice with acute lymphoblastic leukemia</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Hematology</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Mar 28];13:333–43. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/19055861" id="intref0915" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/19055861</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0955">William BM, Goodrich A, Peng C, Li S. Curcumin inhibits proliferation and induces apoptosis of leukemic cells expressing wild-type or T315I-BCR-ABL and prolongs survival of mice with acute lymphoblastic leukemia. Hematology [Internet]. 2008 [cited 2017 Mar 28];13:333-43. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19055861</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib187">
                     <ce:label>[187]</ce:label>
                     <sb:reference id="sref187">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Guo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Shan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>He</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Lin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Gong</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Curcumin potentiates the anti-leukemia effects of imatinib by downregulation of the AKT/mTOR pathway and BCR/ABL gene expression in Ph+ acute lymphoblastic leukemia</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Int. J. Biochem. Cell Biol.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Mar 28];65:1–11. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.sciencedirect.com/science/article/pii/S1357272515001247" id="intref0920" xlink:type="simple">http://www.sciencedirect.com/science/article/pii/S1357272515001247</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0960">Guo Y, Li Y, Shan Q, He G, Lin J, Gong Y. Curcumin potentiates the anti-leukemia effects of imatinib by downregulation of the AKT/mTOR pathway and BCR/ABL gene expression in Ph+ acute lymphoblastic leukemia. Int. J. Biochem. Cell Biol. [Internet]. 2015 [cited 2017 Mar 28];65:1-11. Available from: http://www.sciencedirect.com/science/article/pii/S1357272515001247</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib188">
                     <ce:label>[188]</ce:label>
                     <sb:reference id="sref188">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.Z.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.H.</ce:given-name>
                                 <ce:surname>Xu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.W.</ce:given-name>
                                 <ce:surname>Huang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.X.</ce:given-name>
                                 <ce:surname>Wu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Su</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.Z.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Curcumin synergistically augments bcr/abl phosphorothioate antisense oligonucleotides to inhibit growth of chronic myelogenous leukemia cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]. Nature Publishing Group</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Acta Pharmacol. Sin.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2007</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>cited 2017 Mar 28];28:105–10. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.nature.com/doifinder/10.1111/j.1745-7254.2007.00471.x" id="intref0925" xlink:type="simple">http://www.nature.com/doifinder/10.1111/j.1745-7254.2007.00471.x</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0965">Zhang KZ, Xu JH, Huang XW, Wu LX, Su Y, Chen YZ. Curcumin synergistically augments bcr/abl phosphorothioate antisense oligonucleotides to inhibit growth of chronic myelogenous leukemia cells. Acta Pharmacol. Sin. [Internet]. Nature Publishing Group; 2007 [cited 2017 Mar 28];28:105-10. Available from: http://www.nature.com/doifinder/10.1111/j.1745-7254.2007.00471.x</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib189">
                     <ce:label>[189]</ce:label>
                     <sb:reference id="sref189">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Guo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Qing Shan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Yu Gong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Chun Wang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The autophagy induced by curcumin via MEK/ERK pathway plays an early anti-leukemia role in human Philadelphia chromosome-positive acute lymphoblastic leukemia SUP-B15 cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Cancer Res. Ther.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Mar 28]; Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.cancerjournal.net/temp/JCanResTher000-6327996_173439.pdf" id="intref0930" xlink:type="simple">http://www.cancerjournal.net/temp/JCanResTher000-6327996_173439.pdf</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0970">Guo Y, Qing Shan Q, Yu Gong P, Chun Wang S. The autophagy induced by curcumin via MEK/ERK pathway plays an early anti-leukemia role in human Philadelphia chromosome-positive acute lymphoblastic leukemia SUP-B15 cells. J. Cancer Res. Ther. [Internet]. 2017 [cited 2017 Mar 28]; Available from: http://www.cancerjournal.net/temp/JCanResTher000-6327996_173439.pdf</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib190">
                     <ce:label>[190]</ce:label>
                     <sb:reference id="sref190">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.Y.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Regulation of cell death by the Abl tyrosine kinase</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]. Nature Publishing Group</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncogene</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2000</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>cited 2017 Mar 30];19:5643–50. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.nature.com/doifinder/10.1038/sj.onc.1203878" id="intref0935" xlink:type="simple">http://www.nature.com/doifinder/10.1038/sj.onc.1203878</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0975">Wang JY. Regulation of cell death by the Abl tyrosine kinase. Oncogene [Internet]. Nature Publishing Group; 2000 [cited 2017 Mar 30];19:5643-50. Available from: http://www.nature.com/doifinder/10.1038/sj.onc.1203878</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib191">
                     <ce:label>[191]</ce:label>
                     <sb:reference id="sref191">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Kamath</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Jiang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Sun</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.C.</ce:given-name>
                                 <ce:surname>Yalowich</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Baskaran</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>c-Abl kinase regulates curcumin-induced cell death through activation of c-Jun N-terminal kinase</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Mol. Pharmacol.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2007</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Mar 30];71:61–72. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/17021249" id="intref0940" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/17021249</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0980">Kamath R, Jiang Z, Sun G, Yalowich JC, Baskaran R. c-Abl kinase regulates curcumin-induced cell death through activation of c-Jun N-terminal kinase. Mol. Pharmacol. [Internet]. 2007 [cited 2017 Mar 30];71:61-72. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17021249</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib192">
                     <ce:label>[192]</ce:label>
                     <sb:reference id="sref192">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.R.</ce:given-name>
                                 <ce:surname>Robinson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.-M.</ce:given-name>
                                 <ce:surname>Wu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.-F.</ce:given-name>
                                 <ce:surname>Lin</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The protein tyrosine kinase family of the human genome</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncogene</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2000</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Mar 27];19:5548–57. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.nature.com/doifinder/10.1038/sj.onc.1203957" id="intref0945" xlink:type="simple">http://www.nature.com/doifinder/10.1038/sj.onc.1203957</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0985">Robinson DR, Wu Y-M, Lin S-F. The protein tyrosine kinase family of the human genome. Oncogene [Internet]. 2000 [cited 2017 Mar 27];19:5548-57. Available from: http://www.nature.com/doifinder/10.1038/sj.onc.1203957</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib193">
                     <ce:label>[193]</ce:label>
                     <sb:reference id="sref193">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>V.M.</ce:given-name>
                                 <ce:surname>Golubovskaya</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.A.</ce:given-name>
                                 <ce:surname>Kweh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.G.</ce:given-name>
                                 <ce:surname>Cance</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Focal adhesion kinase and cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Histol. Histopathol.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Mar 29];24:503–10. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;id=19224453&amp;retmode=ref&amp;cmd=prlinks%5Cnpapers3://publication/uuid/F9270BDB-2236-4248-8BE1-90C4CA40D7EA" id="intref0950" xlink:type="simple">http://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=19224453&retmode=ref&cmd=prlinks%5Cnpapers3://publication/uuid/F9270BDB-2236-4248-8BE1-90C4CA40D7EA</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0990">Golubovskaya VM, Kweh FA, Cance WG. Focal adhesion kinase and cancer. Histol. Histopathol. [Internet]. 2009 [cited 2017 Mar 29];24:503-10. Available from: http://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=19224453&retmode=ref&cmd=prlinks%5Cnpapers3://publication/uuid/F9270BDB-2236-4248-8BE1-90C4CA40D7EA</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib194">
                     <ce:label>[194]</ce:label>
                     <sb:reference id="sref194">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Y.-L.</ce:given-name>
                                 <ce:surname>Tai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.-C.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.-L.</ce:given-name>
                                 <ce:surname>Shen</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Emerging roles of focal adhesion kinase in cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]. Hindawi Publishing Corporation</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>BioMed Res. Int.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>cited 2017 Mar 29];2015:690690. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://apps.webofknowledge.com.proxy.library.cornell.edu/full_record.do?product=UA&amp;search_mode=GeneralSearch&amp;qid=1&amp;SID=2CLUzMiGCzMnkMsBrqx&amp;page=1&amp;doc=2" id="intref0955" xlink:type="simple">http://apps.webofknowledge.com.proxy.library.cornell.edu/full_record.do?product=UA&search_mode=GeneralSearch&qid=1&SID=2CLUzMiGCzMnkMsBrqx&page=1&doc=2</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0995">Tai Y-L, Chen L-C, Shen T-L. Emerging roles of focal adhesion kinase in cancer. BioMed Res. Int. [Internet]. Hindawi Publishing Corporation; 2015 [cited 2017 Mar 29];2015:690690. Available from: http://apps.webofknowledge.com.proxy.library.cornell.edu/full_record.do?product=UA&search_mode=GeneralSearch&qid=1&SID=2CLUzMiGCzMnkMsBrqx&page=1&doc=2</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib195">
                     <ce:label>[195]</ce:label>
                     <sb:reference id="sref195">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Halder</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.G.</ce:given-name>
                                 <ce:surname>Lin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.M.</ce:given-name>
                                 <ce:surname>Merritt</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.A.</ce:given-name>
                                 <ce:surname>Spannuth</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.M.</ce:given-name>
                                 <ce:surname>Nick</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Honda</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.A.</ce:given-name>
                                 <ce:surname>Kamat</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.Y.</ce:given-name>
                                 <ce:surname>Han</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.K.</ce:given-name>
                                 <ce:surname>Tae</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Lu</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Therapeutic efficacy of a novel focal adhesion kinase inhibitor TAE226 in ovarian carcinoma</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancer Res.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2007</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Mar 29];67:10976–83. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/7796399" id="intref0960" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/7796399</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct1000">Halder J, Lin YG, Merritt WM, Spannuth WA, Nick AM, Honda T, Kamat AA, Han LY, Tae JK, Lu C, et al. Therapeutic efficacy of a novel focal adhesion kinase inhibitor TAE226 in ovarian carcinoma. Cancer Res. [Internet]. 2007 [cited 2017 Mar 29];67:10976-83. Available from: http://www.ncbi.nlm.nih.gov/pubmed/7796399</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib196">
                     <ce:label>[196]</ce:label>
                     <sb:reference id="sref196">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>E.A.</ce:given-name>
                                 <ce:surname>Beierle</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.A.</ce:given-name>
                                 <ce:surname>Massoll</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Hartwich</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.V.</ce:given-name>
                                 <ce:surname>Kurenova</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.M.</ce:given-name>
                                 <ce:surname>Golubovskaya</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.G.</ce:given-name>
                                 <ce:surname>Cance</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>McGrady</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.B.</ce:given-name>
                                 <ce:surname>London</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Focal adhesion kinase expression in human neuroblastoma: immunohistochemical and real-time PCR analyses</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Clin. Cancer Res.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Mar 29];14:3299–305. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/18519756" id="intref0965" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/18519756</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct1005">Beierle EA, Massoll NA, Hartwich J, Kurenova E V, Golubovskaya VM, Cance WG, McGrady P, London WB. Focal adhesion kinase expression in human neuroblastoma: immunohistochemical and real-time PCR analyses. Clin. Cancer Res. [Internet]. 2008 [cited 2017 Mar 29];14:3299-305. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18519756</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib197">
                     <ce:label>[197]</ce:label>
                     <sb:reference id="sref197">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>V.M.</ce:given-name>
                                 <ce:surname>Golubovskaya</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Focal adhesion kinase as a cancer therapy target</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]. NIH Public Access</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Anti Cancer Agents Med. Chem.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Mar 29];10:735–41. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/21214510" id="intref0970" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/21214510</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct1010">Golubovskaya VM. Focal adhesion kinase as a cancer therapy target. Anti Cancer Agents Med. Chem. [Internet]. NIH Public Access; 2010 [cited 2017 Mar 29];10:735-41. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21214510</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib198">
                     <ce:label>[198]</ce:label>
                     <sb:reference id="sref198">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>V.M.</ce:given-name>
                                 <ce:surname>Golubovskaya</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>FAK and Nanog cross talk with p53 in cancer stem cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Anti Cancer Agents Med. Chem.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Mar 29];13:576–80. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/22934707" id="intref0975" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/22934707</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct1015">Golubovskaya VM. FAK and Nanog cross talk with p53 in cancer stem cells. Anti Cancer Agents Med. Chem. [Internet]. 2013 [cited 2017 Mar 29];13:576-80. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22934707</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib199">
                     <ce:label>[199]</ce:label>
                     <sb:reference id="sref199">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>F.J.</ce:given-name>
                                 <ce:surname>Sulzmaier</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Jean</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.D.</ce:given-name>
                                 <ce:surname>Schlaepfer</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>FAK in cancer: mechanistic findings and clinical applications</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Cancer</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Mar 29];14:598–610. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/25098269" id="intref0980" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/25098269</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct1020">Sulzmaier FJ, Jean C, Schlaepfer DD. FAK in cancer: mechanistic findings and clinical applications. Nat. Rev. Cancer [Internet]. 2014 [cited 2017 Mar 29];14:598-610. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25098269</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib200">
                     <ce:label>[200]</ce:label>
                     <sb:reference id="sref200">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Xing</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Cao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Ai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Wei</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Jiang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The interaction between cancer stem cell marker CD133 and Src protein promotes Focal Adhesion Kinase (FAK) phosphorylation and cell migration</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Biol. Chem.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Mar 29];291:15540–50. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/27226554" id="intref0985" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/27226554</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct1025">Liu C, Li Y, Xing Y, Cao B, Yang F, Yang T, Ai Z, Wei Y, Jiang J. The interaction between cancer stem cell marker CD133 and Src protein promotes Focal Adhesion Kinase (FAK) phosphorylation and cell migration. J. Biol. Chem.[Internet]. 2016 [cited 2017 Mar 29];291:15540-50. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27226554</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib201">
                     <ce:label>[201]</ce:label>
                     <sb:reference id="sref201">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.E.</ce:given-name>
                                 <ce:surname>Williams</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.J.</ce:given-name>
                                 <ce:surname>Bundred</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Landberg</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.B.</ce:given-name>
                                 <ce:surname>Clarke</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Farnie</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Focal adhesion kinase and wnt signaling regulate human ductal carcinoma in situ stem cell activity and response to radiotherapy</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Stem Cells</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Mar 29];33:327–41. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/25187396" id="intref0990" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/25187396</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct1030">Williams KE, Bundred NJ, Landberg G, Clarke RB, Farnie G. Focal adhesion kinase and wnt signaling regulate human ductal carcinoma in situ stem cell activity and response to radiotherapy. Stem Cells [Internet]. 2015 [cited 2017 Mar 29];33:327-41. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25187396</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib202">
                     <ce:label>[202]</ce:label>
                     <sb:reference id="sref202">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Mitra</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Chakrabarti</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Banerji</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Chatterjee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.R.</ce:given-name>
                                 <ce:surname>Das</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Curcumin, a potential inhibitor of MMP-2 in human laryngeal squamous carcinoma cells HEp 2</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Environ. Pathol. Toxicol. Oncol.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2006</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Mar 29];25:679–90. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/17341208" id="intref0995" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/17341208</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct1035">Mitra A, Chakrabarti J, Banerji A, Chatterjee A, Das BR. Curcumin, a potential inhibitor of MMP-2 in human laryngeal squamous carcinoma cells HEp 2. J. Environ. Pathol. Toxicol. Oncol. [Internet]. 2006 [cited 2017 Mar 29];25:679-90. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17341208</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib203">
                     <ce:label>[203]</ce:label>
                     <sb:reference id="sref203">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Mukherjee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Mazumdar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Chakraborty</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Manna</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Saha</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Khan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Bhattacharjee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Guha</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Adhikary</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Mukhjerjee</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Curcumin inhibits breast cancer stem cell migration by amplifying the E-cadherin/??-catenin negative feedback loop</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Stem Cell Res. Ther.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Mar 29];5:116. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/25315241" id="intref1000" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/25315241</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct1040">Mukherjee S, Mazumdar M, Chakraborty S, Manna A, Saha S, Khan P, Bhattacharjee P, Guha D, Adhikary A, Mukhjerjee S, et al. Curcumin inhibits breast cancer stem cell migration by amplifying the E-cadherin/??-catenin negative feedback loop. Stem Cell Res. Ther. [Internet]. 2014 [cited 2017 Mar 29];5:116. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25315241</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib204">
                     <ce:label>[204]</ce:label>
                     <sb:reference id="sref204">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.C.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Sureshbabul</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.W.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.S.</ce:given-name>
                                 <ce:surname>Lin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.Y.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.S.</ce:given-name>
                                 <ce:surname>Hong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.C.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.L.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Curcumin suppresses metastasis via Sp-1, FAK inhibition, and E-cadherin upregulation in colorectal cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]. Hindawi Publishing Corporation</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Evid. Based Complement Altern. Med.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Mar 29];2013:541695. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/23970932" id="intref1005" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/23970932</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct1045">Chen CC, Sureshbabul M, Chen HW, Lin YS, Lee JY, Hong QS, Yang YC, Yu SL. Curcumin suppresses metastasis via Sp-1, FAK inhibition, and E-cadherin upregulation in colorectal cancer. Evid. Based Complement Altern. Med. [Internet]. Hindawi Publishing Corporation; 2013 [cited 2017 Mar 29];2013:541695. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23970932</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib205">
                     <ce:label>[205]</ce:label>
                     <sb:reference id="sref205">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.Y.L.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.C.</ce:given-name>
                                 <ce:surname>Fan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.A.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.W.</ce:given-name>
                                 <ce:surname>Cheng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.J.</ce:given-name>
                                 <ce:surname>Sung</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.P.</ce:given-name>
                                 <ce:surname>Hsu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.Y.</ce:given-name>
                                 <ce:surname>Kao</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Curcumin inhibits invasiveness and epithelial-mesenchymal transition in oral squamous cell carcinoma through reducing matrix metalloproteinase 2, 9 and modulating p53-E-cadherin pathway</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Integr. Cancer Ther.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Mar 29];14:484–90. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/26036622" id="intref1010" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/26036622</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct1050">Lee AYL, Fan CC, Chen YA, Cheng CW, Sung YJ, Hsu CP, Kao TY. Curcumin inhibits invasiveness and epithelial-mesenchymal transition in oral squamous cell carcinoma through reducing matrix metalloproteinase 2, 9 and modulating p53-E-cadherin pathway. Integr. Cancer Ther. [Internet]. 2015 [cited 2017 Mar 29];14:484-90. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26036622</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib206">
                     <ce:label>[206]</ce:label>
                     <sb:reference id="sref206">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Bose</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.K.</ce:given-name>
                                 <ce:surname>Panda</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Mukherjee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Sa</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Curcumin and tumor immune-editing: resurrecting the immune system</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]. BioMed Central</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cell Div.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Mar 29];10:6. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/26464579" id="intref1015" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/26464579</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct1055">Bose S, Panda AK, Mukherjee S, Sa G. Curcumin and tumor immune-editing: resurrecting the immune system. Cell Div. [Internet]. BioMed Central; 2015 [cited 2017 Mar 29];10:6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26464579</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib207">
                     <ce:label>[207]</ce:label>
                     <sb:reference id="sref207">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.P.</ce:given-name>
                                 <ce:surname>Sordillo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Helson</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Curcumin and cancer stem cells: curcumin has asymmetrical effects on cancer and normal stem cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Anticancer Res.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Mar 29];35:599–614. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/25667437" id="intref1020" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/25667437</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct1060">Sordillo PP, Helson L. Curcumin and cancer stem cells: curcumin has asymmetrical effects on cancer and normal stem cells. Anticancer Res. [Internet]. 2015 [cited 2017 Mar 29];35:599-614. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25667437</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib208">
                     <ce:label>[208]</ce:label>
                     <sb:reference id="sref208">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.-H.H.</ce:given-name>
                                 <ce:surname>Leu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.L.</ce:given-name>
                                 <ce:surname>Su</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.-C.C.</ce:given-name>
                                 <ce:surname>Chuang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.-C.C.</ce:given-name>
                                 <ce:surname>Maa</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Direct inhibitory effect of curcumin on Src and focal adhesion kinase activity</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Biochem. Pharmacol.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2003</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Mar 30];66:2323–31. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/14637190" id="intref1025" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/14637190</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct1065">Leu T-HH, Su SL, Chuang Y-CC, Maa M-CC. Direct inhibitory effect of curcumin on Src and focal adhesion kinase activity. Biochem. Pharmacol. [Internet]. 2003 [cited 2017 Mar 30];66:2323-31. Available from: http://www.ncbi.nlm.nih.gov/pubmed/14637190</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib209">
                     <ce:label>[209]</ce:label>
                     <sb:reference id="sref209">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.N.</ce:given-name>
                                 <ce:surname>Constantinescu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Girardot</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Pecquet</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Mining for JAK-STAT mutations in cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]. Elsevier</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Trends Biochem. Sci.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Mar 30];33:122–31. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/18291658" id="intref1030" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/18291658</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct1070">Constantinescu SN, Girardot M, Pecquet C. Mining for JAK-STAT mutations in cancer. Trends Biochem. Sci. [Internet]. Elsevier; 2008 [cited 2017 Mar 30];33:122-31. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18291658</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib210">
                     <ce:label>[210]</ce:label>
                     <sb:reference id="sref210">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.J.</ce:given-name>
                                 <ce:surname>Thomas</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.A.</ce:given-name>
                                 <ce:surname>Snowden</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.P.</ce:given-name>
                                 <ce:surname>Zeidler</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.J.</ce:given-name>
                                 <ce:surname>Danson</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The role of JAK/STAT signalling in the pathogenesis, prognosis and treatment of solid tumours</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]. Nature Publishing Group</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Br. J. Canc.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>cited 2017 Mar 29];113:365–71. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/26151455" id="intref1035" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/26151455</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct1075">Thomas SJ, Snowden JA, Zeidler MP, Danson SJ. The role of JAK/STAT signalling in the pathogenesis, prognosis and treatment of solid tumours. Br. J. Canc. [Internet]. Nature Publishing Group; 2015 [cited 2017 Mar 29];113:365-71. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26151455</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib211">
                     <ce:label>[211]</ce:label>
                     <sb:reference id="sref211">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Sriuranpong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.I.</ce:given-name>
                                 <ce:surname>Park</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Amornphimoltham</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Patel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.D.</ce:given-name>
                                 <ce:surname>Nelkin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.S.</ce:given-name>
                                 <ce:surname>Gutkind</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Epidermal growth factor receptor-independent constitutive activation of STAT3 in head and neck squamous cell carcinoma is mediated by the autocrine/paracrine stimulation of the interleukin 6/gp130 cytokine system</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancer Res.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2003</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Mar 29];63:2948–56. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/12782602" id="intref1040" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/12782602</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct1080">Sriuranpong V, Park JI, Amornphimoltham P, Patel V, Nelkin BD, Gutkind JS. Epidermal growth factor receptor-independent constitutive activation of STAT3 in head and neck squamous cell carcinoma is mediated by the autocrine/paracrine stimulation of the interleukin 6/gp130 cytokine system. Cancer Res. [Internet]. 2003 [cited 2017 Mar 29];63:2948-56. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12782602</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib212">
                     <ce:label>[212]</ce:label>
                     <sb:reference id="sref212">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Buchert</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.J.</ce:given-name>
                                 <ce:surname>Burns</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Ernst</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Targeting JAK kinase in solid tumors: emerging opportunities and challenges</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncogene</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Mar 29];35:939–51. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/25982279" id="intref1045" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/25982279</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct1085">Buchert M, Burns CJ, Ernst M. Targeting JAK kinase in solid tumors: emerging opportunities and challenges. Oncogene [Internet]. 2016 [cited 2017 Mar 29];35:939-51. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25982279</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib213">
                     <ce:label>[213]</ce:label>
                     <sb:reference id="sref213">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.H.</ce:given-name>
                                 <ce:surname>Chuang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.G.</ce:given-name>
                                 <ce:surname>Greenside</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.N.</ce:given-name>
                                 <ce:surname>Rogers</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.J.</ce:given-name>
                                 <ce:surname>Brady</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.K.</ce:given-name>
                                 <ce:surname>Ma</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.R.</ce:given-name>
                                 <ce:surname>Caswell</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.H.</ce:given-name>
                                 <ce:surname>Chiou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.F.</ce:given-name>
                                 <ce:surname>Winters</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.M.</ce:given-name>
                                 <ce:surname>Grüner</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Molecular definition of a metastatic lung cancer state reveals a targetable CD109-Janus kinase-Stat axis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Med.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Mar 29];23:291–300. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/28191885" id="intref1050" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/28191885</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct1090">Chuang CH, Greenside PG, Rogers ZN, Brady JJ, Yang D, Ma RK, Caswell DR, Chiou SH, Winters AF, Gruner BM, et al. Molecular definition of a metastatic lung cancer state reveals a targetable CD109-Janus kinase-Stat axis. Nat. Med. [Internet]. 2017 [cited 2017 Mar 29];23:291-300. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28191885</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib214">
                     <ce:label>[214]</ce:label>
                     <sb:reference id="sref214">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.Y.</ce:given-name>
                                 <ce:surname>Kim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.J.</ce:given-name>
                                 <ce:surname>Park</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.-H.</ce:given-name>
                                 <ce:surname>Joe</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Jou</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Curcumin suppresses Janus kinase-STAT inflammatory signaling through activation of Src homology 2 domain-containing tyrosine phosphatase 2 in brain microglia</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Immunol.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2003</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Mar 30];171:6072–9. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/14634121" id="intref1055" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/14634121</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct1095">Kim HY, Park EJ, Joe E-H, Jou I. Curcumin suppresses Janus kinase-STAT inflammatory signaling through activation of Src homology 2 domain-containing tyrosine phosphatase 2 in brain microglia. J. Immunol. [Internet]. 2003 [cited 2017 Mar 30];171:6072-9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/14634121</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib215">
                     <ce:label>[215]</ce:label>
                     <sb:reference id="sref215">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.L.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.Y.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.G.</ce:given-name>
                                 <ce:surname>Ma</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.X.</ce:given-name>
                                 <ce:surname>Xue</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.G.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Ren</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.B.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Curcumin blocks small cell lung cancer cells migration, invasion, angiogenesis, cell cycle and neoplasia through janus kinase-STAT3 signalling pathway</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:editors>
                                 <sb:editor>
                                    <ce:given-name>R.P.</ce:given-name>
                                    <ce:surname>Singh</ce:surname>
                                 </sb:editor>
                              </sb:editors>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>PLoS One</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Mar 30];7:e37960. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/22662257" id="intref1060" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/22662257</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct1100">Yang CL, Liu YY, Ma YG, Xue YX, Liu DG, Ren Y, Liu XB, Li Y, Li Z. Curcumin blocks small cell lung cancer cells migration, invasion, angiogenesis, cell cycle and neoplasia through janus kinase-STAT3 signalling pathway. Singh RP, editor. PLoS One [Internet]. 2012 [cited 2017 Mar 30];7:e37960. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22662257</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib216">
                     <ce:label>[216]</ce:label>
                     <sb:reference id="sref216">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Blasius</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Reuter</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Henry</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Dicato</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Diederich</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Curcumin regulates signal transducer and activator of transcription (STAT) expression in K562 cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Biochem. Pharmacol.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2006</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Mar 30];72:1547–54. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/16959222" id="intref1065" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/16959222</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct1105">Blasius R, Reuter S, Henry E, Dicato M, Diederich M. Curcumin regulates signal transducer and activator of transcription (STAT) expression in K562 cells. Biochem. Pharmacol. [Internet]. 2006 [cited 2017 Mar 30];72:1547-54. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16959222</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib217">
                     <ce:label>[217]</ce:label>
                     <sb:reference id="sref217">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.G.</ce:given-name>
                                 <ce:surname>Alexandrow</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.J.</ce:given-name>
                                 <ce:surname>Song</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Altiok</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Gray</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.B.</ce:given-name>
                                 <ce:surname>Haura</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.B.</ce:given-name>
                                 <ce:surname>Kumar</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Curcumin: a novel Stat3 pathway inhibitor for chemoprevention of lung cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]. NIH Public Access</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Cancer Prev.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Mar 30];21:407–12. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/22156994" id="intref1070" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/22156994</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct1110">Alexandrow MG, Song LJ, Altiok S, Gray J, Haura EB, Kumar NB. Curcumin: a novel Stat3 pathway inhibitor for chemoprevention of lung cancer. Eur. J. Cancer Prev. [Internet]. NIH Public Access; 2012 [cited 2017 Mar 30];21:407-12. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22156994</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib218">
                     <ce:label>[218]</ce:label>
                     <sb:reference id="sref218">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Zhao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Gao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Han</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Potential anti-cancer effect of curcumin in human lung squamous cell carcinoma</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]. Wiley-Blackwell</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Thorac. Cancer</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>cited 2017 Mar 30];6:508–16. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/26273408" id="intref1075" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/26273408</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct1115">Zhao W, Wang Y, Wang Y, Gao N, Han Z, Yu H. Potential anti-cancer effect of curcumin in human lung squamous cell carcinoma. Thorac. Cancer [Internet]. Wiley-Blackwell; 2015 [cited 2017 Mar 30];6:508-16. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26273408</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib219">
                     <ce:label>[219]</ce:label>
                     <sb:reference id="sref219">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.K.</ce:given-name>
                                 <ce:surname>Guest</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Ribas</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Pancholi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Nikitorowicz-Buniak</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Simigdala</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Dowsett</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.R.</ce:given-name>
                                 <ce:surname>Johnston</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.A.</ce:given-name>
                                 <ce:surname>Martin</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Src is a potential therapeutic target in endocrine-resistant breast cancer exhibiting low estrogen receptor-mediated transactivation. Migliaccio A</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>PLoS One</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Mar 31];11:e0157397. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/27308830" id="intref1080" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/27308830</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct1120">Guest SK, Ribas R, Pancholi S, Nikitorowicz-Buniak J, Simigdala N, Dowsett M, Johnston SR, Martin LA. Src is a potential therapeutic target in endocrine-resistant breast cancer exhibiting low estrogen receptor-mediated transactivation. Migliaccio A, editor. PLoS One [Internet]. 2016 [cited 2017 Mar 31];11:e0157397. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27308830</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib220">
                     <ce:label>[220]</ce:label>
                     <sb:reference id="sref220">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Manek</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Pakzamir</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Mhawech-Fauceglia</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Pejovic</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Sowter</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.A.</ce:given-name>
                                 <ce:surname>Gayther</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Lawrenson</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Targeting Src in endometriosis-associated ovarian cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]. Nature Publishing Group</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncogenesis</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>cited 2017 Mar 31];5:e251. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.nature.com/doifinder/10.1038/oncsis.2016.54" id="intref1085" xlink:type="simple">http://www.nature.com/doifinder/10.1038/oncsis.2016.54</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct1125">Manek R, Pakzamir E, Mhawech-Fauceglia P, Pejovic T, Sowter H, Gayther SA, Lawrenson K. Targeting Src in endometriosis-associated ovarian cancer. Oncogenesis [Internet]. Nature Publishing Group; 2016 [cited 2017 Mar 31];5:e251. Available from: http://www.nature.com/doifinder/10.1038/oncsis.2016.54</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib221">
                     <ce:label>[221]</ce:label>
                     <sb:reference id="sref221">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Patel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Sabbineni</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Clarke</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.R.</ce:given-name>
                                 <ce:surname>Somanath</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Novel roles of Src in cancer cell epithelial-to-mesenchymal transition, vascular permeability, microinvasion and metastasis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Life Sci.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Mar 31];157:52–61. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/27245276" id="intref1090" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/27245276</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct1130">Patel A, Sabbineni H, Clarke A, Somanath PR. Novel roles of Src in cancer cell epithelial-to-mesenchymal transition, vascular permeability, microinvasion and metastasis. Life Sci. [Internet]. 2016 [cited 2017 Mar 31];157:52-61. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27245276</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib222">
                     <ce:label>[222]</ce:label>
                     <sb:reference id="sref222">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Elfiky</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Han</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.W.</ce:given-name>
                                 <ce:surname>Saif</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The role of src in colon cancer and its therapeutic implications</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Clin. Colorectal Cancer</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Mar 31];13:5–13. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.sciencedirect.com/science/article/pii/S1533002813001217" id="intref1095" xlink:type="simple">http://www.sciencedirect.com/science/article/pii/S1533002813001217</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct1135">Chen J, Elfiky A, Han M, Chen C, Saif MW. The role of src in colon cancer and its therapeutic implications. Clin. Colorectal Cancer [Internet]. 2014 [cited 2017 Mar 31];13:5-13. Available from: http://www.sciencedirect.com/science/article/pii/S1533002813001217</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib223">
                     <ce:label>[223]</ce:label>
                     <sb:reference id="sref223">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Guarino</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Src signaling in cancer invasion</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Cell. Physiol.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Mar 31];223:14–26. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/20049846" id="intref1100" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/20049846</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct1140">Guarino M. Src signaling in cancer invasion. J. Cell. Physiol. [Internet]. 2010 [cited 2017 Mar 31];223:14-26. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20049846</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib224">
                     <ce:label>[224]</ce:label>
                     <sb:reference id="sref224">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Wilson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Nicholes</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Bustos</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Lin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Song</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.-P.</ce:given-name>
                                 <ce:surname>Stephan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.S.</ce:given-name>
                                 <ce:surname>Kirkpatrick</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Settleman</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Overcoming EMT-associated resistance to anti-cancer drugs via Src/FAK pathway inhibition</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]. Impact Journals, LLC</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncotarget</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>cited 2017 Mar 31];5:7328–41. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4202126&amp;tool=pmcentrez&amp;rendertype=abstract" id="intref1105" xlink:type="simple">http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4202126&tool=pmcentrez&rendertype=abstract</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct1145">Wilson C, Nicholes K, Bustos D, Lin E, Song Q, Stephan J-P, Kirkpatrick DS, Settleman J. Overcoming EMT-associated resistance to anti-cancer drugs via Src/FAK pathway inhibition. Oncotarget [Internet]. Impact Journals, LLC; 2014 [cited 2017 Mar 31];5:7328-41. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4202126&tool=pmcentrez&rendertype=abstract</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib225">
                     <ce:label>[225]</ce:label>
                     <sb:reference id="sref225">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>N.S.</ce:given-name>
                                 <ce:surname>Nagathihalli</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Src-mediated regulation of E-cadherin and EMT in pancreatic cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Front. Biosci.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Mar 31];17:2059. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.bioscience.org/2012/v17/af/4037/list.htm" id="intref1110" xlink:type="simple">http://www.bioscience.org/2012/v17/af/4037/list.htm</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct1150">Nagathihalli NS. Src-mediated regulation of E-cadherin and EMT in pancreatic cancer. Front. Biosci. [Internet]. 2012 [cited 2017 Mar 31];17:2059. Available from: http://www.bioscience.org/2012/v17/af/4037/list.htm</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib226">
                     <ce:label>[226]</ce:label>
                     <sb:reference id="sref226">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Ke</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Xiang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Guo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Lu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Xia</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Peng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Ye</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>c-Src activation promotes nasopharyngeal carcinoma metastasis by inducing the epithelial-mesenchymal transition via PI3K/Akt signaling pathway: a new and promising target for NPC</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]. Impact Journals</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncotarget</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>cited 2017 Mar 31];7:28340–55. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/27078847%0Ahttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC5053730" id="intref1115" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/27078847%0Ahttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC5053730</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct1155">Ke L, Xiang Y, Guo X, Lu J, Xia W, Yu Y, Peng Y, Wang L, Wang G, Ye Y, et al. c-Src activation promotes nasopharyngeal carcinoma metastasis by inducing the epithelial-mesenchymal transition via PI3K/Akt signaling pathway: a new and promising target for NPC. Oncotarget [Internet]. Impact Journals; 2016 [cited 2017 Mar 31];7:28340-55. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27078847%0Ahttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC5053730</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib227">
                     <ce:label>[227]</ce:label>
                     <sb:reference id="sref227">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Vlaeminck-Guillem</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Gillet</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Rimokh</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Src: marker or actor in prostate cancer aggressiveness</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Front. Oncol.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Mar 31];4:222. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://journal.frontiersin.org/article/10.3389/fonc.2014.00222/abstract" id="intref1120" xlink:type="simple">http://journal.frontiersin.org/article/10.3389/fonc.2014.00222/abstract</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct1160">Vlaeminck-Guillem V, Gillet G, Rimokh R. Src: marker or actor in prostate cancer aggressiveness. Front. Oncol. [Internet]. 2014 [cited 2017 Mar 31];4:222. Available from: http://journal.frontiersin.org/article/10.3389/fonc.2014.00222/abstract</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib228">
                     <ce:label>[228]</ce:label>
                     <sb:reference id="sref228">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.T.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Pham</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.J.</ce:given-name>
                                 <ce:surname>Pandol</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Ptasznik</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Src as the link between inflammation and cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]. Frontiers Media SA</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Front. Physiol.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Mar 31];4 JAN:416. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/24474940" id="intref1125" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/24474940</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct1165">Liu ST, Pham H, Pandol SJ, Ptasznik A. Src as the link between inflammation and cancer. Front. Physiol. [Internet]. Frontiers Media SA; 2014 [cited 2017 Mar 31];4 JAN:416. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24474940</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib229">
                     <ce:label>[229]</ce:label>
                     <sb:reference id="sref229">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Saini</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Arora</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Majid</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Shahryari</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Deng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Yamamura</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Ueno</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Dahiya</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Curcumin modulates microRNA-203-mediated regulation of the Src-Akt axis in bladder cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancer Prev. Res.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Mar 30];4:1698–709. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/21836020" id="intref1130" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/21836020</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct1170">Saini S, Arora S, Majid S, Shahryari V, Chen Y, Deng G, Yamamura S, Ueno K, Dahiya R. Curcumin modulates microRNA-203-mediated regulation of the Src-Akt axis in bladder cancer. Cancer Prev. Res. [Internet]. 2011 [cited 2017 Mar 30];4:1698-709. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21836020</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib230">
                     <ce:label>[230]</ce:label>
                     <sb:reference id="sref230">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Shakibaei</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Mobasheri</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Lueders</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Busch</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Shayan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Goel</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Curcumin enhances the effect of chemotherapy against colorectal cancer cells by inhibition of NF-κB and src protein kinase signaling pathways</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:editors>
                                 <sb:editor>
                                    <ce:given-name>B.B.</ce:given-name>
                                    <ce:surname>Aggarwal</ce:surname>
                                 </sb:editor>
                              </sb:editors>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>PLoS One</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Mar 30];8:e57218. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/23451189" id="intref1135" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/23451189</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct1175">Shakibaei M, Mobasheri A, Lueders C, Busch F, Shayan P, Goel A. Curcumin enhances the effect of chemotherapy against colorectal cancer cells by inhibition of NF-κB and src protein kinase signaling pathways. Aggarwal BB, editor. PLoS One [Internet]. 2013 [cited 2017 Mar 30];8:e57218. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23451189</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib231">
                     <ce:label>[231]</ce:label>
                     <sb:reference id="sref231">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Targeting Src family kinases in anti-cancer therapies: turning promise into triumph</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Trends Pharmacol. Sci.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2017 Mar 31];33:122–8. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/22153719" id="intref1140" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/22153719</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct1180">Zhang S, Yu D. Targeting Src family kinases in anti-cancer therapies: turning promise into triumph. Trends Pharmacol. Sci. [Internet]. 2012 [cited 2017 Mar 31];33:122-8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22153719</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib232">
                     <ce:label>[232]</ce:label>
                     <sb:reference id="sref232">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.M.</ce:given-name>
                                 <ce:surname>Nelson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.L.</ce:given-name>
                                 <ce:surname>Dahlin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Bisson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Graham</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.F.</ce:given-name>
                                 <ce:surname>Pauli</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.A.</ce:given-name>
                                 <ce:surname>Walters</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The essential medicinal chemistry of curcumin: miniperspective</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct1185">Nelson KM, Dahlin JL, Bisson J, Graham J, Pauli GF, Walters MA. The Essential Medicinal Chemistry of Curcumin: Miniperspective. J Med Chem. 2017;</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib233">
                     <ce:label>[233]</ce:label>
                     <sb:reference id="sref233">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>F.C.</ce:given-name>
                                 <ce:surname>Rodrigues</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.V.</ce:given-name>
                                 <ce:surname>Anil Kumar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Thakur</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Developments in the anticancer activity of structurally modified curcumin: an up-to-date review</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2019 Jul 2];177:76–104. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/31129455" id="intref1145" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/31129455</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct1190">Rodrigues FC, Anil Kumar NV, Thakur G. Developments in the anticancer activity of structurally modified curcumin: an up-to-date review. Eur. J. Med. Chem. [Internet]. 2019 [cited 2019 Jul 2];177:76-104. Available from: http://www.ncbi.nlm.nih.gov/pubmed/31129455</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib234">
                     <ce:label>[234]</ce:label>
                     <sb:reference id="sref234">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Salehi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Stojanović-Radić</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Matejić</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Sharifi-Rad</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.V.</ce:given-name>
                                 <ce:surname>Anil Kumar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Martins</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Sharifi-Rad</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The therapeutic potential of curcumin: a review of clinical trials</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2019 Jul 3];163:527–45. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/30553144" id="intref1150" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/30553144</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct1195">Salehi B, Stojanovic-Radic Z, Matejic J, Sharifi-Rad M, Anil Kumar N V., Martins N, Sharifi-Rad J. The therapeutic potential of curcumin: a review of clinical trials. Eur. J. Med. Chem. [Internet]. 2019 [cited 2019 Jul 3];163:527-45. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30553144</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib235">
                     <ce:label>[235]</ce:label>
                     <sb:reference id="sref235">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Vyas</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Dandawate</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Padhye</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Ahmad</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Sarkar</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Perspectives on new synthetic curcumin analogs and their potential anticancer properties</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Curr. Pharmaceut. Des.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>19</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2047</sb:first-page>
                              <sb:last-page>2069</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct1200">Vyas A, Dandawate P, Padhye S, Ahmad A, Sarkar F. Perspectives on new synthetic curcumin analogs and their potential anticancer properties. Curr Pharm Des. 2013;19:2047-2069.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib236">
                     <ce:label>[236]</ce:label>
                     <sb:reference id="sref236">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Yim-im</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Suksamrarn</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>O.</ce:given-name>
                                 <ce:surname>Sawatdichaikul</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Choowongkomon</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>In Silico Study of Curcumin Analogs as HER2 Kinase Inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:book>
                              <sb:date>2014</sb:date>
                              <sb:publisher>
                                 <sb:name>Khon Kaen University and Chemical Society of Thailand</sb:name>
                              </sb:publisher>
                           </sb:book>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct1205">Yim-im W, Suksamrarn A, Sawatdichaikul O, Choowongkomon K. In silico study of curcumin analogs as HER2 kinase inhibitors. Khon Kaen University and Chemical Society of Thailand; 2014.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib237">
                     <ce:label>[237]</ce:label>
                     <sb:reference id="sref237">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.J.</ce:given-name>
                                 <ce:surname>Ahsan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Khalilullah</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Yasmin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.S.</ce:given-name>
                                 <ce:surname>Jadav</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Govindasamy</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Synthesis, characterisation, and <ce:italic>in vitro</ce:italic> anticancer activity of curcumin analogues bearing pyrazole/pyrimidine ring targeting EGFR tyrosine kinase</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>BioMed Res. Int.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>2013</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct1210">Ahsan MJ, Khalilullah H, Yasmin S, Jadav SS, Govindasamy J. Synthesis, characterisation, and in vitro anticancer activity of curcumin analogues bearing pyrazole/pyrimidine ring targeting EGFR tyrosine kinase. Biomed Res Int. 2013;2013.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib238">
                     <ce:label>[238]</ce:label>
                     <sb:reference id="sref238">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Ishida</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Ohtsu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Tachibana</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Nakanishi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.F.</ce:given-name>
                                 <ce:surname>Bastow</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Nagai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.-K.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Itokawa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.-H.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Antitumor agents. Part 214: synthesis and evaluation of curcumin analogues as cytotoxic agents</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>10</sb:volume-nr>
                              </sb:series>
                              <sb:date>2002</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3481</sb:first-page>
                              <sb:last-page>3487</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct1215">Ishida J, Ohtsu H, Tachibana Y, Nakanishi Y, Bastow KF, Nagai M, Wang H-K, Itokawa H, Lee K-H. Antitumor agents. Part 214: Synthesis and evaluation of curcumin analogues as cytotoxic agents. Bioorg Med Chem. 2002;10:3481-3487.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib239">
                     <ce:label>[239]</ce:label>
                     <sb:reference id="sref239">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Dutta</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Padhye</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.I.</ce:given-name>
                                 <ce:surname>Priyadarsini</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Newton</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Antioxidant and antiproliferative activity of curcumin semicarbazone</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem. Lett</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>15</sb:volume-nr>
                              </sb:series>
                              <sb:date>2005</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2738</sb:first-page>
                              <sb:last-page>2744</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct1220">Dutta S, Padhye S, Priyadarsini KI, Newton C. Antioxidant and antiproliferative activity of curcumin semicarbazone. Bioorg Med Chem Lett. 2005;15:2738-2744.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib240">
                     <ce:label>[240]</ce:label>
                     <sb:reference id="sref240">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.K.</ce:given-name>
                                 <ce:surname>Agrawal</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.K.</ce:given-name>
                                 <ce:surname>Mishra</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Curcumin and its analogues: potential anticancer agents</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Med. Res. Rev.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>30</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>818</sb:first-page>
                              <sb:last-page>860</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct1225">Agrawal DK, Mishra PK. Curcumin and its analogues: potential anticancer agents. Med Res Rev. 2010;30:818-860.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib241">
                     <ce:label>[241]</ce:label>
                     <sb:reference id="sref241">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Das</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Pany</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Panchal</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Majhi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.M.</ce:given-name>
                                 <ce:surname>Rahman</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Binding of isoxazole and pyrazole derivatives of curcumin with the activator binding domain of novel protein kinase C</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>19</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>6196</sb:first-page>
                              <sb:last-page>6202</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct1230">Das J, Pany S, Panchal S, Majhi A, Rahman GM. Binding of isoxazole and pyrazole derivatives of curcumin with the activator binding domain of novel protein kinase C. Bioorg Med Chem. 2011;19:6196-6202.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib242">
                     <ce:label>[242]</ce:label>
                     <sb:reference id="sref242">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.W.</ce:given-name>
                                 <ce:surname>Amolins</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.B.</ce:given-name>
                                 <ce:surname>Peterson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.S.</ce:given-name>
                                 <ce:surname>Blagg</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Synthesis and evaluation of electron-rich curcumin analogues</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>17</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>360</sb:first-page>
                              <sb:last-page>367</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct1235">Amolins MW, Peterson LB, Blagg BS. Synthesis and evaluation of electron-rich curcumin analogues. Bioorg Med Chem. 2009;17:360-367.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib243">
                     <ce:label>[243]</ce:label>
                     <sb:reference id="sref243">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Simoni</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Rizzi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Rondanin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Baruchello</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Marchetti</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.P.</ce:given-name>
                                 <ce:surname>Invidiata</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Labbozzetta</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Poma</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Carina</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Notarbartolo</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Antitumor effects of curcumin and structurally β-diketone modified analogs on multidrug resistant cancer cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem. Lett</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>18</sb:volume-nr>
                              </sb:series>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>845</sb:first-page>
                              <sb:last-page>849</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct1240">Simoni D, Rizzi M, Rondanin R, Baruchello R, Marchetti P, Invidiata FP, Labbozzetta M, Poma P, Carina V, Notarbartolo M. Antitumor effects of curcumin and structurally β-diketone modified analogs on multidrug resistant cancer cells. Bioorg Med Chem Lett. 2008;18:845-849.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib244">
                     <ce:label>[244]</ce:label>
                     <sb:reference id="sref244">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>B.K.</ce:given-name>
                                 <ce:surname>Adams</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.M.</ce:given-name>
                                 <ce:surname>Ferstl</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.C.</ce:given-name>
                                 <ce:surname>Davis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Herold</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Kurtkaya</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.F.</ce:given-name>
                                 <ce:surname>Camalier</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.G.</ce:given-name>
                                 <ce:surname>Hollingshead</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Kaur</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.A.</ce:given-name>
                                 <ce:surname>Sausville</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.R.</ce:given-name>
                                 <ce:surname>Rickles</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Synthesis and biological evaluation of novel curcumin analogs as anti-cancer and anti-angiogenesis agents</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[cited 2018 Aug 11];12:3871–83. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/15210154" id="intref1155" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/15210154</ce:inter-ref>
                              <sb:date>2004</sb:date>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct1245">Adams BK, Ferstl EM, Davis MC, Herold M, Kurtkaya S, Camalier RF, Hollingshead MG, Kaur G, Sausville EA, Rickles FR, et al. Synthesis and biological evaluation of novel curcumin analogs as anti-cancer and anti-angiogenesis agents. 2004 [cited 2018 Aug 11];12:3871-83. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15210154</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib245">
                     <ce:label>[245]</ce:label>
                     <sb:reference id="sref245">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Lin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Hutzen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Ball</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Foust</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Sobo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Deangelis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Pandit</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Friedman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.-K.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>New curcumin analogues exhibit enhanced growth-suppressive activity and inhibit AKT and signal transducer and activator of transcription 3 phosphorylation in breast and prostate cancer cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancer Sci.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2018 Aug 11];100:1719–27. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/19558577" id="intref1160" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/19558577</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct1250">Lin L, Hutzen B, Ball S, Foust E, Sobo M, Deangelis S, Pandit B, Friedman L, Li C, Li P-K, et al. New curcumin analogues exhibit enhanced growth-suppressive activity and inhibit AKT and signal transducer and activator of transcription 3 phosphorylation in breast and prostate cancer cells. Cancer Sci. [Internet]. 2009 [cited 2018 Aug 11];100:1719-27. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19558577</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib246">
                     <ce:label>[246]</ce:label>
                     <sb:reference id="sref246">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Yamakoshi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Ohori</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Kudo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Sato</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Kanoh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Ishioka</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Shibata</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Iwabuchi</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Structure–activity relationship of C5-curcuminoids and synthesis of their molecular probes thereof</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2018 Aug 11];18:1083–92. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/20060305" id="intref1165" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/20060305</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct1255">Yamakoshi H, Ohori H, Kudo C, Sato A, Kanoh N, Ishioka C, Shibata H, Iwabuchi Y. Structure-activity relationship of C5-curcuminoids and synthesis of their molecular probes thereof. Bioorg. Med. Chem. [Internet]. 2010 [cited 2018 Aug 11];18:1083-92. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20060305</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib247">
                     <ce:label>[247]</ce:label>
                     <sb:reference id="sref247">
                        <sb:comment>[Internet]</sb:comment>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Masuda</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Jitoe</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Isobe</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Nakatani</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Yonemori</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>(Laboratory of FCF of S of LOCUSO 558 (Japan)). Anti-oxidative and anti-inflammatory curcumin-related phenolics from rhizomes of Curcuma domestica. Phytochem (United Kingdom)</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[cited 2018 Aug 11]; Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://agris.fao.org/agris-search/search.do?recordID=GB9417213" id="intref1170" xlink:type="simple">http://agris.fao.org/agris-search/search.do?recordID=GB9417213</ce:inter-ref>
                              <sb:date>1993</sb:date>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct1260">Masuda T, Jitoe A, Isobe J, Nakatani N, Yonemori S (Laboratory of FCF of S of LOCUSO 558 (Japan)). Anti-oxidative and anti-inflammatory curcumin-related phenolics from rhizomes of Curcuma domestica. Phytochem (United Kingdom) [Internet]. 1993 [cited 2018 Aug 11]; Available from: http://agris.fao.org/agris-search/search.do?recordID=GB9417213</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib248">
                     <ce:label>[248]</ce:label>
                     <sb:reference id="sref248">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Simon</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Allais</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Duroux</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Basly</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Durand-Fontanier</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Delage</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Inhibitory effect of curcuminoids on MCF-7 cell proliferation and structure–activity relationships</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancer Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>129</sb:volume-nr>
                              </sb:series>
                              <sb:date>1998</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>111</sb:first-page>
                              <sb:last-page>116</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct1265">Simon A, Allais D, Duroux J, Basly J, Durand-Fontanier S, Delage C. Inhibitory effect of curcuminoids on MCF-7 cell proliferation and structure-activity relationships. Cancer Lett. 1998;129:111-116.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib249">
                     <ce:label>[249]</ce:label>
                     <sb:reference id="sref249">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>E.M.</ce:given-name>
                                 <ce:surname>Al-Hujaily</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.G.</ce:given-name>
                                 <ce:surname>Mohamed</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Al-Sharif</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.M.</ce:given-name>
                                 <ce:surname>Youssef</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.S.</ce:given-name>
                                 <ce:surname>Manogaran</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Al-Otaibi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Al-Haza’a</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Al-Jammaz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Al-Hussein</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Aboussekhra</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>PAC, a novel curcumin analogue, has anti-breast cancer properties with higher efficiency on ER-negative cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Breast Canc. Res. Treat.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>128</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>97</sb:first-page>
                              <sb:last-page>107</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct1270">Al-Hujaily EM, Mohamed AG, Al-Sharif I, Youssef KM, Manogaran PS, Al-Otaibi B, Al-Haza’a A, Al-Jammaz I, Al-Hussein K, Aboussekhra A. PAC, a novel curcumin analogue, has anti-breast cancer properties with higher efficiency on ER-negative cells. Breast Cancer Res Treat. 2011;128:97-107.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib250">
                     <ce:label>[250]</ce:label>
                     <sb:reference id="sref250">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Liang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Shao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Zhao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Chu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Xiao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Zhao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Exploration and synthesis of curcumin analogues with improved structural stability both <ce:italic>in vitro</ce:italic> and <ce:italic>in vivo</ce:italic> as cytotoxic agents</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>17</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2623</sb:first-page>
                              <sb:last-page>2631</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct1275">Liang G, Shao L, Wang Y, Zhao C, Chu Y, Xiao J, Zhao Y, Li X, Yang S. Exploration and synthesis of curcumin analogues with improved structural stability both in vitro and in vivo as cytotoxic agents. Bioorg Med Chem. 2009;17:2623-2631.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib251">
                     <ce:label>[251]</ce:label>
                     <sb:reference id="sref251">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Deters</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Knochenwefel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Lindhorst</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Koal</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.H.</ce:given-name>
                                 <ce:surname>Meyer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Hänsel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Resch</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Kaever</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Different curcuminoids inhibit T-lymphocyte proliferation independently of their radical scavenging activities</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Pharm. Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>25</sb:volume-nr>
                              </sb:series>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1822</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct1280">Deters M, Knochenwefel H, Lindhorst D, Koal T, Meyer HH, Hansel W, Resch K, Kaever V. Different curcuminoids inhibit T-lymphocyte proliferation independently of their radical scavenging activities. Pharm Res. 2008;25:1822.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib252">
                     <ce:label>[252]</ce:label>
                     <sb:reference id="sref252">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>W.-F.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.-L.</ce:given-name>
                                 <ce:surname>Deng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Zhou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.-L.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Curcumin and its analogues as potent inhibitors of low density lipoprotein oxidation: H-atom abstraction from the phenolic groups and possible involvement of the 4-hydroxy-3-methoxyphenyl groups</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Free Radic. Biol. Med.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>40</sb:volume-nr>
                              </sb:series>
                              <sb:date>2006</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>526</sb:first-page>
                              <sb:last-page>535</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct1285">Chen W-F, Deng S-L, Zhou B, Yang L, Liu Z-L. Curcumin and its analogues as potent inhibitors of low density lipoprotein oxidation: H-atom abstraction from the phenolic groups and possible involvement of the 4-hydroxy-3-methoxyphenyl groups. Free Radic Biol Med. 2006;40:526-535.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib253">
                     <ce:label>[253]</ce:label>
                     <sb:reference id="sref253">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.-Y.</ce:given-name>
                                 <ce:surname>Feng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.-Q.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Phenolic and enolic hydroxyl groups in curcumin: which plays the major role in scavenging radicals?</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Agric. Food Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>57</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>11041</sb:first-page>
                              <sb:last-page>11046</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct1290">Feng J-Y, Liu Z-Q. Phenolic and enolic hydroxyl groups in curcumin: which plays the major role in scavenging radicals? J Agric Food Chem. 2009;57:11041-11046.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib254">
                     <ce:label>[254]</ce:label>
                     <sb:reference id="sref254">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Lü</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.H.</ce:given-name>
                                 <ce:surname>Lin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Yao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Chemical and molecular mechanisms of antioxidants: experimental approaches and model systems</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Cell Mol. Med.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>14</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>840</sb:first-page>
                              <sb:last-page>860</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct1295">Lu J, Lin PH, Yao Q, Chen C. Chemical and molecular mechanisms of antioxidants: experimental approaches and model systems. J Cell Mol Med. 2010;14:840-860.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib255">
                     <ce:label>[255]</ce:label>
                     <sb:reference id="sref255">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.W.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.M.</ce:given-name>
                                 <ce:surname>Hong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.D.</ce:given-name>
                                 <ce:surname>Kwon</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.-O.</ce:given-name>
                                 <ce:surname>Pae</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.J.</ce:given-name>
                                 <ce:surname>Jeong</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Dimethoxycurcumin, a structural analogue of curcumin, induces apoptosis in human renal carcinoma caki cells through the production of reactive oxygen species, the release of cytochrome C, and the activation of caspase-3</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Korean J. Urol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>51</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>870</sb:first-page>
                              <sb:last-page>878</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct1300">Lee JW, Hong HM, Kwon DD, Pae H-O, Jeong HJ. Dimethoxycurcumin, a structural analogue of curcumin, induces apoptosis in human renal carcinoma caki cells through the production of reactive oxygen species, the release of cytochrome C, and the activation of caspase-3. Korean J Urol. 2010;51:870-878.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib256">
                     <ce:label>[256]</ce:label>
                     <sb:reference id="sref256">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Hatcher</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Planalp</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Cho</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Torti</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Torti</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Curcumin: from ancient medicine to current clinical trials</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cell. Mol. Life Sci.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>65</sb:volume-nr>
                              </sb:series>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1631</sb:first-page>
                              <sb:last-page>1652</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct1305">Hatcher H, Planalp R, Cho J, Torti F, Torti S. Curcumin: from ancient medicine to current clinical trials. Cell Mol Life Sci. 2008;65:1631-1652.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib257">
                     <ce:label>[257]</ce:label>
                     <sb:reference id="sref257">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.-M.</ce:given-name>
                                 <ce:surname>Katsori</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Palagani</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Bougarne</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Hadjipavlou-Litina</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Haegeman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Vanden Berghe</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Inhibition of the NF-κB signaling pathway by a novel heterocyclic curcumin analogue</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Molecules</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>20</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>863</sb:first-page>
                              <sb:last-page>878</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct1310">Katsori A-M, Palagani A, Bougarne N, Hadjipavlou-Litina D, Haegeman G, Vanden Berghe W. Inhibition of the NF-κB signaling pathway by a novel heterocyclic curcumin analogue. Molecules. 2015;20:863-878.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib258">
                     <ce:label>[258]</ce:label>
                     <sb:reference id="sref258">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.J.</ce:given-name>
                                 <ce:surname>Somers-Edgar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Taurin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Larsen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Chandramouli</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.A.</ce:given-name>
                                 <ce:surname>Nelson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.J.</ce:given-name>
                                 <ce:surname>Rosengren</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Mechanisms for the activity of heterocyclic cyclohexanone curcumin derivatives in estrogen receptor negative human breast cancer cell lines</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Investig. New Drugs</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>29</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>87</sb:first-page>
                              <sb:last-page>97</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct1315">Somers-Edgar TJ, Taurin S, Larsen L, Chandramouli A, Nelson MA, Rosengren RJ. Mechanisms for the activity of heterocyclic cyclohexanone curcumin derivatives in estrogen receptor negative human breast cancer cell lines. Invest New Drugs. 2011;29:87-97.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib259">
                     <ce:label>[259]</ce:label>
                     <sb:reference id="sref259">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Limtrakul</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Chearwae</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Shukla</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Phisalphong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.V.</ce:given-name>
                                 <ce:surname>Ambudkar</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Mol. Cell. Biochem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>296</sb:volume-nr>
                              </sb:series>
                              <sb:date>2007</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>85</sb:first-page>
                              <sb:last-page>95</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct1320">Limtrakul P, Chearwae W, Shukla S, Phisalphong C, Ambudkar S V. Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin. Mol Cell Biochem. 2007;296:85-95.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib260">
                     <ce:label>[260]</ce:label>
                     <sb:reference id="sref260">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Changtam</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.P.</ce:given-name>
                                 <ce:surname>de Koning</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Ibrahim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.S.</ce:given-name>
                                 <ce:surname>Sajid</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.K.</ce:given-name>
                                 <ce:surname>Gould</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Suksamrarn</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Curcuminoid analogs with potent activity against Trypanosoma and Leishmania species</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>45</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>941</sb:first-page>
                              <sb:last-page>956</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct1325">Changtam C, de Koning HP, Ibrahim H, Sajid MS, Gould MK, Suksamrarn A. Curcuminoid analogs with potent activity against Trypanosoma and Leishmania species. Eur J Med Chem. 2010;45:941-956.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib261">
                     <ce:label>[261]</ce:label>
                     <sb:reference id="sref261">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>B.B.</ce:given-name>
                                 <ce:surname>Aggarwal</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Deb</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Prasad</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Curcumin differs from tetrahydrocurcumin for molecular targets, signaling pathways and cellular responses</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Molecules</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>20</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>185</sb:first-page>
                              <sb:last-page>205</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct1330">Aggarwal BB, Deb L, Prasad S. Curcumin differs from tetrahydrocurcumin for molecular targets, signaling pathways and cellular responses. Molecules. 2014;20:185-205.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib262">
                     <ce:label>[262]</ce:label>
                     <sb:reference id="sref262">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.-H.</ce:given-name>
                                 <ce:surname>Pan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.-M.</ce:given-name>
                                 <ce:surname>Huang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.-K.</ce:given-name>
                                 <ce:surname>Lin</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Biotransformation of curcumin through reduction and glucuronidation in mice</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Drug Metab. Dispos.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>27</sb:volume-nr>
                              </sb:series>
                              <sb:date>1999</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>486</sb:first-page>
                              <sb:last-page>494</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct1335">Pan M-H, Huang T-M, Lin J-K. Biotransformation of curcumin through reduction and glucuronidation in mice. Drug Metab Dispos. 1999;27:486-494.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib263">
                     <ce:label>[263]</ce:label>
                     <sb:reference id="sref263">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.I.</ce:given-name>
                                 <ce:surname>Hoehle</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Pfeiffer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.M.</ce:given-name>
                                 <ce:surname>Sólyom</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Metzler</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Metabolism of curcuminoids in tissue slices and subcellular fractions from rat liver</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Agric. Food Chem.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2006</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2018 Sep 26];54:756–64. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/16448179" id="intref1175" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/16448179</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct1340">Hoehle SI, Pfeiffer E, Solyom AM, Metzler M. Metabolism of curcuminoids in tissue slices and subcellular fractions from rat liver. J. Agric. Food Chem. [Internet]. 2006 [cited 2018 Sep 26];54:756-64. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16448179</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib264">
                     <ce:label>[264]</ce:label>
                     <sb:reference id="sref264">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.K.</ce:given-name>
                                 <ce:surname>Sandur</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.K.</ce:given-name>
                                 <ce:surname>Pandey</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Sung</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.S.</ce:given-name>
                                 <ce:surname>Ahn</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Murakami</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Sethi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Limtrakul</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Badmaev</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.B.</ce:given-name>
                                 <ce:surname>Aggarwal</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Curcumin, demethoxycurcumin, bisdemethoxycurcumin, tetrahydrocurcumin and turmerones differentially regulate anti-inflammatory and anti-proliferative responses through a ROS-independent mechanism</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Carcinogenesis (Oxf.)</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2007</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2018 Sep 26];28:1765–73. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/17522064" id="intref1180" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/17522064</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct1345">Sandur SK, Pandey MK, Sung B, Ahn KS, Murakami A, Sethi G, Limtrakul P, Badmaev V, Aggarwal BB. Curcumin, demethoxycurcumin, bisdemethoxycurcumin, tetrahydrocurcumin and turmerones differentially regulate anti-inflammatory and anti-proliferative responses through a ROS-independent mechanism. Carcinogenesis (Oxf.) Internet]. 2007 [cited 2018 Sep 26];28:1765-73. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17522064</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib265">
                     <ce:label>[265]</ce:label>
                     <sb:reference id="sref265">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Wanninger</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Lorenz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Subhan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.T.</ce:given-name>
                                 <ce:surname>Edelmann</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Metal complexes of curcumin–synthetic strategies, structures and medicinal applications</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Chem. Soc. Rev.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>44</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>4986</sb:first-page>
                              <sb:last-page>5002</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct1350">Wanninger S, Lorenz V, Subhan A, Edelmann FT. Metal complexes of curcumin-synthetic strategies, structures and medicinal applications. Chem Soc Rev. 2015;44:4986-5002.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib266">
                     <ce:label>[266]</ce:label>
                     <sb:reference id="sref266">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Deptuła</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Gruber</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Krówczyński</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Curcumin and its derivatives application in cancer therapy and chemoprevention</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Postępy Fitoter</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct1355">Deptula T, Gruber B, Krowczynski A. Curcumin and its derivatives application in cancer therapy and chemoprevention. Postepy Fitoter. 2014;</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib267">
                     <ce:label>[267]</ce:label>
                     <sb:reference id="sref267">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Mohammadi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.H.</ce:given-name>
                                 <ce:surname>Thompson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.O.</ce:given-name>
                                 <ce:surname>Patrick</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Storr</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Martins</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Polishchuk</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.G.</ce:given-name>
                                 <ce:surname>Yuen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.H.</ce:given-name>
                                 <ce:surname>McNeill</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Orvig</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Synthesis and characterization of dual function vanadyl, gallium and indium curcumin complexes for medicinal applications</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Inorg. Biochem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>99</sb:volume-nr>
                              </sb:series>
                              <sb:date>2005</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2217</sb:first-page>
                              <sb:last-page>2225</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct1360">Mohammadi K, Thompson KH, Patrick BO, Storr T, Martins C, Polishchuk E, Yuen VG, McNeill JH, Orvig C. Synthesis and characterization of dual function vanadyl, gallium and indium curcumin complexes for medicinal applications. J Inorg Biochem. 2005;99:2217-2225.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib268">
                     <ce:label>[268]</ce:label>
                     <sb:reference id="sref268">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Krishnankutty</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>John</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Synthesis, characterization, and antitumour studies of metal chelates of some synthetic curcuminoids</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Synth. React. Inorg. Met. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>33</sb:volume-nr>
                              </sb:series>
                              <sb:date>2003</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>343</sb:first-page>
                              <sb:last-page>358</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct1365">Krishnankutty K, John V. Synthesis, characterization, and antitumour studies of metal chelates of some synthetic curcuminoids. Synth React Inorg Met Chem. 2003;33:343-358.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib269">
                     <ce:label>[269]</ce:label>
                     <sb:reference id="sref269">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>John</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Krishnankutty</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Antitumour activity of synthetic curcuminoid analogues (1, 7-diaryl-1, 6-heptadiene-3, 5-diones) and their copper complexes</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Appl. Organomet. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>20</sb:volume-nr>
                              </sb:series>
                              <sb:date>2006</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>477</sb:first-page>
                              <sb:last-page>482</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct1370">John V, Krishnankutty K. Antitumour activity of synthetic curcuminoid analogues (1, 7-diaryl-1, 6-heptadiene-3, 5-diones) and their copper complexes. Appl Organomet Chem. 2006;20:477-482.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib270">
                     <ce:label>[270]</ce:label>
                     <sb:reference id="sref270">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.P.</ce:given-name>
                                 <ce:surname>Verma</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.R.</ce:given-name>
                                 <ce:surname>Goldin</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Copper modulates activities of genistein, nitric oxide, and curcumin in breast tumor cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Biochem. Biophys. Res. Commun.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>310</sb:volume-nr>
                              </sb:series>
                              <sb:date>2003</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>104</sb:first-page>
                              <sb:last-page>108</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct1375">Verma SP, Goldin BR. Copper modulates activities of genistein, nitric oxide, and curcumin in breast tumor cells. Biochem Biophys Res Commun. 2003;310:104-108.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib271">
                     <ce:label>[271]</ce:label>
                     <sb:reference id="sref271">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Annaraj</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Srinivasan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Ponvel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Athappan</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Mixed ligand copper (II) complexes of phenanthroline/bipyridyl and curcumin diketimines as DNA intercalators and their electrochemical behavior under Nafion® and clay modified electrodes</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Inorg. Biochem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>99</sb:volume-nr>
                              </sb:series>
                              <sb:date>2005</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>669</sb:first-page>
                              <sb:last-page>676</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct1380">Annaraj J, Srinivasan S, Ponvel K, Athappan P. Mixed ligand copper (II) complexes of phenanthroline/bipyridyl and curcumin diketimines as DNA intercalators and their electrochemical behavior under Nafion® and clay modified electrodes. J Inorg Biochem. 2005;99:669-676.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib272">
                     <ce:label>[272]</ce:label>
                     <sb:reference id="sref272">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Barik</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Mishra</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Shen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Mohan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Kadam</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Dutta</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.-Y.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.I.</ce:given-name>
                                 <ce:surname>Priyadarsini</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Evaluation of a new copper (II)–curcumin complex as superoxide dismutase mimic and its free radical reactions</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Free Radic. Biol. Med.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>39</sb:volume-nr>
                              </sb:series>
                              <sb:date>2005</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>811</sb:first-page>
                              <sb:last-page>822</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct1385">Barik A, Mishra B, Shen L, Mohan H, Kadam R, Dutta S, Zhang H-Y, Priyadarsini KI. Evaluation of a new copper (II)-curcumin complex as superoxide dismutase mimic and its free radical reactions. Free Radic Biol Med. 2005;39:811-822.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib273">
                     <ce:label>[273]</ce:label>
                     <sb:reference id="sref273">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Barik</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Mishra</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Kunwar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.M.</ce:given-name>
                                 <ce:surname>Kadam</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Shen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Dutta</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Padhye</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.K.</ce:given-name>
                                 <ce:surname>Satpati</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.-Y.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.I.</ce:given-name>
                                 <ce:surname>Priyadarsini</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Comparative study of copper (II)–curcumin complexes as superoxide dismutase mimics and free radical scavengers</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>42</sb:volume-nr>
                              </sb:series>
                              <sb:date>2007</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>431</sb:first-page>
                              <sb:last-page>439</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct1390">Barik A, Mishra B, Kunwar A, Kadam RM, Shen L, Dutta S, Padhye S, Satpati AK, Zhang H-Y, Priyadarsini KI. Comparative study of copper (II)-curcumin complexes as superoxide dismutase mimics and free radical scavengers. Eur J Med Chem. 2007;42:431-439.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib274">
                     <ce:label>[274]</ce:label>
                     <sb:reference id="sref274">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>O.</ce:given-name>
                                 <ce:surname>Vajragupta</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Boonchoong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.J.</ce:given-name>
                                 <ce:surname>Berliner</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Manganese complexes of curcumin analogues: evaluation of hydroxyl radical scavenging ability, superoxide dismutase activity and stability towards hydrolysis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Free Radic. Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>38</sb:volume-nr>
                              </sb:series>
                              <sb:date>2004</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>303</sb:first-page>
                              <sb:last-page>314</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct1395">Vajragupta O, Boonchoong P, Berliner LJ. Manganese complexes of curcumin analogues: evaluation of hydroxyl radical scavenging ability, superoxide dismutase activity and stability towards hydrolysis. Free Radic Res. 2004;38:303-314.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib275">
                     <ce:label>[275]</ce:label>
                     <sb:reference id="sref275">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Ohigashi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Ueno</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Nonaka</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Nakanoma</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Furukawa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Deguchi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Murai</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Tyrosine kinase inhibitors reduce bcl-2 expression and induce apoptosis in androgen-dependent cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Am. J. Physiol. Physiol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>278</sb:volume-nr>
                              </sb:series>
                              <sb:date>2000</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>C66</sb:first-page>
                              <sb:last-page>C72</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct1400">Ohigashi T, Ueno M, Nonaka S, Nakanoma T, Furukawa Y, Deguchi N, Murai M. Tyrosine kinase inhibitors reduce bcl-2 expression and induce apoptosis in androgen-dependent cells. Am J Physiol Physiol. 2000;278:C66-72.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib276">
                     <ce:label>[276]</ce:label>
                     <sb:reference id="sref276">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.S.</ce:given-name>
                                 <ce:surname>Parvathy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.S.</ce:given-name>
                                 <ce:surname>Negi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Srinivas</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Curcumin–amino acid conjugates: synthesis, antioxidant and antimutagenic attributes</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]. Elsevier</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Food Chem.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2018 Sep 26];120:523–30. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://www.sciencedirect.com/science/article/pii/S0308814609012400" id="intref1185" xlink:type="simple">https://www.sciencedirect.com/science/article/pii/S0308814609012400</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct1405">Parvathy KS, Negi PS, Srinivas P. Curcumin-amino acid conjugates: synthesis, antioxidant and antimutagenic attributes. Food Chem. [Internet]. Elsevier; 2010 [cited 2018 Sep 26];120:523-30. Available from: https://www.sciencedirect.com/science/article/pii/S0308814609012400</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib277">
                     <ce:label>[277]</ce:label>
                     <sb:reference id="sref277">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.M.M.</ce:given-name>
                                 <ce:surname>Arafa</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Possible contribution of β-glycosidases and caspases in the cytotoxicity of novel glycoconjugates in colon cancer cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Investig. New Drugs</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2018 Sep 26];28:306–17. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/19415182" id="intref1190" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/19415182</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct1410">Arafa HMM. Possible contribution of β-glycosidases and caspases in the cytotoxicity of novel glycoconjugates in colon cancer cells. Investig. New Drugs [Internet]. 2010 [cited 2018 Sep 26];28:306-17. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19415182</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib278">
                     <ce:label>[278]</ce:label>
                     <sb:reference id="sref278">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Manju</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Sreenivasan</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Conjugation of curcumin onto hyaluronic acid enhances its aqueous solubility and stability</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Colloid Interface Sci.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2018 Sep 26];359:318–25. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/21492865" id="intref1195" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/21492865</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct1415">Manju S, Sreenivasan K. Conjugation of curcumin onto hyaluronic acid enhances its aqueous solubility and stability. J. Colloid Interface Sci. [Internet]. 2011 [cited 2018 Sep 26];359:318-25. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21492865</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib279">
                     <ce:label>[279]</ce:label>
                     <sb:reference id="sref279">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Tang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.J.</ce:given-name>
                                 <ce:surname>Murphy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Shen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Sui</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.A.</ce:given-name>
                                 <ce:surname>Van Kirk</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Feng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.J.</ce:given-name>
                                 <ce:surname>Murdoch</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Amphiphilic curcumin conjugate-forming nanoparticles as anticancer prodrug and drug carriers: in vitro and in vivo effects</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nanomedicine</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2018 Sep 26];5:855–65. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/20735222" id="intref1200" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/20735222</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct1420">Tang H, Murphy CJ, Zhang B, Shen Y, Sui M, Van Kirk EA, Feng X, Murdoch WJ. Amphiphilic curcumin conjugate-forming nanoparticles as anticancer prodrug and drug carriers: in vitro and in vivo effects. Nanomedicine [Internet]. 2010 [cited 2018 Sep 26];5:855-65. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20735222</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib280">
                     <ce:label>[280]</ce:label>
                     <sb:reference id="sref280">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>G.I.</ce:given-name>
                                 <ce:surname>Harisa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.K.</ce:given-name>
                                 <ce:surname>Alanazi</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Low density lipoprotein bionanoparticles: from cholesterol transport to delivery of anti-cancer drugs</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Saudi Pharm. J.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2018 Sep 26];22:504–15. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/25561862" id="intref1205" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/25561862</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct1425">Harisa GI, Alanazi FK. Low density lipoprotein bionanoparticles: from cholesterol transport to delivery of anti-cancer drugs. Saudi Pharm. J. [Internet]. 2014 [cited 2018 Sep 26];22:504-15. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25561862</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib281">
                     <ce:label>[281]</ce:label>
                     <sb:reference id="sref281">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Bobo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.J.</ce:given-name>
                                 <ce:surname>Robinson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Islam</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.J.</ce:given-name>
                                 <ce:surname>Thurecht</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.R.</ce:given-name>
                                 <ce:surname>Corrie</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Nanoparticle-based medicines: a review of FDA-approved materials and clinical trials to date</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Pharm. Res.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2018 Sep 26];33:2373–87. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/27299311" id="intref1210" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/27299311</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct1430">Bobo D, Robinson KJ, Islam J, Thurecht KJ, Corrie SR. Nanoparticle-based medicines: a review of FDA-approved materials and clinical trials to date. Pharm. Res. [Internet]. 2016 [cited 2018 Sep 26];33:2373-87. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27299311</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib282">
                     <ce:label>[282]</ce:label>
                     <sb:reference id="sref282">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Mukerjee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.K.</ce:given-name>
                                 <ce:surname>Vishwanatha</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Formulation, characterization and evaluation of curcumin-loaded PLGA nanospheres for cancer therapy</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Anticancer Res.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2018 Sep 26];29:3867–75. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/19846921" id="intref1215" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/19846921</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct1435">Mukerjee A, Vishwanatha JK. Formulation, characterization and evaluation of curcumin-loaded PLGA nanospheres for cancer therapy. Anticancer Res. [Internet]. 2009 [cited 2018 Sep 26];29:3867-75. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19846921</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib283">
                     <ce:label>[283]</ce:label>
                     <sb:reference id="sref283">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>B.N.</ce:given-name>
                                 <ce:surname>Waghela</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Sharma</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Dhumale</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.M.</ce:given-name>
                                 <ce:surname>Pandey</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Pathak</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Curcumin conjugated with PLGA potentiates sustainability, anti-proliferative activity and apoptosis in human colon carcinoma cells. Anto RJ</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>PLoS One</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2018 Sep 26];10:e0117526. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/25692854" id="intref1220" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/25692854</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct1440">Waghela BN, Sharma A, Dhumale S, Pandey SM, Pathak C. Curcumin conjugated with PLGA potentiates sustainability, anti-proliferative activity and apoptosis in human colon carcinoma cells. Anto RJ, editor. PLoS One [Internet]. 2015 [cited 2018 Sep 26];10:e0117526. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25692854</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib284">
                     <ce:label>[284]</ce:label>
                     <sb:reference id="sref284">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.M.</ce:given-name>
                                 <ce:surname>Yallapu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.R.</ce:given-name>
                                 <ce:surname>Dobberpuhl</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.M.</ce:given-name>
                                 <ce:surname>Maher</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Jaggi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.C.</ce:given-name>
                                 <ce:surname>Chauhan</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Design of curcumin loaded cellulose nanoparticles for prostate cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Curr. Drug Metabol.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2018 Sep 26];13:120–8. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/21892919" id="intref1225" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/21892919</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct1445">Yallapu MM, Dobberpuhl MR, Maher DM, Jaggi M, Chauhan SC. Design of curcumin loaded cellulose nanoparticles for prostate cancer. Curr. Drug Metabol. [Internet]. 2012 [cited 2018 Sep 26];13:120-8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21892919</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib285">
                     <ce:label>[285]</ce:label>
                     <sb:reference id="sref285">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Esmaili</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.M.</ce:given-name>
                                 <ce:surname>Ghaffari</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Moosavi-Movahedi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.S.</ce:given-name>
                                 <ce:surname>Atri</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Sharifizadeh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Farhadi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Yousefi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.-M.</ce:given-name>
                                 <ce:surname>Chobert</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Haertlé</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.A.</ce:given-name>
                                 <ce:surname>Moosavi-Movahedi</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Beta casein-micelle as a nano vehicle for solubility enhancement of curcumin food industry application</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]. Academic Press</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>LWT - Food Sci. Technol.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2018 Sep 26];44:2166–72. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://www.sciencedirect.com/science/article/pii/S002364381100171X" id="intref1230" xlink:type="simple">https://www.sciencedirect.com/science/article/pii/S002364381100171X</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct1450">Esmaili M, Ghaffari SM, Moosavi-Movahedi Z, Atri MS, Sharifizadeh A, Farhadi M, Yousefi R, Chobert J-M, Haertle T, Moosavi-Movahedi AA. Beta casein-micelle as a nano vehicle for solubility enhancement of curcumin food industry application. LWT - Food Sci. Technol. [Internet]. Academic Press; 2011 [cited 2018 Sep 26];44:2166-72. Available from: https://www.sciencedirect.com/science/article/pii/S002364381100171X</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib286">
                     <ce:label>[286]</ce:label>
                     <sb:reference id="sref286">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.B.</ce:given-name>
                                 <ce:surname>Ruttala</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.T.</ce:given-name>
                                 <ce:surname>Ko</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Liposomal co-delivery of curcumin and albumin/paclitaxel nanoparticle for enhanced synergistic antitumor efficacy</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Colloids Surfaces B Biointerfaces</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2018 Sep 26];128:419–26. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/25797481" id="intref1235" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/25797481</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct1455">Ruttala HB, Ko YT. Liposomal co-delivery of curcumin and albumin/paclitaxel nanoparticle for enhanced synergistic antitumor efficacy. Colloids Surfaces B Biointerfaces [Internet]. 2015 [cited 2018 Sep 26];128:419-26. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25797481</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib287">
                     <ce:label>[287]</ce:label>
                     <sb:reference id="sref287">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.A.</ce:given-name>
                                 <ce:surname>Gawde</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Kesharwani</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Sau</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.H.</ce:given-name>
                                 <ce:surname>Sarkar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Padhye</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.K.</ce:given-name>
                                 <ce:surname>Kashaw</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.K.</ce:given-name>
                                 <ce:surname>Iyer</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Synthesis and characterization of folate decorated albumin bio-conjugate nanoparticles loaded with a synthetic curcumin difluorinated analogue</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Colloid Interface Sci.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2018 Sep 26];496:290–9. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/28236692" id="intref1240" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/28236692</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct1460">Gawde KA, Kesharwani P, Sau S, Sarkar FH, Padhye S, Kashaw SK, Iyer AK. Synthesis and characterization of folate decorated albumin bio-conjugate nanoparticles loaded with a synthetic curcumin difluorinated analogue. J. Colloid Interface Sci. [Internet]. 2017 [cited 2018 Sep 26];496:290-9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28236692</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib288">
                     <ce:label>[288]</ce:label>
                     <sb:reference id="sref288">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Kim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.S.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.S.</ce:given-name>
                                 <ce:surname>Shin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.S.</ce:given-name>
                                 <ce:surname>Youn</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Paclitaxel and curcumin co-bound albumin nanoparticles having antitumor potential to pancreatic cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]. Elsevier</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Asian J. Pharm. Sci.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2018 Sep 26];11:708–14. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://www.sciencedirect.com/science/article/pii/S181808761630037X" id="intref1245" xlink:type="simple">https://www.sciencedirect.com/science/article/pii/S181808761630037X</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct1465">Kim B, Lee C, Lee ES, Shin BS, Youn YS. Paclitaxel and curcumin co-bound albumin nanoparticles having antitumor potential to pancreatic cancer. Asian J. Pharm. Sci. [Internet]. Elsevier; 2016 [cited 2018 Sep 26];11:708-14. Available from: https://www.sciencedirect.com/science/article/pii/S181808761630037X</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib289">
                     <ce:label>[289]</ce:label>
                     <sb:reference id="sref289">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>O.</ce:given-name>
                                 <ce:surname>Naksuriya</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Okonogi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.M.</ce:given-name>
                                 <ce:surname>Schiffelers</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.E.</ce:given-name>
                                 <ce:surname>Hennink</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Curcumin nanoformulations: a review of pharmaceutical properties and preclinical studies and clinical data related to cancer treatment</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Biomaterials</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2018 Sep 27];35:3365–83. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/24439402" id="intref1250" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/24439402</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct1470">Naksuriya O, Okonogi S, Schiffelers RM, Hennink WE. Curcumin nanoformulations: a review of pharmaceutical properties and preclinical studies and clinical data related to cancer treatment. Biomaterials [Internet]. 2014 [cited 2018 Sep 27];35:3365-83. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24439402</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib290">
                     <ce:label>[290]</ce:label>
                     <sb:reference id="sref290">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.M.</ce:given-name>
                                 <ce:surname>Yallapu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Jaggi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.C.</ce:given-name>
                                 <ce:surname>Chauhan</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Curcumin nanomedicine: a road to cancer therapeutics</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]. NIH Public Access</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Curr. Pharmaceut. Des.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2018 Sep 27];19:1994–2010. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/23116309" id="intref1255" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/23116309</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct1475">Yallapu MM, Jaggi M, Chauhan SC. Curcumin nanomedicine: a road to cancer therapeutics. Curr. Pharmaceut. Des. [Internet]. NIH Public Access; 2013 [cited 2018 Sep 27];19:1994-2010. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23116309</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib291">
                     <ce:label>[291]</ce:label>
                     <sb:reference id="sref291">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Anitha</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.G.</ce:given-name>
                                 <ce:surname>Deepagan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.V.</ce:given-name>
                                 <ce:surname>Divya Rani</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Menon</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.V.</ce:given-name>
                                 <ce:surname>Nair</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Jayakumar</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Preparation, characterization, <ce:italic>in vitro</ce:italic> drug release and biological studies of curcumin loaded dextran sulphate–chitosan nanoparticles</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]. Elsevier</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Carbohydr. Polym.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2018 Sep 27];84:1158–64. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://www.sciencedirect.com/science/article/pii/S0144861711000130" id="intref1260" xlink:type="simple">https://www.sciencedirect.com/science/article/pii/S0144861711000130</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct1480">Anitha A, Deepagan VG, Divya Rani VV, Menon D, Nair SV, Jayakumar R. Preparation, characterization, in vitro drug release and biological studies of curcumin loaded dextran sulphate-chitosan nanoparticles. Carbohydr. Polym. [Internet]. Elsevier; 2011 [cited 2018 Sep 27];84:1158-64. Available from: https://www.sciencedirect.com/science/article/pii/S0144861711000130</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib292">
                     <ce:label>[292]</ce:label>
                     <sb:reference id="sref292">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Gao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Xu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Bao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Chu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>He</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Tian</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Preparation and characterization of curcumin thermosensitive hydrogels for intratumoral injection treatment</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Drug Dev. Ind. Pharm.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2018 Sep 27];40:1557–64. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/24059282" id="intref1265" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/24059282</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct1485">Gao M, Xu H, Zhang C, Liu K, Bao X, Chu Q, He Y, Tian Y. Preparation and characterization of curcumin thermosensitive hydrogels for intratumoral injection treatment. Drug Dev. Ind. Pharm. [Internet]. 2014 [cited 2018 Sep 27];40:1557-64. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24059282</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib293">
                     <ce:label>[293]</ce:label>
                     <sb:reference id="sref293">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Cui</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Wu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Sun</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Gong</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Improving anti-tumor activity of curcumin by polymeric micelles in thermosensitive hydrogel system in colorectal peritoneal carcinomatosis model</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Biomed. Nanotechnol.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2018 Sep 27];11:1173–82. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/26307840" id="intref1270" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/26307840</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct1490">Zhang W, Cui T, Liu L, Wu Q, Sun L, Li L, Wang N, Gong C. Improving anti-tumor activity of curcumin by polymeric micelles in thermosensitive hydrogel system in colorectal peritoneal carcinomatosis model. J. Biomed. Nanotechnol. [Internet]. 2015 [cited 2018 Sep 27];11:1173-82. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26307840</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib294">
                     <ce:label>[294]</ce:label>
                     <sb:reference id="sref294">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Xu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Xu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Ma</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Zhu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Xu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.A.</ce:given-name>
                                 <ce:surname>Kotov</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Multifunctional magnetoplasmonic nanoparticle assemblies for cancer therapy and diagnostics (theranostics)</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Macromol. Rapid Commun.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2018 Sep 27];31:NA-NA. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/21590896" id="intref1275" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/21590896</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct1495">Chen W, Xu N, Xu L, Wang L, Li Z, Ma W, Zhu Y, Xu C, Kotov NA. Multifunctional magnetoplasmonic nanoparticle assemblies for cancer therapy and diagnostics (theranostics). Macromol. Rapid Commun. [Internet]. 2010 [cited 2018 Sep 27];31:NA-NA. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21590896</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib295">
                     <ce:label>[295]</ce:label>
                     <sb:reference id="sref295">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.M.</ce:given-name>
                                 <ce:surname>Yallapu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Jaggi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.C.</ce:given-name>
                                 <ce:surname>Chauhan</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Curcumin nanoformulations: a future nanomedicine for cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Drug Discov. Today</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2018 Sep 27];17:71–80. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/21959306" id="intref1280" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/21959306</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct1500">Yallapu MM, Jaggi M, Chauhan SC. Curcumin nanoformulations: a future nanomedicine for cancer. Drug Discov. Today [Internet]. 2012 [cited 2018 Sep 27];17:71-80. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21959306</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib296">
                     <ce:label>[296]</ce:label>
                     <sb:reference id="sref296">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Kunwar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Barik</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Mishra</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Rathinasamy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Pandey</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.I.</ce:given-name>
                                 <ce:surname>Priyadarsini</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Quantitative cellular uptake, localization and cytotoxicity of curcumin in normal and tumor cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Biochim. Biophys. Acta Gen. Subj.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2018 Sep 27];1780:673–9. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/18178166" id="intref1285" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/18178166</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct1505">Kunwar A, Barik A, Mishra B, Rathinasamy K, Pandey R, Priyadarsini KI. Quantitative cellular uptake, localization and cytotoxicity of curcumin in normal and tumor cells. Biochim. Biophys. Acta Gen. Subj. [Internet]. 2008 [cited 2018 Sep 27];1780:673-9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18178166</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib297">
                     <ce:label>[297]</ce:label>
                     <sb:reference id="sref297">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Montazeri</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Sadeghizadeh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Pilehvar-Soltanahmadi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Zarghami</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Khodi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Mohaghegh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Sadeghzadeh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Zarghami</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Dendrosomal curcumin nanoformulation modulate apoptosis-related genes and protein expression in hepatocarcinoma cell lines</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Int. J. Pharm.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2018 Sep 27];509:244–54. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/27234697" id="intref1290" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/27234697</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct1510">Montazeri M, Sadeghizadeh M, Pilehvar-Soltanahmadi Y, Zarghami F, Khodi S, Mohaghegh M, Sadeghzadeh H, Zarghami N. Dendrosomal curcumin nanoformulation modulate apoptosis-related genes and protein expression in hepatocarcinoma cell lines. Int. J. Pharm. [Internet]. 2016 [cited 2018 Sep 27];509:244-54. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27234697</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib298">
                     <ce:label>[298]</ce:label>
                     <sb:reference id="sref298">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Xiao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Lin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Zheng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Shi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Di</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Qi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Zhu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Zhou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Fang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Telomerase: a target for therapeutic effects of curcumin and a curcumin derivative in aβ1-42 insult in vitro</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:editors>
                                 <sb:editor>
                                    <ce:given-name>G.</ce:given-name>
                                    <ce:surname>Saretzki</ce:surname>
                                 </sb:editor>
                              </sb:editors>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>PLoS One</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2018 Sep 27];9:e101251. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/24983737" id="intref1295" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/24983737</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct1515">Xiao Z, Zhang A, Lin J, Zheng Z, Shi X, Di W, Qi W, Zhu Y, Zhou G, Fang Y. Telomerase: a target for therapeutic effects of curcumin and a curcumin derivative in aβ1-42 insult in vitro. Saretzki G, editor. PLoS One [Internet]. 2014 [cited 2018 Sep 27];9:e101251. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24983737</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib299">
                     <ce:label>[299]</ce:label>
                     <sb:reference id="sref299">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.K.T.</ce:given-name>
                                 <ce:surname>Thulasidasan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.P.</ce:given-name>
                                 <ce:surname>Retnakumari</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Shankar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Vijayakurup</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Anwar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Thankachan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.S.</ce:given-name>
                                 <ce:surname>Pillai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.J.</ce:given-name>
                                 <ce:surname>Pillai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.D.</ce:given-name>
                                 <ce:surname>Nandan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.V.</ce:given-name>
                                 <ce:surname>Alex</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Folic acid conjugation improves the bioavailability and chemosensitizing efficacy of curcumin-encapsulated PLGA-PEG nanoparticles towards paclitaxel chemotherapy</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]. Impact Journals, LLC</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncotarget</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>cited 2018 Sep 27];8:107374–89. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/29296172" id="intref1300" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/29296172</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct1520">Thulasidasan AKT, Retnakumari AP, Shankar M, Vijayakurup V, Anwar S, Thankachan S, Pillai KS, Pillai JJ, Nandan CD, Alex V V, et al. Folic acid conjugation improves the bioavailability and chemosensitizing efficacy of curcumin-encapsulated PLGA-PEG nanoparticles towards paclitaxel chemotherapy. Oncotarget [Internet]. Impact Journals, LLC; 2017 [cited 2018 Sep 27];8:107374-89. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29296172</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib300">
                     <ce:label>[300]</ce:label>
                     <sb:reference id="sref300">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Zhai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Guo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Ji</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Gao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Sun</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Sun</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Zhai</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>A novel folate-modified self-microemulsifying drug delivery system of curcumin for colon targeting</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Int. J. Nanomed.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2018 Sep 27];7:151. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/22275831" id="intref1305" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/22275831</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct1525">Zhai G, Zhang W, Guo C, Yu H, Ji A, Gao J, Sun Y, Sun M, Zhai G. A novel folate-modified self-microemulsifying drug delivery system of curcumin for colon targeting. Int. J. Nanomed. [Internet]. 2012 [cited 2018 Sep 27];7:151. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22275831</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib301">
                     <ce:label>[301]</ce:label>
                     <sb:reference id="sref301">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Manju</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Sreenivasan</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Enhanced drug loading on magnetic nanoparticles by layer-by-layer assembly using drug conjugates: blood compatibility evaluation and targeted drug delivery in cancer cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Langmuir</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2018 Sep 27];27:14489–96. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/21988497" id="intref1310" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/21988497</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct1530">Manju S, Sreenivasan K. Enhanced drug loading on magnetic nanoparticles by layer-by-layer assembly using drug conjugates: blood compatibility evaluation and targeted drug delivery in cancer cells. Langmuir [Internet]. 2011 [cited 2018 Sep 27];27:14489-96. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21988497</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib302">
                     <ce:label>[302]</ce:label>
                     <sb:reference id="sref302">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Manju</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Sreenivasan</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Gold nanoparticles generated and stabilized by water soluble curcumin–polymer conjugate: blood compatibility evaluation and targeted drug delivery onto cancer cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Colloid Interface Sci.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2018 Sep 27];368:144–51. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/22200330" id="intref1315" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/22200330</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct1535">Manju S, Sreenivasan K. Gold nanoparticles generated and stabilized by water soluble curcumin-polymer conjugate: blood compatibility evaluation and targeted drug delivery onto cancer cells. J. Colloid Interface Sci. [Internet]. 2012 [cited 2018 Sep 27];368:144-51. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22200330</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib303">
                     <ce:label>[303]</ce:label>
                     <sb:reference id="sref303">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Mathew</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Fukuda</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Nagaoka</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Hasumura</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Morimoto</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Yoshida</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Maekawa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Venugopal</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.S.</ce:given-name>
                                 <ce:surname>Kumar</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Curcumin loaded-PLGA nanoparticles conjugated with tet-1 peptide for potential use in alzheimer's disease</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]. Public Library of Science</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:editors>
                                 <sb:editor>
                                    <ce:given-name>D.</ce:given-name>
                                    <ce:surname>Fatouros</ce:surname>
                                 </sb:editor>
                              </sb:editors>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>PLoS One</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2018 Sep 27];7:e32616. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://dx.plos.org/10.1371/journal.pone.0032616" id="intref1320" xlink:type="simple">http://dx.plos.org/10.1371/journal.pone.0032616</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct1540">Mathew A, Fukuda T, Nagaoka Y, Hasumura T, Morimoto H, Yoshida Y, Maekawa T, Venugopal K, Kumar DS. Curcumin loaded-PLGA nanoparticles conjugated with tet-1 peptide for potential use in alzheimer's disease. Fatouros D, editor. PLoS One [Internet]. Public Library of Science; 2012 [cited 2018 Sep 27];7:e32616. Available from: http://dx.plos.org/10.1371/journal.pone.0032616</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib304">
                     <ce:label>[304]</ce:label>
                     <sb:reference id="sref304">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>U.</ce:given-name>
                                 <ce:surname>Gandapu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.K.</ce:given-name>
                                 <ce:surname>Chaitanya</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Kishore</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.C.</ce:given-name>
                                 <ce:surname>Reddy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.K.</ce:given-name>
                                 <ce:surname>Kondapi</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Curcumin-loaded apotransferrin nanoparticles provide efficient cellular uptake and effectively inhibit HIV-1 replication in vitro</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:editors>
                                 <sb:editor>
                                    <ce:given-name>M.</ce:given-name>
                                    <ce:surname>Antopolsky</ce:surname>
                                 </sb:editor>
                              </sb:editors>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>PLoS One</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2018 Sep 27];6:e23388. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/21887247" id="intref1325" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/21887247</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct1545">Gandapu U, Chaitanya RK, Kishore G, Reddy RC, Kondapi AK. Curcumin-loaded apotransferrin nanoparticles provide efficient cellular uptake and effectively inhibit HIV-1 replication in vitro. Antopolsky M, editor. PLoS One [Internet]. 2011 [cited 2018 Sep 27];6:e23388. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21887247</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib305">
                     <ce:label>[305]</ce:label>
                     <ce:other-ref id="sref305">
                        <ce:textref>Limtrakul P. Curcumin as Chemosensitizer. The Molecular Targets and Therapeutic Uses of Curcumin in Health and Disease [Internet]. Boston, MA: Springer US; [cited 2018 Sep 27]. pp. 269–300. Available from: <ce:inter-ref xlink:href="http://link.springer.com/10.1007/978-0-387-46401-5_12" id="intref1330" xlink:type="simple">http://link.springer.com/10.1007/978-0-387-46401-5_12</ce:inter-ref>.</ce:textref>
                     </ce:other-ref>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib306">
                     <ce:label>[306]</ce:label>
                     <sb:reference id="sref306">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Duan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.M.</ce:given-name>
                                 <ce:surname>Mansour</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Deng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Pan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Zhao</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Reversion of multidrug resistance by co-encapsulation of doxorubicin and curcumin in chitosan/poly(butyl cyanoacrylate) nanoparticles</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Int. J. Pharm.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2018 Sep 27];426:193–201. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/22274587" id="intref1335" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/22274587</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct1550">Duan J, Mansour HM, Zhang Y, Deng X, Chen Y, Wang J, Pan Y, Zhao J. Reversion of multidrug resistance by co-encapsulation of doxorubicin and curcumin in chitosan/poly(butyl cyanoacrylate) nanoparticles. Int. J. Pharm. [Internet]. 2012 [cited 2018 Sep 27];426:193-201. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22274587</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib307">
                     <ce:label>[307]</ce:label>
                     <sb:reference id="sref307">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Hu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Increase of therapeutic activity of doxorubicin by long circulating liposomes in combination with curcumin</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Die Pharmazie</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2018 Sep 27];66:871–4. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/22204133" id="intref1340" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/22204133</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct1555">Wang H, Hu L, Li C, Zhang J, Zhang T. Increase of therapeutic activity of doxorubicin by long circulating liposomes in combination with curcumin. Die Pharmazie [Internet]. 2011 [cited 2018 Sep 27];66:871-4. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22204133</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib308">
                     <ce:label>[308]</ce:label>
                     <sb:reference id="sref308">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Ganta</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Amiji</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Coadministration of paclitaxel and curcumin in nanoemulsion formulations to overcome multidrug resistance in tumor cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Mol. Pharm.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2018 Sep 27];6:928–39. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/19278222" id="intref1345" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/19278222</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct1560">Ganta S, Amiji M. Coadministration of paclitaxel and curcumin in nanoemulsion formulations to overcome multidrug resistance in tumor cells. Mol. Pharm. [Internet]. 2009 [cited 2018 Sep 27];6:928-39. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19278222</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib309">
                     <ce:label>[309]</ce:label>
                     <sb:reference id="sref309">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.M.</ce:given-name>
                                 <ce:surname>Yallapu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.M.</ce:given-name>
                                 <ce:surname>Maher</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Sundram</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.C.</ce:given-name>
                                 <ce:surname>Bell</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Jaggi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.C.</ce:given-name>
                                 <ce:surname>Chauhan</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Curcumin induces chemo/radio-sensitization in ovarian cancer cells and curcumin nanoparticles inhibit ovarian cancer cell growth</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>[Internet]</sb:comment>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Ovarian Res.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>[cited 2018 Sep 27];3:11. Available from:</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/20429876" id="intref1350" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/20429876</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct1565">Yallapu MM, Maher DM, Sundram V, Bell MC, Jaggi M, Chauhan SC. Curcumin induces chemo/radio-sensitization in ovarian cancer cells and curcumin nanoparticles inhibit ovarian cancer cell growth. J. Ovarian Res. [Internet]. 2010 [cited 2018 Sep 27];3:11. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20429876</ce:source-text>
                  </ce:bib-reference>
               </ce:bibliography-sec>
            </ce:bibliography>
         </tail>
      </article>
   </xocs:serial-item></xocs:doc></originaltext></full-text-retrieval-response>